

**Cochrane** Database of Systematic Reviews

# Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review)

Page MJ, Green S, Kramer S, Johnston RV, McBain B, Chau M, Buchbinder R

Page MJ, Green S, Kramer S, Johnston RV, McBain B, Chau M, Buchbinder R. Manual therapy and exercise for adhesive capsulitis (frozen shoulder). *Cochrane Database of Systematic Reviews* 2014, Issue 8. Art. No.: CD011275. DOI: 10.1002/14651858.CD011275.

www.cochranelibrary.com



#### TABLE OF CONTENTS

PLAIN LANGUAGE SUMMARY       2         SUMMARY OF FINDINGS       4         BACKGROUND       16         OBJECTIVES       16         REFHODS       16         Figure 1.       21         Figure 2.       23         DISCUSSION       30         AUTHORS CONCLUSIONS       32         ACKROW LEDGEMENTS       32         REFERENCES       33         CARACCTERSTICS OF STUDIES       33         DATA AND ANALYSES       32         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus gluccocrticiol       122         Injection, Outcome 1 Overall pain.       123         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus gluccocrticiol       123         Injection, Outcome 2 Function       114         Analysis 1.3. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus gluccocrticiol       124         Injection, Outcome 3 Quality of life.       124         Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus gluccocrticiol       124         Injection, Outcome 4 Active range of motion (edgrees).       124       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plu	ABSTRACT	1
SUMMARY OF FINDINGS       4         BACKGROUND       16         OBJECTIVES       16         DRACKGROUND       16         OBJECTIVES       16         METHODS       16         Figure 1       21         Figure 2       23         Figure 3       24         DISCUSSION       30         UTHORS' CONCLUSIONS       32         ACKNOWLEDGEMENTS       23         EFFERENCES       33         CHARACTERISTICS OF STUDIES       33         CHARACTERISTICS OF STUDIES       34         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticidi       122         injection, Outcome 1 Overall pain.       4         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticidi       13         injection, Outcome 4 Active range of motion (degrees).       124       16         Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection versus glucocorticidi       124         injection, Outcome 6 Active range of motion (cm).       124       16         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection       124 </td <td>PLAIN LANGUAGE SUMMARY</td> <td>2</td>	PLAIN LANGUAGE SUMMARY	2
BACKGROUND       16         DORLECTIVES       16         METHODS       16         RESUITS       20         Figure 1       21         Figure 2       23         Figure 3       24         DISCUSSION       30         AUTHORS' CONCLUSIONS       22         CARKOWLEDGEMENTS       23         CHARACTERISTICS OF STUDIES       33         CHARACTERISTICS OF STUDIES       33         CHARACTERISTICS OF STUDIES       34         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus gluccocriticial       122         injection, Outcome 2 Function.       123         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus gluccocriticial       124         Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus gluccocriticial       124         Injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus gluccocriticial       124         Injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, 127	SUMMARY OF FINDINGS	4
OBJECTIVES       16         RETHODS       20         Figure 1       21         Figure 2       23         Figure 3       24         DSCUSSION       30         AUTHORS' CONCLUSIONS       32         ACKNOWLEDGEMENTS       32         ACKNOWLEDGEMENTS       32         ACKNOWLEDGEMENTS       32         ACKNOWLEDGEMENTS       32         ACANDARYSES       33         CHARACTERISTICS OF STUDIES       34         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         Injection, Outcome 1 Overall pain       123         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         Injection, Outcome 2 Vernell pain       124         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         Injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.2. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection       125         Injection, Outcome 4 Overall pain.       127         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus place	BACKGROUND	16
METHODS       16         RESULTS       20         Figure 1.       21         Figure 2.       23         Figure 3.       24         DISCUSSION       30         AUTHORS' CONCLUSIONS       32         ACKNOWLEDGEMENTS       32         REFERENCES       33         CHARACTERISTICS OF STUDIES       38         DATA AND ANALYSES       32         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 2 Function.       123         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         Injection, Outcome 3 Quality of life.       123         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         Injection, Outcome 4 Active range of motion (digenes).       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         Injection, Outcome 4 Active range of motion (cm).       124         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         Injection, Outcome 4 Active range of	OBJECTIVES	16
RESULTS       20         Figure 1.       21         Figure 2.       23         Figure 3.       24         DSCUSSION       30         ARNOWLEDGEMENTS       32         CHRACTERISTICS OF STUDIES       33         CHARACTERISTICS OF STUDIES       34         DATA AND ANALYSES       30         CHARACTERISTICS OF STUDIES       34         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         Injection, Outcome 1 Overall pain.       133         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       141         Injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         Injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         Injection, Outcome 6 Active range of motion (cm).       124       125         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection       125         Injection, Outcome 6 Active range	METHODS	16
Figure 1.       21         Figure 2.       23         Figure 3.       24         DISCUSSION       30         AUTHORS' CONCLUSIONS       30         ACKNOWLEDGEMENTS       32         REFERENCES       33         CHARACTERISTICS OF STUDIES       38         DATA AND ANALYSES       32         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       120         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       123         injection, Outcome 4 Diverall pain.       124         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       123         injection, Outcome 4 Active range of motion (edgrees).       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         Injection, Outcome 5 Active range of motion (cm).       124         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, versu	RESULTS	20
Figure 2.       23         Figure 3.       24         DISCUSSION       30         ALTHORS' CONCLUSIONS       32         ACKNOWLEDGEMENTS       32         REFERENCES       33         CHARACTERISTICS OF STUDIES       34         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 1 Verentl pain.       34         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       123         injection, Outcome 2 Function.       4.4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	Figure 1	21
Figure 3.       24         DISCUSSION       30         AUTHORS' CONCLUSIONS       32         ACKNOWLEDGEMENTS       32         ACKNOWLEDGEMENTS       32         CHARACTERISTICS OF STUDIES       33         DATA AND ANALYSES       32         DATA AND ANALYSES       32         CHARACTERISTICS OF STUDIES       33         DATA AND ANALYSES       32         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 2 Function.       123         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 4 Active range of motion (cm).       125         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         injection, Outcome 6 Active range of motion (cm).       127         Outcome 1 Overall pain.       127         Outcome 2 Junnal therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125	Figure 2	23
DISCUSSION       30         AUTHORS' CONCLUSIONS       32         ACKNOWLEDGEMENTS       32         ACKNOWLEDGEMENTS       32         REFERENCES       33         REFERENCES       38         DATA AND ANALYSES       32         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 1 Querall pain.       40         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       123         injection, Outcome 4 Curve range of motion (degrees).       40       124         Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 4 Active range of motion.       (mainterange)       124         injection, Outcome 4 Active range of motion.       (mainterange)       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 4 Active range of motion.       (mainterange)       125         injection, Outcome 6 Active range of motion.       (mainterange)       127         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid	Figure 3	24
AUTHORS CONCLUSIONS       32         REFERENCES       33         CHARACTERISTICS OF STUDIES       34         DATA AND ANALYSES       32         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         Injection, Outcome 1 Overall pain.       31         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         Injection, Outcome 4 Zunction.       123         Analysis 1.3. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         Injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         Injection, Outcome 5 Active range of motion.       124         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         Injection, Outcome 6 Passive range of motion.       127         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       127         Outcome 4 Active range of motion.       127         Outcome 5 Active range of motion.       127         Outcome 4 Active range of motion. <td>DISCUSSION</td> <td>30</td>	DISCUSSION	30
ACKNOWLEDGEMENTS       32         REFERENCES       33         CHARACTERISTICS OF STUDIES       38         DATA AND ANALYSES       120         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 1 Overall pain.       123         Analysis 1.3. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 2 Active range of motion (degrees).       124         Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 6 Active range of motion (degrees).       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 6 Passive range of motion.       124         injection, Outcome 6 Passive range of motion.       124         Analysis 1.6. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glacebo injection,       127         Outcome 2 Function.       128       127         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo in	AUTHORS' CONCLUSIONS	32
REFERENCES       33         CHARACTERISTICS OF STUDIES       38         DATA AND ANALYSES       38         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 1 Overall pain.       120         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 3 Quality of life.       121         Analysis 1.3. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       123         injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 6 Active range of motion (cm).       125         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         injection, Outcome 6 Passive range of motion.       127         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       127         Outcome 1 Overall pain.       128         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       128         Outcome 4 Activ	ACKNOWLEDGEMENTS	32
CHARACTERISTICS OF STUDIES       38         DATA AND ANAYSES       120         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 1 Overall pain.       120         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 3 Function.       120         Analysis 1.3. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 6 Active range of motion (m).       125         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         injection, Outcome 6 Passive range of motion (m).       126         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       127         Outcome 2 Active range of motion (em).       128         Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       127         Outcome 4 Active range of motion (em).       128 <td>REFERENCES</td> <td>33</td>	REFERENCES	33
DATA AND ANALYSES       120         Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 2 Function.       123         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       123         injection, Outcome 2 Quality of life.       124         Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         injection, Outcome 6 Passive range of motion (degrees).       126         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         injection, Outcome 6 Passive range of motion.       127         Outcome 1 Overall pain.       128         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, versus placebo in	CHARACTERISTICS OF STUDIES	38
Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 1 Overall pain.       123         Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       123         Analysis 1.3. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 4 Active range of motion (degrees).       125         Analysis 2.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         injection, Outcome 4 Active range of motion.       127         Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glacebo injection, 0utcome 3 Quality of life.       127         Analysis 2.4. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, 128       128         Outcome 4 Active range of motion (cm).       128         Analysis 2.5. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo i	DATA AND ANALYSES	120
Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       122         injection, Outcome 3 Quality of life.       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 3 Quality of life.       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         injection, Outcome 6 Passive range of motion (m).       128         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       127         Outcome 1 Overall pain.       127         Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       127         Outcome 4 Cuive range of motion (degrees).       128         Analysis 2.4. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       127         Outcome 4 Active range of motion (degrees).       128         Analysis 2.5. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injectio	Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 1 Overall pain.	122
Analysis 1.3. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       123         injection, Outcome 3 Quality of life.       124         Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 5 Active range of motion (m.)       125         Analysis 1.6. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         injection, Outcome 6 Passive range of motion (m.)       127         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, versus placebo injection, versus placebo injection, versus placebo injection, 2127         Outcome 1 Overall pain.       127         Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, 2128         Outcome 4 Active range of motion (degrees).       128         Outcome 4 Active range of motion (degrees).       129         Outcome 4 Active range of motion (m.       129         Analysis 2.6. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, 00       129 </td <td>Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 2 Function.</td> <td>122</td>	Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 2 Function.	122
Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 4 Active range of motion (degrees).       124         Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         injection, Outcome 6 Active range of motion (cm).       125         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         injection, Outcome 6 Passive range of motion (cm).       126         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       127         Outcome 1 Overall pain.       128         Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       127         Outcome 3 Quality of life.       128         Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       128         Outcome 4 Active range of motion (degrees).       129         Analysis 2.5. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       129         Outcome 6 Passive range of motion (cm).       129         Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucco	Analysis 1.3. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 3 Quality of life.	123
Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       124         injection, Outcome 5 Active range of motion (cm).       125         Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid       125         Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       127         Outcome 2 Function.       127         Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       127         Outcome 3 Quality of life.       128         Analysis 2.4. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       128         Outcome 4 Active range of motion (degrees).       129         Analysis 2.5. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,       129         Outcome 6 Passive range of motion (cm).       130         Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus gluceorticoid injection versus gluccorticoid injection versus gluccorticoid injection versus gluccorticoid       132         Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus gluccorticoid injection versus gluccorticoid       133         Analysis 3.2. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocor	Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 4 Active range of motion (degrees).	124
Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid125injection, Outcome 6 Passive range of motion.127Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,127Outcome 1 Overall pain.128Analysis 2.2. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,127Outcome 2 Function.128Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,128Outcome 3 Quality of life.129Analysis 2.4. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,129Outcome 4 Active range of motion (degrees).129Analysis 2.6. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,129Outcome 6 Passive range of motion (cm).130Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid133injection, Outcome 1 Overall pain.133Analysis 3.2. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid133injection, Outcome 2 Function.134Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid134injection, Outcome 4 Active range of motion (cm).134Analysis 3.4. Comparison 3 Manual therapy plus exercise plus	Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 5 Active range of motion (cm).	124
Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 1 Overall pain.127Analysis 2.2. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 3 Quality of life.128Analysis 2.4. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 4 Active range of motion (degrees).129Analysis 2.5. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 5 Active range of motion (cm).129Analysis 2.6. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 6 Passive range of motion.130Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 2 Function.131Analysis 3.3. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 2 Quality of life.133Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 2 Guality of life.131Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 4 Active range of motion (cm).133Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 4 Active range of motion (cm).134Analysis 3.5. Comparison 3 Manual therapy plus exercise plu	Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 6 Passive range of motion.	125
Analysis 2.2. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,127Outcome 2 Function.128Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,128Outcome 3 Quality of life.129Analysis 2.4. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,129Outcome 4 Active range of motion (degrees).129Analysis 2.5. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,129Outcome 5 Active range of motion (cm).130Analysis 2.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,130Outcome 6 Passive range of motion.132Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid132injection, Outcome 1 Overall pain.133Analysis 3.3. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid133injection, Outcome 2 Function.133Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid134injection, Outcome 4 Active range of motion (cm).134Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid135injection, Outcome 5 Active range of motion (cm).135Analysis 3.6. Comparison 3 Manual therap	Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 1 Overall pain.	127
Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 3 Quality of life.128Analysis 2.4. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 4 Active range of motion (degrees).129Analysis 2.5. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 5 Active range of motion (cm).129Analysis 2.6. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 6 Passive range of motion.130Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 1 Overall pain.132Analysis 3.2. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 2 Function.133Analysis 3.3. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 4 Active range of motion (degrees).133Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 4 Active range of motion (degrees).134Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 5 Active range of motion (cm).135Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 5 Active range of motion (cm).135Analysis 3.	Analysis 2.2. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 2 Function.	127
Analysis 2.4. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,129Outcome 4 Active range of motion (degrees).129Analysis 2.5. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,129Outcome 5 Active range of motion (cm).130Analysis 2.6. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection,130Outcome 6 Passive range of motion.132Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid132injection, Outcome 1 Overall pain.133Analysis 3.2. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid133injection, Outcome 2 Function.133Analysis 3.3. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid134injection, Outcome 3 Quality of life.134Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid134injection, Outcome 4 Active range of motion (degrees).135Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid135injection, Outcome 5 Active range of motion (cm).135Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid135injection, Outcome 6 Passive range of motion.135	Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 3 Quality of life.	128
Analysis 2.5. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 5 Active range of motion (cm).129Analysis 2.6. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 6 Passive range of motion.130Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 1 Overall pain.132Analysis 3.2. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 2 Function.133Analysis 3.3. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 2 Function.133Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 4 Active range of motion (degrees).134Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 5 Active range of motion (cm).135Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 5 Active range of motion (cm).135Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 5 Active range of motion (cm).135Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 6 Passive range of motion (cm).135 <td< td=""><td>Analysis 2.4. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 4 Active range of motion (degrees).</td><td>129</td></td<>	Analysis 2.4. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 4 Active range of motion (degrees).	129
Analysis 2.6. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 6 Passive range of motion.130Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 1 Overall pain.132Analysis 3.2. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 2 Function.133Analysis 3.3. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 2 Function.133Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 3 Quality of life.134Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 4 Active range of motion (degrees).135Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 5 Active range of motion (cm).135Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 6 Passive range of motion.135Analysis 4.1. Comparison 4 Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus ultrasound plus exercises, Outcome 1 Overall pain (VAS 0-10).136	Analysis 2.5. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 5 Active range of motion (cm).	129
Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid132injection, Outcome 1 Overall pain.133Analysis 3.2. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid133injection, Outcome 2 Function.133Analysis 3.3. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid133injection, Outcome 3 Quality of life.133Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid134injection, Outcome 4 Active range of motion (degrees).135Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid135injection, Outcome 5 Active range of motion (cm).135Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid135injection, Outcome 6 Passive range of motion.135Analysis 4.1. Comparison 4 Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus136ultrasound plus exercises, Outcome 1 Overall pain (VAS 0-10).136	Analysis 2.6. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 6 Passive range of motion.	130
Analysis 3.2. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid133injection, Outcome 2 Function.133Analysis 3.3. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid133injection, Outcome 3 Quality of life.134Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid134injection, Outcome 4 Active range of motion (degrees).135Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid135injection, Outcome 5 Active range of motion (cm).135Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid135injection, Outcome 6 Passive range of motion.135Analysis 4.1. Comparison 4 Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus136ultrasound plus exercises, Outcome 1 Overall pain (VAS 0-10).136	Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 1 Overall pain.	132
Analysis 3.3. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid133injection, Outcome 3 Quality of life.134Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid134injection, Outcome 4 Active range of motion (degrees).135Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid135injection, Outcome 5 Active range of motion (cm).135Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid135injection, Outcome 6 Passive range of motion.135Analysis 4.1. Comparison 4 Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus136ultrasound plus exercises, Outcome 1 Overall pain (VAS 0-10).136	Analysis 3.2. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 2 Function.	133
<ul> <li>Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection versus glucocorticoid</li> <li>134 injection, Outcome 4 Active range of motion (degrees).</li> <li>Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid</li> <li>135 injection, Outcome 5 Active range of motion (cm).</li> <li>Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid</li> <li>135 injection, Outcome 6 Passive range of motion.</li> <li>Analysis 4.1. Comparison 4 Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus ultrasound plus exercises, Outcome 1 Overall pain (VAS 0-10).</li> </ul>	Analysis 3.3. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 3 Quality of life.	133
<ul> <li>Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection versus glucocorticoid injection, outcome 5 Active range of motion (cm).</li> <li>Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid ve</li></ul>	Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 4 Active range of motion (degrees).	134
<ul> <li>Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, versus glucocorticoid injection, outcome 6 Passive range of motion.</li> <li>Analysis 4.1. Comparison 4 Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus ultrasound plus exercises, outcome 1 Overall pain (VAS 0-10).</li> </ul>	Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 5 Active range of motion (cm).	135
Analysis 4.1. Comparison 4 Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus 136 ultrasound plus exercises, Outcome 1 Overall pain (VAS 0-10).	Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, outcome 6 Passive range of motion.	135
	Analysis 4.1. Comparison 4 Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus ultrasound plus exercises, Outcome 1 Overall pain (VAS 0-10).	136



Analysis 4.2. Comparison 4 Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus ultrasound plus exercises, Outcome 2 Active range of motion.	136
Analysis 5.1. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 1 Overall pain.	138
Analysis 5.2. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 2 Function.	139
Analysis 5.3. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 3 Quality of life.	139
Analysis 5.4. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 4 Active range of motion (degrees).	140
Analysis 5.5. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 5 Active range of motion (cm).	141
Analysis 5.6. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 6 Passive range of motion.	141
ADDITIONAL TABLES	142
APPENDICES	170
HISTORY	171
CONTRIBUTIONS OF AUTHORS	172
DECLARATIONS OF INTEREST	172
SOURCES OF SUPPORT	172
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	172
NOTES	172
INDEX TERMS	172



#### [Intervention Review]

### Manual therapy and exercise for adhesive capsulitis (frozen shoulder)

Matthew J Page<sup>1</sup>, Sally Green<sup>1</sup>, Sharon Kramer<sup>1</sup>, Renea V Johnston<sup>2</sup>, Brodwen McBain<sup>3</sup>, Marisa Chau<sup>4</sup>, Rachelle Buchbinder<sup>2</sup>

<sup>1</sup>School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia. <sup>2</sup>Monash Department of Clinical Epidemiology, Cabrini Hospital, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Malvern, Australia. <sup>3</sup>Melbourne Hand Rehab, Melbourne, Australia. <sup>4</sup>National Trauma Research Institute, Alfred Hospital, Monash University, Melbourne, Australia

**Contact:** Rachelle Buchbinder, Monash Department of Clinical Epidemiology, Cabrini Hospital, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, 154 Wattletree Road, Malvern, Victoria, 3144, Australia. rachelle.buchbinder@monash.edu.

**Editorial group:** Cochrane Musculoskeletal Group. **Publication status and date:** New, published in Issue 8, 2014.

**Citation:** Page MJ, Green S, Kramer S, Johnston RV, McBain B, Chau M, Buchbinder R. Manual therapy and exercise for adhesive capsulitis (frozen shoulder). *Cochrane Database of Systematic Reviews* 2014, Issue 8. Art. No.: CD011275. DOI: 10.1002/14651858.CD011275.

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### ABSTRACT

#### Background

Adhesive capsulitis (also termed *frozen shoulder*) is commonly treated by manual therapy and exercise, usually delivered together as components of a physical therapy intervention. This review is one of a series of reviews that form an update of the Cochrane review, 'Physiotherapy interventions for shoulder pain.'

#### Objectives

To synthesise available evidence regarding the benefits and harms of manual therapy and exercise, alone or in combination, for the treatment of patients with adhesive capsulitis.

#### Search methods

We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL Plus, ClinicalTrials.gov and the WHO ICTRP clinical trials registries up to May 2013, unrestricted by language, and reviewed the reference lists of review articles and retrieved trials, to identify potentially relevant trials.

#### Selection criteria

We included randomised controlled trials (RCTs) and quasi-randomised trials, including adults with adhesive capsulitis, and comparing any manual therapy or exercise intervention versus placebo, no intervention, a different type of manual therapy or exercise or any other intervention. Interventions included mobilisation, manipulation and supervised or home exercise, delivered alone or in combination. Trials investigating the primary or adjunct effect of a combination of manual therapy and exercise were the main comparisons of interest. Main outcomes of interest were participant-reported pain relief of 30% or greater, overall pain (mean or mean change), function, global assessment of treatment success, active shoulder abduction, quality of life and the number of participants experiencing adverse events.

#### Data collection and analysis

Two review authors independently selected trials for inclusion, extracted the data, performed a risk of bias assessment and assessed the quality of the body of evidence for the main outcomes using the GRADE approach.



#### **Main results**

We included 32 trials (1836 participants). No trial compared a combination of manual therapy and exercise versus placebo or no intervention. Seven trials compared a combination of manual therapy and exercise versus other interventions but were clinically heterogeneous, so opportunities for meta-analysis were limited. The overall impression gained from these trials is that the few outcome differences between interventions that were clinically important were detected only up to seven weeks. Evidence of moderate quality shows that a combination of manual therapy and exercise for six weeks probably results in less improvement at seven weeks but a similar number of adverse events compared with glucocorticoid injection. The mean change in pain with glucocorticoid injection was 58 points on a 100-point scale, and 32 points with manual therapy and exercise (mean difference (MD) 26 points, 95% confidence interval (CI) 15 points to 37 points; one RCT, 107 participants), for an absolute difference of 26% (15% to 37%). Mean change in function with glucocorticoid injection was 39 points on a 100-point scale, and 14 points with manual therapy and exercise (MD 25 points, 95% CI 35 points to 15 points; one RCT, 107 participants), for an absolute difference of 25% (15% to 35%). Forty-six per cent (26/56) of participants reported treatment success with manual therapy and exercise compared with 77% (40/52) of participants receiving glucocorticoid injection (risk ratio (RR) 0.6, 95% CI 0.44 to 0.83; one RCT, 108 participants), with an absolute risk difference of 30% (13% to 48%). The number reporting adverse events did not differ between groups: 56% (32/57) reported events with manual therapy and exercise, and 53% (30/57) with glucocorticoid injection (RR 1.07, 95% CI 0.76 to 1.49; one RCT, 114 participants), with an absolute risk difference of 4% (-15% to 22%). Group differences in improvement in overall pain and function at six months and 12 months were not clinically important.

We are uncertain of the effect of other combinations of manual therapy and exercise, as most evidence is of low quality. Meta-analysis of two trials (86 participants) suggested no clinically important differences between a combination of manual therapy, exercise, and electrotherapy for four weeks and placebo injection compared with glucocorticoid injection alone or placebo injection alone in terms of overall pain, function, active range of motion and quality of life at six weeks, six months and 12 months (though the 95% CI suggested function may be better with glucocorticoid injection at six weeks). The same two trials found that adding a combination of manual therapy, exercise and electrotherapy for four weeks to glucocorticoid injection did not confer clinically important benefits over glucocorticoid injection alone at each time point. Based on one high quality trial (148 participants), following arthrographic joint distension with glucocorticoid and saline, a combination of manual therapy and supervised exercise for six weeks conferred similar effects to those of sham ultrasound in terms of overall pain, function and quality of life at six weeks and at six months, but provided greater patient-reported treatment success and active shoulder abduction at six weeks. One trial (119 participants) found that a combination of manual therapy, exercise, electrotherapy and oral non-steroidal anti-inflammatory drug (NSAID) for three weeks did not confer clinically important benefits over oral NSAID alone in terms of function and patient-reported treatment success at three weeks.

On the basis of 25 clinically heterogeneous trials, we are uncertain of the effect of manual therapy or exercise when not delivered together, or one type of manual therapy or exercise versus another, as most reported differences between groups were not clinically or statistically significant, and the evidence is mostly of low quality.

#### Authors' conclusions

The best available data show that a combination of manual therapy and exercise may not be as effective as glucocorticoid injection in the short-term. It is unclear whether a combination of manual therapy, exercise and electrotherapy is an effective adjunct to glucocorticoid injection or oral NSAID. Following arthrographic joint distension with glucocorticoid and saline, manual therapy and exercise may confer effects similar to those of sham ultrasound in terms of overall pain, function and quality of life, but may provide greater patient-reported treatment success and active range of motion. High-quality RCTs are needed to establish the benefits and harms of manual therapy and exercise interventions that reflect actual practice, compared with placebo, no intervention and active interventions with evidence of benefit (e.g. glucocorticoid injection).

#### PLAIN LANGUAGE SUMMARY

#### Manual therapy and exercise for frozen shoulder (adhesive capsulitis)

#### Background

Frozen shoulder is a common cause of shoulder pain and stiffness. The pain and stiffness can last up to two to three years before going away, and in the early stages it can be very painful.

Manual therapy comprises movement of the joints and other structures by a healthcare professional (e.g. physiotherapist). Exercise includes any purposeful movement of a joint, muscle contraction or prescribed activity. The aims of both treatments are to relieve pain, increase joint range and improve function.

#### **Study characteristics**

This summary of an updated Cochrane review presents what we know from research about the benefits and harms of manual therapy and exercise in people with frozen shoulder. After searching for all relevant studies published up to May 2013, we included 32 trials (1836 participants). Among the included participants, 54% were women, average age was 55 years and average duration of the condition was six months. The average duration of manual therapy and exercise interventions was four weeks.



## Key results—manual therapy and exercise compared with glucocorticoid (a steroid that reduces inflammation) injection into the shoulder

#### Pain (higher scores mean worse pain)

People who had manual therapy and exercise for six weeks did not improve as much as people who had glucocorticoid injection improvement in pain was 26 points less (ranging from 15 to 37 points less) at seven weeks (26% absolute less improvement).

• People who had manual therapy and exercise rated their change in pain score as 32 points on a scale of 0 to 100 points.

• People who had glucocorticoid injection rated their change in pain score as 58 points on a scale of 0 to 100 points.

#### Function (lower scores mean better function)

People who had manual therapy and exercise for six weeks did not improve as much as people who had glucocorticoid injection improvement in function was 25 points less (ranging from 15 to 35 points less) at seven weeks (25% absolute less improvement).

• People who had manual therapy and exercise rated their change in function as 14 points on a scale of 0 to 100 points.

• People who had glucocorticoid injection rated their change in function as 39 points on a scale of 0 to 100 points.

#### Treatment success

31 fewer people out of 100 rated their treatment as successful with manual therapy and exercise for six weeks compared with glucocorticoid injection—31% absolute less improvement (ranging from 13% to 48% less improvement).

• 46 out of 100 people reported treatment success with manual therapy and exercise.

• 77 out of 100 people reported treatment success with glucocorticoid injection.

#### Side effects

Out of 100 people, three had minor side effects such as temporary pain after treatment with manual therapy and exercise for six weeks compared with glucocorticoid injection.

• 56 out of 100 people reported side effects with manual therapy and exercise.

• 53 out of 100 people reported side effects with glucocorticoid injection.

#### **Quality of the evidence**

Evidence of moderate quality shows that the combination of manual therapy and exercise probably improves pain and function less than glucocorticoid injection up to seven weeks, and probably does not result in more adverse events. Further research may change the estimate.

Low-quality evidence suggests that (1) the combination of manual therapy, exercise and electrotherapy (such as therapeutic ultrasound) may not improve pain or function more than glucocorticoid injection or placebo injection into the shoulder, (2) the combination of manual therapy, exercise, electrotherapy and glucocorticoid injection may not improve pain or function more than glucocorticoid injection alone and (3) the combination of manual therapy, exercise, electrotherapy and real non-steroidal anti-inflammatory drug (NSAID) may not improve function more than oral NSAID alone. Further research is likely to change the estimate.

High-quality evidence shows that following arthrographic joint distension, the combination of manual therapy and exercise does not improve pain or function more than sham ultrasound, but may provide greater patient-reported treatment success and active range of motion. Further research is very unlikely to change our confidence in the estimate of effect.

No trial compared the combination of manual therapy and exercise versus placebo or no intervention.

#### SUMMARY OF FINDINGS

Summary of findings for the main comparison. Combination of manual therapy and exercise compared with glucocorticoid injection for adhesive capsulitis (frozen shoulder)

Combination of manual therapy and exercise compared with glucocorticoid injection for adhesive capsulitis (frozen shoulder)

Patient or population: patients with adhesive capsulitis (frozen shoulder)

Settings: general practices in high-income countries

Intervention: manual therapy plus exercise for six weeks

**Comparison:** glucocorticoid injection

Outcomes	Illustrative compa	rative risks* (95% CI)	Relative effect	No. of partici-	Quality of the	Comments
	Assumed risk	Corresponding risk		(studies)	(GRADE)	
	Glucocorticoid injection	Manual therapy plus exercise				
Participant-reported pain relief ≥ 30%	See comment	See comment	Not estimable	-	See comment	No studies reported this outcome
<b>Overall pain (change from baseline)</b> 0-100 visual analogue scale (lower score = less pain) Follow-up: 7 weeks	Mean overall pain (change from baseline) in the control group was <b>58 points</b>	Mean overall pain (change from base- line) in the interven- tion group was <b>26 points lower</b> (36.8-15.2 lower)		107 (1 study)	⊕⊕⊕⊝ moderate <sup>a</sup>	Absolute risk difference 26% (37% to 15% fewer); relative percentage change 30% (43% to 17% fewer) NNTB 3 (2 to 4)
Function (change from baseline) Shoulder Disabilty Questionnaire 0-100 (lower scores = better function) Follow-up: 7 weeks	Mean function (change from baseline) in the control group was <b>39 points</b>	Mean function (change from baseline) in the intervention group was <b>25 points lower</b> (35.24-14.76 lower)		107 (1 study)	⊕⊕⊕⊙ moderate <sup>a</sup>	Absolute risk difference 25% (35% to 15% fewer); relative percentage change 38% (51% to 22% fewer) NNTB 3 (2 to 4)
Global assessment of	Study population <b>b</b>		<b>RR 0.6</b>	108 (1 study)		Absolute risk difference 30% (48%
Complete recovery or much improvement (self-rated) Follow-up: 7 weeks	769 per 1000	<b>462 per 1000</b> (338-638)	(0.77-0.05)		יייסמנו ארה <sub>מ</sub>	change 40% (56% to 17% fewer).

Cochrane Database of Systematic Reviews

4

Active shoulder abduc- tion	See comment	See comment	Not estimable	-	See comment	No studies reported this outcome
Quality of life	See comment	See comment	Not estimable	-	See comment	No studies reported this outcome
Adverse events	Study population		<b>RR 1.07</b>	$114^{\circ}$	⊕⊕⊕⊝ moderate <i>a</i>	Absolute risk difference 4% (15% few- er to 22% more): relative percentage
	526 per 1000	<b>563 per 1000</b>	- (0.10 1.43)	(I study)	inouerate <sup>o</sup>	change 7% (24% fewer to 49% more)
		(400-784)				NNTH not applicable
						Adverse events recorded included pain after treatment < 1 day or > 2 days, facial flushing, irregular menstrual bleeding, fever and skin irritation

\*The basis for the **assumed risk** (e.g. median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome; RR: risk ratio.

GRADE Working Group grades of evidence.

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

#### <sup>a</sup>Participants were not blinded.

<sup>b</sup>Risk of treatment success in the glucocorticoid injection group of van der Windt 1998 used as the assumed control group risk.

<sup>c</sup>Includes 56 participants in the manual therapy and exercises group, who were treated according to protocol, 1 participant treated with both interventions, 52 participants in the glucocorticoid injection group who were treated according to protocol and 5 participants treated with both interventions.

## Summary of findings 2. Combination of manual therapy, exercise, electrotherapy and placebo injection compared with glucocorticoid injection for adhesive capsulitis (frozen shoulder)

Combination of manual therapy, exercise, electrotherapy and placebo injection compared with glucocorticoid injection for adhesive capsulitis (frozen shoulder)

**Patient or population:** patients with adhesive capsulitis (frozen shoulder) **Settings:** outpatient rheumatology clinic and general practices in high-income countries

**Intervention:** manual therapy plus exercise plus electrotherapy for four weeks plus placebo injection

Comparison: glucocorticoid injection

chrane

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect	No. of partici-	Quality of the	Comments
	Assumed risk	Corresponding risk	- (55% CI)	(studies)	(GRADE)	
	Glucocorticoid in- jection	Manual therapy plus ex- ercise plus electrothera- py plus placebo injection				
Participant-reported pain relief≥30%	See comment	See comment	Not estimable	-	See comment	No studies reported this out- come
<b>Overall pain (change from baseline)</b> Shoulder Pain and Disability Questionnaire (SPADI, 0-100) (lower scores = less pain) <sup>a</sup> Follow-up: mean 6 weeks	Mean overall pain (change from base- line) in the control groups was <b>39.1</b> <sup>b</sup>	Mean overall pain (change from baseline) in the inter- vention groups was <b>3.78 lower</b> (19.26 lower-11.7 higher) <sup>c</sup>		86 (2 studies)	⊕⊕⊝⊝ low <sup>d,e,f</sup>	Absolute risk difference 4% (19% fewer to 12% more); relative percentage change 5% (27% fewer to 17% more). NNTB not applicable SMD 0.21 (-0.65 to 1.07)
Function (change from baseline) Shoulder Pain and Disability Questionnaire (SPADI, 0-100) (lower scores = better func- tion) <sup>g</sup> Follow-up: mean 6 weeks	Mean function (change from base- line) in the control groups was <b>34.2</b> <i>h</i>	Mean function (change from baseline) in the inter- vention groups was <b>8.56 lower</b> (0.56-16.56 lower) <sup><i>i</i></sup>		86 (2 studies)	⊕⊕⊝⊝ <b>low</b> <sup>d</sup> ,j	Absolute risk difference 9% (1% to 16% fewer); relative percentage change 14% (1% to 26% fewer) NNTB 5 (3 to 68) SMD 0.46 (0.03 to 0.89)
Global assessment of treat- ment success	See comment	See comment	Not estimable	-	See comment	No studies reported this out- come
Active shoulder abduction	See comment	See comment	Not estimable	-	See comment	No studies reported this out- come
Quality of life (change from baseline) SF-36 Physical Component Score (0-100) (lower scores = worse quality of life)	Mean quality of life (change from base- line) in the control group was <b>4.4</b>	Mean quality of life (change from baseline) in the intervention group was <b>3.3 lower</b>		49 (1 study)	⊕⊕⊝⊝ low <sup>k,l</sup>	Absolute risk difference 3% (9% fewer to 2% more); relative percentage change 9% (23% fewer to 5% more) NNTB not applicable
Follow-up: 6 weeks		(8.57 lower-1.97 higher)				

Cochrane Database of Systematic Reviews

Cochrane Library

7

Cochrane Database of Systematic Reviews

ochrane

Outcomes	Illustrative compa	rative risks* (95% CI)	Relative effect	No. of partici-	Quality of the	Comments
	Assumed risk	Corresponding risk	(95% CI)	(studies)	(GRADE)	
	Placebo injec- tion	Manual therapy plus ex- ercise plus electrothera- py plus placebo injection				
Participant-reported pain relief≥30%	See comment	See comment	Not estimable	-	See comment	No studies reported this out- come
Overall pain (change from baseline) Shoulder Pain and Disability Questionnaire (SPADI, 0-100) (lower scores = less pain) <sup>a</sup> Follow-up: mean 6 weeks	Mean overall pain (change from baseline) in the control groups was <b>17.3</b> <sup>b</sup>	Mean overall pain (change from baseline) in the inter- vention groups was <b>4.32 higher</b> (3.24 lower-12.06 higher) <sup>c</sup>		86 (2 studies)	⊕⊕⊙© low <sup>d</sup> ,e	Absolute risk difference 4% (3% fewer to 12% more); relative percentage change 6% (5% fewer to 17% more) NNTB not applicable SMD -0.24 (-0.67 to 0.18)
Function (change from baseline) Shoulder Pain and Disability Questionnaire (SPADI, 0-100) (lower scores = better func- tion) <sup>f</sup> Follow-up: mean 6 weeks	Mean function (change from baseline) in the control groups was <b>20.4</b> g	Mean function (change from baseline) in the inter- vention groups was <b>1.67 higher</b> (6.14 lower-9.67 higher) <sup>h</sup>		86 (2 studies)	⊕⊕⊝⊝ low <sup>d,e</sup>	Absolute risk difference 2% (6% fewer to 10% more); relative percentage change 3% (9% fewer to 15% more) NNTB not applicable SMD -0.09 (-0.52 to 0.33)
Global assessment of treat- ment success	See comment	See comment	Not estimable	-	See comment	No studies reported this out- come
Active shoulder abduction	See comment	See comment	Not estimable	-	See comment	No studies reported this out- come
Quality of life (change from baseline) SF-36 Physical Component Score (0-100) (lower scores = worse quality of life) Follow-up: 6 weeks	Mean quality of life (change from baseline) in the control group was <b>2.5</b>	Mean quality of life (change from baseline) in the intervention group was <b>1.4 lower</b> (6.67 lower-3.87 higher)		49 (1 study)	⊕⊕⊝⊝ low <sup>i,j</sup>	Absolute risk difference 1% (7% fewer to 4% more); relative percentage change 4% (18% fewer to 11% more) NNTB not applicable
Adverse events	See comment	See comment	Not estimable	-	See comment	No studies reported this out- come

Cochrane Library

\*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; SMD: standardised mean difference; SPADI: Shoulder Pain an Disability Index.

GRADE Working Group grades of evidence.

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>a</sup>Pain measured using the SPADI in Carette 2003 and daytime rest pain (VAS 0-100) in Ryans 2005. Results analysed using SMDs and back-transformed to 0-100 SPADI scale units. <sup>b</sup>Placebo injection group mean reported in Carette 2003 used as the assumed control group risk.

<sup>c</sup>To convert SMDs in the Carette 2003 and Ryans 2005 meta-analyses of overall pain scores, the pooled baseline SD in Carette 2003 (SD = 18) was multiplied by the SMDs and the 95% CIs to convert values to a 100-point SPADI pain score.

<sup>d</sup>Participants were not blinded in either trial, and risk of attrition bias was high in 1 trial (Ryans 2005).

e95% CIs relatively wide, incorporating (1) a clinically insignificant difference favouring combined intervention, (2) no difference between groups and (3) a clinically insignificant difference favouring placebo injection as possible estimates of effect.

<sup>f</sup>Function measured using the SPADI in Carette 2003 and using the Croft Shoulder Disability Questionnaire in Ryans 2005. Results analysed using SMDs and back-transformed to 0-100 SPADI scale units.

gPlacebo injection group mean reported in Carette 2003 used as the assumed control group risk.

hTo convert SMDs in the Carette 2003 and Ryans 2005 meta-analyses of function scores, the pooled baseline SD in Carette 2003 (SD = 18.6) was multiplied by the SMDs and the 95% CIs to convert values to a 100-point SPADI disability score.

<sup>*i*</sup>Participants not blinded.

*i*95% CIs relatively wide, incorporating (1) a clinically insignificant difference favouring combined intervention, (2) no difference between groups and (3) a clinically insignificant difference favouring placebo injection as possible estimates of effect.

#### Summary of findings 4. Combination of manual therapy, exercise, electrotherapy and glucocorticoid injection compared with glucocorticoid injection for adhesive capsulitis (frozen shoulder)

Combination of manual therapy, exercise, electrotherapy and glucocorticoid injection compared with glucocorticoid injection for adhesive capsulitis (frozen shoulder)

**Patient or population:** patients with adhesive capsulitis (frozen shoulder)

Settings: outpatient rheumatology clinic and general practices in high-income countries

Intervention: manual therapy plus exercise plus electrotherapy for four weeks plus glucocorticoid injection

**Comparison:** glucocorticoid injection

Outcomes	Illustrative compa	arative risks* (95% CI)	Relative effect	No. of partici-	Quality of the	Comments
	Assumed risk	Corresponding risk	(55%) (1)	(studies)	(GRADE)	

Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd Manual therapy and exercise for adhesive capsulitis (frozen shoulder)

(Review

	Glucocorticoid injection	Manual therapy plus exercise plus elec- trotherapy plus gluco- corticoid injection				
Participant-reported pain relief≥30%	See comment	See comment	Not estimable	-	See comment	No studies reported this outcome
<b>Overall pain (change from</b> <b>baseline)</b> Shoulder Pain and Disabil- ity Questionnaire (SPADI, 0-100) (lower scores = less pain) <sup>a</sup> Follow-up: mean 6 weeks	Mean overall pain (change from baseline) in the control groups was <b>39.1</b> <sup>b</sup>	Mean overall pain (change from base- line) in the intervention groups was <b>5.76 lower</b> (13.86 lower-2.34 high- er) <sup>c</sup>		86 (2 studies)	⊕⊕⊝⊝ low <sup>d</sup> ,e	Absolute risk difference 6% (14% fewer to 2% more); relative percentage change 8% (20% fewer to 3% more) NNTB not applicable SMD -0.32 (-0.77 to 0.13)
Function (change from baseline) Shoulder Pain and Disabil- ity Questionnaire (SPADI, 0-100) (lower scores = better function) <sup>f</sup> Follow-up: mean 6 weeks	Mean function (change from baseline) in the control groups was <b>34.2</b> g	Mean function (change from baseline) in the in- tervention groups was <b>6.51 lower</b> (14.88 lower-1.86 high- er) <sup>h</sup>		86 (2 studies)	⊕⊕⊝⊝ <b>low</b> d,e	Absolute risk difference 7% (15% fewer to 2% more); relative percentage change 10% (24% fewer to 3% more) NNTB not applicable SMD -0.35 (-0.80 to 0.10)
Global assessment of treatment success	See comment	See comment	Not estimable	-	See comment	No studies reported this outcome
Active shoulder abduction	See comment	See comment	Not estimable	-	See comment	No studies reported this outcome
Quality of life (change from baseline) SF-36 Physical Component Score (0-100) (lower scores = worse quality of life) Follow-up: 6 weeks	Mean quality of life (change from baseline) in the control group was <b>4.4</b>	Mean quality of life (change from base- line) in the intervention group was <b>2 higher</b> (3.27 lower-7.27 higher)		44 (1 study)	⊕⊕⊝⊝ low <sup>i,j</sup>	Absolute risk difference 2% (3% fewer to 7% more); relative percentage change 5% (9% fewer to 19% more) NNTB not applicable
Adverse events	See comment	See comment	Not estimable	-	See comment	No studies reported this outcome

\*The basis for the **assumed risk** (e.g. median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; SF: Short Form; SMD: standardised mean difference; SPADI: Shoulder Pain and Disability Index.



GRADE Working Group grades of evidence.

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

#### Very low quality: We are very uncertain about the estimate.

<sup>a</sup>Pain measured using the SPADI in Carette 2003 and daytime rest pain (VAS 0-100) in Ryans 2005. Results analysed using SMDs and back-transformed to 0-100 SPADI scale units. <sup>b</sup>Glucocorticoid injection group mean reported in Carette 2003 used as the assumed control group risk.

<sup>c</sup>To convert SMDs in the Carette 2003 and Ryans 2005 meta-analyses of overall pain scores, the pooled baseline SD in Carette 2003 (SD = 18) was multiplied by the SMDs and the 95% CIs to convert values to a 100-point SPADI pain score.

<sup>d</sup>Participants were not blinded in either trial, and risk of attrition bias was high in 1 trial (Ryans 2005).

e95% CIs relatively wide, incorporating (1) a minimal clinically important difference favouring combined intervention, (2) no difference between groups and (3) a clinically insignificant difference favouring glucocorticoid injection alone as possible estimates of effect.

<sup>f</sup>Function measured using the SPADI in Carette 2003 and using the Croft Shoulder Disability Questionnaire in Ryans 2005. Results analysed using SMDs and back-transformed to 0-100 SPADI scale units.

gGlucocorticoid injection group mean reported in Carette 2003 used as the assumed control group risk.

<sup>h</sup>To convert SMDs in the Carette 2003 and Ryans 2005 meta-analyses of function scores, the pooled baseline SD in Carette 2003 (SD = 18.6) was multiplied by the SMDs and the 95% CIs to convert values to a 100-point SPADI disability score.

<sup>i</sup>Participants not blinded.

*j*95% CIs relatively wide, incorporating (1) a clinically insignificant difference favouring combined intervention, (2) no difference between groups and (3) a clinically insignificant difference favouring glucocorticoid injection as possible estimates of effect.

## Summary of findings 5. Combination of manual therapy and exercise following joint distension compared with sham ultrasound following joint distension for adhesive capsulitis (frozen shoulder)

Combination of manual therapy and exercise following joint distension compared with sham ultrasound following joint distension for adhesive capsulitis (frozen shoulder)

Patient or population: patients with adhesive capsulitis (frozen shoulder) Settings: primary care and specialist practice in high-income country Intervention: manual therapy plus exercise for six weeks following joint distension Comparison: sham ultrasound following joint distension

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect	No. of partici- pants	Quality of the	Comments
	Assumed risk	Corresponding risk (95% CI) p	(studies)	(GRADE)		
	Sham ultrasound following joint distension	Manual therapy plus exercise following joint distension				

ochrane

Participant-reported pain relief≥30%	See comment	See comment	Not estimable	-	See comment	No studies reported this outcome
Overall pain (change from baseline) 0-10 visual analogue scale (lower scores = lower pain) Follow-up: 6 weeks	Mean overall pain (change from base- line) in the control group was <b>3.4</b>	Mean overall pain (change from base- line) in the intervention group was <b>0 higher</b> (0.69 lower-0.69 higher)		148 (1 study)	⊕⊕⊕⊕ high	Absolute risk difference 0% (7% fewer to 7% more); relative percentage change 0% (13% fewer to 13% more) NNTB not applicable
Function (change from baseline) SPADI 0-100 (lower scores = better function) Follow-up: 6 weeks	Mean function (change from base- line) in the control group was <b>38.5</b>	Mean function (change from baseline) in the in- tervention group was <b>0.5 lower</b> (7.6 lower-6.6 higher)		148 (1 study)	⊕⊕⊕⊕ high	Absolute risk difference 1% (8% fewer-7% more); relative percentage change 1% (12% fewer to 11% more) NNTB not applicable
Active shoulder ab- duction (change from baseline) Degrees Follow-up: 6 weeks	Mean active range of abduction (change from base- line) in the control group was <b>36</b>	Mean active range of ab- duction (change from baseline) in the inter- vention group was <b>13.1 higher</b> (4.2-22 higher)		148 (1 study)	⊕⊕⊕⊕ high	Absolute risk difference 7% (2% fewer to 12% more); relative percentage change 19% (6% to 33% more). NNTB not calculated because there is no established minimal clinical- ly important difference for this out- come.
Quality of life (change from baseline) SF-36 Physical Compo- nent Score (0-100) (low- er scores = worse quality of life) Follow-up: 6 weeks	Mean quality of life (change from base- line) in the control group was <b>8.3</b>	Mean quality of life (change from base- line) in the intervention group was <b>0.5 lower</b> (4.25 lower-3.25 higher)		148 (1 study)	⊕⊕⊕⊕ high	Absolute risk difference 1% (4% fewer to 3% more); relative percentage change 2% (14% fewer to 11% more) NNTB not applicable
Global assessment of treatment success "Success, much im- proved, and/or com- pletely recovered" (self- rated) Follow-up: 6 weeks	Study population <i>a</i> 562 per 1000	<b>747 per 1000</b> (584-949)	<b>RR 1.33</b> (1.04-1.69)	148 (1 study)	⊕⊕⊕⊕ high	Absolute risk difference 19% (3% to 34% more); relative percentage change 33% (4% to 69% more) NNTB = 6 (3 to 45)

Cochrane Database of Systematic Reviews

Cochrane Library

dverse events Stud	Study population		<b>RR 0.99</b>	149 (1 study)	⊕⊕⊕⊕ high	Absolute risk difference 0% (5%
27 pe	r 1000 27 p (4-1)	<b>er 1000</b> 84)	0.14-0.82)	(I study)	nign	relative percentage change 1% (86% fewer to 582% more)
						NNTH not applicable
<sup>t</sup> The basis for the <b>assumed risk</b> ( on the assumed risk in the compa <b>Cl:</b> confidence interval; <b>NNTB:</b> nu tio	e.g. median control gr rison group and the <b>r</b> mber needed to treat	oup risk across studies) i elative effect of the inte for an additional benefic	s provided in footr rvention (and its 9: ial outcome; <b>NNTI</b>	notes. The <b>corres</b> 5% Cl). <b>H:</b> number neede	<b>ponding risk</b> (and it d to treat for an add	s 95% confidence interval) is based itional harmful outcome; <b>RR:</b> risk ra-
GRADE Working Group grades of o High quality: Further research is Moderate quality: Further resea Low quality: Further research is Very low quality: We are very un	vidence very unlikely to chang ch is likely to have an very likely to have an i certain about the estin	e our confidence in the e important impact on ou mportant impact on our nate.	estimate of effect. r confidence in the confidence in the e	estimate of effec estimate of effect	t and may change th and is likely to chan	ne estimate. Ige the estimate.
Pick of treatment success in the sl	am ultracound group	of Duchbinder 2007 user	has the assumed c	ontrol group risk.		
Also of treatment success in the si	iani uttrasound group	of Buchbinder 2007 used				
isk of treatment success in the si	am utrasound group	of Buchbinder 2007 used				
ummary of findings 6. Com	pination of manual	therapy, exercise, ele	ectrotherapy an	d oral NSAID co	mpared with ora	l NSAID for adhesive capsulitis
ummary of findings 6. Com rozen shoulder)	bination of manual	therapy, exercise, ele	ectrotherapy an	d oral NSAID co	mpared with ora	l NSAID for adhesive capsulitis
ummary of findings 6. Com rozen shoulder) Combination of manual therapy	pination of manual	therapy, exercise, ele	ectrotherapy an ared with NSAID fo	d oral NSAID co or adhesive caps	mpared with ora ulitis (frozen shoul	l NSAID for adhesive capsulitis der)
ummary of findings 6. Com frozen shoulder) Combination of manual therapy Patient or population: patients Settings: orthopaedic and rehab Intervention: manual therapy pl Comparison: oral NSAID	<b>pination of manual</b> <b>r, exercise, electroth</b> vith adhesive capsulit litation clinic in low- t us exercise plus electr	therapy, exercise, ele erapy and NSAID compa is (frozen shoulder) to middle-income countr otherapy plus oral NSAID	ectrotherapy an ared with NSAID fo	d oral NSAID co	mpared with ora ulitis (frozen shoul	l NSAID for adhesive capsulitis der)
ummary of findings 6. Com frozen shoulder) Combination of manual therapy Patient or population: patients Settings: orthopaedic and rehab Intervention: manual therapy pl Comparison: oral NSAID Outcomes	pination of manual r, exercise, electroth vith adhesive capsulit litation clinic in low- t us exercise plus electr Illustrative com CI)	therapy, exercise, ele erapy and NSAID compa is (frozen shoulder) to middle-income countr otherapy plus oral NSAID	ectrotherapy an ared with NSAID fo jes Relative effect (95% CI)	d oral NSAID co or adhesive caps No. of partici pants (studies)	ulitis (frozen shoul Quality of the evidence	l NSAID for adhesive capsulitis der)
ummary of findings 6. Com frozen shoulder) Combination of manual therapy Patient or population: patients Settings: orthopaedic and rehab Intervention: manual therapy pl Comparison: oral NSAID Outcomes	pination of manual r, exercise, electroth vith adhesive capsulit litation clinic in low- t us exercise plus electr Illustrative com CI) Assumed risk	therapy, exercise, eld erapy and NSAID compa is (frozen shoulder) to middle-income countr otherapy plus oral NSAID parative risks* (95% Corresponding risk	ectrotherapy an ared with NSAID fo jes Relative effect (95% CI)	d oral NSAID co or adhesive caps No. of partici pants (studies)	ulitis (frozen shoul - Quality of the evidence (GRADE)	l NSAID for adhesive capsulitis der)
ummary of findings 6. Com frozen shoulder) Combination of manual therapy Patient or population: patients Settings: orthopaedic and rehab Intervention: manual therapy pl Comparison: oral NSAID Outcomes	pination of manual r, exercise, electroth vith adhesive capsulit litation clinic in low- t us exercise plus electr Illustrative com CI) Assumed risk Oral NSAID	therapy, exercise, eld erapy and NSAID compa is (frozen shoulder) to middle-income countr otherapy plus oral NSAID parative risks* (95% Corresponding risk Manual therapy plus exercise plus electrotherapy plus oral NSAID	ectrotherapy an ared with NSAID fo jes Relative effect (95% CI)	d oral NSAID co or adhesive caps No. of partici pants (studies)	ulitis (frozen shoul - Quality of the evidence (GRADE)	der) Comments

Overall pain	See comment	See comment	Not estimable	-	See comment	No studies reported this out- come
<b>Function (change from baseline)</b> Shoulder Pain and Disability Ques- tionnaire (SPADI, 0-100) (lower scores = better function) Follow-up: 3 weeks	Mean function (change from baseline) in the control group was	Mean function (change from base- line) in the interven- tion group was <b>8.6 higher</b>		119 (1 study)	⊕⊕⊙⊝ low <sup>a,b</sup>	Absolute risk difference 9% (3% to 14% more); relative percentage change 17% (6% to 28% more)
	11.9	(3.28-13.92 higher)				
Global assessment of treatment success	Study populatio	n	<b>RR 1.45</b> (0.99-2.12)	109 (1 studv)	⊕⊕⊝⊝ Iow a	Absolute risk difference 19% (1% to 38% more):
"Disappearance of shoulder com- plaints or some pain/limitation	423 per 1000	<b>613 per 1000</b> (419-897)	(,	()		relative percentage change 45% (1% fewer to 112% more)
which does not interfere with everyday life" Follow-up: 6 weeks						NNTH not applicable
Active shoulder abduction	See comment	See comment	Not estimable	-	See comment	No studies reported this out- come
Quality of life	See comment	See comment	Not estimable	-	See comment	No studies reported this out- come
Adverse events	Study populatio	n	RR 8.85	119	000	Absolute risk difference 7% (1%
Pain persisting longer than 2 hours after treatment (during the 3-week treatment period) Follow-up: 3 weeks	0 per 1000	<b>0 per 1000</b> (0-0)	- (0.49-160.87)	(1 study)	low <sup>a,c</sup>	fewer to 14% more); relative percentage change 785% (51% fewer to 15987% more)
						NNTH not applicable
*The basis for the <b>assumed risk</b> (e.g. based on the assumed risk in the cor <b>CI:</b> confidence interval; <b>NNTB:</b> numb non-steroidal anti-inflammatory dru GRADE Working Group grades of evic	the median contro nparison group and per needed to treat g; <b>RR:</b> risk ratio; <b>SP</b> lence.	I group risk across studie I the <b>relative effect</b> of th for an additional benefici <b>ADI:</b> Shoulder Pain and D	es) is provided in fo e intervention (and al outcome; <b>NNTH</b> visability Index.	otnotes. The <b>corr</b> d its 95% CI). <b>:</b> number needed	responding risk (and to treat for an addition	its 95% confidence interval) is onal harmful outcome; <b>NSAID:</b>
GRADE Working Group grades of evic High quality: Further research is ver	lence. y unlikely to chang	e our confidence in the e	stimate of effect.			

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

<sup>*a*</sup>Participants were not blinded.

Cochrane Library

<sup>b</sup>95% CI relatively wide, incorporating both a clinically insignificant difference and a minimal clinically important difference favouring the combined intervention group. <sup>c</sup>95% CI very wide.





#### BACKGROUND

#### **Description of the condition**

This review is one of a series of reviews seeking to gather evidence for benefits and harms of common interventions for shoulder pain. This series of reviews forms the update of an earlier Cochrane review of physical therapy for shoulder disorders (Green 2003). Since the time of our original review, many new clinical trials studying a diverse range of interventions have been performed. To improve usability of this series, we have subdivided the reviews by type of shoulder disorder, as patients within different diagnostic groupings may respond differently to interventions. This review focuses on manual therapies and exercise alone or in combination for adhesive capsulitis (frozen shoulder). Separate reviews of (1) electrotherapy modalities for adhesive capsulitis, (2) manual therapy, exercise and taping for rotator cuff disorders and (3) electrotherapy modalities for rotator cuff disorders are currently under way.

Adhesive capsulitis (also termed frozen shoulder, painful stiff shoulder or periarthritis) is a common condition characterised by spontaneous onset of pain, progressive restriction of movement of the shoulder and disability that restricts activities of daily living, work and leisure (Codman 1934; Neviaser 1945; Reeves 1975). Lack of specific diagnostic criteria for the condition has been acknowledged. Reviews of the diagnostic criteria used in clinical trials of adhesive capsulitis have found that all trialists reported that restricted movement must be present, but the amount of restriction, whether the restriction had to be active or passive or both and the direction of restriction were inconsistently defined (Green 1998; Schellingerhout 2008). The cumulative incidence of adhesive capsulitis has been reported as 2.4 per 1000 people per year (95% confidence interval (CI) 1.9 to 2.9) based on presentations to Dutch general practice (van der Windt 1995). Adhesive capsulitis has been reported to affect slightly more women than men (Tekavec 2012; Walker 2004). Most studies indicate that it is a self-limiting condition lasting up to two to three years (Reeves 1975), although some people may have residual clinically detectable restriction of movement and disability beyond this time point (Binder 1984; Hazelman 1972). The largest case series (269 shoulders in 223 patients) found that at a mean followup of 4.4 years (range two to 20 years), 41% had ongoing symptoms (Hand 2008).

#### **Description of the intervention**

Manual therapy and exercise, usually delivered together as components of a physical therapy intervention, are commonly used interventions for adhesive capsulitis (Hanchard 2011a). Manual therapy includes any clinician-applied movement of the joints and other structures, for example, mobilisation (of which several types exist, e.g. Kaltenborn 1976; Maitland 1977) or manipulation. Exercise includes any purposeful movement of a joint, muscle contraction or prescribed activity. It may be performed under the supervision of a clinician or unsupervised at home. Examples include range of motion, stretching, strengthening, pendulum, pulley, "shoulder wheel" and "wall climbing" exercises. Manual therapy and exercises are delivered by various clinicians, including physiotherapists, physical therapists, chiropractors and osteopaths. The aims of both types of interventions are to relieve pain, promote healing, reduce muscle spasms, increase joint range, strengthen weakened muscles and improve biomechanics and function (Hanchard 2011b). In practice, patients with adhesive capsulitis seldom receive a single intervention in isolation (i.e. manual therapy or exercise alone). In addition, electrotherapy modalities (e.g. therapeutic ultrasound, laser therapy) may be delivered along with manual therapy and exercise as part of a physical therapy intervention (Hanchard 2011a).

#### How the intervention might work

Although previous systematic reviews have found limited evidence for the benefit of manual therapy and exercise when used in isolation to treat adhesive capsulitis (Green 1998; Green 2003), these interventions are hypothesised to produce a number of beneficial physiological and biomechanical effects. Restricted movement of the shoulder for an extended period of time can result in loss of strength, proprioception and coordination of the shoulder complex (Ballantyne 1993), along with contraction of muscles, tendons and ligaments around the shoulder (Mao 1997). Mobilisation is employed to reduce pain by stimulating peripheral mechanoreceptors and inhibiting nociceptors, and to increase joint mobility by enhancing exchange between synovial fluid and cartilage matrix (Frank 1984; Mangus 2002; Vermeulen 2006). Exercises aim to improve range of motion and muscle function by restoring shoulder mobility, proprioception and stability (Nicholson 1985).

#### Why it is important to do this review

The previous version of this review (Green 2003), which included four trials investigating the benefits and harms of manual therapy or exercise (or both) for adhesive capsulitis (Bulgen 1984; Dacre 1989; Nicholson 1985; van der Windt 1998), concluded that little evidence was available to support or refute the benefits or harms of these interventions for adhesive capsulitis. Other recently published systematic reviews of interventions for adhesive capsulitis (Blanchard 2010; Favejee 2011; Hanchard 2011b; Maund 2012) have identified several new trials. Therefore, this review of manual therapy and exercise for adhesive capsulitis needs to be updated.

#### OBJECTIVES

To synthesise available evidence regarding the benefits and harms of manual therapy and exercise, alone or in combination, for the treatment of patients with adhesive capsulitis.

#### METHODS

#### Criteria for considering studies for this review

#### **Types of studies**

We included randomised controlled trials (RCTs) of any design (e.g. parallel, cross-over, factorial) and controlled clinical trials using a quasi-randomised method of allocation, such as by alternation or date of birth. Reports of trials were eligible regardless of the language or date of publication.

#### **Types of participants**

We included trials that enrolled adults (> 16 years of age) with adhesive capsulitis (as defined by trialists) for any duration. We included trials consisting of participants with various soft tissue disorders only if the results for participants with adhesive capsulitis were presented separately, or if 90% or more of participants



in the trial had adhesive capsulitis. We excluded trials that enrolled participants with a history of significant trauma or systemic inflammatory conditions such as rheumatoid arthritis, osteoarthritis, hemiplegic shoulder and pain in the shoulder region as part of a complex myofascial neck/shoulder/arm pain condition.

#### **Types of interventions**

We included trials comparing any manual therapy or exercise intervention versus no treatment, placebo, a different type of manual therapy or exercise or any other intervention. Eligible interventions included mobilisation, manipulation and supervised or home exercise. Exercises could be land-based or water-based but had to consist of tailored shoulder exercises rather than just general activity (e.g. swimming). Trials primarily evaluating the effects of electrotherapy modalities such as therapeutic ultrasound, low-level laser therapy, transcutaneous electrical nerve stimulation (TENS), pulsed electromagnetic field therapy, interferential current, phonophoresis, iontophoresis or continuous short-wave diathermy were excluded and are included in a separate Cochrane review.

#### Types of outcome measures

We did not consider outcomes as part of the eligibility criteria.

Considerable variation has been noted in the outcome measures reported in clinical trials of interventions for pain. However, it is generally agreed that outcome measures of greatest importance to patients should be considered.

The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) has published consensus recommendations for determining clinically important changes in outcome measures in clinical trials of interventions for chronic pain (Dworkin 2008). Reductions in pain intensity of  $\geq$  30% and  $\geq$  50% reflect moderate and substantial clinically important differences, respectively, and it is recommended that the proportion of participants who respond with these degrees of pain relief should be reported.

Continuous outcome measures in pain trials (such as mean change on a 100-mm visual analogue scale (VAS)) may not follow a Gaussian distribution. Often, a bimodal distribution is seen instead, in which participants tend to report very good or very poor pain relief (Moore 2010). This creates difficulty in interpreting the meaning of average changes in continuous pain measures. For this reason, a dichotomous outcome measure (the proportion of participants reporting  $\geq$  30% pain relief) may be clinically relevant for trials of adhesive capsulitis.

The original review determined that no trials had included a dichotomous outcome for pain, in keeping with the recognition that it has been the practice in most trials of interventions for chronic pain to report continuous measures only. We therefore also included a continuous measure of overall pain.

A global rating of treatment success, such as the Patient Global Impression of Change scale (PGIC), which provides an outcome measure that integrates pain relief, changes in function and adverse events into a single, interpretable measure, is also recommended by IMMPACT and was included as a main outcome measure (Dworkin 2008).

#### Main outcomes

- Participant-reported pain relief of 30% or greater (a moderate clinically important difference).
- Overall pain (mean or mean change measured by VAS, numerical or categorical rating scale).
- Function. When trialists reported outcome data for more than one function scale, we extracted data on the scale that was highest on the following a priori defined list: (1) Shoulder Pain and Disability Index (SPADI); (2) Croft Shoulder Disability Questionnaire; (3) Constant Score; (4) Short Form (SF)-36 Physical Component Score; (5) Health Assessment Questionnaire; and (6) any other function scale.
- Global assessment of treatment success as defined by trialists (e.g. proportion of participants with significant overall improvement).
- Active shoulder abduction (measured in degrees or other).
- Quality of life as measured by generic measures (such as components of the SF-36 or disease-specific tools).
- Number of participants experiencing any adverse events.

#### Other outcomes

- Night pain measured by VAS, numerical or categorical rating scale.
- Pain on motion measured by VAS, numerical or categorical rating scale.
- Other measures of range of motion (ROM) (flexion, external rotation and internal rotation (measured in degrees or other, e.g. hand-behind-back distance in centimetres)). When trialists reported outcome data for both active and passive ROM measures, we extracted the data on active ROM only.
- Work disability.
- Requiring surgery (e.g. manipulation under anaesthesia, arthroscopy).

We extracted benefit outcome measures (e.g. overall pain or function) at the following time points.

- Up to three weeks.
- Longer than three weeks and up to six weeks (this was the main time point).
- Longer than six weeks and up to six months.
- Longer than six months.

If data were available in a trial at multiple time points within each of the above periods (e.g. at four, five and six weeks), we extracted only data at the latest possible time point of each period. We extracted adverse events reported at all time points.

We collated the main results of the review into summary of findings (SoF) tables, which provide key information on the quality of evidence and the magnitude and precision of the effects of interventions. We included the main outcomes (see above) in the SoF tables, with results at, or nearest, the main time point (six weeks) presented.

#### Search methods for identification of studies

#### Electronic searches

We searched the Central Register of Controlled Trials (CENTRAL) (to 2013, Issue 4), MEDLINE (January 1966 to May 2013), EMBASE (January 1980 to May 2013) and Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus (January 1937 to May 2013). The complete search strategies are presented in Appendix 1. Note that the search terms used included clinical terms relevant to rotator cuff disorders and electrotherapy interventions, as the current review and Cochrane reviews of (1) electrotherapy modalities for adhesive capsulitis, (2) manual therapy and exercise for rotator cuff disorders and (3) electrotherapy modalities for rotator cuff disorders were conducted simultaneously.

In May 2014, we reran the search of all four electronic bibliographic databases and screened the results for potentially eligible records, but we did not incorporate any studies identified in the updated search.

#### Searching other resources

We searched for ongoing trials and protocols of published trials in the clinical trials register that is maintained by the US National Institutes of Health (http://clinicaltrials.gov) and the Clinical Trial Register at the International Clinical Trials Registry Platform of the World Health Organization (http://www.who.int/ictrp/en/). We also reviewed the reference lists of included trials and of relevant review articles retrieved from the electronic searches to identify other potentially relevant trials.

#### Data collection and analysis

#### **Selection of studies**

Two review authors (MJP and BM) independently selected trials for possible inclusion against a predetermined checklist of inclusion criteria (see Criteria for considering studies for this review). We screened titles and abstracts and initially categorised studies into the following groups.

- Possibly relevant—trials that met the inclusion criteria and trials from which it was not possible to determine from their title or abstract whether they met the criteria.
- Excluded—trials clearly not meeting the inclusion criteria.

If a title or abstract suggested that the trial was eligible for inclusion, or if we could not tell, we obtained a full-text version of the article, and two review authors (MJP and BM) performed an independent assessment to determine whether it met the inclusion criteria. The review authors resolved discrepancies through discussion or through adjudication by a third review author (SG or RB).

#### Data extraction and management

Two review authors (MJP and SK, RJ or MC) independently extracted data using a standard data extraction form developed for this review. The review authors resolved discrepancies through discussion or adjudication by a third review author (SG or RB) until consensus was reached. We pilot-tested the data extraction form and modified it as needed before use. In addition to items for assessing risk of bias and numerical outcome data, we recorded the following characteristics.

- Participant characteristics, including age, sex, duration of symptoms and inclusion/exclusion criteria.
- Intervention characteristics, including type of manual therapy or exercise, duration of treatment and use of co-interventions.
- Outcomes reported, including the measurement instrument used and timing of outcome assessment.

One review author (MJP) compiled all comparisons and entered outcome data into Review Manager 5.2.

For a particular systematic review outcome, a multiplicity of results may be available in the trial reports (e.g. multiple scales, time points, analyses). To prevent selective inclusion of data based on the results (Page 2013), we used the following a priori defined decision rules to select data from trials.

- When trialists reported both final values and change from baseline values for the same outcome, we extracted final values.
- When trialists reported both unadjusted and adjusted values for the same outcome, we extracted unadjusted values.
- When trialists reported data analysed on the basis of the intention-to-treat (ITT) sample and another sample (e.g. per-protocol, as-treated), we extracted ITT-analysed data.
- For cross-over RCTs, we extracted data from the first period only.

When trials did not include a measure of overall pain but included one or more other measures of pain, for the purpose of combining data for the primary analysis of overall pain, we combined overall pain with other types of pain in the following hierarchy: unspecified pain; pain with activity; daytime pain.

#### Assessment of risk of bias in included studies

Two review authors (MJP and SK, RJ or MC) independently assessed the risk of bias in included trials using the tool of The Cochrane Collaboration for assessing risk of bias, as described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011a). The following domains were assessed.

- Random sequence generation.
- Allocation concealment.
- Blinding of participants and personnel.
- Blinding of outcome assessment (assessed separately for selfreported and objectively assessed outcomes).
- Incomplete outcome data.
- Selective reporting.
- Other sources of bias (specifically, baseline imbalance).

Each item was rated as at 'Low risk,' 'Unclear risk' or 'High risk' of bias. We resolved discrepancies through discussion or adjudication by a third review author (SG or RB).

#### **Measures of treatment effect**

We used the statistical software of The Cochrane Collaboration, Review Manager 5.2, to perform data analysis. We expressed dichotomous outcomes as risk ratios (RRs) with 95% confidence intervals (CIs) and continuous outcomes as mean differences (MDs) with 95% CIs if different trials used the same measurement

instrument to measure the same outcome. Alternatively, we analysed continuous outcomes using the standardised mean difference (SMD) when trials measured the same outcome but employed different measurement instruments. To enhance interpretability of dichotomous outcomes, risk differences and number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) were calculated. To enhance interpretability of continuous outcomes, pooled SMDs for overall pain and function were back-transformed to an original SPADI (0 to 100) pain or disability score by multiplying SMDs and 95% CIs by a representative pooled standard deviation (SD) at baseline for one of the included trials.

#### Unit of analysis issues

The unit of analysis was the participant. Two trials included a small number of participants with bilateral adhesive capsulitis. For these trials, we analysed data based on the number of participants, not the number of shoulders, to produce conservative estimates of effect.

#### Dealing with missing data

When required, we contacted trialists via email (twice, separated by three weeks) to retrieve missing information about trial design, outcome data or attrition rates, such as dropouts, losses to followup and postrandomisation exclusions in the included trials. For continuous outcomes with no SD reported, we calculated SDs from standard errors (SEs), 95% CIs or P values. If no measures of variation were reported and SDs could not be calculated, we planned to impute SDs from other trials in the same meta-analysis, using the median of other available SDs (Ebrahim 2013). When data were imputed or calculated (e.g. SDs calculated from SEs, 95% CIs or P values, or imputed from graphs or from SDs in other trials), we reported this in the Characteristics of included studies tables.

#### Assessment of heterogeneity

We assessed clinical heterogeneity by determining whether characteristics of participants, interventions, outcome measures and timing of outcome measurement were similar across trials. We assessed statistical heterogeneity using the Chi<sup>2</sup> statistic and the I<sup>2</sup> statistic (Higgins 2002). We interpreted the I<sup>2</sup> statistic by using the following as an approximate guide.

- 0% to 40% may not be important heterogeneity.
- 30% to 60% may represent moderate heterogeneity.
- 50% to 90% may represent substantial heterogeneity.
- 75% to 100% may represent considerable heterogeneity (Deeks 2011).

#### Assessment of reporting biases

To assess publication bias, we planned to generate funnel plots if at least 10 trials examining the same intervention comparison were included in the review and to comment on whether asymmetry in the funnel plot was due to publication bias or to methodological or clinical heterogeneity of the trials (Sterne 2011). To assess outcome reporting bias, we compared outcomes specified in trial protocols versus outcomes reported in corresponding trial publications; if trial protocols were unavailable, we compared outcomes reported in the methods and results sections of trial publications (Dwan 2011; Norris 2012). We generated an outcome reporting bias in trials (ORBIT) matrix (http://ctrc.liv.ac.uk/orbit/) using the ORBIT classification system (Kirkham 2010).

#### Data synthesis

For this review update, a large number of identified trials studied a diverse range of interventions. To define the most clinically important questions to be answered in the review, after data extraction was completed, one review author (MJP) sent the list of all possible trial comparisons to both of the original primary authors of this review (SG and RB). After reviewing the list of possible trial comparisons, both of these review authors discussed and drafted a list of clinically important review questions and categorised each trial comparison under the review question with which it fit best. This process was conducted iteratively until all trial comparisons were allocated to a single review question, and it was conducted without knowledge of the results of any outcomes. The following review questions were defined.

- 1. Is the combination of manual therapy and exercise (with or without electrotherapy) effective compared with placebo, no intervention or another active intervention (e.g. glucocorticoid injection, oral non-steroidal anti-inflammatory drug (NSAID), arthrographic joint distension)?
- 2. Is the combination of manual therapy and exercise (with or without electrotherapy) delivered in addition to another active intervention more effective than the other active intervention alone?
- 3. Is manual therapy (with or without electrotherapy) effective compared with placebo, no intervention or another active intervention?
- 4. Are supervised or home exercises (with or without electrotherapy) effective compared with placebo, no intervention or another active intervention?
- 5. Is one type of manual therapy or exercise (with or without electrotherapy) more effective than another (i.e. one type of manual therapy vs another type of manual therapy or one type of exercise vs another type of exercise)?
- 6. Is the combination of manual therapy and exercise (with or without electrotherapy) delivered in addition to another active intervention more effective than placebo or no treatment?

The first two of these were considered the main questions of the review, as these combination interventions are best reflective of clinical practice.

We combined results of trials with similar characteristics (participants, interventions, outcome measures and timing of outcome measurement) to provide estimates of benefits and harms. When we could not combine data, we summarised effect estimates and 95% CIs of each trial narratively. We combined results using a random-effects meta-analysis model based on the assumption that clinical and methodological heterogeneity was likely to exist and to have an impact on the results.

#### Subgroup analysis and investigation of heterogeneity

We did not undertake any subgroup analyses.

#### Sensitivity analysis

We planned to perform a sensitivity analysis to investigate the robustness of the treatment effect (of main outcomes) to allocation

concealment and participant blinding, by removing trials that reported inadequate or unclear allocation concealment and lack of participant blinding from the meta-analysis, to see if this changed the overall treatment effect.

#### Summary of findings tables

We presented the results of the most important comparisons of the review in Summary of findings tables, which summarise the quality of evidence, the magnitude of effect of the interventions examined and the sum of available data on outcomes, as recommended by The Cochrane Collaboration (Schünemann 2011a). The Summary of findings tables include an overall grading of the evidence related to each of the main outcomes, using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) approach (Schünemann 2011b).

In the Comments column of the Summary of findings table, we report the absolute per cent difference, the relative per cent change from baseline and the number needed to treat for an additional beneficial outcome (NNTB) (the NNTB is provided only when the outcome shows a statistically significant difference).

For dichotomous outcomes (pain relief  $\geq$  30%, global assessment, adverse events), the absolute risk difference was calculated using the risk difference statistic in RevMan, and the result expressed as a percentage; the relative per cent change was calculated as the risk ratio -1 and was expressed as a percentage. For continuous outcomes (overall pain, function, active shoulder abduction, quality of life), the absolute risk difference was calculated as the improvement in the intervention group minus the improvement in the control group, expressed in the original units (i.e. mean difference from RevMan divided by units in the original scale), expressed as a percentage. The relative per cent change is calculated as the absolute change (or mean difference) divided by the baseline mean of the control group, expressed as a percentage.

In addition to the absolute and relative magnitude of effect provided in the SoF table, for dichotomous outcomes the NNTB

or the number needed to treat for an additional harmful effect (NNTH) was calculated from the control group event rate and the risk ratio using the Visual Rx NNT calculator (Cates 2004). For continuous outcomes of overall pain and function, the NNTB was calculated using Wells calculator software, which is available at the Cochrane Musculoskeletal Group (CMSG) editorial office (http:// musculoskeletal.cochrane.org). We assumed a minimal clinically important difference (MCID) of 1.5 points on a 10-point scale for pain, and of 10 points on a 100-point scale for function or disability, for input into the calculator.

#### RESULTS

#### **Description of studies**

#### **Results of the search**

The search, which was conducted up to May 2013, yielded 3173 records across the four databases. Three additional records were identified by screening reference lists of previously published systematic reviews and included trials. After duplicates were removed, 2118 unique records remained. Of these, 290 were retrieved for full-text screening on the basis of title and abstract. Thirty-two trials were deemed eligible for inclusion (Buchbinder 2007; Bulgen 1984; Carette 2003; Celik 2010; Chan 2010; Chauhan 2011; Cheing 2008; Dacre 1989; Dundar 2009; Ghosh 2012; Guler-Uysal 2004; Harsimran 2011; Johnson 2007; Ma 2006; Maricar 1999; Maryam 2012; Nellutla 2009; Nicholson 1985; Pajareya 2004; Rainbow 2008; Ryans 2005; Samnani 2004; Sharad 2011; Shrivastava 2011; Sirajuddin 2010; Tanaka 2010; van der Windt 1998; Vermeulen 2006; Wen 2009; Yan 2005; Yang 2007; Yang 2012). Two additional trials are available only as conference abstracts (Uddin 2012; Wies 2003); one is written in German and requires translation (Fink 2012). These three trials are awaiting classification (see Characteristics of studies awaiting classification table). Three ongoing trials were identified in clinical trials registries (see Characteristics of ongoing studies table). A flow diagram of the study selection process is presented in Figure 1.



#### Figure 1. Study flow diagram.





#### Figure 1. (Continued)

in quantitati∨e synthesis (meta-analysis)

The updated search in May 2014 yielded three studies deemed eligible for inclusion (Doner 2013; Ibrahim 2013; Russell 2014). These studies did not address the two main questions of the review (which focus on the effects of the combination of manual therapy and exercise) so were not incorporated into the review, but they are listed in the Characteristics of studies awaiting classification table. We will include these studies in a future update of the review.

#### **Included studies**

A full description of all included trials is provided in the Characteristics of included studies table. We contacted authors of 26 trials to retrieve (1) information about study design, participants, interventions and outcomes of the trial, (2) information required to complete the risk of bias assessments or (3) missing data for unreported or partially reported outcomes. We received replies from seven trialists (Carette 2003; Chan 2010; Maryam 2012; Pajareya 2004; Ryans 2005 Yang 2007; Yang 2012).

#### Design

All trials except two were described as RCTs (Nicholson 1985 and Rainbow 2008 used a quasi-random method of allocation). All trials except one used a parallel-group design (Yang 2007 used a multiple-treatment trial design, which involves the application of two or more treatments for a single participant and was used to assess differences among three interventions in two groups of participants). Twenty-one trials included two intervention arms (Buchbinder 2007; Celik 2010; Chan 2010; Chauhan 2011; Dundar 2009; Guler-Uysal 2004; Harsimran 2011; Johnson 2007; Maricar 1999; Nellutla 2009; Nicholson 1985; Pajareya 2004; Rainbow 2008; Samnani 2004; Sharad 2011; Shrivastava 2011; van der Windt 1998; Vermeulen 2006; Wen 2009; Yan 2005; Yang 2012), eight included three arms (Cheing 2008; Dacre 1989; Ghosh 2012; Ma 2006; Maryam 2012; Sirajuddin 2010; Tanaka 2010; Yang 2007) and three included four arms (Bulgen 1984; Carette 2003; Ryans 2005).

#### Participants

A total of 1836 participants were included in the 32 trials, and the number of participants per trial ranged from eight to 156. The median of the mean age of participants was 55 years, and the median of the mean duration of symptoms was six months. Fifty-four per cent of participants were female. Diagnostic criteria for (or definitions of) adhesive capsulitis varied with regards to type, amount and direction of shoulder restriction, ranging from undefined (e.g. Samnani 2004) to very specific (e.g.  $\geq$  50% loss of passive movement of the shoulder joint relative to the non-affected side, in one or more of three movement directions (i.e. abduction in the frontal plane, forward flexion or external rotation in 0° of abduction)) (Vermeulen 2006). Trials were conducted in India (N = 8); UK (N = 4); Turkey, USA and Taiwan (N = 3 each); China and The Netherlands (N = 2); and Australia, Canada, Hong Kong, Iran, Japan, Singapore and Thailand (N = 1 each).

#### Interventions

A detailed description of the interventions delivered in each trial is summarised in the Characteristics of included studies table. A summary of the manual therapy or exercise intervention components tested in each trial is presented in Table 1. The types of manual therapy and exercise delivered were very heterogeneous across trials; Maitland's mobilisation techniques were the most common type of manual therapy, and Codman's pendulum exercises, active and passive ROM exercises, pulley exercises and shoulder wheel exercises were the most common types of exercise. The median duration of manual therapy or exercise interventions was four weeks (range one to 18), with a median of three treatment sessions delivered per week (range one to seven) and a median of 12 treatment sessions provided in total across the treatment period (range five to 84).

#### Outcomes

An ORBIT matrix that presents outcomes measured and level of reporting for each outcome in each trial (rated as fully reported, partially reported, measured but not reported, unclear if measured or not measured) is presented in Table 2. Of the main outcomes, no trial measured "participant-reported pain relief of 30% or greater." Twenty-three trials measured overall pain (mean or mean change), 20 measured function, seven measured global assessment of treatment success, 10 measured active shoulder abduction, six measured quality of life and seven measured adverse events. Overall pain was most commonly measured using a zero to 10 or zero to 100 VAS. Function was most commonly measured using the SPADI, followed by the Constant Score and the Croft Shoulder Disability Questionnaire. Of the other outcomes, 28 trials measured other measures of ROM, eight measured night pain and seven measured pain on motion. No trials reported measuring work disability or requiring surgery. Partial reporting of outcomes occurred in 15 trials. We contacted authors of all 15 trials to retrieve missing outcome data, and we obtained data from two (Yang 2007; Yang 2012).

#### **Excluded studies**

Of 290 full-text articles retrieved for further scrutiny, most (n = 237) were excluded because they were studies or commentaries focused on shoulder pain due to conditions other than adhesive capsulitis (e.g. rotator cuff disorders). We have listed 18 adhesive capsulitis studies in the Characteristics of excluded studies table. Reasons for their exclusion were that the same manual therapy or exercise intervention was provided to all groups (n = 14), the study was not an RCT or a quasi-RCT (n = 2) or the intervention was ineligible (n = 2).

#### **Risk of bias in included studies**

A summary of the risk of bias in included trials is presented in Figure 2 and Figure 3.

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Note that the white areas in "Blinding of outcome assessment (detection bias): self-reported outcomes" and "Blinding of outcome assessment (detection bias): objective outcomes" indicate that the domain was not applicable to all trials because some trials did not measure any self-reported or objective outcomes, respectively.





Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Note that white squares indicate that the domain was not applicable to the trial, because no self-reported or objective outcomes, respectively, were measured in the trial.



#### Figure 3. (Continued)



#### Allocation

Eleven trials reported using an adequate method to generate a random allocation sequence (Buchbinder 2007; Carette 2003; Chan 2010; Johnson 2007; Pajareya 2004; Ryans 2005; Shrivastava 2011; van der Windt 1998; Vermeulen 2006; Yang 2007; Yang 2012), and only eight trials reported using an adequate method of allocation concealment (Buchbinder 2007; Carette 2003; Chan 2010; Pajareya 2004; Ryans 2005; van der Windt 1998; Yang 2007; Yang 2012). Two trials allocated participants using a quasi-random sequence (Nicholson 1985; Rainbow 2008), and one trial used a method that did not conceal the allocation sequence (Johnson 2007), so all three were rated at high risk of selection bias. Nineteen trials did not report how the allocation sequence was concealed. The risk of selection bias in these trials was therefore unclear.

#### Blinding

Three trials were rated at low risk of performance bias because of successful blinding of participants (Buchbinder 2007; Shrivastava 2011; Tanaka 2010). Seven trials were rated at unclear risk of performance bias because participants received different types of manual therapy or exercise, but it is unclear whether they were provided any information that would make them perceive the type of manual therapy or exercise they received as superior or inferior to the alternative type of manual therapy or exercise (Harsimran 2011; Johnson 2007; Nellutla 2009; Sirajuddin 2010; Vermeulen

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2006; Yan 2005; Yang 2007). All remaining trials were rated at high risk of performance bias, as participants were not blinded and may have had different expectations about the benefits of each intervention. Of 29 trials assessing self-reported outcomes, two were rated at low risk of detection bias because of clear participant blinding (Buchbinder 2007; Shrivastava 2011), seven were rated at unclear risk of detection bias because of unclear participant blinding (Harsimran 2011; Johnson 2007; Nellutla 2009; Sirajuddin 2010; Vermeulen 2006; Yan 2005; Yang 2007) and the remaining trials were rated at high risk of detection bias for selfreported outcomes because of lack of participant blinding. Of 31 trials measuring objectively rated outcomes (e.g. ROM), 17 reported blinding of outcome assessors and thus were rated at low risk of detection bias for objective outcomes (Buchbinder 2007; Bulgen 1984; Carette 2003; Chan 2010; Cheing 2008; Dacre 1989; Guler-Uysal 2004; Harsimran 2011; Nicholson 1985; Pajareya 2004; Ryans 2005; Shrivastava 2011; Tanaka 2010; van der Windt 1998; Vermeulen 2006; Yang 2007; Yang 2012). Three trials failed to blind assessors of objective outcomes, so the risk of detection bias for objective outcomes was high (Johnson 2007; Maryam 2012; Sharad 2011). Eleven trials did not report whether such blinding was done, so the risk of detection bias for objective outcomes in these trials was unclear.



#### Incomplete outcome data

Twenty-four trials had no dropouts, losses to follow-up or exclusions, or had a small quantity of incomplete data that was deemed unlikely to bias the results (Buchbinder 2007; Bulgen 1984; Celik 2010; Chan 2010; Cheing 2008; Dacre 1989; Dundar 2009; Ghosh 2012; Guler-Uysal 2004; Harsimran 2011; Johnson 2007; Ma 2006; Nellutla 2009; Nicholson 1985; Rainbow 2008; Shrivastava 2011; Sirajuddin 2010; Tanaka 2010; van der Windt 1998; Vermeulen 2006; Wen 2009; Yan 2005; Yang 2007; Yang 2012). One trial reported differential dropout across groups, with reasons appearing to be related to the treatments received, and thus was rated at high risk of attrition bias (Ryans 2005). The remaining seven trials did not report the quantity of or reasons for incomplete outcome data and so had an unclear risk of attrition bias.

#### Selective reporting

Two trials were rated at low risk of selective reporting bias because all outcomes specified in the trial registry entry or the trial protocol were fully reported in the trial publication (Buchbinder 2007; Maryam 2012). Six trials were rated at high risk of selective reporting bias because some of the outcomes that were reported in the trial registry entry or the methods section of the publication were not reported in the results section at all (Bulgen 1984; Chauhan 2011; Cheing 2008; Dacre 1989; Ryans 2005; Yang 2007). The remaining 24 trials were rated at unclear risk of selective reporting bias because (1) outcome data were completely reported for all outcomes specified in the methods section of the publication, but none of these trials were registered in a trials registry or had an available trial protocol, so it is unclear whether other outcomes were measured but not reported based on the results, or (2) outcome data were incompletely reported (e.g. reporting means without measures of variation), but it was unclear whether data were incompletely reported based on the statistical significance or magnitude of the results.

#### Other potential sources of bias

All trials were rated as free from other potential sources of bias (specifically, baseline imbalance).

#### Effects of interventions

See: Summary of findings for the main comparison Combination of manual therapy and exercise compared with glucocorticoid injection for adhesive capsulitis (frozen shoulder); Summary of findings 2 Combination of manual therapy, exercise, electrotherapy and placebo injection compared with glucocorticoid injection for adhesive capsulitis (frozen shoulder); Summary of findings 3 Combination of manual therapy, exercise, electrotherapy and placebo injection compared with placebo injection for adhesive capsulitis (frozen shoulder); Summary of findings 4 Combination of manual therapy, exercise, electrotherapy and glucocorticoid injection compared with glucocorticoid injection for adhesive capsulitis (frozen shoulder); Summary of findings 5 Combination of manual therapy and exercise following joint distension compared with sham ultrasound following joint distension for adhesive capsulitis (frozen shoulder); Summary of findings 6 Combination of manual therapy, exercise, electrotherapy and oral NSAID compared with oral NSAID for adhesive capsulitis (frozen shoulder)

Summary data and effect estimates (with 95% CIs) of all outcomes are presented in the Data and analyses or Additional tables section. To enhance readability, we have reported in the following main text only effect estimates and 95% CIs for main outcomes at, or nearest, the main time point (six weeks) for comparisons addressing the two primary questions of the review (i.e. Is the combination of manual therapy and exercise (with or without electrotherapy) effective compared with placebo, no intervention or another active intervention? and Is the combination of manual therapy and exercise (with or without electrotherapy) delivered in addition to another active intervention more effective than the other active intervention alone?). Unless otherwise stated, differences between groups in overall pain and function reported as 'significant' mean that the effect estimate met our criteria for an MCID (i.e. 1.5 points on a 10-point scale for pain, and 10 points on a 100-point scale for function or disability) and were statistically significant (P value < 0.05).

As the result of heterogeneity of interventions, comparators and outcomes, we were able to conduct meta-analyses to synthesise outcome data in only four trials. We synthesised results of two trials (Carette 2003; Ryans 2005) that addressed review questions 1 and 2. Both trials delivered an intervention lasting four weeks, which comprised mobilisation techniques, supervised exercise (active ROM exercises in Carette 2003 and active exercises with gym equipment in Ryans 2005), electrotherapy (TENS or ultrasound in Carette 2003 and interferential modality in Ryans 2005) and glucocorticoid or placebo injection. Both trials included participants with adhesive capsulitis for less than six months. To conduct meta-analyses of overall pain, we combined SPADI pain data in Carette 2003 with VAS daytime rest pain data in Ryans 2005 using SMDs, and we back-transformed the SMDs using the pooled baseline SD of SPADI pain scores reported in Carette 2003 (SD = 18). To conduct meta-analyses of function, we combined SPADI disability data in Carette 2003 with Croft Shoulder Disability Questionnaire data in Ryans 2005 using SMDs, and we backtransformed the SMDs using the pooled baseline SD of SPADI disability scores reported in Carette 2003 (SD = 18.6). We combined (1) six-week data reported in both trials and (2) six-month data reported in Carette 2003 with four-month data provided in Ryans 2005.

We combined results of two trials (Johnson 2007; Sirajuddin 2010) that addressed review question 5 (Is one type of manual therapy or exercise (with or without electrotherapy) more effective than another?). Both trials compared anterior glide mobilisation plus ultrasound and exercise versus posterior glide mobilisation plus ultrasound and exercise, delivered twice a week for three weeks. Both trials measured overall pain using the same VAS (0 to 10) at three weeks.

#### Is the combination of manual therapy and exercise (with or without electrotherapy) more effective than placebo, no intervention or another active intervention (e.g. glucocorticoid injection, oral non-steroidal anti-inflammatory drug (NSAID), arthrographic joint distension)?

No trial compared a combination of manual therapy and exercise versus placebo or no intervention. Five trials compared a combination of manual therapy and exercise versus another active intervention (Carette 2003; Chauhan 2011; Ma 2006; Ryans 2005; van der Windt 1998). Outcome data from three trials were available for analysis (Carette 2003; Ryans 2005; van der Windt 1998).

Cochrane Library

Trusted evidence. Informed decisions. Better health.

#### Manual therapy plus exercise versus glucocorticoid injection

See Table 3; Summary of findings for the main comparison. One trial compared passive mobilisation and supervised exercise for six weeks versus glucocorticoid injection (van der Windt 1998). Given the inability to blind participants and personnel, the trial had a high risk of performance bias and detection bias for self-reported outcomes.

#### **Main outcomes**

A combination of passive mobilisation and supervised exercise for six weeks resulted in significantly less improvement than glucocorticoid injection in overall pain at three weeks, seven weeks (MD -26.00, 95% CI -36.80 to -15.20; 100-point scale, 107 participants) and 12 months, and significantly less improvement in function at three weeks and seven weeks (MD -25.00, 95% CI -35.24 to -14.76; 100-point scale, 107 participants). In addition, participants receiving passive mobilisation and supervised exercise were 40% less likely to rate themselves as having global treatment success at seven weeks (RR 0.60, 95% CI 0.44 to 0.83; 108 participants). However, 95% CIs for overall pain and function include both MCIDs and clinically insignificant differences as possible estimates of effect. Differences between groups in improvement in overall pain at six months, improvement in function at six months and 12 months and the number of participants with adverse events (RR 1.07, 95% CI 0.76 to 1.49; 114 participants) were not clinically or statistically significant.

#### **Other outcomes**

Participants receiving passive mobilisation and supervised exercise for six weeks had statistically significantly less improvement in night pain and passive abduction at three and seven weeks, and less improvement in passive external rotation at three weeks, seven weeks and six months.

#### Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection

See Summary of findings 2. Two trials compared a combination of mobilisation, supervised exercise and electrotherapy for four weeks and placebo injection versus glucocorticoid injection alone (Carette 2003; Ryans 2005). Both trials were unable to blind participants and personnel to the physical therapy component of the intervention, so they had a high risk of performance bias and detection bias for self-reported outcomes. Ryans 2005 also had a high risk of attrition bias.

#### **Main outcomes**

The combination of mobilisation, supervised exercise and electrotherapy for four weeks and placebo injection was not significantly different from glucocorticoid injection alone in terms of improvement in overall pain at six weeks (SMD 0.21, 95% CI -0.65 to 1.07;  $I^2 = 75\%$ , 86 participants; this is equivalent to an MD of 3.78 (95% CI -11.7 to 19.26) on a 100-point scale), six months or 12 months (12-month data based on Carette 2003 only) (Analysis 1.1). Note that a large amount of statistical heterogeneity was noted in the meta-analyses of overall pain, with the direction of effect differing between trials. Improvement in function was statistically (but not clinically) significantly lower in the "mobilisation, exercise, electrotherapy and placebo injection" group at six weeks (SMD 0.46, 95% CI 0.03 to 0.89;  $I^2 = 0\%$ , 86 participants; this is equivalent to an MD of 8.56 (95% CI 0.56 to 16.56) on a 100-point scale) but

not significantly different at six months or 12 months (12-month data based on Carette 2003 only) (Analysis 1.2). Carette 2003 also found no significant differences between groups in improvement in quality of life at six weeks (SF-36 Physical Component Score: MD -3.30, 95% CI -8.57 to 1.97; 100-point scale, 86 participants; SF-36 Mental Component Score: MD 0.50, 95% CI -5.60 to 6.60; 100-point scale, 49 participants), six months and 12 months (Analysis 1.3).

#### Other outcomes

Carette 2003 found no significant differences between groups in active ROM at six weeks, six months and 12 months (Analysis 1.4; Analysis 1.5). Ryans 2005 found no significant differences between groups in passive external rotation at six weeks and four months (Analysis 1.6).

## Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection

See Summary of findings 3. The two trials above also compared the combination of mobilisation, supervised exercise and electrotherapy for four weeks and placebo injection versus placebo injection alone (Carette 2003; Ryans 2005).

#### Main outcomes

The combination of mobilisation, supervised exercise, and electrotherapy for four weeks and placebo injection was not significantly different from placebo injection alone in terms of improvement in overall pain at six weeks (SMD -0.24, 95% CI -0.67 to 0.18;  $I^2 = 0\%$ , 86 participants; this is equivalent to an MD of -4.32 (95% CI -12.06 to 3.24) on a 100-point scale), six months or 12 months (12-month data based on Carette 2003 only) (Analysis 2.1). No significant difference between groups was found in improvement in function at six weeks (SMD -0.09, 95% CI -0.52 to 0.33;  $I^2 = 0\%$ , 86 participants; this is equivalent to an MD of -1.67 (95% CI -9.67 to 6.14) on a 100-point scale), six months or 12 months (12-month data based on Carette 2003 only) (Analysis 2.2). Carette 2003 also found no significant differences between groups in improvement in quality of life at six weeks (SF-36 Physical Component Score: MD -1.40, 95% CI -6.67 to 3.87; 100-point scale, 49 participants; SF-36 Mental Component Score: MD -0.60, 95% CI -6.70 to 5.50; 100-point scale, 49 participants), six months and 12 months (Analysis 2.3).

#### Other outcomes

Carette 2003 found no significant differences between groups in active ROM at all time points (Analysis 2.4; Analysis 2.5). In contrast, Ryans 2005 reported statistically significantly greater improvement in passive external rotation in the multi-component intervention group at six weeks, but not at four months (Analysis 2.6).

#### Is the combination of manual therapy and exercise (with or without electrotherapy) delivered in addition to another active intervention more effective than the other active intervention alone?

Five trials addressed this question (Buchbinder 2007; Carette 2003; Ma 2006; Pajareya 2004; Ryans 2005). Outcome data in four trials were available for analysis (Buchbinder 2007; Carette 2003; Pajareya 2004; Ryans 2005).



#### Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection

See Summary of findings 4. The two trials above also compared the combination of mobilisation, supervised exercise and electrotherapy for four weeks and glucocorticoid injection versus glucocorticoid injection alone (Carette 2003; Ryans 2005).

#### **Main outcomes**

The combination of mobilisation, supervised exercise and electrotherapy for four weeks and glucocorticoid injection was not significantly different from glucocorticoid injection alone in terms of improvement in overall pain at six weeks (SMD -0.32, 95% CI -0.77 to 0.13;  $I^2 = 0\%$ , 86 participants; this is equivalent to an MD of -5.76 (95% CI -13.86 to 2.34) on a 100-point scale), six months or 12 months (12-month data based on Carette 2003 only) (Analysis 3.1). In addition, improvements in function were not significantly different between groups at six weeks (SMD -0.35, 95% CI -0.80 to 0.10;  $I^2 = 0\%$ , 86 participants; this is equivalent to an MD of -6.51 (95% CI -14.88 to 1.86) on a 100-point scale), six months or 12 months (12-month data based on Carette 2003 only) (Analysis 3.2). Carette 2003 also found no significant differences between groups in improvement in quality of life at six weeks (SF-36 Physical Component Score: MD 2.00, 95% CI -3.27 to 7.27; 100-point scale, 44 participants; SF-36 Mental Component Score: MD 4.20, 95% CI -2.04 to 10.44; 100-point scale, 44 participants), six months and 12 months (Analysis 3.3).

#### Other outcomes

Carette 2003 found that the combination of mobilisation, supervised exercise, electrotherapy and glucocorticoid injection resulted in statistically significantly greater improvement than glucocorticoid injection alone in active ROM at six weeks, but not at six months or 12 months (Analysis 3.4; Analysis 3.5). Ryans 2005 reported no significant differences between groups in improvement in passive external rotation at six weeks or at four months (Analysis 3.6).

#### Manual therapy plus exercise following arthrographic joint distension versus sham ultrasound following arthrographic joint distension

See Table 4; Summary of findings 5. One trial, following arthrographic joint distension, compared passive mobilisation plus supervised exercise (stretching, strength and coordination) for six weeks versus sham ultrasound. All risk of bias domains were rated as low risk.

#### **Main outcomes**

Following arthrographic joint distension, no significant differences were found between passive mobilisation plus supervised exercise for six weeks and sham ultrasound for six weeks, in terms of improvement in overall pain at six weeks (MD 0.00, 95% CI -0.69 to 0.69; 10-point scale, 148 participants) and six months, improvement in function at six weeks (MD -0.50, 95% CI -7.60 to 6.60; 100-point scale, 148 participants) and six months, and the number of participants with adverse events (RR 0.99, 95% CI 0.14 to 6.82; 149 participants). Participants receiving passive mobilisation and supervised exercise for six weeks were statistically significantly more likely to self-report having global treatment success at six weeks (RR 1.33, 95% CI 1.04 to 1.69; 148 participants) and six months, and had greater improvement in active shoulder

abduction at six weeks (MD 13.10, 95% CI 4.2 to 22; 148 participants), but not at six months, compared with participants receiving sham ultrasound. Differences between groups in quality of life were small and not significant at six weeks (SF-36 Physical Component Score: MD -0.50, 95% CI -4.25 to 3.25; 100-point scale, 148 participants; SF-36 Mental Component Score: MD -0.80, 95% CI -4.74 to 3.14; 100-point scale, 148 participants) and six months.

#### Other outcomes

Participants receiving passive mobilisation and supervised exercise for six weeks had greater improvement in active hand-behind-back distance at six weeks and six months, and had greater improvement in active flexion and external rotation at six weeks, compared with participants receiving sham ultrasound. However, no significant differences between groups were found in night pain nor pain on motion at either time point.

## Manual therapy plus exercise plus electrotherapy plus oral NSAID versus oral NSAID

See Table 5; Summary of findings 6. One trial compared a combination of passive mobilisation, supervised stretching and pulley exercises, electrotherapy and oral NSAID for three weeks versus oral NSAID alone. Given the inability to blind participants and personnel, this trial had a high risk of performance bias and detection bias for self-reported outcomes.

#### **Main outcomes**

The combination of passive mobilisation, supervised stretching and pulley exercises, electrotherapy and oral NSAID for three weeks resulted in statistically significantly greater improvement in function at three weeks than oral NSAID alone (MD 8.60, 95% CI 3.28 to 13.92; 100-point scale, 119 participants). However this result did not reach our criterion for a minimal clinically important difference. The number of participants with global treatment success did not significantly differ between groups at three weeks, six weeks (RR 1.45, 95% CI 0.99 to 2.12; 109 participants) or six months. A slightly greater number of participants receiving the multi-component intervention reported the adverse event of pain persisting for longer than two hours after treatment, but the 95% CI of the RR was very wide and includes no association and decreased risk as plausible estimates of association (RR 8.85, 95% CI 0.49 to 160.87; 119 participants).

#### Other outcomes

The multi-component intervention resulted in greater improvement in passive abduction and internal rotation at three weeks than with oral NSAID alone, but improvement in passive external rotation at three weeks did not significantly differ.

# Is manual therapy (with or without electrotherapy) more effective than placebo, no intervention or another active intervention?

One trial compared manual therapy versus no treatment but reported no useable outcome data (Bulgen 1984). Nine trials compared manual therapy (with or without electrotherapy) versus another active intervention (Bulgen 1984; Chan 2010; Dacre 1989; Guler-Uysal 2004; Maricar 1999; Nicholson 1985; Sharad 2011; Sirajuddin 2010; Yang 2012). Given the nature of the interventions, all trials had a high risk of performance bias and detection bias for



self-reported outcomes. Outcome data in four trials were available for analysis.

- Table 6 presents results of Guler-Uysal 2004 (40 participants), which compared deep friction massage (Cyriax approach) and active stretching and pendulum exercises versus short-wave diathermy, hot pack and active stretching and pendulum exercises.
- Table 7 presents results of Nicholson 1985 (20 participants), which compared passive mobilisation and supervised exercise versus supervised exercise alone.
- Table 8 and Table 9 present results of Sirajuddin 2010 (45 participants), which compared (1) anterior glide mobilisation, exercise and electrotherapy and (2) posterior glide mobilisation, exercise and electrotherapy versus exercise and electrotherapy alone.
- Table 10 presents results of Yang 2012 (23 participants), which compared end range and scapular mobilisation, exercise and electrotherapy versus exercise and electrotherapy alone.

The magnitude, direction of effect and statistical significance of between-group differences in outcomes varied across trials. In terms of the main benefit outcomes, statistically significant differences favouring the manual therapy group were reported only in Guler-Uysal 2004 (for global treatment success, pain on motion and passive internal and external rotation at two weeks), Sirajuddin 2010 (for overall pain at three weeks) and Yang 2012 (for function at eight weeks). However, 95% CIs included estimates of effect that were not clinically important. Only one trial (66 participants) measured adverse events, and none were recorded in either group (Dacre 1989).

#### Is supervised or home exercise (with or without electrotherapy) more effective than placebo, no intervention or another active intervention?

One trial compared home exercise (with electrotherapy) versus no intervention but reported no useable outcome data (Cheing 2008). Eight trials compared supervised or home exercise (with or without electrotherapy) versus another active intervention (Bulgen 1984; Celik 2010; Cheing 2008; Dundar 2009; Ghosh 2012; Maryam 2012; Samnani 2004; Wen 2009). Given the nature of the interventions, all trials had a high risk of performance bias and detection bias for self-reported outcomes. Outcome data for analysis were available in four trials.

- Table 11 presents results of Celik 2010 (29 participants), which compared scapulothoracic exercises, ROM exercises, electrotherapy, cold pack and NSAID versus the same intervention without scapulothoracic exercises.
- Table 12 presents results of Dundar 2009 (57 participants), which compared supervised stretching and pendulum exercises versus continuous passive motion.
- Table 13 and Table 14 present results of Ghosh 2012 (72 participants), which compared supervised active and passive mobilisation exercises and electrotherapy versus (1) manipulation under anaesthesia, and (2) glucocorticoid injection.
- Table 15 and Table 16 presents results of Maryam 2012 (87 participants), which compared glucocorticoid injection versus (1) supervised active ROM exercises, electrotherapy and ice,

and (2) supervised active ROM exercises, electrotherapy, ice and glucocorticoid injection.

Nearly all between-group differences in outcomes were not statistically significant. In terms of the main benefit outcomes, statistically significant differences favouring the exercise group were reported only in Celik 2010 (for overall pain at six weeks and 12 weeks); however 95% CIs included estimates of effect that were not clinically important. Only one trial measured adverse events, and none were recorded in either group (Dundar 2009).

## Is one type of manual therapy or exercise (with or without electrotherapy) more effective than another?

Ten trials compared one type of manual therapy or exercise versus another (with or without electrotherapy) (Harsimran 2011; Johnson 2007; Nellutla 2009; Rainbow 2008; Shrivastava 2011; Sirajuddin 2010; Tanaka 2010; Vermeulen 2006; Yan 2005; Yang 2007). Given the nature of the interventions, all trials except two (Shrivastava 2011; Tanaka 2010) had a high risk of performance bias and detection bias for self-reported outcomes. Outcome data for analysis were available in eight trials.

- Analysis 4.1 and Analysis 4.2 present results of Johnson 2007 and Sirajuddin 2010 (48 participants), both of which compared anterior versus posterior glide mobilisation, each with exercise and electrotherapy.
- Table 17 presents results of Nellutla 2009 (40 participants), which compared proprioceptive neuromuscular facilitation (PNF) exercises versus conventional free exercises including finger ladder, Codman's pendulum, overhead shoulder pulley and shoulder wheel exercises.
- Table 18 presents results of Rainbow 2008 (eight participants), which compared high-velocity, low-amplitude chiropractic manipulative therapy to the cervical and thoracic spine along with home exercise versus grade IV mobilisation and home exercise.
- Table 19, Table 20 and Table 21 present results of Tanaka 2010 (120 participants), which compared high-frequency (more often than twice a week) versus moderate-frequency (once a week) and low-frequency (less often than once a week) end range mobilisation.
- Table 22 presents results of Vermeulen 2006 (100 participants), which compared high-grade mobilisation (intensive passive end range mobilisation) versus low-grade mobilisation (passive mobilisation within the pain-free zone).
- Table 23 presents results of Yan 2005 (54 participants), which compared dumbbell exercises versus bare-handed exercises
- Table 24 presents results of Yang 2007 (30 participants), which compared end range mobilisation following midrange mobilisation versus mobilisation with movement following midrange mobilisation.

Most between-group differences in outcomes were not statistically significant. In terms of the main benefit outcomes, statistically significant differences favouring one type of manual therapy or exercise over another were reported only in Rainbow 2008 (for overall pain at six weeks, which was less in the chiropractic manipulative therapy group) and Yan 2005 (for global assessment of treatment success, which was more likely in the dumbbell exercises group). Only two trials measured adverse events, and



none were recorded in either group (Rainbow 2008; Shrivastava 2011).

#### Is the combination of manual therapy and exercise (with or without electrotherapy) delivered in addition to another active intervention more effective than placebo or no treatment?

The two trials above (total of 78 participants) compared the combination of mobilisation, supervised exercise and electrotherapy for four weeks and glucocorticoid injection versus placebo injection alone (Carette 2003; Ryans 2005). Both trials were unable to blind participants and personnel to the physical therapy component of the intervention, so they had a high risk of performance bias and detection bias for self-reported outcomes. Ryans 2005 also had a high risk of attrition bias. The multi-component intervention resulted in significantly more improvement in overall pain (Analysis 5.1) and function (Analysis 5.2) than placebo injection alone at six weeks, but not at six months or 12 months. In terms of secondary outcomes, the multi-component intervention group had statistically significantly greater improvement in quality of life (Analysis 5.3) and ROM at some, but not all, time points (Analysis 5.4; Analysis 5.5; Analysis 5.6).

#### Other outcome data

Partially reported outcome data (e.g. where trialists did not report SDs or any other measures of variance) in Chan 2010, Dacre 1989, Harsimran 2011, Johnson 2007, Ma 2006, Maricar 1999, Samnani 2004, Sharad 2011 and Shrivastava 2011 are presented in Table 25.

## Subgroup and sensitivity analyses, and assessment of publication bias

Because of the limited opportunity for meta-analysis, no subgroup or sensitivity analyses were undertaken. We were unable to formally assess publication bias using funnel plots because of the small number of trials included in each meta-analysis.

#### DISCUSSION

#### Summary of main results

Overall, based on the results of 32 trials involving 1836 participants, limited evidence is available from which firm conclusions can be drawn about the benefits or harms of (1) the combination of manual therapy and exercise compared with another active intervention (e.g. glucocorticoid injection), (2) the combination of manual therapy, exercise and another active intervention compared with the other active intervention alone, (3) manual therapy compared with another active intervention, (4) exercise compared with another active intervention or (5) one type of manual therapy or exercise versus another, in terms of patient-relevant outcomes such as pain, function, global assessment of treatment success, ROM and quality of life. Only seven trials measured adverse events, with three reporting marginal differences between groups (Buchbinder 2007; Pajareya 2004; van der Windt 1998), and four reporting no adverse events in any group (Dacre 1989; Dundar 2009; Rainbow 2008; Shrivastava 2011).

The two main questions of the review (which focus on the effects of the combination of manual therapy and exercise) were investigated in only seven trials (Buchbinder 2007; Carette 2003; Chauhan 2011; Ma 2006; Pajareya 2004; Ryans 2005; van der Windt 1998).

The overall impression gained from these trials is that the few outcome differences between interventions that were clinically important were detected only at short-term follow-up (i.e. up to seven weeks). Based on one trial that did not blind participants, glucocorticoid injection was superior to the combination of manual therapy and exercise for six weeks in terms of overall pain, function, global treatment success, night pain and passive range of abduction at three weeks and seven weeks, but differences were small at six months and 12 months (van der Windt 1998) (Summary of findings for the main comparison). Meta-analysis of two trials that did not blind participants (one of which had a high risk of attrition bias) suggested no clinically important differences between a combination of manual therapy, exercise, and electrotherapy for four weeks and placebo injection compared with glucocorticoid injection alone or placebo injection alone in terms of overall pain, function, active range of motion and quality of life at six weeks, six months and 12 months (though the 95% CI suggested function may be better with glucocorticoid injection at six weeks) (Carette 2003; Ryans 2005) (Summary of findings 2; Summary of findings 3). The same two trials found that adding a combination of manual therapy, exercise and electrotherapy for four weeks to glucocorticoid injection did not confer clinically important benefits over glucocorticoid injection alone at each time point (Summary of findings 4). The only trial rated at low risk of bias on each domain of the Cochrane risk of bias tool found that following arthrographic joint distension, the combination of manual therapy and supervised exercise for six weeks was superior to sham ultrasound in terms of global treatment success and active shoulder abduction at six weeks, but conferred similar effects in terms of overall pain, function, adverse events, night pain, pain on motion and quality of life at six weeks and at six months (Buchbinder 2007) (Summary of findings 5). Finally, one trial that did not blind participants (Pajareya 2004) found that a combination of manual therapy, exercise, electrotherapy and oral non-steroidal anti-inflammatory drug (NSAID) for three weeks did not confer clinically important benefits over oral NSAID alone in terms of function, patient-reported treatment success and passive ROM at three weeks (Summary of findings 6). Two trials (Chauhan 2011; Ma 2006) reported no or partial outcome data, thus preventing their inclusion in this summary analysis.

that a combination of manual therapy, exercise, electrotherapy and oral non-steroidal anti-inflammatory drug (NSAID) for three weeks did not confer clinically important benefits over oral NSAID alone in terms of function and patient-reported treatment success at three weeks.

For all other comparisons, most of the differences between groups in both primary and secondary outcomes were small and were not statistically significant. Any statistically significant differences that were detected in these trials are likely to be exaggerated because of the high risk of performance and detection bias resulting from nonblinding of participants and personnel.

#### **Overall completeness and applicability of evidence**

Similar to what has been found in previous reviews (Green 1998; Schellingerhout 2008), the diagnostic criteria for (or definitions of) adhesive capsulitis varied across trials with regard to type, extent and direction of shoulder restriction. Despite this, the study populations in all trials appeared to be representative of patients seen in routine care, and age, gender ratio and symptom duration were similar across trials. Also, trials were conducted in a range of



high- and low- to middle-income countries. The median duration of the manual therapy or exercise intervention was four weeks (range one to 18), with a median of three treatment sessions delivered per week (range one to seven). Of major clinical concern is that few of the identified trials tested multi-component interventions (manual therapy combined with exercise or manual therapy and exercise combined with a non-physical therapy intervention (e.g. glucocorticoid injection)), although this is the most common way in which adhesive capsulitis is treated in practice (Hanchard 2011a). Of our six review questions, 'Is one type of manual therapy or exercise (with or without electrotherapy) more effective than another?' was the one addressed by the largest number of trials (n = 10). This failure of trials to reflect actual practice in their tested interventions needs to be considered not only in interpreting available evidence for the management of adhesive capsulitis, but also in planning future research. Trials should consider testing standardised delivery methods for combinations of manual therapy and exercise. Several of the identified trials delivered an electrotherapy modality (e.g. ultrasound, TENS) to the group receiving manual therapy or exercise, so the effect of manual therapy or exercise cannot be isolated from that of electrotherapy in these trials. This issue applies to three of the seven trials included under our two primary review questions (Carette 2003; Pajareya 2004; Ryans 2005). However, this is not necessarily problematic, as delivery of electrotherapy modalities along with manual therapy and exercise is reflective of many types of physical therapy practice.

An issue of greater concern is the variable choice of outcomes assessed in the trials. Various measures of ROM were measured in nearly all trials, but no trial measured pain using a dichotomous measure, as recommended by IMMPACT (Dworkin 2008). The proportion of trials measuring other main outcomes of the review were as follows: overall pain measured by visual analogue scale, numerical or categorical rating scale (72%); function (63%); global assessment of treatment success (22%); active shoulder abduction (31%); quality of life (19%); and adverse events (22%). Development of a core set of outcomes for trials of adhesive capsulitis and other shoulder disorders would improve our ability to synthesise the evidence.

#### **Quality of the evidence**

The overall quality of evidence for most comparisons was low according to the GRADE approach (Schünemann 2011b). Although we presented only SoF tables for trials addressing the two primary questions of the review, we used the GRADE approach to assess the quality of all included trials. Most trials were of low or very low quality, with the evidence downgraded for three reasons: (1) Risk of performance and detection bias for self-reported outcomes was high, (2) risk of selection bias was unclear because trialists did not report whether the allocation sequence was concealed and (3) some imprecision surrounded the effect estimate. Few trials were rated at low risk of performance bias and detection bias for self-reported outcomes because of lack of participant and personnel blinding. Blinding of participants and personnel is difficult to achieve in procedural trials; therefore performance bias and detection bias are often difficult to minimise. However, this is problematic because trials with unblinded assessment of subjective outcomes (such as pain and function) are estimated to exaggerate the treatment benefit by 22% on average (ratio of odds ratios 0.78, 95% credible interval 0.65 to 0.92) (Savovic 2012). In addition, trials with inadequate or unclear allocation concealment have been found to exaggerate treatment effect by 7% on average (ratio of odds ratios 0.93, 95% credible interval 0.87 to 0.99) (Savovic 2012). Overall, for most comparisons and outcomes in our review, further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Only two trials were not rated as of low or very low quality: van der Windt 1998 was a moderate-quality trial that was downgraded only for lack of participant blinding, and Buchbinder 2007 was a high-quality trial.

#### Potential biases in the review process

Upon completion of a thorough search of all major databases with no language restrictions, we believe that all relevant trials were identified. Two review authors independently assessed the trials for inclusion in this review, extracted data and assessed the risk of bias, and a third review author adjudicated when any discrepancy arose. Two of the review authors (SG and RB) are authors of one of the trials included in this review (Buchbinder 2007). To avoid bias, the paper was sent to an independent review author for assessment of whether it met the inclusion criteria for this review. Neither review author was involved in data extraction or assessment of risk of bias for this trial. Review questions of interest were defined with full knowledge of comparisons reported in the trials, but with no knowledge of the results. We used a priori defined decision rules to select data from trials when multiple measurement scales, time points and analyses were reported, to prevent selective inclusion of results (Page 2013). The biggest limitation of the review process was that many trials did not report sufficient outcome data or did not present data in a form that would allow them to be extracted for meta-analysis, and attempts to obtain data from trialists were often unsuccessful. In addition, measures of both pain and function varied across trials. For overall pain-one of our prespecified primary outcomes—we elected to combine results for overall pain severity and daytime rest pain, each measured on different scales. For function, we also combined different measures that may not necessarily be measuring the exact same concept.

## Agreements and disagreements with other studies or reviews

We are aware of four other relevant systematic reviews of interventions for adhesive capsulitis published within the past five years (Blanchard 2010; Favejee 2011; Hanchard 2011b; Maund 2012). All examined a range of conservative and surgical interventions, except for Blanchard 2010, which included only trials comparing physical therapy versus glucocorticoid injections. Some differences were noted in the meta-analysis methods used across the reviews. For example, the results of our meta-analyses of data in Carette 2003 and Ryans 2005 are slightly different from those reported by Maund 2012, who, rather than including the change from baseline data reported in both trials, as we did, calculated final values and imputed SDs of final values. Maund 2012 also combined data at different time points from ours. Blanchard 2010 chose to combine data from Carette 2003 and Ryans 2005 with those from van der Windt 1998; this was not done in our review or in the reviews by Hanchard 2011b and Maund 2012, as the intervention in van der Windt 1998 was not deemed sufficiently similar to that in Carette 2003 and Ryans 2005. Despite this fact, we reached a similar conclusion to that of Blanchard 2010, Hanchard 2011b and Maund 2012-that a multi-component intervention comprising manual therapy and exercise is potentially less effective than glucocorticoid injection in the short term but no different in the long term, and that

this result should be interpreted with caution because of the high risk of performance bias.

Favejee 2011 concluded that moderate evidence favours mobilisation techniques, which is a stronger conclusion than ours and that of Hanchard 2011b and Maund 2012. However, this conclusion appears to be based on the statistically significant effects of mobilisation on particular measures of ROM, as reported in Johnson 2007, Nicholson 1985, Vermeulen 2006 and Yang 2007, and does not take into consideration the finding that effects on patient-relevant outcomes like pain and function were not clinically or statistically important.

#### AUTHORS' CONCLUSIONS

#### Implications for practice

No trials have investigated the effect of the combination of manual therapy and exercise compared with placebo or no treatment for adhesive capsulitis. The best currently available data indicate that the combination of manual therapy and exercise may not be as effective as glucocorticoid injection in the short term. It is unclear whether the combination of manual therapy, exercise and electrotherapy is an effective adjunct to glucocorticoid injection or oral NSAIDs. Following arthrographic joint distension with glucocorticoid and saline, manual therapy and exercise may confer similar effects to those of sham ultrasound in terms of overall pain, function and quality of life, but may provide greater patient-reported treatment success and active range of motion.

#### Implications for research

High-quality randomised controlled trials are needed to investigate whether the combination of manual therapy and exercise is more effective than placebo or no treatment for adhesive capsulitis. Additional high-quality randomised controlled trials are needed to establish the benefits and harms of manual therapy and exercise interventions that reflect actual practice, compared with active interventions with evidence of benefit (e.g. glucocorticoid injection). Future trials should include strategies designed to minimise the potential for bias, including adequate allocation concealment and blinding of participants and outcome assessors. Development of a core set of outcomes for trials of adhesive capsulitis and other shoulder disorders would enhance this endeavour and improve our ability to synthesise the evidence.

#### ACKNOWLEDGEMENTS

We are grateful to Steve McDonald from the Australasian Cochrane Centre for help provided with the search strategy. We thank Simon Carette, Sharon Chan, Jiu-jenq Lin, Mobini Maryam, Kingkaew Pajareya and Ian Ryans for providing us with unpublished trial data.

#### REFERENCES

#### References to studies included in this review

#### Buchbinder 2007 {published data only}

Buchbinder R, Youd JM, Green S, Stein A, Forbes A, Harris A, et al. Efficacy and cost-effectiveness of physiotherapy following glenohumeral joint distension for adhesive capsulitis: a randomized trial. *Arthritis and Rheumatism* 2007;**57**:1027-37.

#### Bulgen 1984 {published data only}

Bulgen DY, Binder AI, Hazleman BI, Dutton J, Roberts S. Frozen shoulder: prospective clinical study with an evaluation of three treatment regimens. *Annals of the Rheumatic Diseases* 1984;**43**:353-60.

#### Carette 2003 {published data only}

Carette S, Moffet H, Tardif J, Bessette L, Morin F, Frémont P, et al. Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: a placebo-controlled trial. *Arthritis and Rheumatism* 2003;**48**:829-38.

#### Celik 2010 {published data only}

Celik D. Comparison of the outcomes of two different exercise programs on frozen shoulder. *Acta Orthopaedica et Traumatologica Turcica* 2010;**44**:285-92.

#### Chan 2010 {published data only}

Chan S, Hill R, Kerr J. Passive joint mobilisation: does it enhance outcome of adhesive capsulitis of the shoulder following corticosteroid injection?. *International Musculoskeletal Medicine* 2010;**32**:58-67.

#### Chauhan 2011 {published data only}

Chauhan V, Saxena S, Grover S. Effect of deep transverse friction massage and capsular stretching in idiopathic adhesive capsulitis. *Indian Journal of Physiotherapy & Occupational Therapy* 2011;**5**:185-8.

#### Cheing 2008 {published data only}

Cheing GLY, So EML, Chao CYL. Effectiveness of electroacupuncture and interferential electrotherapy in the management of frozen shoulder. *Journal of Rehabilitation Medicine* 2008;**40**:166-70.

#### Dacre 1989 {published data only}

Dacre JE, Beeney N, Scott DL. Injections and physiotherapy for the painful stiff shoulder. *Annals of the Rheumatic Diseases* 1989;**48**:322-5.

#### Dundar 2009 {published data only}

Dundar U, Toktas H, Cakir T, Evcik D, Kavuncu V. Continuous passive motion provides good pain control in patients with adhesive capsulitis. *International Journal of Rehabilitation Research* 2009;**32**:193-8.

#### Ghosh 2012 {published data only}

Ghosh TK, Bera AK, Hossain ME, Sarkar PS. Comparison of results of three different methods of treatment for adhesive

capsulitis of shoulder. *Journal of the Indian Medical Association* 2012;**110**(11):827-8.

#### Guler-Uysal 2004 {published data only}

Guler-Uysal F, Kozanoglu E. Comparison of the early response to two methods of rehabilitation in adhesive capsulitis. *Swiss Medical Weekly* 2004;**134**:353-8.

#### Harsimran 2011 {published data only}

Harsimran K, Ranganath G, Ravi SR. Comparing effectiveness of antero-posterior and postero-anterior glides on shoulder range of motion in adhesive capsulitis—a pilot study. *Indian Journal of Physiotherapy & Occupational Therapy* 2011;**5**:69-72.

#### Johnson 2007 {published data only}

Johnson AJ, Godges JJ, Zimmerman GJ, Ounanian LL. The effect of anterior versus posterior glide joint mobilization on external rotation range of motion in patients with shoulder adhesive capsulitis. *Journal of Orthopaedic and Sports Physical Therapy* 2007;**37**:88-99.

#### Ma 2006 {published data only}

Ma T, Kao MJ, Lin IH, Chiu YL, Chien C, Ho TJ, et al. A study on the clinical effects of physical therapy and acupuncture to treat spontaneous frozen shoulder. *The American Journal of Chinese Medicine* 2006;**34**:759-75.

#### Maricar 1999 {published data only}

Maricar NN, Chok B. A comparison of the effect of manual therapy with exercise therapy and exercise therapy alone for stiff shoulders. *Physiotherapy Singapore* 1999;**2**(3):99-104.

#### Maryam 2012 {published data only}

Maryam M, Zahra K, Adeleh B, Morteza Y. Comparison of corticosteroid injections, physiotherapy, and combination therapy in treatment of frozen shoulder. *Pakistan Journal of Medical Sciences* 2012;**28**:648-51.

#### Nellutla 2009 {published data only}

Nellutla M, Gin P. Comparative study between efficacy of PNF movement patterns versus conventional free exercises on functional activities among patients with chronic peri-arthritis of shoulder. *Indian Journal of Physiotherapy & Occupational Therapy* 2011;**5**:62-7.

Nellutla M, Giri P, M'Kumbuzi VRP, Patel HC. PNF movement patterns compared to the use of conventional free exercises to improve joint ROM in chronic peri-arthritis of the shoulder. *Indian Journal of Physiotherapy & Occupational Therapy* 2009;**3**:31-4.

#### Nicholson 1985 {published data only}

Nicholson GG. The effects of passive joint mobilization on pain and hypomobility associated with adhesive capsulitis of the shoulder. *Journal of Orthopaedic and Sports Physical Therapy* 1985;**6**:238-46.


### Pajareya 2004 {published data only}

Pajareya K, Chadchavalpanichaya N, Painmanakit S, Kaidwan C, Puttaruksa P, Wongsaranuchit Y. Effectiveness of physical therapy for patients with adhesive capsulitis: a randomized controlled trial. *Journal of the Medical Association of Thailand* 2004;**87**:473-80.

# Rainbow 2008 {published data only}

Rainbow DM, Weston JP, Brantingham JW, Globe G, Lee F. A prospective clinical trial comparing chiropractic manipulation and exercise therapy vs. chiropractic mobilization and exercise therapy for treatment of patients suffering from adhesive capsulitis/frozen shoulder. *Journal of the American Chiropractic Association* 2008;**45**:12-28.

### Ryans 2005 {published data only}

Ryans I, Montgomery A, Galway R, Kernohan WG, McKane R. A randomized controlled trial of intra-articular triamcinolone and/or physiotherapy in shoulder capsulitis. *Rheumatology* 2005;**44**:529-35.

### Samnani 2004 {published data only}

Samnani M. Passive exercises coupled with therapeutic activities—a comparative study in the management of frozen shoulder. *Indian Journal of Occupational Therapy* 2004;**36**:37-40.

#### Sharad 2011 {published data only}

Sharad KS. A Comparative study on the efficacy of end range mobilization techniques in treatment of adhesive capsulitis of shoulder. *Indian Journal of Physiotherapy & Occupational Therapy* 2011;**5**:28-31.

#### Shrivastava 2011 {published data only}

Shrivastava A, Shyam AK, Sabnis S, Sancheti P. Randomised controlled study of Mulligan's vs. Maitland's mobilization technique in adhesive capsulitis of shoulder joint. *Indian Journal of Physiotherapy & Occupational Therapy* 2011;**5**:12-5.

#### Sirajuddin 2010 {published data only}

Sirajuddin M, Quddus N, Grover D. Comparison of anterior versus posterior glide mobilisation techniques for improving internal rotation range of motion in shoulder adhesive capsulitis. *Indian Journal of Physiotherapy & Occupational Therapy* 2010;**4**:152-7.

## Tanaka 2010 {published data only}

Tanaka K, Saura R, Takahashi N, Hiura Y, Hashimoto R. Joint mobilization versus self-exercises for limited glenohumeral joint mobility: randomized controlled study of management of rehabilitation. *Clinical Rheumatology* 2010;**29**:1439-44.

#### van der Windt 1998 {published data only}

van der Windt D, Koes BW, Deville W, Boeke AJP, de Jong BA, Bouter LM. Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial. *British Medical Journal* 1998;**317**:1292-6.

### Vermeulen 2006 {published data only}

\* Vermeulen HM, Rozing PM, Obermann WR, le Cessie S, Vliet Vlieland TP. Comparison of high-grade and low-grade mobilization techniques in the management of adhesive capsulitis of the shoulder: randomized controlled trial. *Physical Therapy* 2006;**86**:355-68.

van den Hout WB, Vermeulen HM, Rozing PM, Vliet Vlieland TP. Impact of adhesive capsulitis and economic evaluation of high-grade and low-grade mobilisation techniques. *Australian Journal of Physiotherapy* 2005;**51**:141-9.

#### Wen 2009 {published data only}

Wen L. Analysis on effect of functional exercises to promote rehabilitation of patients with periarthritis of shoulder. *Chinese Nursing Research* 2009;**23**:1925-6.

#### Yan 2005 {published data only}

Yan F. Comparison of dumbbell gymnastics and bare-handed exercise in ameliorating the symptoms of shoulder periarthritis. *Chinese Journal of Clinical Rehabilitation* 2005;**7**:187-9.

#### Yang 2007 {published data only}

Yang JL, Chang CW, Chen SY, Wang SF, Lin JJ. Mobilization techniques in subjects with frozen shoulder syndrome: randomized multiple-treatment trial. *Physical Therapy* 2007;**87**:1307-15.

#### Yang 2012 {published data only}

Yang JL, Jan MH, Chang CW, Lin JJ. Effectiveness of the endrange mobilization and scapular mobilization approach in a subgroup of subjects with frozen shoulder syndrome: a randomized control trial. *Manual Therapy* 2012;**17**:47-52.

#### References to studies excluded from this review

#### Abdelshafi 2011 {published data only}

Abdelshafi ME, Yosry M, Elmulla AF, Al-Shahawy EA, Adou Aly M, Eliewa EA. Relief of chronic shoulder pain: a comparative study of three approaches. *Middle East Journal of Anesthesiology* 2011;**21**:83-92.

#### Alicicco 2000 {published data only}

Alicicco E, Chinni LM, Castellano V, Aparo UL. Hyperthermia in scapulohumeral periarthritis due to overuse in athletes. *Journal of Sports Sciences* 2000;**18**:489.

### Amir-us-Saqlain 2007 {published data only}

Amir-us-Saqlain H, Zubairi A, Taufiq I. Functional outcome of frozen shoulder after manipulation under anaesthesia. *Journal of Pakistan Medical Association* 2007;**57**:181-5.

### Arslan 2001 {published data only}

Arslan S, Celiker R. Comparison of the efficacy of local corticosteroid injections and physiotherapy for the treatment of adhesive capsulitis. *Rheumatology International* 2001;**21**:20-3.

#### Bumin 2001 {published data only}

Bumin G, Can F. Effects of iontophoresis and phonophoresis methods on pain in cases with shoulder periarthritis. *Pain Clinic* 2001;**13**:159-62.

#### Calis 2006 {published data only}

Calis M, Demir H, Ulker S, Kirnap M, Duygulu F, Calis HT. Is intraarticular sodium hyaluronate injection an alternative

treatment in patients with adhesive capsulitis?. *Rheumatology International* 2006;**26**:536-40.

# Diercks 2004 {published data only}

Diercks RL, Stevens M. Gentle thawing of the frozen shoulder: a prospective study of supervised neglect versus intensive physical therapy in seventy-seven patients with frozen shoulder syndrome followed up for two years. *Journal of Shoulder and Elbow Surgery* 2004;**13**:499-502.

### Khan 2005 {published data only}

Khan AA, Mowla A, Shakoor MA, Rahman MR. Arthrographic distension of the shoulder joint in the management of frozen shoulder. *Mymensingh Medical Journal* 2005;**14**:67-70.

### Kivimaki 2007 {published data only}

Kivimaki J, Pohjolainen T, Malmivaara A, Kannisto M, Guillaume J, Seitsalo S, et al. Manipulation under anesthesia with home exercises versus home exercises alone in the treatment of frozen shoulder: a randomized, controlled trial with 125 patients. *Journal of Shoulder and Elbow Surgery* 2007;**16**:722-6.

## Koh 2013 {published data only}

Koh PS, Seo BK, Cho NS, Park HS, Park DS, Baek YH. Clinical effectiveness of bee venom acupuncture and physiotherapy in the treatment of adhesive capsulitis: a randomized controlled trial. *Journal of Shoulder and Elbow Surgery* 2013;**22**(8):1053-62.

### Leclaire 1991 {published data only}

Leclaire R, Bourgouin J. Electromagnetic treatment of shoulder periarthritis: a randomized controlled trial of the efficiency and tolerance of magnetotherapy. *Archives of Physical Medicine and Rehabilitation* 1991;**72**:284-7.

### Lee 1973 {published data only}

Lee M, Haq AM, Wright V, Longton EB. Periarthritis of the shoulder: a controlled trial of physiotherapy. *Physiotherapy* 1973;**59**:312-5.

#### Leung 2008 {published data only}

Leung MS, Cheing GL. Effects of deep and superficial heating in the management of frozen shoulder. *Journal of Rehabilitation Medicine* 2008;**40**:145-50.

#### Longbottom 2009 {published data only}

Longbottom J, Green A. Effectiveness of single-point acupuncture to Stomach 38 (Tiaokou) on pain and disability in subjects with frozen shoulder. *Journal of the Acupuncture Association of Chartered Physiotherapists* 2009:37-46.

# Ma 2013 {published data only}

Ma S-Y, Je HD, Jeong JH, Kim H-Y, Kim H-D. Effects of wholebody cryotherapy in the management of adhesive capsulitis of the shoulder. *Archives of Physical Medicine and Rehabilitation* 2013;**94**(1):9-16.

# Rizk 1991 {published data only}

Rizk TE, Pinals RS, Talaiver AS. Corticosteroid injections in adhesive capsulitis: investigation of their value and site. *Archives of Physical Medicine and Rehabilitation* 1991;**72**:20-2.

### Srour 2008 {published data only}

Srour F. Use of cold for the management of acute retractile capsulitis of the shoulder joint. *Kinesitherapie Revue* 2008, (83):29-33.

#### Zhu 2004 {published data only}

Zhu ZZ, Liu CM, Feng WX. Analgesic effects of traditional Chinese medicine iontophoresis and rehabilitation training on periarthritis of shoulder: a randomized controlled study. *Chinese Journal of Clinical Rehabilitation* 2004;**8**:2698-9.

### **References to studies awaiting assessment**

#### Doner 2013 {published data only}

Doner G, Guven Z, Atalay A, Celiker R. Evalution of Mulligan's technique for adhesive capsulitis of the shoulder. *Journal of Rehabilitation Medicine* 2013;**45**(1):87-91.

### Fink 2012 {published data only}

Fink M, Schiller J, Buhck H. Efficacy of a manual treatment method according to the fascial distortion model in the management of contracted ("frozen") shoulder. *Zeitschrift für Orthopädie und Unfallchirurgie* 2012;**150**(4):420-7.

#### Ibrahim 2013 {published data only}

Ibrahim M, Donatelli R, Hellman M, Echternach J. Efficacy of a static progressive stretch device as an adjunct to physical therapy in treating adhesive capsulitis of the shoulder: a prospective, randomised study. *Physiotherapy* 2013:pii:S0031-9406(13)00085-0. doi: 10.1016/ j.physio.2013.08.006. [Epub ahead of print].

#### Russell 2014 {published data only}

Russell S, Jariwala A, Conlon R, Selfe J, Richards J, Walton M. A blinded, randomized, controlled trial assessing conservative management strategies for frozen shoulder. *Journal of Shoulder and Elbow Surgery* 2014;**23**(4):500-7.

#### Uddin 2012 {published data only}

Uddin T, Raihan H, Bashar MS, Rahman S. Effectiveness of supervised physiotherapy on patients with adhesive capsulitis. *Journal of Rehabilitation Medicine* 2012;**44**(Suppl 52):65-66.

#### Wies 2003 {published data only}

Wies J. A pilot randomised placebo controlled trial of osteopathic and physiotherapy treatment for frozen shoulder. *Journal of Osteopathic Medicine* 2003;**6**:40.

#### **References to ongoing studies**

#### NCT00873158 {published data only}

http://clinicaltrials.gov/show/NCT00873158. Outcomes following dynamic splinting and/or physical therapy for patients with adhesive capsulitis.

#### NCT01249040 {published data only}

http://clinicaltrials.gov/show/NCT01249040. The study of different treatment programs for patients with frozen shoulder.



### NCT01483963 {published data only}

http://clinicaltrials.gov/show/NCT01483963. A Phase 2a, openlabel, dose-ranging study of the safety and effectiveness of AA4500 for the treatment of adhesive capsulitis of the shoulder.

# **Additional references**

# Ballantyne 1993

Ballantyne BT, O'Hare SJ, Paschall JL, Pavia-Smith MM, Pitz AM, Gillon JF, et al. Electromyographic activity of selected shoulder muscles in commonly used therapeutic exercises. *Physical Therapy* 1993;**73**:668-77.

#### Binder 1984

Binder AI, Bulgen DY, Hazelman BL, Roberts S. Frozen shoulder: a long-term prospective study. *Annals of the Rheumatic Diseases* 1984;**43**:361-4.

### **Blanchard 2010**

Blanchard V, Barr S, Cerisola FL. The effectiveness of corticosteroid injections compared with physiotherapeutic interventions for adhesive capsulitis: a systematic review. *Physiotherapy* 2010;**96**:95-107.

### Cates 2004 [Computer program]

Dr Chris Cates EBM website. http://www.nntonline.net/. Visual Rx NNT Calculator. Dr Chris Cates EBM website. http:// www.nntonline.net/, 2004.

#### Codman 1934

Codman EA. The Shoulder. Boston: Thomas Toddog, 1934.

#### Deeks 2011

Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011:www.cochrane-handbook.org.

#### Dwan 2011

Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR. Comparison of protocols and registry entries to published reports for randomised controlled trials. *Cochrane Database of Systematic Reviews* 2011, Issue 1. [DOI: 10.1002/14651858.MR000031.pub2]

#### Dworkin 2008

Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *The Journal of Pain* 2008;**9**(2):105-21.

#### Ebrahim 2013

Ebrahim S, Akl EA, Mustafa RA, Sun X, Walter SD, Heels-Ansdell D, et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. *Journal of Clinical Epidemiology* 2013;**66**(9):1014-21.

### Favejee 2011

Favejee MM, Huisstede BMA, Koes BW. Frozen shoulder: the effectiveness of conservative and surgical interventions —systematic review. *British Journal of Sports Medicine* 2011;**45**:49-56.

### Frank 1984

Frank C, Akeson WH, Woo SL, Amiel D, Couts RD. Physiology and therapeutic value of passive joint motion. *Clinical Orthopaedics and Related Research* 1984;**185**:113-25.

#### Hanchard 2011a

Hanchard NCA, Goodchild L, Thompson J, O'Brien T, Davison D, Richardson C. A questionnaire survey of UK physiotherapists on the diagnosis and management of contracted (frozen) shoulder. *Physiotherapy* 2011;**97**:115-25.

### Hanchard 2011b

Hanchard N, Goodchild L, Thompson J, O'Brien T, Richardson C, Davison D, et al. Evidence-based clinical guidelines for the diagnosis, assessment and physiotherapy management of contracted (frozen) shoulder, v. 1.7, 'standard' physiotherapy. *Endorsed by the Chartered Society of Physiotherapy, www.csp.org.uk/skipp*, 2011.

# Hand 2008

Hand C, Clipsham K, Rees JL, Carr AJ. Long-term outcome of frozen shoulder. *Journal of Shoulder and Elbow Surgery* 2008;**17**:231-6.

### Hazelman 1972

Hazleman BL. The painful stiff shoulder. *Rheumatology and Physical Medicine* 1972;**11**(8):413-21.

### Higgins 2002

Higgins JPT, Thompson SG. Quantifying heterogeneity in metaanalysis. *Statistics in Medicine* 2002;**21**(11):1539-58. [PUBMED: 12111919]

## Higgins 2011a

Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, www.cochrane-handbook.org.

### Kaltenborn 1976

Kaltenborn FM. Manual Therapy for the Extremity Joints. Oslo, Norway: Olaf Norlis Bokhandel, 1976.

## Kirkham 2010

Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. *BMJ* 2010;**340**:c365.

### Maitland 1977

Maitland GD. Peripheral manipulation. London, United Kingdom: Butterworths, 1977.



#### Mangus 2002

Mangus BC, Hoffman LA, Hoffman MA, Altenburger P. Basic principles of extremity joint mobilization using a Kaltenborn approach. *Journal of Sport Rehabilitation* 2002;**11**:235-50.

#### Mao 1997

Mao CY, Jaw WC, Cheng HC. Frozen shoulder: correlation between the response to physical therapy and follow-up shoulder arthrography. *Archives of Physical Medicine and Rehabilitation* 1997;**78**:857-9.

### Maund 2012

Maund E, Craig D, Suekarran S, Neilson Ar, Wright K, Brealey S, et al. Management of frozen shoulder: a systematic review and cost-effectiveness analysis. *Health Technology Assessment* 2012;**16**:1-264.

### Moore 2010

Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain—establishing best practice in the reporting of systematic reviews. *Pain* 2010;**150**(3):386-9.

#### Neviaser 1945

Neviaser JS. Adhesive capsulitis of the shoulder: a study of the pathological findings in periarthritis of the shoulder. *Journal of Bone and Joint Surgery* 1945;**27**:211-22.

#### Norris 2012

Norris SL, Holmer HK, Ogden LA, Fu R, Abou-Setta AM, Viswanathan MS, et al. Selective outcome reporting as a source of bias in reviews of comparative effectiveness. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I.) AHRQ Publication No. 12-EHC110-EF. Rockville, MD: Agency for Healthcare Research and Quality, August 2012. www.effectivehealthcare.ahrq.gov/reports/ final.cfm.

### Page 2013

Page MJ, McKenzie JE, Forbes A. Many scenarios exist for selective inclusion and reporting of results in randomized trials and systematic reviews. *Journal of Clinical Epidemiology* 2013;**66**(5):524-37.

## Reeves 1975

Reeves B. The natural history of the frozen shoulder syndrome. *Scandinavian Journal of Rheumatology* 1975;**4**:193-6.

### Savovic 2012

Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. *Annals of Internal Medicine* 2012;**157**(6):429-38.

# Schellingerhout 2008

Schellingerhout JM, Verhagen AP, Thomas S, Koes BW. Lack of uniformity in diagnostic labeling of shoulder pain: time for a different approach. *Manual Therapy* 2008;**13**:478-83.

#### Schünemann 2011a

Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of

findings' tables. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011:www.cochrane-handbook.org.

### Schünemann 2011b

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011:www.cochrane-handbook.org.

### Sterne 2011

Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011:www.cochranehandbook.org.

#### Tekavec 2012

Tekavec E, Joud A, Rittner R, Mikoczy Z, Nordander C, Petersson IF, et al. Population-based consultation patterns in patients with shoulder pain diagnoses. *BMC Musculoskeletal Disorders* 2012;**13**:238.

#### van der Windt 1995

van der Windt DA, Koes BW, de Jong BA, Bouter LM. Shoulder disorders in general practice: incidence, patient characteristics, and management. *Annals of Rheumatic Disease* 1995;**54**:959-64.

### van der Windt 1998b

van der Windt DAWM, Van der Heijden GJMG, Koes BW, De Winter AF, Devillé W, Bouter LM. The responsiveness of the shoulder disability questionnaire. *Annals of Rheumatic Disease* 1998;**57**:82-7.

#### Vermeulen 2000

Vermeulen HM, Obermann WR, Burger BJ, Kok GJ, Rozing PM, van den Ende CH. End-range mobilization techniques in adhesive capsulitis of the shoulder joint: a multiple-subject case report. *Physical Therapy* 2000;**80**:1204–13.

#### Walker 2004

Walker-Bone K, Palmer KT, Reading I, Coggon D, Cooper C. Prevalence and impact of musculoskeletal disorders of the upper limb in the general population. *Arthritis Care & Research* 2004;**51**:642-51.

#### References to other published versions of this review

#### Green 1998

Green S, Buchbinder R, Glazier R, Forbes A. Systematic review of randomised controlled trials of interventions for painful shoulder: selection criteria, outcome assessment and efficacy. *British Medical Journal* 1998;**316**:354-60.

#### Green 2003

Green S, Buchbinder R, Hetrick S. Physiotherapy interventions for shoulder pain. *Cochrane Database of Systematic Reviews* 2003, Issue 2. [DOI: 10.1002/14651858.CD004258]



\* Indicates the major publication for the study

# CHARACTERISTICS OF STUDIES

# **Characteristics of included studies** [ordered by study ID]

Buchbinder 2007				
Methods	Design: parallel-group, 2-arm, single-blind randomised controlled trial (Australia)			
	<b>Interventions:</b> following arthrographic joint distension, manual therapy plus directed exercises or sham ultrasound			
	<b>Sample size calculation:</b> 78 participants per group were estimated to be needed on the basis of detection of a clinically relevant difference of 10 points in the Shoulder Pain and Disability Index (SPADI) (SD = 23.9) at 3 months at the 5% level of statistical significance with 80% power, including a 10% rate of loss at follow-up			
	<b>Analysis:</b> intention-to-treat analysis using all randomly assigned participants who provided any post- baseline data planned			
	<b>Source of funding:</b> Australian National Health and Medical Research Council Project Grant (non-indus- try)			
Participants	Number of participants: 156 (78 per group)			
	Baseline characteristics			
	Group receiving arthrographic joint distension followed by manual therapy plus directed exercises			
	Mean (SD) age = 55 (9.3) years; male:female = 24:51			
	Median (range) duration of symptoms: 6 (3-60) months			
	Group receiving arthrographic joint distension followed by sham ultrasound			
	Mean (SD) age = 55.3 (7.7) years; male:female = 31:43			
	Median (range) duration of symptoms: 6 (3-57) months			
	Inclusion criteria			
	• Age > 18 years			
	<ul> <li>Symptoms of pain and stiffness in predominantly 1 shoulder for ≥ 3 months, and restriction of passive motion ≥ 30° in ≥ 2 planes of movement, measured to onset of pain with a gravity inclinometer</li> </ul>			
	Exclusion criteria			
	<ul> <li>Severe pain at rest (&gt; 7 of 10 on a visual analogue scale)</li> </ul>			
	Systemic inflammatory joint disease			
	<ul> <li>Radiological evidence of shoulder osteoarthritis, fracture or calcification; reason to suspect a com- plete rotator cuff tear (arm elevation weakness, positive drop arm sign, high-riding humerus on shoul- der radiograph or complete rotator cuff tear on ultrasound)</li> </ul>			
	Contraindications to arthrogram and/or distension such as current warfarin therapy			
	Allergy to local anaesthetic or iodinated contrast			
	Pregnancy			
	<ul> <li>Likely not to attend for treatment or comply with follow-up</li> </ul>			
	Inability to partake in moderate exercise			
	Previous postdistension physiotherapy			
	Lack of written informed consent			
Interventions	Before active physiotherapy or placebo interventions, all participants received arthrographic disten- sion of the glenohumeral joint with glucocorticoid and normal saline performed under radiological			



## Buchbinder 2007 (Continued)

guidance. Both groups were permitted to use analgesia and non-steroidal anti-inflammatory drugs during the study period. At the end of 6 weeks' treatment, participants were instructed to maintain a 10minute daily exercise programme

#### Arthrographic joint distension followed by manual therapy plus directed exercises (N = 78)

Components of intervention

- Manual therapy: both passive and self-executed muscle stretching techniques to stretch muscles passing over the glenohumeral joint; cervical and thoracic spine mobilisation, glenohumeral joint passive accessory glides; glenohumeral joint passive physiological mobilisation including rotation
- Supervised exercise: strength and co-ordination exercises for rotator cuff and scapular stabilisers; proprioceptive challenge

Dosage: 30 minutes each session

Frequency of administration: Twice per week for 2 weeks, then once per week for 4 weeks (8 sessions)

Provider: physiotherapist

#### Arthrographic joint distension followed by sham ultrasound (N = 78)

*Components of intervention:* sham ultrasound and application of a non-therapeutic gel. Participants received no instruction in exercise techniques and no manual therapy

Dosage: 30 minutes each session

Frequency of administration: Twice per week for 2 weeks, then once per week for 4 weeks (8 sessions)

Outcomes

Outcomes assessed at the end of 6 weeks' treatment, at 12 weeks (post randomisation) and 26 weeks (post randomisation)

#### Primary outcome

 Shoulder pain and disability index (SPADI) (0-100 scale, where a higher score indicates worse pain and/ or disability)

#### Secondary outcomes

- Overall pain using a 10-cm Likert scale comprising a vertical line with 0 (no pain) at the bottom and 10 (maximal imaginable pain) at the top
- Pain at night using a 10-cm Likert scale comprising a vertical line with 0 (no pain) at the bottom and 10 (maximal imaginable pain) at the top
- Activity-related pain using a 10-cm Likert scale comprising a vertical line with 0 (no pain) at the bottom and 10 (maximal imaginable pain) at the top
- Pain at rest using a 10-cm Likert scale comprising a vertical line with 0 (no pain) at the bottom and 10 (maximal imaginable pain) at the top
- Active range of motion in total shoulder flexion, total shoulder abduction and external rotation using
  a gravity inclinometer (in degrees), and internal rotation measured as the distance (in centimetres)
  from the base of the occiput to how high the hand would reach up behind the back
- Health-related quality of life using the SF-36 (8 subscales ranging from 0 to 100, where a higher score represents better health)
- Health-related quality of life using the Assessment of Quality of Life (AQoL) instrument, which comprises 15 items in 5 dimensions (illness, independent living, social relationships, physical senses and psychological well-being). All item responses are ordinal scales with 4 levels per item, and scores are scaled from 0.00 (death) to 1.00 (perfect health)
- Participant-perceived improvement using a 5-point ordinal scale (from 1 = failure: marked worsening to 5 = success: much improved and/or completely recovered)
- Blinded assessor-perceived improvement using a 5-point ordinal scale (1 = marked worsening to 5 = marked improvement)
- Adverse events (elicited by open-ended questions)

# Buchbinder 2007 (Continued)

Notes

Trial registered in ANZCTR (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?AC-TRN=12605000685617)

**Risk of bias** 

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "Consenting, eligible participants were randomized in permuted blocks of 4 and 6, stratified by treatment center, to receive either active or placebo regimens according to a computer-generated table of random numbers creat- ed by the study biostatistician" Comment: An adequate method was used to generate the allocation se- quence
Allocation concealment (selection bias)	Low risk	Quote: "To ensure treatment allocation concealment, just prior to commence- ment of treatment, study centers telephoned a central number for the treat- ment allocation according to the participant's identification number. Only the telephone receptionist had access to the allocation schedule (and no other role in the trial)" Comment: An adequate method was used to conceal the allocation sequence
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Quote: "Thirty-nine participants (53%) in the active group correctly identified their treatment group compared with 35 participants (50%) in the placebo group; 31 participants (42%) in the active group were uncertain which treat- ment they had received compared with 23 participants (33%) in the placebo group. Blinding index was 0.49 (bootstrap 95% Cl 0.40, 0.56), interpreted as moderate success of blinding" Comment: Given the nature of the interventions, personnel could not be blinded to treatment. However, participants were not informed which inter- vention was expected to be superior
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	Low risk	Quote: "Between March 2002 and April 2005, we performed a randomized, placebo-controlled, participant and single assessor blinded trial in partici- pants with adhesive capsulitis" Quote: "All participants were evaluated by the same blinded outcome asses- sor (JMY) at baseline (just prior to arthrographic joint distension), 6 weeks (at the conclusion of the physiotherapy or placebo program), 12 weeks, and 26 weeks" Comment: Participants who completed self-reported outcome measures were blind to treatment
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "Between March 2002 and April 2005, we performed a randomized, placebo-controlled, participant and single assessor blinded trial in partici- pants with adhesive capsulitis" Quote: "All participants were evaluated by the same blinded outcome asses- sor (JMY) at baseline (just prior to arthrographic joint distension), 6 weeks (at the conclusion of the physiotherapy or placebo program), 12 weeks, and 26 weeks" Comment: An assessor of objective outcomes was blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "We recruited 156 study participants (78 in both groups), and 144 (74 active, 70 placebo; 92.3%) completed the 26-week trial. Participants moved through the trial as outlined in Figure 2. Seven participants (3 active, 4 placebo) withdrew from the trial prior to completing the allocated intervention. Because there were no postbaseline followup data for these participants, they were excluded from the efficacy analysis. Three participants (2 placebo) withdrew prior to the 12-week followup (1 active, 2 placebo) and 2 participants were excluded from the 26-week followup. These participants were excluded from the 12-week and 26-week efficacy analyses, respectively. Six participants (2



Buchbinder 2007 (Continued)

		active, 4 placebo) had a second arthrographic joint distension during the trial period but remained in the efficacy analysis. Overall, of those who completed their allocated treatment, 3 (4%) of 75 in the active group and 8 (10.8%) of 74 in the placebo group had further treatment during the 26-week trial (P = 0.11)" Quote: "Characteristics of the 7 participants with no followup data are also provided in Table 1. Although comparisons with the 149 participants are limit- ed, these 7 participants appeared somewhat younger and had worse symptom severity" Quote: "To assess the sensitivity of the results to the exclusion of the 7 partici- pants who provided no postbaseline data and to the missing data from partic- ipants lost to followup during the trial period, we performed a single imputa- tion of these participants' 3-month postbaseline values using regression mod- eling. These models predicted the 12-week data for these participants based on the relationship between the 12-week data, baseline characteristics, and randomized treatment arm among the 149 participants who did have post- baseline data. All analyses in Table 3 corresponding to the 12-week time point were then repeated using the complete data set with these imputed values and the results differed very minimally" Comment: The numbers and reasons for dropouts and losses to follow-up were relatively small and balanced between groups, so they are unlikely to have biased the results
Selective reporting (re- porting bias)	Low risk	Comment: Outcome data were fully reported for all outcomes reported in the trial protocol of the publication
Other bias	Low risk	Comment: No other sources of bias were identified

Bulgen 1984				
Methods	Design: Parallel-group, 4-arm randomised controlled trial (United Kingdom)			
	<b>Interventions:</b> Mobilisation 3 times per week for 6 weeks or intra-articular glucocorticoid injection every week for 3 weeks or ice therapy plus proprioceptive neuromuscular facilitation (PNF) 3 times per week for 6 weeks or no treatment (all were taught pendular exercises)			
	Sample size calculation: not reported			
	Analysis: intention-to-treat analysis			
	Source of funding: Arthritis and Rheumatism Council (non-industry)			
Participants	Number of participants: 42 (11, 11, 12 and 8 in each respective group)			
	Baseline characteristics: Baseline characteristics were not reported by group			
	Mean (range) age: 55.8 (44-74) years; male:female = 14:28			
	Mean (range) duration of symptoms: 4.8 (1-12) months			
	Inclusion criteria			
	<ul> <li>Pain in the shoulder for at least 1 month, with sleep disturbance due to night pain and inability to lie on the affected shoulder</li> </ul>			
	<ul> <li>All active and passive shoulder movements were restricted, with reduction in external rotation of at least 50%</li> </ul>			
	Exclusion criteria			
	• Sensory symptoms or signs in the affected arm or radiation of pain to the neck			



All participants were taught pendular exercises and were advised to do them for 2 to 3 minutes every hour. Non-salicylate analgesics and diazepam 5 mg at night were available as required <b>Mobilisation (N = 11)</b> <i>Components of intervention</i> • Manual therapy: Maitland's mobilisations <i>Dosage:</i> not reported <i>Frequency of administration:</i> 3 times weekly for 6 weeks (18 sessions) <i>Provider:</i> physiotherapist <b>Glucocorticoid injection (N = 11)</b>			
Mobilisation (N = 11)Components of intervention• Manual therapy: Maitland's mobilisationsDosage: not reportedFrequency of administration: 3 times weekly for 6 weeks (18 sessions)Provider: physiotherapistGlucocorticoid injection (N = 11)			
Components of intervention <ul> <li>Manual therapy: Maitland's mobilisations</li> </ul> <li>Dosage: not reported Frequency of administration: 3 times weekly for 6 weeks (18 sessions) Provider: physiotherapist Glucocorticoid injection (N = 11)</li>			
<ul> <li>Manual therapy: Maitland's mobilisations</li> <li>Dosage: not reported</li> <li>Frequency of administration: 3 times weekly for 6 weeks (18 sessions)</li> <li>Provider: physiotherapist</li> <li>Glucocorticoid injection (N = 11)</li> </ul>			
Dosage: not reported Frequency of administration: 3 times weekly for 6 weeks (18 sessions) Provider: physiotherapist Glucocorticoid injection (N = 11)			
Frequency of administration: 3 times weekly for 6 weeks (18 sessions) Provider: physiotherapist Glucocorticoid injection (N = 11)			
Provider: physiotherapist Glucocorticoid injection (N = 11)			
Glucocorticoid injection (N = 11)			
<i>Components of intervention:</i> methyl prednisolone acetate 20 mg and 1% lignocaine hydrochloride 0-5 mL injected into the subacromial bursa and a similar amount into the shoulder joint by the anterior route			
Frequency of administration: weekly, for 3 weeks			
Provider: rheumatologist			
Ice therapy plus proprioceptive neuromuscular facilitation (N = 12)			
Components of intervention: ice packs followed by proprioceptive neuromuscular facilitation (PNF)			
Frequency of administration: 3 times weekly for 6 weeks (18 sessions)			
Provider: physiotherapist			
No treatment (N = 8)			
Outcomes assessed at baseline, weekly for 6 weeks, then monthly for 6 months. No primary outcome was stated by trialists			
<ul> <li>Night pain using a 10-cm visual analogue scale (VAS) and by verbal reporting of whether the type of pain was "better," "the same" or "worse"</li> </ul>			
<ul> <li>Pain on movement using a 10-cm VAS and by verbal reporting of whether the type of pain was "better,"</li> <li>"the same" or "worse"</li> </ul>			
<ul> <li>Rest pain during the day using a 10-cm VAS and by verbal reporting of whether the type of pain was "better," "the same" or "worse"</li> </ul>			
<ul> <li>Passive range of movement (external rotation, total rotation, glenohumeral abduction, total flexion, total abduction, glenohumeral flexion, internal rotation), all measured with a hydrogoniometer to the nearest 5 degrees</li> </ul>			
No outcome data were reported in a way that was suitable for inclusion in a meta-analysis. In the 2003 version of this review, study authors were contacted, but this attempt was unsuccessful. The trial report states, "All patients reported an improvement in pain during the study, but 17 still had residual pain at the end of it, usually mild, but moderate in four. Residual pain was commoner in the ice group,			



# Bulgen 1984 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "The patients were randomly allocated to one of four treatment groups" Comment: No information was reported about how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported about how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants who may have had different expectations about the benefits of the intervention they received self-reported some out-comes (e.g. pain)
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "Clinical assessment was performed before treatment, weekly for 6 weeks and monthly for a further 6 months by an independent observer who was not aware of the treatment given" Comment: Outcome assessor of objective outcomes was blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "The patients were randomly allocated to one of four treatment groups: (1) steroid group (11 patients); (2) Mobilization group (11 pa- tients); (3) Ice group (12 patients); (4) Non-treatment group (8 patients)" Quote: "Forty-two patients, 28 females and 14 males, with previously untreat- ed frozen shoulder completed this study" Comment: All randomly assigned participants completed the study
Selective reporting (re- porting bias)	High risk	Comment: No outcome data were reported in a way that was suitable for in- clusion in a meta-analysis. Trialists did not report any numerical data for pain outcomes and presented only mean scores (with no measures of variation) for total flexion, total abduction, external rotation and total rotation in figure for- mat. No results for glenohumeral flexion or glenohumeral abduction were re- ported
Other bias	Low risk	Comment: No other sources of bias were identified

Carette 2003	
Methods	Design: parallel-group, 4-arm, single-blind randomised controlled trial (Canada)
	<b>Interventions:</b> 12 sessions of supervised physiotherapy plus glucocorticoid injection (triamcinolone hexacetonide 40 mg) or glucocorticoid injection alone or supervised physiotherapy plus saline injec- tion or saline injection alone
	<b>Sample size calculation:</b> 36 participants per group were estimated to be needed on the basis of detec- tion of a clinically relevant difference ≥ 10 points in the Shoulder Pain and Disability Index (SPADI) (SD ≤ 15) at the 5% level of statistical significance with 80% power
	<b>Analysis:</b> intention-to-treat analysis (analysing all participants randomly assigned, using a last obser- vation carried forward analysis)
	Source of funding: Arthritis Society of Canada (non-industry)



Carette 2003 (Continued)					
Participants	Number of participants: 93 (21, 23, 26 and 23 in each respective group)				
	Baseline characteristics				
	Group receiving supervised physiotherapy plus glucocorticoid injection:				
	Mean (SD) age = 54.9 (10.5) years; male:female = 7:14				
	Mean (SD) duration of symptoms: 22.1 (14.9) weeks				
	Group receiving glucocorticoid injection alone				
	Mean (SD) age = 55.4 (10) years; male:female = 8:15				
	Mean (SD) duration of symptoms: 21.2 (11) weeks				
	Group receiving supervised physiotherapy plus saline injection				
	Mean (SD) age = 54.2 (8.3) years; male:female = 14:12				
	Mean (SD) duration of symptoms: 20.8 (11.2) weeks				
	Group receiving saline injection alone				
	Mean (SD) age = 56.5 (9.4) years; male:female = 9:14				
	Mean (SD) duration of symptoms: 20.3 (7.3) weeks				
	Inclusion criteria				
	<ul> <li>Age 18 years or older</li> <li>Symptomatic for &lt; 1 year (defined as the presence of shoulder pain with limitation of both active and passive movements of the glenohumeral joint of ≥ 25% in at least 2 directions (abduction, flexion, external rotation, internal rotation) as compared with the contralateral shoulder or with normal values)</li> <li>Total score ≥ 30 on the Shoulder Pain and Disability Index (SPADI)</li> </ul>				
	Exclusion criteria				
	<ul> <li>Adhesive capsulitis was secondary to another cause, including inflammatory, degenerative, metabolic or infectious arthritis, cerebrovascular accident or fracture</li> <li>Known blood coagulation disorder or allorgy to radiological contract material</li> </ul>				
	Known blood coagulation disorder of allergy to radiological contrast material				
Interventions	All participants were taught a 10-minute exercise programme consisting of active and auto-assisted ROM exercises in the planes of flexion, abduction, external rotation and internal rotation (hand behind back) to be done at home twice daily for 3 months				
	Supervised physiotherapy plus glucocorticoid injection (N = $21$ )				
	Components of physiotherapy intervention				
	Manual therapy: mobilisation techniques (not specified)				
	<ul> <li>Supervised exercise: active ROM exercises (for acute adhesive capsulitis); active and auto-assisted ROM exercises and isometric strengthening exercises (for chronic adhesive capsulitis)</li> </ul>				
	• Electrotherapy: TENS (for acute adhesive capsulitis); therapeutic ultrasound (for chronic adhesive capsulitis)				
	Other: ice application				
	Dosage: 1 hour overall				
	Frequency of administration: 3 times a week for 4 weeks (12 sessions)				
	Provider: physiotherapist				



Carette 2003 (Continued)	<i>Components of glucocorticoid injection:</i> Under fluoroscopic guidance, a 21-gauge needle, 2.5–3" long, was directed into the shoulder joint space. Aqueous contrast material (Omnipaque; Sanofi-Winthrop, Markham, Ontario, Canada) was injected to confirm the correct location of the needle in the joint. This was followed by injection of 40 mg triamcinolone hexacetonide (2 mL)
	Glucocorticoid injection alone (N = 23)
	The same injection method as described above was delivered
	Supervised physiotherapy plus placebo injection (N = 26)
	The same injection and supervised physiotherapy methods as described above were delivered, except that isotonic saline (2 mL) was injected into the shoulder joint space
	Placebo injection alone (N = 23)
	The same injection method as described above was delivered, except that isotonic saline (2 mL) was injected into the shoulder joint space
Outcomes	Outcomes assessed at 6 weeks, 3 months, 6 months and 1 year post randomisation
	Primary outcome
	<ul> <li>Shoulder pain and disability index (SPADI) (0-100 scale, where a higher score indicates worse pain and/ or disability)</li> </ul>
	Secondary outcomes
	<ul> <li>General health status measured using the SF-36</li> <li>Active and passive range of motion in flexion, abduction and external rotation, assessed using a goniometer with the participant in a supine position</li> </ul>
Notes	Trialists reported the following protocol violation: "Five patients (2 in the combination group and 1 in each of the other groups) received, in addition to their assigned injection, a glucocorticoid injection (triamcinolone hexacetonide, 20 mg) after randomization, and 1 patient in the saline group underwent rotator cuff repair 8 months after enrolment. All of these injections were prescribed by study investigators who were blinded to the original treatment assignment, and all were done under fluoroscopic guidance. The patient in the placebo group and the patient in the physiotherapy group each received the injection after the 6-week visit; the 3 patients in the corticosteroid and combination group received it after the 3-month or 6-month visits"
	Unpublished data regarding study design (required for risk of bias assessment) provided by trialist on request
Risk of bias	

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "The assignment scheme was generated from a table of random num- bers. Random assignments to the treatment groups were stratified according to study center and balanced after every 12 assignments" Comment: An adequate method was used to generate the allocation se- quence
Allocation concealment (selection bias)	Low risk	Quote: "The opaque prenumbered envelopes containing the assignments were kept by the hospital pharmacist at each center" Comment: An adequate method was probably used to conceal the allocation sequence
Blinding of participants and personnel (perfor- mance bias)	High risk	Quote: "The syringes containing the triamcinolone hexacetonide or saline were prepared by the hospital pharmacist and covered with aluminum foil so

Carette 2003 (Continued) All outcomes		the radiologist administering the injections and the patient were not aware of the treatment"
		Comment: Participants and personnel were blind to the injection component of the intervention, but not the physiotherapy component. Participants may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Participants self-reported their SPADI and general health scores and were not blind to whether they had received physiotherapy. Participants may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "Each subject was assessed by the same physiotherapist throughout the trial, with a few exceptions. The physiotherapists involved in these assess- ments were unaware of the treatment allocation and did not normally work in the clinics where the physiotherapy was administered" Comment: Outcome assessors of objective outcomes were blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "The primary analysis was based on an intent-to-treat principle, and all subjects were included in the analysis. In the case of subjects lost to followup, the data from the last available assessment were imputed to all subsequent evaluations" Quote: "Of the remaining 93 patients, 2 in the combination group, 9 in the cor- ticosteroid group, 4 in the physiotherapy group, and 1 in the placebo group did not return for all visits" Comment: Greater loss to follow-up was seen in the glucocorticoid injection group compared with the other 3 groups, but it is unclear whether the reasons for loss to follow-up were related to treatment received (or whether they were balanced across groups)
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Celik 2010			
Methods	Design: parallel-group, 2-arm randomised controlled trial (Turkey)		
	<b>Interventions:</b> scapulothoracic exercises added or not added to glenohumeral ROM exercises, TENS, cold pack, home exercise and NSAIDs		
	Sample size calculation: not reported		
	Analysis: intention-to-treat analysis		
	Source of funding: not reported		
Participants	Number of participants: 29 (14 and 15 in each respective group)		
	Baseline characteristics		
	Group receiving scapulothoracic exercises plus glenohumeral ROM exercises, TENS, cold pack, home exer- cise and NSAIDs		
	Mean (range) age = 49.6 (38-62) years; male:female = 2:13		
	Duration of symptoms not reported		
	Group receiving glenohumeral ROM exercises, TENS, cold pack, home exercise and NSAIDs		



Mean (range) age = 54.78 (42-65) years; male:female = 5:9

Duration of symptoms not reported

### **Inclusion criteria**

- Range of motion in external rotation, abduction and flexion less than 50% in comparison with the other shoulder
- Normal radiography (anteroposterior, lateral)
- Secondary frozen shoulder diagnosis with MRI showing a small rotator cuff tear
- Secondary frozen shoulder with type II subacromial impingement syndrome on physical examination • and MRI

### **Exclusion criteria**

- · Radiculopathy
- Thoracic outlet syndrome
- Rheumatological disorders •
- Fractures and tumours of the upper extremity •
- Neurological disorders causing muscle weakness in the shoulder •

#### Interventions

### Scapulothoracic exercises plus glenohumeral ROM exercises, TENS, cold pack, home exercise and NSAIDs (N = 15)

Components of intervention:

	<ul> <li>Supervised exercise: scapulotionactic strengthening (serratus anterior, middle and lower trapezids, latissimus dorsi), upper trapezius stretching and postural exercises as follows: (1) scapular retraction with exercise band; (2) extension with exercise band; (3) scapular adduction and elevation; (4) wall, table and floor push-ups; (5) scapular stabilisation with exercise ball in upright standing position; (6) scapular adduction in prone position; (7) extension in prone position; (8) scapular protraction in supine position; (9) push-up in sitting position; and (10) scapular abduction in upright standing position. In addition, participants were given passive or active assistive ROM and pulley exercises led by physiotherapists at minimum pain level</li> <li>Home exercise: active-assistive ROM exercises (flexion, scapular elevation and internal and external rotation exercises), posterior and inferior capsule stretching exercises and self-stick exercises (depending on the pain status of participants)</li> <li>Electrotherapy: TENS</li> <li>Other: cold pack, NSAIDs</li> </ul>
	<i>Dosage:</i> Supervised exercises gradually increased according to the pain and muscle strength of participants. TENS delivered for 20 minutes. During the fifth and sixth weeks of treatment, the dose of scapulothoracic and glenohumeral stretching exercises was increased (considering pain levels), TENS and NSAIDs were terminated and cold pack was applied only when the participant had pain
	<i>Frequency of administration:</i> 5 times a week for 6 weeks (30 sessions) for supervised exercises, twice a day for home exercise
	Provider: physiotherapist
	Glenohumeral ROM exercises, TENS, cold pack, home exercise and NSAIDs (N = 14)
	The same intervention as described above was delivered, except that scapulothoracic exercises were not undertaken
Outcomes	Outcomes assessed at the end of 6 weeks' treatment and at 12 weeks from baseline. No primary out- come was reported by trialists
	<ul> <li>Pain using a visual analogue scale (scale units not reported)</li> <li>Function using the modified Constant score (0-100 scale, where a higher score indicates better functional ability)</li> </ul>



Celik 2010 (Continued)

• Passive range of motion (elevation/flexion, external rotation and internal rotation)

Notes

**Risk of bias** 

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "The patients were divided randomly into two groups" Comment: No information was reported about how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported about how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions (the same multi-component physical therapy intervention with or without additional exercises), partici- pants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants who may have had different expectations about the benefits of the intervention they received self-reported pain and function
Blinding of outcome as- sessment (detection bias) Objective outcomes	Unclear risk	Comment: Blinding of outcome assessors was not reported, although this could have been done for the objectively assessed outcome—range of motion
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: No dropouts, losses to follow-up or exclusions were reported, and analyses are reported as based on the number of randomly assigned participants
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

### Chan 2010

Methods	Design: parallel-group, 2-arm, single-blind randomised controlled trial (United Kingdom)
	<b>Interventions:</b> passive mobilisation plus home care programme or home care programme alone, 2 weeks after receiving a glucocorticoid injection
	Sample size calculation: not reported
	Analysis: intention-to-treat analysis
	Source of funding: not reported
Participants	Number of participants: 14 (7 per group)
	Baseline characteristics
	Group receiving passive mobilisation plus home care programme
	Mean (range) age = 50.9 (48-76) years; male:female = 2:5



Chan 2010 (Continued)

Mean duration of symptoms = 2.5 months

Group receiving home care programme alone

Mean (range) age = 56.7 (39-59) years; male:female = 6:1

Mean duration of symptoms = 2.4 months

### Inclusion criteria

- Diagnosis of stage II capsulitis, defined as pain spreading beyond the elbow in the C5 dermatone distribution and participant cannot sleep on that side at night; a full capsular pattern is present (lateral rotation > abduction > medial rotation) with the characteristics 'hard' end-feel due to involuntary muscle spasm and capsular contracture
- Corticosteroid injection is indicated as the result of irritable symptoms in stage II capsulitis
- Clear cervical spine assessment
- Age over 18 years
- Ability to read, complete the SPADI and understand the VAS
- Ability to attend all physiotherapy treatment and measurement sessions

### **Exclusion criteria**

- Absolute contraindication to corticosteroid injection including previous history of hypersensitivity to local anaesthetic and/or steroid, and local infection in the shoulder region/systematic infection
- Signs and symptoms of systemic inflammatory disease, for example, rheumatoid arthritis, polymyalgia and fibromyalgia
- Malignant disease or osteoporosis in the shoulder region
- Immunosuppressed patient
- Pregnant
- Younger than 18 years of age
- Inability to gain informed consent, for example, those with unstable diagnosed psychiatric disorders or dementia
- Taking oral steroids, oral antibiotics or anticoagulants
- Unstable diabetes
- Shoulder symptoms due to other causes such as neurological abnormalities or congenital deficits affecting shoulder function
- Before surgery
- History of fracture, dislocation and shoulder surgery
- Prosthetic joint in the shoulder

Interventions

Before randomisation, all participants received a glucocorticoid injection given by the posterior approach, containing 30 mg triamcinolone acetonide (Kenalog) and 3.25 mL 1% lidocaine Participants were randomly allocated to the intervention or control group 2 weeks later.

## Passive mobilisation plus home care programme (N = 7)

Components of intervention:

- Manual therapy: passive mobilisation (grade A and grade B mobilisation techniques, as advocated by Cyriax for treatment of stage II capsulitis). The Grade A mobilisation technique, which included caudal and lateral distraction and aims to restore the accessory range of joint movement and to regain some elastic end-feel of the limited movement, was repeated 10 times—3 sets in total, with rest between sets. Once the end-feel regained some elasticity at the affected glenohumeral joint, the Grade B mobilisation was started, which aimed to stretch the contracted capsule and restore the movements limited in the capsular pattern
- Home care programme: exercise programme (active and active-assisted ROM exercises, capsular stretching exercise, postural correction and scapular stabilising work), instruction for simple pain relief, education and self-management techniques. As symptoms improved, participants were instructed to progress their rehabilitation with more advanced exercise during their follow-up

Chan 2010 (Continued)	<i>Dosage:</i> 30 minutes (fo (for home exercise)	r manual therapy); 10 repetitions and a 15-second hold in all capsular stretches
	<i>Frequency of administr</i> home exercise comple	<i>ation:</i> 6 weekly sessions of manual therapy over period of 10 weeks (6 sessions); ted 3 times daily
	Provider: physiotherap	ist
	Home care programm	ne alone (N = 7)
	The same home care p	rogramme as described above was delivered
Outcomes	Outcomes assessed at the trialists	weeks 2, 4, 7 and 10 (end of treatment). No primary outcome was reported by
	• Pain using a 10-cm	visual analogue scale labelled "no pain" to "unbearable pain"
	<ul> <li>Shoulder pain and d or disability)</li> </ul>	lisability index (SPADI) (0-100 scale, where a higher score indicates worse pain and/
	<ul> <li>Active range of mot niometer</li> </ul>	ion (abduction, lateral rotation, medial rotation (hand behind back)) using a go-
Notes	Mean scores for each outcome were presented in figure format at each time point, but with no mea- sures of variation. For 3 of the 5 outcomes, trialists reported (numerically) the mean change from base- line to the end of 10 weeks' treatment (with no measure of variation); for the other 2 outcomes, only percentage improvement data were reported; this is not suitable for inclusion in a meta-analysis. At- tempts to retrieve non-reported outcome data from trialists were unsuccessful (although other infor- mation about the trial was provided)	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "The random assignments were placed into a sealed, opaque, prenum- bered envelope. The 14 subjects were randomized 1:1 into two treatment groups, based on a computer-generated randomisation list prepared and held

		by staff not involved in the research process, and the sealed envelope was only opened at this point to ensure allocation concealment" Comment: An adequate method was used to generate the allocation se- quence
Allocation concealment (selection bias)	Low risk	Quote: "The random assignments were placed into a sealed, opaque, prenum- bered envelope. The 14 subjects were randomized 1:1 into two treatment groups, based on a computer-generated randomisation list prepared and held by staff not involved in the research process, and the sealed envelope was only opened at this point to ensure allocation concealment" Comment: An adequate method was used to conceal the allocation sequence
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Quote: "A single-blinded procedure was used, aiming to reduce the bias from the experimenter's expectations and predictions. The independent observers, who collected data, were unaware to which intervention the subjects had been allocated. The subject was also instructed not to reveal any information about their treatment. This blinding method was used in previous shoulder studies" Quote: "All subjects were treated by the senior author (SC): because she was not blind to the hypothesis being tested, any personal pre-conceptions regard- ing treatment outcome could influence the results. Double-blinding of the pas- sive mobilisation was not considered practical" Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention

Cochrane Library	Trusted evidence. Informed decisions. Better health.	Cochrane Database of Systematic Reviews
Chan 2010 (Continued)		
Blinding of outcome as- sessment (detection bias Self-reported outcomes	High risk )	Quote: "A single-blinded procedure was used, aiming to reduce the bias from the experimenter's expectations and predictions. The independent observers, who collected data, were unaware to which intervention the subjects had been allocated. The subject was also instructed not to reveal any information about their treatment. This blinding method was used in previous shoulder studies" Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported some out- comes (pain, SPADI)
Blinding of outcome as- sessment (detection bias Objective outcomes	Low risk )	Quote: "A single-blinded procedure was used, aiming to reduce the bias from the experimenter's expectations and predictions. The independent observers, who collected data, were unaware to which intervention the subjects had been allocated. The subject was also instructed not to reveal any information about their treatment. This blinding method was used in previous shoulder studies" Comment: Assessors of objective outcomes were blind to treatment
Incomplete outcome dat (attrition bias) All outcomes	a Low risk	Quote: "All subjects entering the study fully attended their sessions and were followed up to week 10" Comment: No dropouts, losses to follow-up or exclusions occurred
Selective reporting (reporting bias)	Unclear risk	Comment: Mean scores were presented in figure format at each time point, but with no measures of variation. For 3 of the 5 outcomes, trialists reported (numerically) the mean change from baseline to the end of 10 weeks' treat- ment (with no measure of variation); for the other 2 outcomes, only percent- age improvement data were reported; this is not suitable for inclusion in a meta-analysis. However, it is not clear whether data were incompletely report- ed based on the statistical significance or magnitude of the results. Also, with- out a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Chau	han	20	11
CIICA			-

Methods	Design: parallel-group, 2-arm randomised controlled trial (India)
	<b>Interventions:</b> deep transverse friction massage of the 2 tendon supraspinatus and subscapularis as laid by Cyriax, followed by inferior capsular stretching, passive ROM exercises, hot packs and home exercise programme or only hot packs and home exercise programme
	Sample size calculation: not reported
	Analysis: per-protocol analysis
	Source of funding: not reported
Participants	Number of participants: 30 (14 and 16 in each respective group)
Participants	Number of participants: 30 (14 and 16 in each respective group) Baseline characteristics: Age by group was not reported, and duration of symptoms was not reported at all
Participants	Number of participants: 30 (14 and 16 in each respective group) Baseline characteristics: Age by group was not reported, and duration of symptoms was not reported at all Age range: 40-60 years
Participants	Number of participants: 30 (14 and 16 in each respective group)         Baseline characteristics: Age by group was not reported, and duration of symptoms was not reported at all         Age range: 40-60 years         Group receiving deep transverse friction massage, capsular stretching, passive ROM exercises, hot packs and home exercise programme
Participants	Number of participants: 30 (14 and 16 in each respective group)         Baseline characteristics: Age by group was not reported, and duration of symptoms was not reported at all         Age range: 40-60 years         Group receiving deep transverse friction massage, capsular stretching, passive ROM exercises, hot packs and home exercise programme         Male:female = 6:7



Chauhan 2011 (Continued)

Interventions

Group receiving hot packs and home exercise programme

Male:female = 5:8

# Inclusion criteria

- Primary adhesive capsulitis or idiopathic
- Age 40-60 years
- Shoulder pain and loss of range of motion longer than 2 months but less than 1 year (minimum)
- Normal findings on anterior-posterior and axillary lateral radiographs of glenohumeral joint
- Absence of any rheumatoid tendinous lesions, local sepsis and skin disease
- Range of motion loss of 50% or greater than in the non-involved shoulder (in abduction)
- Sufficient English to complete the questionnaires

# **Exclusion criteria**

- Presence of any medical condition such as cardiac disease and diabetes mellitus
- Patients who had adhesive capsulitis secondary to shoulder dislocation, fracture
- Disorder such as shoulder disease, reflex sympathetic dystrophy, rotator cuff injury, rheumatoid arthritis and ankylosing spondylitis
- Patients with bilateral involvement of the shoulder
- Presence of cervical radiculopathy
- Patients who have had prior shoulder surgery

Deep transverse friction massage, capsular stretching, passive ROM exercises, hot packs and home exercise programme (N = 14)

Components of intervention:

Risk of bias	
Notes	Mean scores with no measures of variation are reported in figure format for all outcomes at days 1, 3, 5, 7, 9 and 11 (except for SPADI score, which was reported only at days 5 and 11)
	<ul> <li>Shoulder Pain and Disability Index (SPADI) (0-100 scale, where a higher score indicates worse pain and/or disability)</li> </ul>
	<ul> <li>Range of motion (abduction, lateral rotation, medial rotation) using a goniometer (not reported whether passive or active)</li> </ul>
	Pain using a visual analogue scale (scale units not reported)
Outcomes	Outcomes assessed at end of first session (day 1), second session (day 3), third session (day 5), fourth session (day 7), fifth session (day 9) and sixth session (day 11). No primary outcome reported by trialists
	Hot pack and home exercise programme 3 times a week for 2 weeks
	Hot packs and home exercise programme (N = 16)
	Provider: physiotherapist
	Frequency of administration: 3 times a week for 2 weeks (6 sessions)
	Dosage: 1 hour
	Other: hot pack
	<ul> <li>Supervised exercises: passive ROM exercises</li> <li>Home exercise: not specified</li> </ul>
	• Manual therapy: deep transverse friction massage of the 2 tendon supraspinatus and subscapularis as laid by Cyriax 1983, followed by inferior capsular stretching. Deep friction was given transverse to the fiber direction, usually 15 per session

### Chauhan 2011 (Continued)

Random sequence generation (selection bias)       Unclear risk       Quote: "The subjects recruited through screening, were then randomly asigned to one of the two treatment groups—Experimental group and Control group via simple randomization method". Comment: No information was reported about how the allocation sequence was generated         Allocation concealment (selection bias)       Unclear risk       Comment: No information was reported about how the allocation sequence was concealed         Blinding of participants and personnel (performance bias)       High risk       Quote: "Neither the subjects nor the therapist were blinded to group assignment". Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention         Blinding of outcome assessment (detection bias)       High risk       Comment: Unblinded participants, who may have had different expectations about the benefits of the benefits of the intervention they received, self-reported some outcomes (pain, SPADI)         Blinding of outcome assessment (detection bias)       Unclear risk       Comment: Blinding of outcome assessors was not reported, although this could have been done for the objective outcome of ange of motion Objective outcome data         All outcomes       Unclear risk       Quote: "Total thirty subjects were recruited and were randomly assigned to 2 groups. The experimental group consisted of males and 7 females whereas control group consisted of males and 8 females as in Experimental group 1 and in control group 2 subjects were unable to continue the treatment" (Comment: A slightly larger number of dropouts were eported in the control group. Subjects w	Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)         Unclear risk         Comment: No information was reported about how the allocation sequence was concealed           Blinding of participants and personnel (perfor- mance bias)         High risk         Quote: "Neither the subjects nor the therapist were blinded to group assign- ment"           Blinding of outcome as- sessment (detection bias)         High risk         Quote: "Neither the subjects nor the therapist were blinded to group assign- ment"           Blinding of outcome as- sessment (detection bias)         High risk         Comment: Given the nature of the interventions, participants, who may have had different expectations about the benefits of the intervention they received, self-reported some out- comes (pain, SPADI)           Blinding of outcome as- sessment (detection bias)         Unclear risk         Comment: Blinding of outcome assessors was not reported, although this could have been done for the objectively assessed outcome of range of motion Objective outcomes           Incomplete outcome data (alt outcomes         Unclear risk         Quote: "Total thirty subjects were recruited and were randomly assigned to 2 group. The experimental group consisted of 6 males and 7 females whereas control group a 3 subjects were unable to continue the treatment" Comment: A slightly larger number of dropouts were reported in the control group, although the reason provided is badiguous (i.e. not clear whether par- ticipants were "unable to continue the treatment" Comment: Trialists reported mean scores with no measures of variation for all outcomes at days 1, 3, 5, 7, 9 and 11 (except for SPADI score, which was re- ported only at days 5 and 11) in figure format. Exact P values for differences between gro	Random sequence genera- tion (selection bias)	Unclear risk	Quote: "The subjects recruited through screening, were then randomly as- signed to one of the two treatment groups—Experimental group and Control group via simple randomization method" Comment: No information was reported about how the allocation sequence was generated
Blinding of participants and personnel (perfor- mance bias) All outcomesHigh riskQuote: "Neither the subjects nor the therapist were blinded to group assign- ment" Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each interventionBlinding of outcome as- sessment (detection bias) Self-reported outcomesHigh riskComment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported some out- comes (pain, SPADI)Blinding of outcome as- sessment (detection bias) Objective outcomesUnclear riskComment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported, although this could have been done for the objectively assessed outcome of range of motion Objective outcomesIncomplete outcome data (loutomes)Unclear riskQuote: "Total thirty subjects were recruited and were randomly assigned to 2 groups. The experimental group consisted of 5 males and 7 females whereas control group orosisted of 5 males and 8 females as in Experimental group 1 and in control group orosisted of 5 males and 8 females as in Experimental group 1 and in control group orosisted of 5 males and 7 females whereas control group, although the reason provided is ambiguous (i.e. not clear whether par- ticipants were "unable to continue the atternent" Comment: Trialists reported mean scores with no measures of variation for all outcomes at days 1, 3, 5, 7, 9 and 11 (except for SPADI score, which was re- ported only at days 5 and 11) in figure format. Exact P values for differences between groups were reported only when statistically significant. Trialista al- so repor	Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported about how the allocation sequence was concealed
Blinding of outcome as- sessment (detection bias) Self-reported outcomesHigh riskComment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported some out- 	Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Quote: "Neither the subjects nor the therapist were blinded to group assign- ment" Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Objective outcomesUnclear riskComment: Blinding of outcome assessors was not reported, although this could have been done for the objectively assessed outcome of range of motionIncomplete outcomesUnclear riskQuote: "Total thirty subjects were recruited and were randomly assigned to 2 groups. The experimental group consisted of 6 males and 7 females whereas control group consisted of 5 males and 8 females as in Experimental group 1 and in control group 3 subjects were unable to continue the treatment" Comment: A slightly larger number of dropouts were reported in the control group, although the reason provided is ambiguous (i.e. not clear whether par- ticipants were "unable to continue treatment" because they moved cities, or because of adverse effects of treatment)Selective reporting (re- porting bias)High riskComment: Trialists reported mean scores with no measures of variation for all outcomes at days 1, 3, 5, 7, 9 and 11 (except for SPAD) score, which was re- ported only at days 5 and 11) in figure format. Exact P values for differences between groups were reported only when statistically significant. Trialists randomly assigned or by the number who completed the study did not pro- duce whole numbers, or values close to whole numbers, so it is not clear how these percentages were calculated by the trialists). Also, the definition of "im- provement" for all of these outcomes was not reported. Finally, it is not clear whether other range of motion measures were collected and not reported based on the resultsOther biasLow riskComment: No other sources of bias were identified	Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported some out-comes (pain, SPADI)
Incomplete outcome data (attrition bias)Unclear riskQuote: "Total thirty subjects were recruited and were randomly assigned to 2 groups. The experimental group consisted of 6 males and 7 females whereas control group consisted of 5 males and 8 females as in Experimental group 1 and in control group of 3 subjects were unable to continue the treatment" Comment: A slightly larger number of dropouts were reported in the control group, although the reason provided is ambiguous (i.e. not clear whether par- 	Blinding of outcome as- sessment (detection bias) Objective outcomes	Unclear risk	Comment: Blinding of outcome assessors was not reported, although this could have been done for the objectively assessed outcome of range of motion
Selective reporting (reporting bias)High riskComment: Trialists reported mean scores with no measures of variation for all outcomes at days 1, 3, 5, 7, 9 and 11 (except for SPADI score, which was re- ported only at days 5 and 11) in figure format. Exact P values for differences between groups were reported only when statistically significant. Trialists al- so reported the proportion of participants with "improvement" in each out- come (although multiplying these percentages by the number of participants randomly assigned or by the number who completed the study did not pro- 	Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "Total thirty subjects were recruited and were randomly assigned to 2 groups. The experimental group consisted of 6 males and 7 females whereas control group consisted of 5 males and 8 females as in Experimental group 1 and in control group 3 subjects were unable to continue the treatment" Comment: A slightly larger number of dropouts were reported in the control group, although the reason provided is ambiguous (i.e. not clear whether par- ticipants were "unable to continue treatment" because they moved cities, or because of adverse effects of treatment)
Other bias Low risk Comment: No other sources of bias were identified	Selective reporting (re- porting bias)	High risk	Comment: Trialists reported mean scores with no measures of variation for all outcomes at days 1, 3, 5, 7, 9 and 11 (except for SPADI score, which was re- ported only at days 5 and 11) in figure format. Exact P values for differences between groups were reported only when statistically significant. Trialists al- so reported the proportion of participants with "improvement" in each out- come (although multiplying these percentages by the number of participants randomly assigned or by the number who completed the study did not pro- duce whole numbers, or values close to whole numbers, so it is not clear how these percentages were calculated by the trialists). Also, the definition of "im- provement" for all of these outcomes was not reported. Finally, it is not clear whether other range of motion measures were collected and not reported based on the results
	Other bias	Low risk	Comment: No other sources of bias were identified

# Cheing 2008

Methods

Design: parallel-group, 3-arm, single-blind randomised controlled trial (Hong Kong)

**Interventions:** home exercise plus electroacupuncture or home exercise plus interferential electrotherapy or no treatment

Sample size calculation: not reported



Cheing 2008 (Continued)	Analysis: per-protocol analysis
	Source of funding: not reported
Participants	Number of participants: 74 (25, 24 and 25 in each respective group)
	<b>Baseline characteristics:</b> Sex of participants was reported as 22 males and 48 females. Age range for all participants was reported as 33-90 years
	Group receiving electroacupuncture plus home exercise
	Mean (SD) duration of treatment = 6.71 (6.5) months
	Group receiving interferential electrotherapy plus home exercise
	Mean (SD) duration of treatment = 6.7 (6.05) months
	Group receiving no treatment
	Mean (SD) duration of treatment = 8.26 (7.94) months
	Inclusion criteria
	<ul> <li>Patients who reported localised pain over 1 shoulder, experienced night pain and had restricted active and passive shoulder motions</li> </ul>
	Exclusion criteria
	<ul> <li>History of trauma, fractures, previous shoulder surgery, cervical or thoracic pain syndrome, complex regional pain syndrome, malignancies or anticoagulant therapy</li> </ul>
	Had received acupuncture treatment to the painful shoulder in the past 6 months
Interventions	Home exercise plus electroacupuncture (N = 25)
Interventions	Home exercise plus electroacupuncture (N = 25) Components of intervention
Interventions	<ul> <li>Home exercise plus electroacupuncture (N = 25)</li> <li>Components of intervention</li> <li>Home exercise: Participants were instructed to follow a chart and perform a standard set of shoulder mobilisation exercises 5 times a day, which included 4 directions: (1) forward flexion—with the help of an overhead pulley system; (2) external rotation—keeping the arm close to the trunk, using a small bamboo to externally rotate the shoulder through pushing against the palm; (3) horizontal adduction—pressing a horizontally adducted arm against the chest with the other arm to achieve horizontal adduction and (4) internal rotation—placing the affected arm behind the back and grasping 1 end of a towel, the other hand then pulling the opposite end of the towel to achieve maximum internal rotation</li> <li>Electrotheracupuncture: Sterile stainless steel acupuncture needles were inserted 15–25 mm intramuscularly into 3 acupoints including 1 trigger point, 1 local point (LI 15: Jianyu) and 1 distal point (ST38: Tiaokou) (14). Trigger points were identified by areas of greatest tenderness around the painful shoulder that were determined on an individual basis. The 2 needles in the shoulder region (trigger point and LI 15) were connected to an electroacupuncture device (Model: ES-160, ITO Co. Ltd, 3-3-3 Tpupta, al-Minami, Nerima-ku, Tokyo 176-86 05, Japan) and were stimulated with an alternating frequency of 2–100 Hz at a pulse duration of 100–400 µs for 20 minutes. The intensity of the stimulation was adjusted to a tolerance level just below the pain threshold. The needle that was applied at the distal point S T38 (Tiaokou) was retained for 20 minutes and was manually lifted and thrusted every 10 minutes</li> </ul>
Interventions	<ul> <li>Home exercise plus electroacupuncture (N = 25)</li> <li>Components of intervention</li> <li>Home exercise: Participants were instructed to follow a chart and perform a standard set of shoulder mobilisation exercises 5 times a day, which included 4 directions: (1) forward flexion—with the help of an overhead pulley system; (2) external rotation—keeping the arm close to the trunk, using a small bamboo to externally rotate the shoulder through pushing against the palm; (3) horizontal adduction—pressing a horizontally adducted arm against the chest with the other arm to achieve horizontal adduction and (4) internal rotation—placing the affected arm behind the back and grasping 1 end of a towel, the other hand then pulling the opposite end of the towel to achieve maximum internal rotation</li> <li>Electrotheracupuncture: Sterile stainless steel acupuncture needles were inserted 15-25 mm intramuscularly into 3 acupoints including 1 trigger point, 1 local point (LI 15: Jianyu) and 1 distal point (ST38: Tiaokou) (14). Trigger points were identified by areas of greatest tenderness around the painful shoulder that were determined on an individual basis. The 2 needles in the shoulder region (trigger point and LI 15) were connected to an electroacupuncture device (Model: ES-160, ITO Co. Ltd, 3-3-3 Tpupta, al-Minami, Nerima-ku, Tokyo 176-86 05, Japan) and were stimulated with an alternating frequency of 2-100 Hz at a pulse duration of 100-400 µs for 20 minutes. The intensity of the stimulation was adjusted to a tolerance level just below the pain threshold. The needle that was applied at the distal point S T38 (Tiaokou) was retained for 20 minutes and was manually lifted and thrusted every 10 minutes</li> </ul>
Interventions	<ul> <li>Home exercise plus electroacupuncture (N = 25)</li> <li>Components of intervention</li> <li>Home exercise: Participants were instructed to follow a chart and perform a standard set of shoulder mobilisation exercises 5 times a day, which included 4 directions: (1) forward flexion—with the help of an overhead pulley system; (2) external rotation—keeping the arm close to the trunk, using a small bamboo to externally rotate the shoulder through pushing against the palm; (3) horizontal adduction—pressing a horizontally adducted arm against the chest with the other arm to achieve horizontal adduction and (4) internal rotation—placing the affected arm behind the back and grasping 1 end of a towel, the other hand then pulling the opposite end of the towel to achieve maximum internal rotation</li> <li>Electrotheracupuncture: Sterile stainless steel acupuncture needles were inserted 15–25 mm intramuscularly into 3 acupoints including 1 trigger point, 1 local point (LI 15: Jianyu) and 1 distal point (ST38: Tiaokou) (14). Trigger points were identified by areas of greatest tenderness around the painful shoulder that were determined on an individual basis. The 2 needles in the shoulder region (trigger point and LI 15) were connected to an electroacupuncture extice (Model: ES-160, ITO Co. Ltd, 3-3-3 Tpupta, al-Minami, Nerima-ku, Tokyo 176-86 05, Japan) and were stimulated with an alternating frequency of 2–100 Hz at a pulse duration of 100–400 µs for 20 minutes. The intensity of the stimulation was adjusted to a tolerance level just below the pain threshold. The needle that was applied at the distal point S T38 (Tiaokou) was retained for 20 minutes and was manually lifted and thrusted every 10 minutes</li> <li>Home exercise: not reported</li> <li>Electroacupuncture: 40 minutes</li> </ul>
Interventions	<ul> <li>Home exercise plus electroacupuncture (N = 25)</li> <li>Components of intervention</li> <li>Home exercise: Participants were instructed to follow a chart and perform a standard set of shoulder mobilisation exercises 5 times a day, which included 4 directions: (1) forward flexion—with the help of an overhead pulley system; (2) external rotation—keeping the arm close to the trunk, using a small bamboo to externally rotate the shoulder through pushing against the palm; (3) horizontal adduction—pressing a horizontally adducted arm against the chest with the other arm to achieve horizontal adduction and (4) internal rotation—placing the affected arm behind the back and grasping 1 end of a towel, the other hand then pulling the opposite end of the towel to achieve maximum internal rotation</li> <li>Electrotheracupuncture: Sterile stainless steel acupuncture needles were inserted 15-25 mm intramuscularly into 3 acupoints including 1 trigger point, 1 local point (L1 15: Jianyu) and 1 distal point (ST38: Tiaokou) (14). Trigger points were identified by areas of greatest tenderness around the painful shoulder that were determined on an individual basis. The 2 needles in the shoulder region (trigger point and L1 15) were connected to an electroacupuncture device (Model: ES-160, ITO Co. Ltd, 3-3-3 Tpupta, al-Minami, Nerima-ku, Tokyo 176-86 05, Japan) and were stimulated with an alternating frequency of 2-100 Hz at a pulse duration of 100-400 µs for 20 minutes. The intensity of the stimulation was adjusted to a tolerance level just below the pain threshold. The needle that was applied at the distal point S T38 (Tiaokou) was retained for 20 minutes and was manually lifted and thrusted every 10 minutes</li> <li>Dosage</li> <li>Home exercise: not reported</li> <li>Electroacupuncture: 40 minutes</li> <li>Frequency of administration</li> </ul>

Cheing 2008 (Continued)

#### Provider: physiotherapist

# Home exercise plus interferential electrotherapy (N = 25)

Components of intervention

- Home exercise: See above
- Interferential electrotherapy: An interferential electrotherapy machine (a Phyaction Guidance E unit) delivered a current swept from 80-120 Hz, and 4 suction-type electrodes were placed around the shoulder region in a co-planar arrangement. The intensity of the stimulation was adjusted to just below the pain threshold, and the stimulation lasted for 20 minutes

### Dosage

- Home exercise: not reported
- Interferential electroacupuncture: 20 minutes

#### Frequency of administration

- Home exercises:5 times a day for 6 months
- Interferential electroacupuncture: 10 sessions over 4 weeks

Provider: physiotherapist

#### No treatment (N = 25)

Outcomes	Outcomes assessed at the end of 4 weeks' treatment and at 1, 3 and 6 months' follow-up for Groups 1 and 2, but only at the end of 4 weeks' treatment for Group 3. No primary outcome was reported by the trialists
	<ul> <li>Constant score (0-100 scale, where a higher score indicates better functional ability)</li> <li>Pain severity at the moment of assessment, measured using a 10-cm visual analogue scale, with "No pain" anchored at the left and "Pain as bad as it could be" anchored at the right</li> </ul>
Notes	No outcome data from this trial could be analysed, as no outcome data were reported for the compari- son group of interest to this review (no treatment group)

#### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "The subjects were randomly allocated into: (i) the EA group (n = 24); (ii) IFE group (n = 23); or (iii) control group (n = 23)" Comment: No information was reported on how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported on how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Quote: "The study was a double-blind, randomized, controlled clinical trial. An independent assessor was blind to the group allocation" Comment: Despite reporting this trial as "double-blind," given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported pain and some components of the Constant score
Blinding of outcome as- sessment (detection bias)	Low risk	Quote: The study was a double-blind, randomized, controlled clinical trial. An independent assessor was blind to the group allocation"



Cheing 2008 (Continued) Objective outcomes		Comment: Outcome assessors of some components of the Constant score were probably blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "One participant dropped out of each of the electroacupuncture group and interferential electrotherapy group, both because of time conflict, and two participants dropped out of the no treatment group because they experienced no improvement"
		Comment: Although dropout is related to treatment in the no treatment group, the number of dropouts is small and is unlikely to affect function and pain outcomes
Selective reporting (re- porting bias)	High risk	Comment: The trialists reported mean (SD) scores for the Constant Murley Assessment scale and VAS pain at the end of 4 weeks' treatment for the elec- troacupuncture and interferential electrotherapy groups, but not for the no treatment group, because the no treatment group did not have a statistically significant improvement from baseline. Also, without a trial protocol, it is un- clear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Dacre 1989			
Methods	Design: parallel-group, 3-arm, single-blind randomised controlled trial (United Kingdom)		
	<b>Interventions:</b> physiotherapy (mobilisation) or local glucocorticoid injection or physiotherapy (mobili- sation) plus local glucocorticoid injection for 6 weeks		
	Sample size calculation: not reported		
	Analysis: per-protocol analysis		
	Source of funding: Arthritis and Rheumatism Council (non-industry)		
Participants	Number of participants: 66 (20, 22 and 20 in each respective group)		
	Baseline characteristics: duration of symptoms not reported		
	Group receiving physiotherapy (mobilisation)		
	Mean age = 53 years; male:female = 9:11		
	Group receiving local glucocorticoid injection		
	Mean age = 55.8 years; male:female = 11:11		
	Group receiving physiotherapy (mobilisation) plus local glucocorticoid injection		
	Mean age = 58.8 years; male:female = 8:12		
	Inclusion criteria		
	<ul> <li>Painful stiff shoulder for at least 4 weeks</li> <li>Inability to use the affected arm with restriction of movement and loss of full function</li> <li>Pain at night causing sleep disturbance and inability to lie on the affected side</li> </ul>		
	Exclusion criterion		

Dacre 1989 (Continued)	<ul> <li>Patients with predis highly localised lesion</li> </ul>	sposing causes such as stroke, generalised arthritis or cervical spondylosis or a on, such as bicipital tendinitis		
Interventions	Physiotherapy (mobilisation) (N = 20)			
	Components of intervention			
	<ul> <li>Manual therapy: The method of physical treatment thought most appropriate was delivered (mobili- sation was the mainstay treatment)</li> </ul>			
	Dosage: not reported			
	Frequency of administration: 4-6 weeks (4-6 sessions)			
	Provider: physiotherap	ist		
	Local glucocorticoid i	njection (N = 22)		
	<i>Components of intervention:</i> 20 mg triamcinolone with 1 mL 2% lignocaine injected anteriorly around the shoulder joint			
	Dosage: See above			
	Frequency of administre	ation: once		
	Provider: rheumatologi	st		
	Physiotherapy (mobilisation) plus local glucocortcoid injection (N = 20)			
	Combination of both interventions described above			
Outcomes	Outcomes assessed at 6 weeks (end of physiotherapy treatment) and at 6 months. No primary outcome reported by the trialists			
	• Pain using a 10-cm visual analogue scale, with separate scores for day pain, night pain, pain during active movement and pain during passive movement			
	<ul> <li>Passive range of motion in complete shoulder abduction, glenohumeral abducti tion using a goniometer, and internal rotation that was quantified by measuring t the spine of C7 and the index finger with the arm fully internally rotated</li> <li>Complications</li> </ul>			
Notes	Trialists reported means (standard errors) for each group in figure format for day pain, pain on active movement, total abduction and internal rotation, but no data for night pain, pain on passive move- ment, glenohumeral abduction and external rotation. No numerical data were reported for any out- come. The study authors were contacted in an attempt to access additional data, but attempts have been unsuccessful. Digitizelt was used to extract data from figures			
	Trialists reported in the Discussion section, "No treatment gave complications"			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "Patients were randomly allocated to receive physiotherapy alone, lo- cal steroid injection alone, or a combination of the two" Comment: No information was reported about how the allocation sequence was generated		
Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported about how the allocation sequence was concealed		

Dacre 1989 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported pain
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "Patients were assessed initially, at six weeks, and at six months by an independent observer unaware of the treatment given" Comment: Assessors of the outcome, passive range of motion, were probably blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Four patients dropped out of the study before completion. They failed to attend for review at six weeks or six months. The analysis was based on 62 patients (34 female, 28 male)" Comment: The number of participants randomly assigned to each group and the number who dropped out of each group were not reported. Also, it is un- clear whether failure of participants to attend for review was related to the treatment they received. Despite this, the relatively low dropout rate is unlike- ly to have biased the results
Selective reporting (re- porting bias)	High risk	Comment: Trialists reported means (standard errors) for each group in figure format for day pain, pain on active movement, total abduction and internal ro- tation, but no data for night pain, pain on passive movement, glenohumeral abduction and external rotation
Other bias	Low risk	Comment: No other sources of bias were identified

Dundar 2009			
Methods	<ul> <li>Design: parallel-group, 2-arm randomised controlled trial (Turkey)</li> <li>Interventions: active stretching and pendulum exercises plus home exercise or continuous passive motion plus home exercise</li> <li>Sample size calculation: not reported</li> </ul>		
	Analysis: intention-to-treat analysis		
	Source of funding: none		
Participants	Number of participants: 57 (29 and 28 in each respective group)		
	Baseline characteristics		
	Group receiving continuous passive motion		
	Mean (SD) age = 56.3 (7.8) years; male:female = 9:20		
	Median (SD) duration of symptoms: 6.3 (4.2) months		
	Group receiving active stretching and pendulum exercises		
	Mean (SD) age = 57.1 (8.3) years; male:female = 9:19		
	Median (SD) duration of symptoms: 5.9 (4) months		

Dundar 2009 (Continued)	<ul> <li>Inclusion criterion</li> <li>Participants with gradually increasing shoulder pain and stiffness (primary frozen shoulder with phase 1 (painful phase) or phase 2 (stiff phase) or both)</li> </ul>			
	Exclusion criteria			
	<ul> <li>Participants with rotator cuff pathology</li> <li>Participants with secondary frozen shoulder</li> <li>Participants with a stiff shoulder associated with a fracture, arthritis, abnormal shoulder radiographs or significant trauma</li> </ul>			
Interventions	All participants were instructed in a standardised home exercise programme consisting of passive ROM and pendulum exercises to be performed every day until week 12. Home exercise was demonstrated by a physiotherapist on 1 occasion, and participants then were given written advice			
	Active stretching and pendulum exercises (N = 28)			
	Components of intervention: supervised active stretching and pendulum exercises			
	Dosage: 1 hour			
	<i>Frequency of administration:</i> once a day for 20 days during a period of 4 weeks (i.e. 5 days per week (20 sessions))			
	Provider: physiotherapist			
	Continuous passive motion (N = 29)			
	Components of intervention: continuous passive motion			
	Dosage: gradual increase in motion for 1 hour			
	<i>Frequency of administration:</i> once a day for 20 days during a period of 4 weeks (i.e. 5 days per week (20 sessions))			
	Provider: physiotherapist			
Outcomes	Outcomes assessed at the end of 4 weeks' treatment and at week 12 (12 weeks from baseline). No pri- mary outcome was reported by trialists			
	• Pain at rest, at movement and at night, each using a 10-cm visual analogue scale, where 0 means no pain and 10 means worst pain			
	Passive range of motion in flexion, abduction, internal rotation, external rotation using a goniometer			
	Constant functional shoulder score (0-100 scale, where a higher score indicates better functional abil- ity)			
	<ul> <li>Shoulder Pain and Disability Index (SPADI) (0-100 scale, where a higher score indicates worse pain and/or disability)</li> </ul>			
	Adverse events			
Notes				

Risk	of	bias
------	----	------

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "Patients were assigned randomly to receive daily CPM treatments or CPT protocol" Comment: No information was reported on how the allocation sequence was generated



Dundar 2009	(Continued)
-------------	-------------

Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported on how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported pain, the SPADI and the Constant score
Blinding of outcome as- sessment (detection bias) Objective outcomes	Unclear risk	Comment: No information was reported on assessors of objective outcomes (range of motion), and this could have been done
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "All patients completed the study" Comment: No dropouts, losses to follow-up or exclusions from this study
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Ghosh 2012	
Methods	Design: parallel-group, 3-arm randomised controlled trial (India)
	<b>Interventions:</b> active and passive mobilisation exercises plus shoulder wheel and pulley exercises plus ultrasound or manipulation under anaesthesia or glucocorticoid injection (all received home exercise)
	Sample size calculation: not reported
	Analysis: per-protocol analysis
	Source of funding: not reported
Participants	Number of participants: 72 (24 per group)
	Baseline characteristics: Baseline characteristics by group were not reported. Sex was not reported
	Age range: 40-73 years
	Duration of symptoms: 0-2 months (n = 33), 2-4 months (n = 23), 4-6 months (n = 16)
	Inclusion criteria
	<ul><li>Pain and stiffness of shoulder for 6 months or less</li><li>Mild osteoporosis</li></ul>
	Exclusion criteria
	<ul> <li>Diabetes mellitus, rheumatoid arthritis, hyperthyroidism, locked posterior and anterior dislocation, subacromial impingement syndrome or rotator cuff lesion</li> </ul>
	Disease duration longer than 6 months
Interventions	All participants were advised to perform active shoulder mobilisation exercises at home



Ghosh 2012 (Continued)

### Mobilisation exercises plus shoulder wheel and pulley exercises plus ultrasound (N = 24)

Components of intervention

- Supervised exercises: active and passive shoulder mobilisation exercises plus shoulder wheel and pulley exercises
- Electrotherapy: ultrasound

Dosage: not reported

Frequency of administration: for 6 months (number of sessions per week not reported)

Provider: physiotherapist

#### Manipulation under anaesthesia (N = 24)

*Components of intervention:* After general anaesthesia, manipulations were done in the sequence of flexion, extension, abduction, adduction, external rotation and internal rotation. Analgesics were given post manipulation period for 2 to 3 days, and shoulder mobilisation exercises started 3 to 4 days after manipulation, which was taught previously

Dosage: not reported

Frequency of administration: once

Provider: not reported

#### Glucocorticoid injection (N = 24)

*Components of intervention:* An injection of methylprednisolone in 40-mg dosage was given intra-articularly by the anterior approach under strict aseptic preparation

Dosage: See above

Frequency of administration: Average of 3 doses at 3-week intervals

Provider: not reported

Outcomes Outcome assessed at the end of 6 months' treatment

Clinical improvement rated as "Good" (no pain, no

 Clinical improvement rated as "Good" (no pain, no tenderness present, ROM is equal or comparable with normal limb and no muscle wasting is present), "Fair" (mild pain and tenderness may or may not be present, mild restriction of ROM still present even after 6 months and muscle wasting may or may not be present) or "Poor" (gross restriction of movement is still present, with or without pain)

To analyse the "treatment success" outcome, we dichotomised participants into those who had a clinical improvement rating of "Good" versus those who had a rating of "Fair" or "Poor."

Trialists reported that participants in the study had "almost equal right and left sided affection with one having bilateral affection." However, the group that the bilaterally affected participant was allocated to was not reported, nor was any mention made of controlling for the correlation between shoulders (but this is unlikely to have affected the results substantially, given the dichotomous 'clinical improvement' outcome used)

**Risk of bias** 

Notes

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "These patients were randomly allocated in 3 groups" Comment: No information was reported about how the allocation sequence was generated

## Ghosh 2012 (Continued)

Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported about how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported pain and tenderness
Blinding of outcome as- sessment (detection bias) Objective outcomes	Unclear risk	Comment: No information was reported about whether assessors of muscle wasting and range of motion were blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: Only 1 participant (in the glucocorticoid injection group) was lost to follow-up. This is unlikely to have biased the results
Selective reporting (re- porting bias)	Unclear risk	Comment: Results of the single outcome reported in the methods section of the publication (treatment success) were fully reported, but without a trial protocol, it is unclear whether other outcomes were measured but not report- ed based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Guler-Uysal 2004			
Methods	Design: parallel-group, 2-arm, single-blind randomised controlled trial (Turkey)		
	<b>Interventions:</b> Cyriax approach of deep friction massage and manipulation, active stretching exercises and home exercises and		
	<b>Sample size calculation:</b> 20 participants per group were estimated to be needed based upon detec- tion of a 40% increase in the number of participants treated successfully in the Cyriax group at the 5% level of statistical significance with 80% power		
	Analysis: per-protocol analysis		
	Source of funding: not reported		
Participants	Number of participants: 42 (21 per group)		
	Baseline characteristics		
	Group receiving Cyriax approach of deep friction massage and manipulation		
	Mean (SD; range) age = 53.6 (6.9; 43-70) years; male:female = 5:15		
	Median (SD; range) duration of symptoms: 7.6 (3.9; 2-12) months		
	Group receiving hot pack and short-wave diathermy application		
	Mean (SD; range) age = 58.4 (9.7; 44-82) years; male:female = 7:13		
	Median (SD: range) duration of symptoms: 5.6 (3.9: 2-12) months		

Guler-Uysal 2004 (Continued)

#### **Inclusion criteria**

- Shoulder pain of minimum 2 months' duration with no major shoulder trauma
- Marked loss of active and passive shoulder motion
- Pain with motion with a minimum visual analogue scale (VAS) score of 30 mm
- Normal findings on anteroposterior and axillary lateral radiographs of the glenohumeral joint
- Absence of polyarthritis or neurological diseases or cervical neuropathy
- Absence of medical conditions such as cardiac disease, infection, coagulation disorders

#### **Exclusion criteria**

• Patients who had adhesive capsulitis secondary to shoulder dislocation, fracture, reflex sympathetic dystrophy and rotator cuff tear

Interventions

Both groups received active stretching and pendulum exercises at the end of each treatment session and were instructed in a standardised home exercise programme consisting of passive ROM and pendulum exercises to be performed every day.

#### Cyriax approach of deep friction massage and manipulation (N = 21)

Components of intervention

• Manual therapy: Cyriax approach of deep friction massage and manipulation

Dosage: 1 hour

Frequency of administration: 3 times per week for 2 weeks (6 sessions)

Provider: physiotherapist

#### Short-wave diathermy application and hot pack (N = 21)

Components of intervention

- Short-wave diathermy: Continuous short-wave diathermy with 220 V/50 Hz power source and 27.12 MHz oscillation frequency was applied to the therapy region for deep heating while the participants were lying supine (short-wave Diathermy KSF Model equipment ITO, Tokyo-Japan)
- · Hot pack: wrapped in towelling and placed on the target shoulder for superficial heating

#### Dosage

- · Short-wave diathermy: 20 minutes
- Hot pack: 20 minutes

Frequency of administration: every day except weekends for 2 weeks (10 sessions)

Provider: physiotherapist

Outcomes assessed at the end of the first and second weeks of treatment

### **Primary outcome**

 Number of participants who reached 80% of normal range of motion of the shoulder at the end of the second week of treatment. Normal ROM was accepted as abduction = 180°, flexion = 180°, inner rotation = 70° and outer rotation = 90°

#### Secondary outcomes

- Pain (spontaneous pain, night pain and pain with motion) using a 100-mm visual analogue scale
- Passive range of motion in flexion, abduction, inner rotation, outer rotation using a goniometer

Notes

Outcomes

# Guler-Uysal 2004 (Continued)

**Risk of bias** 

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "42 patients were randomised for enrolment in the study. The patients were numbered sequentially and allocated to two groups (the Cyriax group and the physical therapy group)" Comment: No information was reported on how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported on how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported pain
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "The pre-treatment evaluation of shoulder pain and ROM was carried out by a blinded observer at the beginning of the study" Comment: Outcome assessors of range of motion were probably blind to treatment (although it is unclear how blinding of pain was achieved, given that it was self-reported by unblinded participants)
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "One patient in the CYR group were excluded from the study due to poor compliance and one from the PT group discontinued the intervention due to attacks of unstable hypertension in the first week" Comment: The number of dropouts or exclusions was low and equal between groups, and reasons are unlikely to influence the results
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Harsimran 2011			
Methods	Design: parallel-group, 2-arm randomised controlled trial (India)		
	<b>Interventions:</b> anteroposterior glide mobilisation (Kaltenborn grade III) plus supervised and home ex- ercise or posteroanterior glide mobilisation (Kaltenborn grade III) plus supervised and home exercise		
	Sample size calculation: not reported		
	Analysis: intention-to-treat analysis (imputed median values for participants with missing data)		
	Source of funding: not reported		
Participants	Number of participants: 15 (8 and 7 in each respective group)		
	Baseline characteristics		
	Group receiving anteroposterior glide mobilisation		



Harsimran 2011 (Continued)			
	Median (interquartile range) age = 52 (50-57.8) years; male:remaie = 5:3		
	Median (interquartile range) duration of symptoms: 3 (3-3.75) months		
	Group receiving posteroanterior glide mobilisation		
	Median (interquartile range) age = 56 (49-62) years; male:female = 4:3		
	Median (interquartile range) duration of symptoms: 1.5 (1-7) months		
	Inclusion criteria		
	<ul> <li>Males and females between 35 and 70 years of age</li> <li>Diagnosed with adhesive capsulitis in the subacute or chronic stage with capsular pattern of shoulder (i.e. external rotation range of motion more limited than abduction, which in turn is more limited than internal rotation)</li> </ul>		
	Exclusion criterion		
	<ul> <li>Patients with diabetes, neurological disorders, previous history of trauma or surgery of the affected shoulder</li> </ul>		
Interventions	Both groups received moist heat for 15 minutes, followed by Codman's exercises and finger ladder ex- ercises following mobilisation. Participants were then advised to continue the same exercises at home		
	Anteroposterior glide mobilisation (N = 8)		
	<i>Components of intervention:</i> anteroposterior glide mobilisation (Kaltenborn grade III). Participants were positioned appropriately on the treatment table in supine position. The affected limb was taken to the available abduction range of motion, and mobilisations were provided for 30 seconds. This technique was repeated 5 times in a single treatment session. Physiological movements of the affected extremity were provided for 1 minute after every 30 seconds of the mobilisation procedure		
	Dosage: See above		
	Frequency of administration: 1 session per day for 5 consecutive days (5 sessions)		
	Provider: physiotherapist		
	Posteroanterior glide mobilisation (N = 7)		
	<i>Components of intervention:</i> posteroanterior glide mobilisation (Kaltenborn grade III). Participants were positioned appropriately on the treatment table in prone position. The affected limb was taken to the available abduction range of motion, and mobilisations were provided for 30 seconds. This technique was repeated 5 times in a single treatment session. Physiological movements of the affected extremity were provided for 1 minute after every 30 seconds of the mobilisation procedure		
	Dosage: See above		
	Frequency of administration: 1 session per day for 5 consecutive days (5 sessions)		
	Provider: physiotherapist		
Outcomes	Outcomes assessed at the end of 5 days' treatment		
	Primary outcome		
	<ul> <li>Range of motion in external rotation at 45 degrees of abduction using a goniometer (not reported whether passive or active)</li> </ul>		
	Secondary outcomes		
	• Range of motion in abduction and internal rotation at 45 degrees of abduction using a goniometer (not reported whether passive or active)		

#### Harsimran 2011 (Continued)

### • Pain using a 10-cm visual analogue scale

Notes

Trialists reported only medians with no measures of variation in figure format for all outcomes and reported that no statistical significance testing was undertaken because this RCT was only a pilot RCT

**Risk of bias** 

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "Subjects were then randomized in 2 treatment groups by block ran- domization, group AP (antero-posterior) & PA (postero-anterior). During Ran- domization 3 blocks were used, with each block consisting of 6 units (3 AP & 3 PA). Two blocks out of 3 were utilized completely & from the 3rd block only 3 units were used. After allocation, group AP consisted of 8 & group PA consisted of 7 subjects" Comment: No information was reported on how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported on how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Quote: "Primary investigator performed the mobilization technique and sec- ond investigator was blinded to the group allocation of the participants and measured range of motion before and after every treatment session" Comment: Participants received slightly different types of mobilisation, but it is unclear whether they were provided any information that would make them perceive the type of mobilisation they received as superior or inferior to the al- ternative type of mobilisation
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	Unclear risk	Comment: Participants self-reported pain, but it is unclear whether they were provided any information that would make them perceive the type of mobili- sation they received as superior or inferior to the alternative type of mobilisa- tion
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "Primary investigator performed the mobilization technique and sec- ond investigator was blinded to the group allocation of the participants and measured range of motion before and after every treatment session" Comment: Assessors of range of motion were probably blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Five subjects out of fifteen were lost to follow up. Three were from AP group and two from PA group. Two subjects from AP group underwent Manip- ulation under anaesthesia and other three subjects could not be followed due to personal constraints. Data of these five subjects was analyzed for intention to treat analysis" Comment: The number of participants lost to follow-up in each group and rea- sons for this were reported and do not appear to be related to the result. Inten- tion-to-treat analysis was conducted
Selective reporting (re- porting bias)	Unclear risk	Comment: Trialists reported only medians with no measures of variation in fig- ure format for all outcomes (and the figure appears to be missing the median values for internal rotation at 45 degrees of abduction range of motion). How- ever, it is not clear whether data were incompletely reported based on the sta- tistical significance or magnitude of the results. Also, without a trial protocol, it is unclear whether other outcomes were assessed but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified



## Johnson 2007

Methods	<b>Design:</b> parallel-group, 2-arm randomised controlled trial (USA)		
	<b>Interventions:</b> anterior or posterior glenohumeral joint mobilisation, both with therapeutic ultra- sound and upper extremity exercises using the upper body ergometer		
	Sample size calculation: not reported		
	Analysis: per-protocol analysis		
	Source of funding: not reported		
Participants	Number of participants: 20 (10 per group)		
	Baseline characteristics		
	Group receiving anterior glenohumeral joint mobilisation		
	Mean (SD) age = 54.7 (8) years; male:female = 2:8		
	Median (range) duration of symptoms: 8.4 (2-12) months		
	Group receiving posterior glenohumeral joint mobilisation		
	Mean (SD) age = 50.4 (6.9) years; male:female = 2:6 (sex reported only for participants completing treat- ment)		
	Median (range) duration of symptoms: 10.9 (4-60) months		
	Inclusion criteria		
	<ul> <li>Idiopathic or primary adhesive capsulitis (i.e. insidious onset with no history of major trauma), not excluding minor injuries</li> <li>Unilateral condition</li> <li>Age between 25 and 80 years</li> <li>Normal findings on radiographs within the previous 12 months</li> <li>No previous shoulder surgeries on the affected shoulder</li> <li>No previous manipulations of the affected shoulder while under anaesthesia</li> <li>External rotation range of motion restriction that worsened with shoulder abduction</li> </ul>		
	Exclusion criteria		
	<ul> <li>Shoulder girdle motor control deficits associated with neurological disorders (e.g. stroke, Parkinson's disease)</li> <li>External rotation range of motion did not change as the arm was abducted</li> </ul>		
Interventions	Both groups received ultrasound and upper extremity exercises using the upper body ergometer. All ul- trasound treatments were applied at 1.5 W/cm <sup>2</sup> continuously for 10 minutes, using a Sonicator Ultra- sound Generator (ME 730; Mettler Electronics Corporation, Anaheim, CA). A coupling gel (Tyco Health Care Group LP, Mansfield, MA) was used and the sound head was moved in a circular pattern at the rate of approximately 4 cm/s. The area covered by the ultrasound head was about twice the size of the sound head. The upper body ergometer was used for 3 minutes in the forward direction only, at an arm position height that allowed pain-free movement		
	Anterior glenohumeral joint mobilisation (N = 10)		
	Components of intervention		
	<ul> <li>Manual therapy: anterior glenohumeral joint mobilisation (Kaltenborn grade III mobilisations). Par- ticipants were positioned supine. In this position, the researcher maintained a lateral humeral dis- traction in its midrange position, while anterior stretch mobilisation was performed to end range, at</li> </ul>		



Johnson 2007 (Continued)

the end range of abduction and external rotation. As the participant was able to tolerate a stronger stretching force, he/she was positioned prone to allow the therapist to utilise the participant's body weight and gravity to generate the mobilisation force in a similar combined fashion of distraction to midrange and anterior glide to end range. The end range position of the mobilisation was held for at least 1 minute. No oscillatory motions were performed. Each stretch mobilisation was repeated, so a total of 15 minutes of sustained stretch was performed at each treatment session

 Electrotherapy: Ultrasound (delivered before mobilisation) was administered to the anterior capsule, with the intent to provide the target tissue with a moderate to vigorous temperature rise of 3°C to 4°C. Most anterior capsules were treated with 3 MHz, as the capsule was determined to be 0.5 to 2 cm deep

#### Dosage: not reported

Frequency of administration: 2-3 sessions per week for 2-3 weeks (6 sessions in total)

Provider: physiotherapist

#### Posterior glenohumeral joint mobilisation (N = 10)

#### Components of intervention

- Manual therapy: posterior glenohumeral joint mobilisation (Kaltenborn grade III mobilisations). Participants were in a prone position. In this position, the researcher maintained a lateral humeral distraction in its midrange position, while the posterior stretch mobilisation was performed to end range, at the end range of abduction and external rotation. The position chosen for progression of the posterior mobilisation takes the humerus into flexion, with the intent to provide greater stretch to the posterior capsule. In this position, the humerus was taken into end range external rotation only, as abduction was not a component of the technique. The end range position of the mobilisation was held for at least 1 minute. No oscillatory motions were performed. Each stretch mobilisation was repeated, so that a total of 15 minutes of sustained stretch was performed at each treatment session
- Electrotherapy: Ultrasound (delivered before mobilisation) was administered to the posterior capsule, with the intent to provide the target tissue with a moderate to vigorous temperature rise of 3°C to 4°C. Most posterior capsules were treated using 1 MHz ultrasound because it was determined that the capsule was 2 to 5 cm deep

#### Dosage: not reported

Frequency of administration: 2-3 sessions per week for 2-3 weeks (6 sessions in total)

#### Provider: physiotherapist

Outcomes

Outcomes assessed at the end of 6 treatment sessions (i.e. 2-3 weeks)

#### **Primary outcome**

Active range of motion in external rotation using a goniometer

#### Secondary outcomes

- Pain using a 10-cm visual analogue scale, where participants were asked to rate the relative unpleasantness that their problem caused them; the higher up the line, the greater the unpleasantness
- Pain at night using a 5-point scale with scores ranging from 4 (worst score) to 0 (best score)
- Overall function 5-point scale with scores ranging from 4 (worst score) to 0 (best score)
- Functional ability to do specific tasks (dressing, grooming and reach), using three 5-point scales rated from 4 (worst score) to 0 (best score); scores for the 3 items were summed to a total score ranging from 0-12

Notes

#### **Risk of bias**

Bias

Authors' judgement Su

ement Support for judgement

Johnson 2007 (Continued)		
Random sequence genera- tion (selection bias)	Low risk	Quote: "The randomization was predetermined by using a random-numbers table" Comment: An adequate method was used to generated the allocation se- quence
Allocation concealment (selection bias)	High risk	Quote: "The randomization was predetermined by using a random-numbers table. Folders labeled with the group name and subject number were made ahead of time and used sequentially as the subjects joined the study" Comment: Folders had the intervention name visible to the person responsi- ble for allocating participants (and thus whether the allocation sequence was not concealed)
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Comment: Participants received slightly different types of mobilisation, but it is unclear whether they were provided any information that would make them perceive the type of mobilisation they received as superior or inferior to the al- ternative type of mobilisation
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	Unclear risk	Comment: Participants self-reported pain, overall function and ability to do specific activities, but it is unclear whether they were provided any informa- tion that would make them perceive the type of mobilisation they received as superior or inferior to the alternative type of mobilisation
Blinding of outcome as- sessment (detection bias) Objective outcomes	High risk	Quote: "The physical therapist assistant measured the first 14 subjects who participated in the study (13 of which remained in the study). This measurer was blinded to treatment and group placement of these subjects. Due to tak- ing a position at another facility, measurements for the final 6 subjects (5 of which remained in the study) were taken by the primary investigator (A.J.). This measurer was therefore not blinded to the treatment or group placement of these subjects" Comment: Most, but not all, assessments of range of motion were conducted by a blinded assessor
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Two subjects, both in the PM group, left the study. One subject, af- ter the third treatment session, for personal reasons, requested arthroscopic surgery to obtain a definitive diagnosis of her condition. The presence of adhe- sive capsulitis was confirmed during surgery and she received manipulation under anesthesia. The second subject left the study after the fourth treatment session as a result of a fall that injured her affected shoulder" Quote: "One subject left the PM group to have arthroscopic surgery and ma- nipulation. However, the external rotation ranges for the first 3 treatment ses- sions that the subject completed show her gaining 15°. Including this subject in an intention-to-treat analysis would not have been a true representation of the effects of the mobilization procedure, so it was decided to not include her data" Comment: The number of dropouts, and reasons for this, were reported and are not related to the treatment received (so are unlikely to bias the results)
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

# Ma 2006

Methods

Design: parallel-group, 3-arm randomised controlled trial (Taiwan)


Ma 2006 (Continued)	<b>Interventions:</b> physical therapy (hot pack, joint mobilisation and active shoulder exercises) only or acupuncture only or physical therapy plus acupuncture		
	Sample size calculation: not reported		
	Analysis: intention-to-treat analysis		
	Source of funding: not reported		
Participants	Number of participants: 75 (30, 30 and 15 in each group, respectively)		
	Baseline characteristics: Sex and duration of symptoms were not reported by group		
	Male:female = 36:39		
	Mean duration of symptoms: 25.8 weeks		
	Group receiving physical therapy only		
	Mean age: 54.1 years		
	Group receiving acupuncture only		
	Mean age: 56.4 years		
	Group receiving physical therapy plus acupuncture		
	Mean age: 52.8 years		
	Inclusion criteria		
	<ul> <li>Spontaneous frozen shoulder pain for at least 3 months</li> <li>Could not lift arms more than 135°</li> <li>Willing to follow the medical treatments designed by study authors</li> </ul>		
	Exclusion criteria		
	<ul> <li>Non-spontaneous frozen shoulders caused by nervous system disease, acute inflammation and broken bones</li> <li>Acupuncture syncope</li> <li>Skin infection surrounding acupuncture points</li> </ul>		
Interventions	Physical therapy (N = 30)		
	Components of intervention		
	<ul> <li>Manual therapy: joint mobilisation</li> <li>Supervised exercises: active shoulder exercises</li> <li>Hot pack (short wave)</li> </ul>		
	Dosage:		
	<ul> <li>Manual therapy: 5–10 minutes</li> <li>Supervised exercise: 5–10 minutes</li> <li>Hot pack (short wave): 15 minutes</li> </ul>		
	Frequency of administration: 5 times a week for 4 weeks (20 sessions)		
	Provider: physical therapist		
	Acupuncture (N = 30)		
	<i>Components of intervention:</i> acupuncture. The therapeutic protocol included (1) therapeutic principles in promoting flow of qi and blood, driving out the wind and cold, removing dampness and activating		



Bias	Authors' judgement Support for judgement
Risk of bias	
Notes	Trialists reported only final value and change from baseline means (with no measures of variation) of outcomes measured before and after the intervention was delivered at the end of 2 and 4 weeks' treat- ment. MP extracted the data only after intervention was delivered at 4 weeks, as this was the final mea- surement (and measures of variation need to be retrieved for this and all other time points)
	<ul> <li>Active and passive range of motion in flexion, extension, abduction, internal rotation and external rotation, using a goniometer</li> <li>Static and dynamic pain using a 0-10 numerical rating scale</li> <li>Health-related quality of life using the Chinese version of the SF-36. 8 subdomains, each with score from 0-100, were calculated: Physical Function, Role Limitation-Physical, Body Pain, General Health, Vitality, Social Function, Role Limitation-Emotional and Mental Health.</li> </ul>
Outcomes	Outcomes assessed at the end of the second and fourth (final) weeks of treatment. No primary out-
	Physical therapy plus acupuncture (N = 15)
	Provider: acupuncturist
	Frequency of administration: twice a week for 4 weeks (8 sessions)
	Dosage: 15 minutes
Ma 2006 (Continued)	meridians; (2) therapeutic methods on 3 yang meridians of the hand and (3) prescriptions with jianjiao, jianyu, fengchi, hegu and yanglingquan

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "Those subjects were randomly assigned to one of three groups" Comment: No information was reported on how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Quote: "Those subjects were randomly assigned to one of three groups" Comment: No information was reported on how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported pain and health-related quality of life
Blinding of outcome as- sessment (detection bias) Objective outcomes	Unclear risk	Comment: No information was reported about whether assessors of range of motion were blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: No dropouts, losses to follow-up or exclusions were reported, and the number of participants randomly assigned was reported as the number of participants analysed
Selective reporting (re- porting bias)	Unclear risk	Comment: Mean scores with no measures of variation were reported for all outcomes specified in the methods section of the publication. However, the incompletely reported data do not appear to have been incompletely report-



Ma 2006 (Continued)

ed based on the statistical significance or magnitude of the results, although without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results

Other bias	Low risk	Comment: No other sources of bias were identified
other blus	LOW HSK	comment. No other sources of blas were identified

Maricar 1999	
Methods	Design: parallel-group, 2-arm randomised controlled trial (Singapore)
	Interventions: manual therapy plus exercise or exercise alone
	Sample size calculation: not reported
	Analysis: per-protocol analysis
	Source of funding: not reported
Participants	<b>Number of participants:</b> 54 (number randomly assigned not reported; 16 per group completed treat- ment)
	Baseline characteristics: Duration of symptoms was not reported by group
	Mean duration of symptoms: 3 months
	Group receiving manual therapy plus exercises
	Mean (SD) age = 57.9 (9.5) years; male:female = 9:7
	Group receiving exercises alone
	Mean (SD) age = 54.9 (5.4) years; male:female = 10:6
	Inclusion criteria
	<ul> <li>Medical diagnosis of shoulder capsulitis, late stage 2 to stage 3 in the disease process, as determined by the research physiotherapist</li> </ul>
	Major complaint was limitation in shoulder range of motion with secondary complaint of pain
	<ul> <li>Ability to place the arms behind the back, reaching the vertebral column</li> </ul>
	90 degrees abduction
	Exclusion criteria
	<ul> <li>History of previous shoulder trauma or previous episode of frozen shoulder</li> <li>Existing or previous diagnosis of heart problems, renal problems, chest problems, metabolic disease, systemic disease, peripheral vascular disease, uncontrolled diabetes, cancer, fracture of the upper limbs, history of subluxation and dislocation of the upper limbs or degenerative conditions such as osteoarthritis and rheumatoid arthritis affecting the shoulder joint</li> </ul>
Interventions	Both groups received exercises for 15 minutes once a week for 8 weeks. The strengthening regime for the rotator cuff muscles was included in the exercise programme from week 5 onwards. Home exercises were also assigned to both groups
	Manual therapy plus exercises (N = 16 completers)
	Components of intervention
	<ul> <li>Manual therapy: mobilisation of shoulder quadrant, shoulder capsular stretch, shoulder flexion, shoulder abduction, shoulder external and internal rotation using Maitland Grade III+ and IV</li> </ul>
	Dosage: not reported

Maricar 1999 (Continued)			
	Frequency of administration: once a week for 8 weeks		
	Provider: physiotherapist		
	Exercises only (N = 16 completers)		
	See above		
Outcomes	Outcomes assessed at weeks 3, 5, 7 and 8 (end of treatment). No primary outcome was reported by tri- alists		
	<ul> <li>Active range of motion in total elevation through flexion, external rotation, internal rotation, hand behind back (combined extension, internal rotation, abduction) and hand behind neck (combined flexion, external rotation, abduction)</li> </ul>		
Notes	Means and 95% CIs of the 5 measures of active range of motion were presented in figure format only (i.e. no numerical data reported). DigitizeIt was used to extract mean values from the figures		

**Risk of bias** 

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "Thirty-two subjects were randomly assigned to either Group A having exercise and manual therapy or to Group B having exercises only" Comment: No information was reported on how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Quote: "Thirty-two subjects were randomly assigned to either Group A having exercise and manual therapy or to Group B having exercises only" Comment: No information was reported on how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions (the same physical therapy in- tervention with or without additional manual therapy), participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Objective outcomes	Unclear risk	Comment: No information was reported about whether assessors of range of motion were blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "Fifty-four subjects were recruited for this study. However, only 32 sub- jects, 19 men and 13 women, were used in the analysis of the results. The attri- tion was due to poor compliance to attendance and home exercise regime" Comment: The number of participants randomly assigned to, and who dropped out of, each group, was not reported, so it is unclear whether dropout was related to the interventions received
Selective reporting (re- porting bias)	Unclear risk	Comment: Means and 95% CIs for each measure of active range of motion were presented in figure format only (i.e. no numerical data reported). Howev- er, it is not clear whether data were incompletely reported based on the statis- tical significance or magnitude of the results. Also, without a trial protocol, it is unclear whether other outcomes were assessed but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Maryam 2012				
Methods	Design: parallel-group, 3-arm, single-blind randomised controlled trial (Iran)			
	<b>Interventions:</b> physiotherapy (including TENS, active range of motion exercises and ice application in 10 sessions) or glucocorticoid injection or physiotherapy plus glucocorticoid injection			
	<b>Sample size calculation:</b> 35 participants per group were estimated to be needed based upon detec- tion of a clinically relevant difference at the 5% level of statistical significance with 80% power (out- come used in power calculation not reported)			
	Analysis: per-protocol analysis			
	Source of funding: not reported			
Participants	Number of participants: 87 (27, 31 and 29 in each respective group)			
	Baseline characteristics			
	Group receiving physiotherapy			
	Mean (SD) age = 53.73 (7.49) years; male:female = 1:26			
	Mean (SD) duration of symptoms: 4.48 (3.37) months			
	Group receiving glucocorticoid injection			
	Mean (SD) age = 53.33 (7.49) years; male:female = 4:25			
	Mean (SD) duration of symptoms: 6.83 (3.75) months			
	Group receiving physiotherapy plus glucocorticoid injection			
	Mean (SD) age = 53.71 (6.69) years; male:female = 4:27			
	Mean (SD) duration of symptoms: 6.21 (3.95) months			
	Inclusion criteria			
	<ul> <li>18 years of age or older</li> <li>Duration of symptoms &lt; 1 year</li> <li>Frozen shoulder defined as the presence of shoulder pain with limitation of both active and passive range of motion in glenohumeral joint ≤ 25% in at least 2 directions: flexion, abduction, external and internal rotation, as compared with normal values or contralateral shoulder</li> <li>Total score ≥ 30 on Shoulder Pain and Disability Index (SPADI)</li> </ul>			
	Exclusion criteria			
	<ul> <li>Disorder was secondary to inflammatory, degenerative, metabolic (except for diabetes mellitus), traumatic, septic arthritis and cerebrovascular accident</li> <li>Treated with injection or physiotherapy in past 6 months</li> </ul>			
Interventions	Physiotherapy (N = 27)			
	<u>Components of intervention</u>			
	<ul> <li>Supervised exercises: active range of motion exercises</li> <li>Electrotherapy: TENS</li> <li>Other: Ice application</li> </ul>			
	Dosage: not reported			
	Frequency of administration: 10 sessions (number of sessions per week not reported)			
	Provider: physiotherapist			

Maryam 2012 (Continued)	Glucocorticoid injection (N = 31)		
	<i>Components of intervention:</i> corticosteroid injection included as 60 mg triamcinolone acetonide and 3 cc lidocaine in shoulder joint with posterior approach and 20 mg triamcinolone acetonide and 1.5 cc lidocaine in subacromial bursa		
	Dosage: See above		
	Frequency of administration: once		
	Provider: rheumatologist		
	Physiotherapy plus glucocorticoid injection (N = 29)		
	Physiotherapy (as above) 1 week after glucocorticoid injection (as above)		
Outcomes	Outcomes assessed at 6 weeks and 6 months. No primary outcome was reported by trialists		
	<ul> <li>Shoulder Pain and Disability Index (SPADI) (0-100 scale, where a higher score indicates worse pain and/or disability)</li> </ul>		
	<ul> <li>Passive range of motion in flexion, abduction, external rotation and distance of hand behind back using a goniometer</li> </ul>		
Notes	Unpublished data regarding study design (required for risk of bias assessment) provided by trialist on request		
	Trial registered in the Iranian Registry of Clinical Trials (http://www.irct.ir/searchre- sult.php?id=1828&number=1)		

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "After taking written informed consent, the patients were randomized to 1 of the following 3 groups" Comment: No information was reported on how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Quote: "After taking written informed consent, the patients were randomized to 1 of the following 3 groups" Comment: No information was reported on how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Quote: "Evaluations of SPADI score were done by an observer blind to treat- ment allocation" Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported some com- ponents of the SPADI
Blinding of outcome as- sessment (detection bias) Objective outcomes	High risk	Comment: Trialists confirmed via personal communication that the assessor of range of motion was not blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "Eight patients in physiotherapy group, 7 in combination therapy group and 3 in injection group did not continue, so statistical analysis was done on 69 remaining patients"



Maryam 2012 (Continued)		Quote: "About 36 patients have been reevaluated in 24 weeks (Table-III). However we cannot consider this stage of study because of a high number of missed patients, but we can see a more subjective improvement during 6 months in physiotherapy group" Comment: Trialists did not report the reasons for participants not continuing (and did not provide this information when requested), so it is unclear whether the reasons were balanced between groups and related to the treatment re- ceived
Selective reporting (re- porting bias)	Low risk	Comment: Outcome data were fully reported for all outcomes specified in the trial registry entry
Other bias	Low risk	Comment: No other sources of bias were identified

Nellutla 2009	
Methods	Design: parallel-group, 2-arm randomised controlled trial (India)
	<b>Interventions:</b> proprioceptive neuromuscular facilitation (PNF) movement patterns for exercises plus mobilisation and ultrasound or conventional free exercises plus mobilisation and ultrasound
	Sample size calculation: not reported
	Analysis: intention-to-treat analysis
	Source of funding: not reported
Participants	Number of participants: 40 (20 per group)
	Baseline characteristics: Baseline characteristics were not reported by group
	Mean (SD) age = 56.15 (8.71) years; male:female = 24:16
	Duration of symptoms not reported
	Inclusion criteria
	Between 40 and 70 years of age
	• Diagnosed with chronic frozen shoulder with restricted joint range of motion and limitations in activ- ities of daily living
	• Mild or no pain on the Constant shoulder functional score (i.e. score of 10 or 15)
	Exclusion criteria
	Not reported
Interventions	Both groups received ultrasound at each session, with dosage of 0.8 W/cm <sup>2</sup> and a pulse ratio of 1:2 for 8 minutes. Both groups also received mobilisation techniques using grade 3 oscillations. For the gleno- humeral joint, caudal glide, posterior glide and anterior glide were provided. For the acromioclavicular joint, anterior glide was provided. For the sternoclavicular joint, posterior glide, anterior glide, inferior glide and superior glide were provided
	Proprioceptive neuromuscular facilitation (PNF) movement patterns for exercises (N = 20)
	<i>Components of intervention:</i> proprioceptive neuromuscular facilitation (PNF) movement patterns for exercises. 2 types of patterns were applied, with the shoulder starting from one position and ending in other position according to PNF movement patterns: (1) shoulder flexion, abduction and external rotation started at shoulder extension, adduction and internal rotation; and (2) shoulder flexion, adduction and external rotation and external rotation started at shoulder started at shoulder extension, abduction and internal rotation. This was performed until the participant understood properly about how he or she should be performing the pat-



Nellutla 2009 (Continued)	terns within the available range. Participants were made to perform in front of a mirror for feedback and to show the performance to the therapist. The participant was advised to perform these patterns thrice daily 10 times for each set and 2 sets for each session <i>Dosage:</i> not reported			
	Frequency of administration: 5 times a week for 3 weeks (15 sessions)			
	Provider: physiotherapist			
	Conventional free exercises (N = 20)			
	<i>Components of intervention:</i> conventional free exercises, such as finger ladder exercises, Codman's pendulum exercises and overhead shoulder pulley and shoulder wheel, 5 times a week for 3 weeks. Each exercise was done with 10 repetitions in a set of movements and with total of 2 sets for each movement. Apart from all these, home exercises were taught to the participant, such as simple Codman's exercises with an iron box in hand, finger wall exercises and all active movements around the shoulder. Participants were told to repeat each movement 10 times and were advised to perform these home exercises twice daily—once in the early morning before coming for the treatment and once in the evening			
Dosage: not reported				
	Frequency of administration: 5 times a week for 3 weeks (15 sessions)			
	Provider: physiotherapist			
Outcomes	Outcomes assessed at the end of 3 weeks' treatment. No primary outcome was reported by the trialists			
	<ul> <li>Range of motion in abduction, flexion, external rotation and internal rotation (not reported whether active or passive)</li> <li>Function using the Simple Shoulder Test, which comprises 12 questions about the function of the involved shoulder, each rated as "yes" or "no"</li> <li>Constant-Morley shoulder score (0-100 scale, where a higher score indicates better functional ability)</li> </ul>			

Notes

**Risk of bias** 

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "The patients were then randomly allocated into two groups, one con- trol group and one experimental group" Comment: No information was reported on how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Quote: "The patients were then randomly allocated into two groups, one con- trol group and one experimental group" Comment: No information was reported on how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Comment: Participants received different types of exercise, but it is unclear whether they were provided any information that would make them perceive the type of exercise they received as superior or inferior to the alternative type of exercise
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	Unclear risk	Comment: Participants self-reported both measures of function, but it is un- clear whether they were provided any information that would make them per- ceive the type of exercise they received as superior or inferior to the alterna- tive type of exercise

### Nellutla 2009 (Continued)

Blinding of outcome as- sessment (detection bias) Objective outcomes	Unclear risk	Comment: No information was reported about whether assessors of range of motion were blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: No dropouts, losses to follow-up or exclusions were reported, and the analyses are reported as based on the number of randomly assigned par- ticipants
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Nicholson 1985				
Methods	Design: parallel-group, 2-arm, single-blind randomised controlled trial (USA)			
	Interventions: passive mobilisation and active exercises or active exercises alone			
	Sample size calculation: not reported			
	Analysis: intention-to-treat analysis			
	Source of funding: not reported			
Participants	Number of participants: 20 (10 per group)			
	Baseline characteristics			
	Group receiving passive mobilisation plus active exercises			
	Mean (SD; range) age = 51 (12.16; 31-70) years; male:female = 4:6			
	Mean (SD; range) duration of symptoms: 27.6 (33.41; 1-104) weeks			
	Group receiving active exercises alone			
	Mean (SD; range) age = 55 (16.43; 20-77) years; male:female = 6:4			
	Mean (SD; range) duration of symptoms: 30.8 (31.28; 3-104) weeks			
	Inclusion criterion			
	Presence of shoulder pain and limited passive motion at the glenohumeral joint			
	Exclusion criteria			
	<ul> <li>Unstable fracture of the humerus, scapula or clavicle</li> <li>Recurrent dislocation or subluxation of the shoulder</li> <li>Rheumatic disease</li> <li>Advanced osteoporosis</li> <li>Malignancy</li> <li>History of extensive steroid therapy</li> <li>Severe pain unrelieved by resting the joint</li> <li>Peripheral neurological involvement in the upper extremity.</li> </ul>			



Blinding of participants

and personnel (perfor-

Blinding of outcome as-

sessment (detection bias)

mance bias)

All outcomes

High risk

High risk

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review)

Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Trusted evidence. Informed decisions. Better health.

Nicholson 1985 (Continued)				
Interventions	Both groups received active exercises in those ranges found to be restricted and additional resistive ex- ercises if weaknesses were present, in 2-3 physiotherapy sessions a week for 4 weeks, and also 3 times per day independently			
	Passive mobilisation	plus active exercises (N = 10)		
	<i>Components of intervention:</i> passive mobilisation. Generally, in the early sessions, gliding and distrac- tive mobilisation techniques were performed with the joint near its neutral position, progressing during later sessions to mobilisation towards the end of the range of motion. The decision to progress to mo- bilisation at the end of the range of motion was based on the participant's satisfactory tolerance of mo- bilisation within the range and "levelling off" of progress made by less vigorous techniques. The force and amplitude of treatment movements varied, but eventually all participants were able to tolerate grade IV oscillations (small amplitude motions at the end of the range of motion) without significant discomfort			
	Dosage: not reported			
	Frequency of administr	ation: 2-3 physiotherapy sessions a week for 4 weeks (8-12 sessions)		
	Provider: physiotherapist			
	Active exercises (N = 10)			
	See above			
Outcomes	Outcomes assessed weekly for 4 weeks. No primary outcome was reported by the trialists			
	<ul> <li>Pain using a questionnaire to assess the degree and nature of symptoms (scale units</li> <li>Range of motion (active internal rotation, active external rotation, active abduction, tion)</li> </ul>			
Notes				
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	High risk	Quote: "the subjects were assigned to either the experimental or control group, using the toss of a coin, i.e., when the first subject consented, a coin toss determined the group assignment and the next successive subject was as- signed to the opposite group. The coin toss was repeated for each odd num- bered subject" Comment: A quasi-random method was used to generate the allocation se- quence		
Allocation concealment (selection bias)	High risk	Quote: "the subjects were assigned to either the experimental or control group, using the toss of a coin, i.e., when the first subject consented, a coin toss determined the group assignment and the next successive subject was as- signed to the opposite group. The coin toss was repeated for each odd num- bered subject". Comment: Using this method, the allocation sequence is unlikely to have been concealed.		

benefits of each intervention

Comment: Given the nature of the interventions (the same physical therapy in-

tervention either with or without additional mobilisation), participants were

Comment: Unblinded participants who may have had different expectations

about the benefits of the intervention received self-reported pain

not blind to treatment and may have had different expectations about the

### Nicholson 1985 (Continued) Self-reported outcomes

Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "All mobility measurements were visualised and recorded by an assis- tant who was unaware of the patient's group designation" Comment: Assessors of range of motion were probably blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: No dropouts, losses to follow-up or exclusions were reported, and outcome data are reported as based on the number of randomly assigned par- ticipants
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Pajareya 2004	
Methods	Design: parallel-group, 2-arm, single blind randomised controlled trial (Thailand)
	<b>Interventions:</b> physical therapy (mobilisation, passive glenohumeral joint-stretching exercises and short-wave diathermy) plus ibuprofen or ibuprofen alone <b>Sample size calculation:</b> 60 participants per group were estimated to be needed based upon detec- tion of a difference in success rate (measured by improvement in global pain and disability index) of 25% at the 5% level of statistical significance with 80% power
	<b>Analysis:</b> per-protocol analysis (reported that intention-to-treat analysis was used to test statistical significance, but outcome data presented in tables was reported as based on the number of participants completing assessments at each week)
	<b>Source of funding:</b> Department of Research Promotion, Faculty of Medicine, Siriraj Hospital, Mahidol University and partially supported by Thailand Research Fund (non-industry)
Participants	Number of participants: 122 (61 per group)
	<b>Baseline characteristics:</b> baseline characteristics reported for participants who completed the week 3 assessment (n = 119)
	Group receiving physical therapy plus ibuprofen
	Mean (SD) age = 56.3 (10.6) years; male:female = 14:45
	Duration of symptoms: number of participants with duration < 6 weeks (n = 6), between 6 and 11 weeks (n = 20) and 12 or more weeks (n = 33)
	Group receiving ibuprofen alone
	Mean (SD) age = 57.7 (10) years; male:female = 24:36
	Duration of symptoms: number of participants with duration < 6 weeks (n = 13), between 6 and 11 weeks (n = 20) and 12 or more weeks (n = 27)
	Inclusion criterion
	<ul> <li>Shoulder pain and limitation of a passive range of shoulder motion in all directions that interfered with their activities of daily living</li> </ul>
	Exclusion criteria
	Secondary adhesive capsulitis

Pajareya 2004 (Continued)				
	<ul> <li>Intrinsic causes of shoulder problems such as a history of fracture or dislocation, or extrinsic causes such as neuromuscular disorders (stroke, parkinsonism), generalised arthritis, bilateral involvement, contraindication for NSAIDs</li> <li>Blooding tondoncies</li> </ul>			
	Bleeding tendencies			
Interventions	Both groups received ibuprofen 400 mg 3 times daily for 3 weeks, and general advice (an information sheet containing advice on protection of the shoulder from vigorous activities such as pushing and pulling, and encouragement to use the arms in a normal fashion for reaching and other activities of daily life)			
	Physical therapy plus ibuprofen (N = 61)			
	Components of intervention			
	<ul> <li>Manual therapy: mobilisation. If, during passive movements, the participant felt pain before the ther- apist reached the end of the range, exercise was not attempted</li> </ul>			
	<ul> <li>Supervised exercise: passive glenohumeral joint stretching exercises up to the participant's tolerance, based on Cyriax</li> </ul>			
	<ul> <li>Home exercise: pulley exercises (actively assisted exercises for 5 minutes) and active non-assisted exercises using a towel and wall (5 minutes after applying a hot pack for 20 minutes)</li> </ul>			
	Electrotherapy: short-wave diathermy			
	Dosage			
	Manual therapy: not reported			
	Supervised exercise: not reported			
	Home exercise: 10 minutes			
	Electrotherapy: 20 minutes			
	Frequency of administration			
	Manual therapy: 3 times a week for 3 weeks (9 sessions)			
	<ul> <li>Supervised exercise: 3 times a week for 3 weeks (9 sessions)</li> </ul>			
	<ul> <li>Home exercise: 4 days a week for 3 weeks (on the days they did not receive the hospital-based physical therapy programme)</li> </ul>			
	Electrotherapy: 3 times a week for 3 weeks (9 sessions)			
	Provider: physical therapist			
	Ibuprofen (N = 61)			
	See above			
Outcomes	All outcomes assessed at the end of 3 weeks' treatment (except for "success," which was also assessed at 6, 12 and 24 weeks)			
	Primary outcome			
	<ul> <li>"Success," measured by participants rating themselves as having disappearance of shoulder complaints or some pain/limitation that does not interfere with everyday life (on a global pain and disability index with a 5-point Likert scale with response options "disappearance of shoulder complaints," "some pain or limitation but which does not interfere with everyday life," "minimal inconvenience to everyday life," "moderate inconvenience" and "marked inconvenience")</li> </ul>			
	Secondary outcomes			
	<ul> <li>Shoulder Pain and Disability Index (SPADI) (0-100 scale, where a higher score indicates worse pain and/or disability)</li> </ul>			
	<ul> <li>Passive range of motion (abduction, external rotation, internal rotation quantified by measuring the distance between thumb and tip of C7 spine in hand behind back position) using a goniometer</li> </ul>			

Pajareya 2004 (Continued)	<ul> <li>Adverse events recorded for the physical therapy group by asking, "Do you have pain that persisted more than 2 hours after treatment or more disability the next morning or not?" and by asking all par- ticipants, "Have the trial drugs and/or treatment programme upset you in any way?" and by examin- ing the participant for signs of ecchymosis or burn during range of motion evaluation</li> </ul>
Notes	Adverse events due to ibuprofen were not reported separately per group: "During the 3-week peri- od, the patients in the study group reported a total of 10 episodes of pain that persisted more than 2 hours after treatment from 4 subjects. There were no other complications recorded. Regarding NSAIDs, 15 subjects (12.6%) had gastrointestinal side effects; the number of those who had severe dyspepsia and had to stop NSAIDs was 6 (4.2%). There were 2 reports of severe oedema and 1 case with a severe headache, which rapidly subsided after the drug was discontinued" (pg 477 of trial publication)
	Unpublished data regarding study design (required for risk of bias assessment) provided by trialist on request

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "The patients who gave informed written consent were randomly al- located to a 3-week treatment protocol by simple randomisation using a ran- dom numbers table and allocation concealed within an opaque envelope" Comment: An adequate method was used to generate the allocation se- quence
Allocation concealment (selection bias)	Low risk	Quote: "The patients who gave informed written consent were randomly al- located to a 3-week treatment protocol by simple randomisation using a ran- dom numbers table and allocation concealed within an opaque envelope" Personal communication: "I prepared opaque envelopes before hand. With- in each envelope, I put the letter 'I' or 'C.' The series of 'I' and 'C' came from the random number table. I didn't remember any part of the series" Comment: An adequate method was used to conceal the allocation sequence
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported global pain and disability index and the SPADI
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "Moreover, at each follow-up, an investigator, blinded to treatment modality asked all patients 'Have the trial drugs and/or treatment program upset you in any way?' and examined the patient for any signs of ecchymosis or burn during range of motion evaluation"
		Quote: "Range of shoulder motion measuredby a investigator blinded to the type of treatment" Personal communication: "The range of motion assessor was blinded. I had told all of the participants that 'Please don't tell the assessor about the treat- ment you have'" Comment: Assessors of adverse events and range of motion were probably blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "At the end of the 3rd week, 2 subjects dropped out from the study; 1 from the control group and 1 from the study group. The total number of cases included in the analysis was 59 in the control and 60 in the study group. By the end of the 24th week, a total of 12 cases (10.1%) had withdrawn from the study



Pajareya 2004 (Continuea)		(Fig. 1). All of them lost to follow-up for unknown reasons and the investigators could not contact them" Quote: "The results were analysed by intention to treat analysis even though the treatments actually received were modified from the protocol, because it was found that the reasons for modifying the treatment were strongly related to the results of allocated interventions" Comment: It is unclear whether reasons for losses to follow-up were related to the interventions received
Selective reporting (re- porting bias)	Unclear risk	Quote: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Quote: ""About three-quarters of the subjects of both groups received NSAIDs as prescribed. The reasons why some patients received fewer NSAIDs than the others was due to gastrointestinal discomfort, forgetting to take them or a misunderstanding about the schedule. In the study group, 7 cases (11.7%) re- ceived fewer than 6 sessions of hospital-based PT, 5 cases (8.3%) performed the home programme exercises fewer than 6 sessions. Two cases from the control group reported that they had additional treatment; 1 had Chinese herbal medicine and 1 received analgesics from a private clinic. No patient in the control group had hospital-based PT or home exercise therapy for their shoulder" Quote: "The deviation from the protocol in the present study might not re- verse the results. On the contrary, the differences of the outcomes at the end of the study should be elicited more easily if there was no protocol deviation. Because the patients in the study group received fewer treatments than the schedule determined (six cases had fewer than 6 sessions of hospital-based PT and 6 cases performed home exercise fewer than 6 sessions), while the sub- jects in the control group received more treatment than the schedule (one case had Chinese herbal medicine and 1 case had analgesics from a private clinic)" Comment: Protocol violations are unlikely to have influenced the results

Rainbow 2008	
Methods	Design: parallel-group, 2-arm quasi-randomised controlled trial (USA)
	<b>Interventions:</b> high-velocity, low-amplitude chiropractic manipulative therapy to the cervical and tho- racic spine and glenohumeral joint plus home exercise therapy, or grade 4 mobilisation of the gleno- humeral joint plus home exercise therapy
	Sample size calculation: not reported
	Analysis: intention-to-treat analysis
	<b>Source of funding:</b> funded and completed as part of a Master's in Science (chiropractic) degree for Dr Daniel Rainbow and supervised by Dr Paul Weston at the Division of Health and Social Care (formerly the European Institute of Health and Medical Sciences), University of Surrey, Guilford, United Kingdom
Participants	Number of participants: 8 (4 per group)
	Baseline characteristics: Baseline characteristics were not reported by group
	Age range: 35-60 years
	Male:female = 2:6
	Duration of symptoms not reported



Rainbow 2008 (Continued)

#### **Inclusion criteria**

- Male or female 30-65 years old
- Diagnosis of primary (idiopathic) phase 2-3 frozen shoulder, confirmed according to modified guidelines developed by Hannafin, Brotzman and Lundberg, and by history and physical examination
- Read and signed informed consent document with the understanding that this study received prior institutional review board approval
- Note that phase 2 frozen shoulder was diagnosed as duration of symptoms 3-9 months with:
  - decreased glenohumeral motion and loss of synchronous shoulder-girdle motion;
  - active and passive restriction in elevation (about 90 degrees);
  - external rotation 50%-60% of normal; and
  - chronic pain with active and passive range of motion
- Note that phase 3 frozen shoulder was diagnosed as duration of symptoms 9-15 months with:
  - minimum pain except at the end of range of motion; and
  - significant limitation in range of motion with "rigid end feel"

#### **Exclusion criteria**

- Past or current history of stroke, cardiac disease, diabetes, thyroid disorders, intracranial and/or intrathoracic disorders
- Relative or absolute contraindications to chiropractic manipulative therapy, particularly dislocation, fracture, instability, autoimmune inflammatory disorders and acute severe capsulitis
- Case history and/or physical and orthopaedic examination findings that disconfirmed a diagnosis of primary phase 2-3 frozen shoulder
- Unwillingness to agree or comply with the allocated interventions for 12 treatments (2 treatments per week for 6 weeks)
- Unwillingness to agree to refrain from or comply with engaging in other forms of treatment during the course of the trial
- Refusal to read, sign and give informed consent

Interventions

Both groups performed home exercises including Codman's pendulum exercise and simple wall walking. Participants were provided with verbal and written home exercise (with technical instructions and fully illustrated for later reference)

#### Chiropractic manipulative therapy (N = 4)

*Components of intervention:* high-velocity, low-amplitude chiropractic manipulative therapy to the cervical and thoracic spine and glenohumeral joint. No more than 2 spinal adjustive procedures and 2 glenohumeral joint adjustive procedures were performed per region (a maximum of 4) per visit. Selected methods for motion palpation and adjustive techniques were left to the discretion of the treating doctor

Dosage: not reported

Frequency of administration: twice a week for 6 weeks (12 sessions)

Provider: chiropractor

#### Mobilisation (N = 4)

*Components of intervention:* grade 4 mobilisation of the glenohumeral joint for 3 minutes according to the supine glenohumeral mobilisation technique. Participant is supine with the arm outstretched and in slight abduction. The chiropractor grasps either side of the proximal humerus with both hands, and the participant's extended forearm is held against the chiropractor's thoracic cage. The chiropractor lightly distracts the shoulder inferiorly and produces mild distraction, circumduction and movement of the shoulder in all directions

Dosage: 3 minutes

Frequency of administration: twice a week for 6 weeks (12 sessions)

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

### Rainbow 2008 (Continued)

### Provider: chiropractor

# Outcomes Outcome assessed at the second treatment session each week for 6 weeks

# **Primary outcome**

- Shoulder Pain and Disability Index (SPADI) (0-100 scale, where a higher score indicates worse pain and/or disability)

# Secondary outcome

Adverse events

### Notes

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	High risk	Quote: "Once selected, subjects were allocated to 1 of 2 treatment groups by systematic assignment. Group allocation was determined by the order in which patients qualified and entered the trial. For example, the 1st subject accepted into the trial was allocated randomly to Group 1, accomplished by folding 2 sheets of completely obscured paper (one marked Group 1, the oth- er marked Group 2) and placed in an envelope. One sheet was picked from the envelope and revealed assignment to Group 1. Further quasi-randomization occurred as the next patient was automatically allocated to Group 2, the 3rd to Group 1, etc. Subjects were unaware of this allocation process prior to presen- tation" Comment: A non-random (predictable) sequence was used to allocate partici- pants
Allocation concealment (selection bias)	High risk	Comment: A non-random (predictable) sequence was used to allocate participants (see above quote)
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Quote: "The SPADI was selected as the primary and singular outcome mea- sure" Quote: "At each treatment session, patients' subjective symptoms were briefly noted by the primary researcher. The treating doctor (a registered/li- censed doctor of chiropractic) was then taken into the room by the primary re- searcher, and the assigned treatment was administered. This procedure was followed for 12 treatments, with the SPADI administered on the 2nd treatment visit of each week immediately prior to the application of any treatment. All treating practitioners remained blinded to the results generated from the out- come measures throughout the duration of the trial" Quote: "These findings must be interpreted cautiously, however, secondary tothe absence of blinded assessors" Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported the SPADI
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "All 8 subjects who entered the trial completed the trial with no report- ed complications, side effects, or adverse reactions" Quote: "Because no subjects dropped out of the study, intention-to-treat analysis was not necessary to calculate" Comment: No losses to follow-up, drop-outs or exclusions occurred

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review)

Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

### Rainbow 2008 (Continued)

Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Ryans 2005				
Methods	Design: parallel-group, 4-arm, single-blind randomised controlled trial (United Kingdom)			
	<b>Interventions:</b> physiotherapy (proprioceptive neuromuscular facilitation, Maitland mobilisations and active exercise, interferential modality) plus glucocorticoid injection or glucocorticoid injection alone or physiotherapy plus placebo injection or placebo injection alone			
	<b>Sample size calculation:</b> 20 participants per group were estimated to be needed based upon detec- tion of a difference of 1.04 points on a 5-point pain scale (SD = 1.6) at 4 weeks at the 5% level of statisti- cal significance with 82% power			
	Analysis: per-protocol analysis			
	Source of funding: Arthritis Research Campaign (non-industry)			
Participants	Number of participants: 80 (20 per group)			
	Baseline characteristics			
	Group receiving physiotherapy plus glucocorticoid injection			
	Mean (SD) age = 56.3 (6.4) years; male:female = 11:9			
	Mean (SD) duration of symptoms: 14.2 (4.4) weeks			
	Group receiving glucocorticoid injection alone			
	Mean (SD) age = 52.3 (9.3) years; male:female = 6:13			
	Mean (SD) duration of symptoms: 12.2 (5.3) weeks			
	Group receiving physiotherapy plus placebo injection			
	Mean (SD) age = 52.6 (7.7) years; male:female = 6:14			
	Mean (SD) duration of symptoms: 14.4 (4.4) weeks			
	Group receiving placebo injection alone			
	Mean (SD) age = 55.2 (9.4) years; male:female = 9:10			
	Mean (SD) duration of symptoms: 14.9 (3.7) weeks			
	Inclusion criteria			
	<ul> <li>18 years of age or older</li> <li>Painful shoulder, in the fifth cervical (C5) dermatome distribution, of more than 4 weeks' and less than 6 months' duration</li> <li>Limitation of active and passive range of movement greater than 25% in abduction and external rotation compared with the other shoulder</li> </ul>			
	Exclusion criteria			
	Pain of less than 4 weeks' duration			



Ryans 2005 (Continued)	
	Symptoms of longer than 6 months' duration
	Previous intra-articular injection or prior physiotherapy for this episode of shoulder pain
	<ul> <li>Presence of restriction of active and passive range of movement in external rotation only or gleno- humeral abduction only</li> </ul>
	Evidence of glenohumeral osteoarthritis on plain x-ray
	<ul> <li>Clinical evidence of a complete rotator cuff tear (i.e. positive drop-off sign or weakness of the rotator cuff muscles)</li> </ul>
	<ul> <li>Clinical evidence of significant cervical spine disease, history of significant trauma to the shoulder or a history of inflammatory joint disease or of a cerebrovascular accident affecting the study shoulder</li> <li>Bilateral adhesive capsulitis</li> </ul>
	Contraindication to triamcinolone injection
Interventions	All participants were provided with 50 × 500 mg paracetamol tablets with suggestions to take 1 or 2 tablets 4- to 6-hourly as required for pain, taking no more than a maximum of 8 tablets daily. All participants were also instructed by a physiotherapist in an identical home exercise programme using a video and home exercise instruction sheet
	Physiotherapy plus glucocorticoid injection (N = 20)
	Components of physiotherapy intervention
	• Manual therapy: Maitland mobilisations, which were progressed as the condition improved, and pro- prioceptive neuromuscular facilitation
	<ul> <li>Supervised exercise: active exercise therapy with gym equipment</li> </ul>
	Electrotherapy: standardised interferential modality
	Dosage: not reported
	Frequency of administration: twice a week for 4 weeks (8 sessions)
	Provider: physiotherapist
	<i>Components of glucocorticoid injection:</i> injections of triamcinolone 20 mg (1 mL) and normal saline 2 mL plus physiotherapy for 4 weeks. Injections were given (without imaging guidance) by a combined approach to the shoulder: Half the solution (1.5 mL) was injected by an anterior approach and half (1.5 mL) by a lateral approach
	Glucocorticoid injection alone (N = 20)
	The same injection method as described above was delivered
	Physiotherapy plus placebo injection (N = 20)
	The same injection and physiotherapy method as described above was delivered, except that normal saline 3 mL was injected into the shoulder
	Placebo injection alone (N = 20)
	The same injection method as described above was delivered, except that normal saline 3 mL was in- jected into the shoulder
Outcomes	Outcomes assessed at 6 and 16 weeks' post randomisation
	Primary outcome
	<ul> <li>Croft Shoulder Disability Questionnaire (0-22 score range, where a score of 0 indicates no disability and a score of 5 and higher represents significant disability)*</li> </ul>
	Secondary outcomes
	• General health status using the SF-36 (assessed at 16 weeks' post randomisation only)

Ryans 2005 (Continued)	<ul> <li>Passive and active range of motion in forward flexion, abduction, external rotation*, internal rotation using a goniometer</li> <li>Daytime pain at rest using a 100-mm visual analogue scale*</li> <li>Global function using a 100-mm visual analogue scale*</li> </ul>
Notes	*Outcome data fully reported only for these outcomes. No outcome data reported for other outcomes
	Unpublished data regarding study design provided by trialist on request
	Trial registered in ISRCTN, but outcomes not provided at time of registration (http://www.con- trolled-trials.com/ISRCTN25152388)

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "Subjects were randomly allocated in permuted blocks of four using random number tables to one of four treatments. The randomization process took place in the hospital pharmacy department. Allocations were placed in sealed envelopes which were opened by the physiotherapist teaching the home exercise programme" Comment: An adequate method was used to generate the allocation se- quence
Allocation concealment (selection bias)	Low risk	Comment: See quote above. An adequate method was used to conceal the al- location sequence
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Quote: "Injections were provided in opaque syringes, and the investigator measuring outcomes (IR) was not present at the time of randomization or in- jection and was blinded to all study interventions. Both patients and the phys- iotherapist were blinded to the nature of the injection. Clearly, it was impossi- ble to blind subjects regarding physiotherapy but subjects were asked not to reveal if they were having physiotherapy treatment" Comment: Participants and personnel were blind to the injection component of the intervention, but not to the physiotherapy component. Participants may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Participants self-reported pain, general health status and function, and were not blind to whether they had received physiotherapy. Participants may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "Injections were provided in opaque syringes, and the investigator measuring outcomes (IR) was not present at the time of randomization or in- jection and was blinded to all study interventions. Both patients and the phys- iotherapist were blinded to the nature of the injection. Clearly, it was impossi- ble to blind subjects regarding physiotherapy but subjects were asked not to reveal if they were having physiotherapy treatment" Comment: Assessors of objective outcomes were blind to treatment
Incomplete outcome data (attrition bias) All outcomes	High risk	Quote: "Eighty subjects were recruited and randomly assigned to four groups. One subject was randomized twice and another failed to attend for interven- tion after randomization; 78 subjects were therefore available for analysis. Twenty subjects were enrolled in Group A (steroid injection and physiother- apy), 19 in Group B (steroid injection and no physiotherapy), 20 in Group C (placebo injection and physiotherapy) and 19 in Group D (placebo injection and no physiotherapy). Six subjects did not return for all follow-up visits: three in Group A, one in Group B, one in Group C and one in Group D. Fifteen sub- jects withdrew from the study due to failure of the study treatment. Six pa- tients withdrew from Group B, three from Group C and six from Group D"

Kyans 2005 (Continued)		Quote: "We also looked to see if there were significant differences in numbers dropping out in each group due to failure of treatment. Significantly more pa- tients dropped out in Group D (placebo injection and no physiotherapy) and in Group B (steroid injection and no physiotherapy (Pearson chi-square=8.72, P=0.033). No subjects dropped out of Group A (steroid injection and physio- therapy)" Comment: The was differential dropout across the groups, and the reasons appear to be related to the treatments received
Selective reporting (reporting bias)	High risk	Quote: "Secondary outcome measures wererange of movement as measured by passive external rotation. External rotation was chosen as the indicator range of movement as restriction in this range has been described as the most severely restricted plane of movement in shoulder capsulitis" Quote: "Analysis of improvement in the range of movement in abduction and internal rotation (thumb–C7 distance) revealed no significant association with either steroid injection or physiotherapy" Comment: Trialists reported measuring passive and active range of motion (forward flexion, abduction, external rotation, internal rotation) using a go- niometer. However, outcome data were reported only for passive external rotation. The decision not to report outcome data for the other measures of range of motion appears to be related to the statistical significance of the re- sults
Other bias	Low risk	Comment: No other sources of bias were identified

### Samnani 2004

Methods	Design: parallel-group, 2-arm randomised controlled trial (India)			
	<b>Interventions:</b> passive range of motion exercises plus therapeutic activity programme and active exer- cises or therapeutic activity programme and active exercises alone			
	Sample size calculation: not reported			
	Analysis: intention-to-treat analysis			
	Source of funding: not reported			
Participants	Number of participants: 20 (10 per group)			
	Baseline characteristics: duration of symptoms not reported			
	Group receiving passive range of motion exercises plus therapeutic activity programme and active exer- cises			
	Mean (SD) age = 42.9 (6.5) years; male:female = 3:7			
	Group receiving therapeutic activity programme and active exercises			
	Mean (SD) age = 42.7 (9) years; male:female = 6:4			
	Inclusion criteria			
	<ul> <li>Diagnosis of primary idiopathic periarthritis of the shoulder</li> <li>Unilateral involvement</li> <li>Previous treatment by analgesics only</li> <li>Symptoms of pain and limited range of motion for not longer than 3 months</li> </ul>			
	Exclusion criteria			

Samnani 2004 (Continued)	<ul> <li>Significant radiological finding</li> <li>Signs of acute joint inflammation and muscle spasm</li> <li>Any neurological deficit</li> </ul>		
Interventions	Both groups received a therapeutic activity programme and active exercises for a period of 45 min- utes, 6 times a week for 6 weeks, consisting of (1) Codman's pendulum exercises; (2) pulley exercises; (3) shoulder wheel; (4) active range of motion exercises using a towel; (5) finger stepping and corner stretch and (6) reaching out tasks		
	Passive range of motion exercises plus therapeutic activity programme and active exercises (N = 10)		
	<i>Components of intervention:</i> passive range of motion exercises consisting of (1) participant in supine: passive range of motion to the shoulder by the therapist from neutral position to maximal flexion avail- able; (2) participant in supine: passive range of motion to the shoulder by the therapist from neutral position to maximal adduction available; (3) shoulder abducted to less than or equal to 90 degree, el- bow flexed 90 degrees: passive range of motion to the shoulder by the therapist from this initial posi- tion to maximal internal rotation available; (4) shoulder abducted to less than or equal to 90 degrees, elbow flexed 90 degrees: passive range of motion to the shoulder by the therapist from this initial posi- tion to maximal external rotation available; (5) shoulder flexed to less than or equal to 90 degrees, el- bow flexed 90 degrees: passive circumductory range of motion to the shoulder; and (6) supraspinatus stretching		
	Dosage: 15 minutes		
	Frequency of administration: 6 times a week for 6 weeks (36 sessions)		
	Provider: occupational therapist		
	Therapeutic activity p	rogramme and active exercises (N = 10)	
	See above		
Outcomes	Outcome assessed at the end of 6 weeks' treatment		
	Primary outcome		
	<ul> <li>Active range of motion: functional hand-to-back, measured after being asked to take his or her hand to the back, keeping an arm abducted, at a position that he or she is able to hold. This was rated using an ordinal scale as follows: 0 = Dorsum of hand to lateral thigh; 2 = Dorsum of hand to buttock; 4 = Dorsum of hand to lumbosacral region; 6 = Dorsum of hand to waist (L3 level); 8 = Dorsum of hand to 12th dorsal vertebra; 10 = Dorsum of hand to interscapular region</li> </ul>		
Notes			
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "The subjects were randomly allocated to one of the two groups, A & B of 10 each" Comment: No information was reported on how the allocation sequence was generated	

of 10 each"

concealed

Quote: "The subjects were randomly allocated to one of the two groups, A  $\&\, B$ 

Comment: No information was reported on how the allocation sequence was

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Unclear risk

Allocation concealment

(selection bias)

### Samnani 2004 (Continued)

Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions (the same multi-component physical therapy intervention with or without additional exercises), partici- pants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Objective outcomes	Unclear risk	Comment: No information on whether assessors were blind to treatment was reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: No dropouts, losses to follow-up or exclusions were reported, but it was unclear whether the outcome data reported were based on the total number of randomly assigned participants (as sample sizes were not reported in data tables)
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

### Sharad 2011

Methods	Design: parallel-group, 2-arm randomised controlled trial (India)			
	<b>Interventions:</b> end range mobilisation techniques plus ultrasound therapy plus active glenohumeral exercises plus home exercises plus home exercise or ultrasound therapy plus active glenohumeral exercises plus home exercise			
	Sample size calculation: not reported			
	Analysis: intention-to-treat analysis			
	Source of funding: not reported			
Participants	Number of participants: 22 (11 per group)			
	Baseline characteristics			
	Group receiving end range mobilisation techniques plus ultrasound therapy plus active glenohumeral ex- ercises plus home exercise			
	Mean (SD; range) age = 46.5 (4.44; 41-55) years; male:female = 5:6			
	Mean (SD; range) duration of symptoms: 4.9 (1.17; 3-7) months			
	Group receiving ultrasound therapy plus active glenohumeral exercises plus home exercise			
	Mean (SD; range) age = 47.45 (5.49; 40-56) years; male:female = 4:7			
	Mean (SD; range) duration of symptoms: 4.63 (1.05; 3-6) months			
	Inclusion criteria			
	<ul> <li>Between 40 to 60 years</li> <li>Insidious onset of adhesive capsulitis with duration of symptoms longer than 3 months and a presentation of movement restrictions in all planes by at least 25%</li> </ul>			
	Exclusion criteria			

• Early onset of pain in the range pain resistance ratio assessment

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Sharad 2011 (Continued)	• History of diabetes	or any other concurrent disorder that may interfere with the study	
Interventions	Both groups received ultrasound therapy plus active glenohumeral exercises plus home exercise 5 days a week for 3 weeks. Ultrasound was delivered for 10 minutes to the glenohumeral joint anteriorly, pos- terior and inferiorly with the arm abducted. A machine with 1 MHz frequency and an output of 0 to 3.5 Watt/cm <sup>2</sup> with head size 2.5 cm <sup>2</sup> was used. Active glenohumeral exercises consisted of self-stretch- ing exercises preceded by warm-up exercises and ending with a cool-down phase, done under thera- pist's supervision and guidance. No mechanical exercises were given. Home exercises comprised sim- ple stretching exercises done at home once daily. The exercises were progressed and modified as per the participant response. End range mobilisation techniques plus ultrasound therapy plus active glenohumeral exercises plus home exercise (N = 11) Components of intervention: End range mobilisation techniques were carried out immediately following the application of ultrasound. Initially a few minutes of warming up was given using midrange mobili- sation with the participant positioned supine, after which intensive end range mobilisation techniques, grades 3 and 4, as described by Maitland in all the movement planes were delivered, interspersed with accessory movements (glides). The effort in each direction had ten to fifteen repetitions. The rhythm speed and duration were varied in accordance with participant presentation and tolerance <i>Dosage:</i> varied in accordance with participant presentation and tolerance <i>Frequency of administration:</i> 5 days a week for 3 weeks (15 sessions) <i>Provider:</i> physiotherapist Ultrasound therapy plus active glenohumeral exercises plus home exercise (N = 11)		
Outcomes	Outcomes assessed at the end of 3 weeks treatment. No primary outcome was reported by the trialists.		
	1. Active and passive range of motion in external rotation, abduction, flexion using a goniometer		
	2. Pain using a visual analogue scale (scale units not reported but assumed to be 0-10 based on the out- come data reported)		
Notes	No measures of variation were reported for any of the outcomes.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "This randomised control trial was conducted to assess the effective- ness of End Range Mobilization Techniques in the treatment of chronic adhe- sive capsulitis" Comment: No information was reported on how the allocation sequence was generated	
Allocation concealment (selection bias)	Unclear risk	Quote: "This randomised control trial was conducted to assess the effective- ness of End Range Mobilization Techniques in the treatment of chronic adhe- sive capsulitis" Comment: No information was reported on how the allocation sequence was concealed	
Blinding of participants	High risk	Comment: Given the nature of the interventions (the same multi-component	

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review) Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

mance bias) All outcomes

### Sharad 2011 (Continued)

Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported pain
Blinding of outcome as- sessment (detection bias) Objective outcomes	High risk	Quote: "no blinding was done this could have biased the results" Comment: Outcome assessors were not blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: No dropouts, losses to follow-up or exclusions were reported, but it was unclear whether the outcome data reported were based on the total number of randomly assigned participants (as sample sizes were not reported in data tables)
Selective reporting (re- porting bias)	Unclear risk	Comment: Only means with no measures of variation were reported for all out- comes specified in the methods section of the publication. However, it is not clear whether data were incompletely reported based on the statistical signif- icance or magnitude of the results. Also, without a trial protocol, it is unclear whether other outcomes were assessed but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

### Shrivastava 2011

Methods	<b>Design:</b> parallel-group, 2-arm, double-blind randomised controlled trial (India) Interventions: Maitland's or Mulligan's mobilisation technique for 2 weeks followed by home exercise programme for 2 weeks		
	Sample size calculation: not reported		
	Analysis: intention-to-treat analysis		
	Source of funding: not reported		
Participants	Number of participants: 40 (20 per group)		
	Baseline characteristics: duration of symptoms not reported		
	Group receiving Maitland's mobilisation technique plus home exercise programme		
	Mean (SD) age = 59.2 (7.18) years; male:female = 7:13		
	Group receiving Mulligan's mobilisation technique plus home exercise programme		
	Mean (SD) age = 51.15 (8.53) years; male:female = 12:8		
	Inclusion criteria		
	<ul> <li>Diagnosis of second-stage adhesive capsulitis with both primary and secondary causes who were showing capsular pattern</li> </ul>		
	Exclusion criteria		
	<ul> <li>Previous shoulder surgery, shoulder arthritis, painful shoulder, severe systemic illness and use of reg- ular analgesics</li> </ul>		
Interventions	Both groups received hot fomentation for 10 minutes, along with a 2-week home exercise programme consisting of Codman's pendulum exercises, scapular setting exercises, finger ladder, wand exercises and stretching of the tightened muscles of the shoulder girdle. The 2-week home exercise programme was delivered after the 2-week mobilisation programme		



### Shrivastava 2011 (Continued)

#### Maitland's mobilisation technique (N = 20)

*Components of intervention:* Maitland's graded oscillations technique. The grade of glide was decided during treatment depending on the participant's symptoms. Individual glides delivered were reported as follows: (1) posterior glide: With participant in supine position, the therapist holds his/her arm proximally, applies a distraction force and glides the humeral head posteriorly; (2) inferior glide: Participant lies supine, while the therapist stands at the head end of the participant facing his/her feet. Holding the proximal arm of the participant, the therapist gives a distraction force to the glenohumeral joint and glides the humeral head inferiorly; and (3) the anterior glide: Participant is positioned prone, and the therapist holds the distal arm above the epicondyles with 1 hand for distraction; with the other hand, the therapist applies anterior glide to the humeral head

Dosage: dependent on participants' symptoms

Frequency of administration: 6 times a week for 2 weeks (12 sessions)

*Provider:* physiotherapist

### Mulligan's mobilisation technique (N = 20)

*Components of intervention:* Mulligan's mobilisation with movement technique. Passive overpressure was applied in the end of range, and 3 sets of 10 repetitions were given for each mobilisation. Individual glides delivered were reported as follows: (1) flexion and abduction: Participant sits with the therapist posterolateral to him/her. Therapist places the Mulligan belt across the humeral head and to his waist. Leaning backward, he applies a posterolateral glide to the shoulder joint and then asks the participant to perform the painful/restricted movement of shoulder flexion or abduction, which would be pain free; (2) internal rotation: Participant sits or stands with the therapist by his/her side. The therapist applies an inferior glide to the humerus head with the participant's shoulder in available degrees of abduction. With the glide maintained, the participant actively rotates the shoulder internally without pain; (3) external rotation: Participant lies supine with his/her shoulder horizontally flexed till 90 degrees. The therapist places the belt at the humeral head, applying a lateral distraction to the joint the participant was asked to rotate the shoulder externally

Dosage: dependent on participants' symptoms

Frequency of administration: 6 times a week for 2 weeks (12 sessions)

Provider: physiotherapist

Outcomes assessed at the end of 4 weeks' treatment. No primary outcome was reported by trialists

- Pain using a 100-mm visual analogue scale (with a total possible score of 10)
- Range of motion in flexion, extension, abduction, internal rotation and external rotation using a goniometer (not reported whether passive or active)
- Shoulder Pain and Disability Index (SPADI) (0-100 scale, where a higher score indicates worse pain and/or disability)
- Adverse events

Notes

No measures of variation were reported for any of the outcomes

**Risk of bias** 

Outcomes

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "Subjects were randomly allotted to the two groups, Maitland group and Mulligan group by computerised random sequence generator" Comment: An adequate method was used to generate the allocation se- quence
Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported on how the allocation sequence was concealed

### Shrivastava 2011 (Continued)

Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Quote: "Double blinding was done with the assessment therapist and the pa- tient both being blinded with respect to treatment protocol followed" Comment: Participants received different types of mobilisation but were not provided information that would make them perceive the intervention they re- ceived as superior or inferior to the alternative intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	Low risk	Quote: "Double blinding was done with the assessment therapist and the pa- tient both being blinded with respect to treatment protocol followed" Comment: Blinded participants self-reported pain, function and adverse events
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "Double blinding was done with the assessment therapist and the pa- tient both being blinded with respect to treatment protocol followed" Comment: Assessors of range of motion were probably blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "no patient dropped out of the study due to problems in therapy" Comment: No dropouts, losses to follow-up or exclusions were reported
Selective reporting (re- porting bias)	Unclear risk	Comment: Only means with no measures of variation were reported for all out- comes specified in the methods section of the publication. However, it is not clear whether data were incompletely reported based on the statistical signif- icance or magnitude of the results. Also, without a trial protocol, it is unclear whether other outcomes were assessed but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Sirajuddin 2010			
Methods	Design: parallel-group, 3-arm randomised controlled trial (India)		
	<b>Interventions:</b> anterior glide mobilisation plus ultrasound therapy plus exercises or posterior glide mobilisation plus ultrasound therapy plus exercises or no mobilisation plus ultrasound therapy plus exercises		
	Sample size calculation: not reported		
	Analysis: intention-to-treat analysis		
	Source of funding: not reported		
Participants	Number of participants: 45 (15 per group)		
	Baseline characteristics: Baseline characteristics were not reported by group		
	Age range 40-60 years; male:female = 17:28		
	Duration of symptoms: longer than 3 months		
	Inclusion criteria		
	<ul> <li>Aged between 40 and 60 years</li> <li>Unilateral condition with duration longer than 3 months</li> <li>Idiopathic/primary adhesive capsulitis (i.e. insidious onset with no history of major trauma)</li> <li>Presence of shoulder pain with limitations of both active and passive movements of glenohumeral joint of more than 25% in at least 2 directions, including internal rotation, external rotation, abduction and flexion as compared with contralateral shoulder or with normal values</li> <li>Normal findings on anteroposterior/axillary lateral radiographs of glenohumeral joint</li> </ul>		



# Sirajuddin 2010 (Continued)

#### Exclusion criteria

- Secondary adhesive capsulitis
- · Shoulder girdle motor control defects associated with neurological disorders
- Intrinsic glenohumeral pathology such as osteoarthritis, rheumatoid arthritis, rotator cuff pathology, biceps tendinitis, calcific tendinitis
- Former manipulations under anaesthesia of affected shoulder
- Taking NSAIDs and other analgesics
- Injections with corticosteroid in affected shoulder in preceding 4 weeks
- Previous shoulder surgeries of affected shoulder

Interventions

All groups received ultrasound therapy and exercises. Ultrasound therapy was delivered at a frequency of 1 Mhz and an intensity of 1.0 W/cm<sup>2</sup> for 8 minutes. To reduce postmobilisation soreness, each participant was given moist heat to the mobilised shoulder for 20 minutes. The exercise programme comprised Codman's pendular exercises for 2 minutes, wall ladder in abduction and flexion (5 repetitions 3 times daily) and wand-assisted exercises for the shoulder (5 repetitions 3 times daily)

#### Anterior glide mobilisation (N = 15)

*Components of intervention:* anterior glide mobilisation. Participant was made prone and lateral humeral distraction was maintained in its midrange position, while the anterior stretch mobilisation was performed to end range, at the end range of abduction and internal rotation. If the participant was able to tolerate a stronger stretching force, body weight and gravity were used to generate the mobilisation force in a similar combined fashion of distraction to midrange and anterior glide to end range. Kaltenborn stretch mobilisation (which loads the restricting tissue at the end of the available range of motion) and Kaltenborn grade 3 mobilisation (which applies force after the slack of the joint has been taken up, to stretch tissues crossing the joint) were used. The end range positions of mobilisation were held for at least 1 minute. Fifteen minutes of sustained stretch was performed at each treatment session. During joint mobilisation, participants were instructed to describe their sensation, so that the therapist could modify the force or position to maintain a moderate stretch on the targeted tissue (however, each participant was encouraged to tolerate the pain to allow a moderate stretch sensation)

Dosage: 15 minutes of sustained stretch

Frequency of administration: twice a week for 3 weeks (6 sessions)

Provider: physiotherapist

### Posterior glide mobilisation (N = 15)

*Components of intervention:* posterior glide mobilisation. The posterior glide to the shoulder joint was given in the supine position. In this position, lateral humeral distraction was maintained in its midrange position, while posterior stretch mobilisation was performed to the end range of abduction and internal rotation. Kaltenborn stretch mobilisation (which loads the restricting tissue at the end of the available range of motion) and Kaltenborn grade 3 mobilisation (which applies force after the slack of the joint has been taken up, to stretch tissues crossing the joint) were used. The end range positions of mobilisation were held for at least 1 minute. Fifteen minutes of sustained stretch was performed at each treatment session. During joint mobilisation, participants were instructed to describe their sensation, so that the therapist could modify the force or position to maintain a moderate stretch on the targeted tissue (however, each participant was encouraged to tolerate the pain to allow a moderate stretch sensation)

Dosage: 15 minutes of sustained stretch

Frequency of administration: twice a week for 3 weeks (6 sessions)

Provider: physiotherapist

#### No mobilisation (N = 15)

Only ultrasound therapy and exercises (see above) were delivered



# Sirajuddin 2010 (Continued)

Outcomes	Outcomes assessed at the sixth and last (i.e. end of 3 weeks' treatment) sessions. No primary outcome was reported by the trialists
	<ul> <li>Pain using a visual analogue scale (scale units not reported although assumed to be 0 to 10 based on outcome data reported)</li> </ul>
	Active range of motion in internal rotation, external rotation and abduction using a goniometer
	• Function using the Shoulder Rating Questionnaire (ranges in scores from minimum of 17 denoting worst functional status to maximum of 100 points denoting best functional status)
Notes	Numerical outcome data were fully reported for VAS pain and active range of motion in internal rota-

Numerical outcome data were fully reported for VAS pain and active range of motion in internal rotation, but data for active range of motion in external rotation and abduction and for the Shoulder Rating Questionnaire were presented in figures with unlabelled error bars only

### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "After screening for inclusion and exclusion criteria the subjects were randomly assigned into either of 3 groups with 15 subjects in each group" Comment: No information was reported on how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported on how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Comment: Participants received slightly different types of mobilisation, but it is unclear whether they were provided any information that would make them perceive the type of mobilisation they received as superior or inferior to the al- ternative type of mobilisation
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	Unclear risk	Comment: Participants self-reported pain and function, but it is unclear whether they were provided any information that would make them perceive the type of mobilisation they received as superior or inferior to the alternative type of mobilisation
Blinding of outcome as- sessment (detection bias) Objective outcomes	Unclear risk	Comment: No information was reported on whether assessors of range of mo- tion were blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: No dropouts, losses to follow-up or exclusions were reported, and outcome data were reported as based on the total number of randomly assigned participants
Selective reporting (re- porting bias)	Unclear risk	Comment: Numerical outcome data were fully reported for VAS pain and ac- tive range of motion in internal rotation, but data for active range of motion in external rotation and abduction and for the Shoulder Rating Questionnaire were presented in figures with unlabelled error bars only. However, the incom- pletely reported data do not appear to have been incompletely reported on the basis of statistical significance or magnitude of results, although without a trial protocol, it is unclear whether other outcomes were measured but not re- ported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified



Tanaka 2010				
Methods	Design: parallel-group, 3-arm, double-blind randomised controlled trial (Japan)			
	<b>Interventions:</b> high-frequency (more than 2 times a week), moderate-frequency (once a week) or low- frequency (less than once a week) joint mobilisation and home self-exercises			
	Sample size calculation: not reported			
	Analysis: per-protocol analysis			
	Source of funding: not reported			
Participants	Number of participants: 120 (40 per group)			
	Baseline characteristics: Age and duration of symptoms were not reported by group			
	Mean (SD) age: 63.7 (9.1) years			
	Duration of symptoms: 37 had condition for less than 1 month, 39 for less than 3 months, 21 for less than 6 months and 13 for longer than 7 months			
	Group receiving high-frequency joint mobilisation			
	Male:female = 18:21			
	Group receiving moderate-frequency joint mobilisation			
	Male:female = 17:18			
	Group receiving low-frequency joint mobilisation			
	Male:female = 17:19			
	Inclusion criteria			
	<ul> <li>Diagnosed with limited glenohumeral joint mobility arising from adhesive capsulitis</li> <li>Unremarkable medical history and no clinical or radiological findings that could explain the decrease in shoulder motion</li> </ul>			
	Exclusion criterion			
	Received corticosteroid injections into the joint during the intervention			
Interventions	All groups received home exercise performed 2 to 3 times a day, including Codman's or pendulum exer- cises (circumduction) and passive stretching exercises such as "climbing the wall exercise" (i.e. facing a wall about three quarters of an arm's length away and raising the affected arm up to the shoulder level using only one's fingers without using shoulder muscles). Mean (SD) duration of treatment was 4.6 (1.2) months			
	High-frequency joint mobilisation (N = 40)			
	<i>Components of intervention:</i> Mobilisation techniques used were those described by Vermeulen 2000, which are performed in the end ranges of limited joint mobility			
	<i>Dosage:</i> 40 minutes			
	<i>Frequency of administration:</i> More than twice a week for a mean (SD) duration of treatment of 4.6 (1.2) months			
	Provider: physical therapist			
	Moderate-frequency joint mobilisation (N = 40)			
	<i>Components of intervention:</i> Mobilisation techniques used were those described by Vermeulen 2000, which are performed in the end ranges of limited joint mobility			

Tanaka 2010 (Continued)				
	Dosage: 40 minutes			
	Frequency of administration: once a week for a mean (SD) duration of treatment of 4.6 (1.2) months			
	Provider: physical therapist			
	Low-frequency joint mobilisation (N = 40)			
	<i>Components of intervention:</i> Mobilisation techniques used were those described by Vermeulen 2000, which are performed in the end ranges of limited joint mobility			
	Dosage: 40 minutes			
	<i>Frequency of administration:</i> less than once a week for a mean (SD) duration of treatment of 4.6 (1.2) months			
	Provider: physical therapist			
Outcomes	Outcomes assessed until the time required to reach the range of motion plateau point (see below). Av- erage length of therapy was 4.6 ± 1.2 months, and follow-up time was 5.9 ± 1.3 months. No primary out- come was reported by the trialists			
	• Improved angle of the shoulder joint, defined as the value obtained by subtracting the affected shoul- der joint angle at baseline from the angle of the ROM plateau point (the point in time at which im- provement in range of motion (ROM) of the shoulder joint had plateaued for longer than 1 month). Unit of measurement was degrees. Angle of joints was evaluated every week using a large handheld goniometer in terms of active abduction angle at which the capsular pattern of frozen shoulder char- acteristically caused the greatest restriction			
	• Time required to reach the range of motion plateau point (point of time at which improvement in range of motion of the shoulder joint had plateaued for longer than 1 month). Unit of measurement was months			
Notes				

Risk of bias

Bias Authors' judgement Support for judgement Random sequence genera-Unclear risk Quote: "From the frequency of sessions for joint mobilization by physical thertion (selection bias) apists in the hospital setting, the patients were divided randomly into the high-frequency session group (HF group, more than two times a week), moderate-frequency session group (MF group, once a week), and low-frequency session group (LF group, less than once a week)" Comment: No information was reported on how the allocation sequence was generated Allocation concealment Unclear risk Comment: No information was reported on how the allocation sequence was (selection bias) concealed Blinding of participants Low risk Quote: "We performed a randomized, placebo-controlled, participant and sinand personnel (perforgle assessor-blinded trial" mance bias) Comment: Participants, but not personnel, were probably blind to treatment All outcomes (i.e. probably did not know how the length of their intervention compared with that of participants in other groups) Blinding of outcome as-Unclear risk sessment (detection bias) Self-reported outcomes Blinding of outcome as-Low risk Quote: "ROM was measured every week by one examiner who was not insessment (detection bias) formed of the group designation of patients"



Tanaka 2010 (Continued) Objective outcomes		Comment: Objectively assessed outcomes were probably assessed by an as- sessor who was blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "The results of ten patients (men, 7; women, 3) were excluded from the data analysis because they received corticosteroidal injections during this study" Comment: One participant in the high-frequency group, 5 participants in the moderate-frequency group and 4 participants in the low-frequency group were excluded from the analysis because they received corticosteroid injec- tions during the study. As the reason for exclusions was the same for each group, the results are unlikely to be biased because of these exclusions
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

van der Windt 1998	
Methods	Design: parallel-group, 2-arm, single-blind randomised controlled trial (The Netherlands)
	<b>Interventions:</b> physiotherapy (passive joint mobilisation and exercise treatment) or glucocorticoid in- jection
	<b>Sample size calculation:</b> 60 participants per group were estimated to be needed based upon detec- tion of a clinically relevant difference of 25% in success rate at the 5% level of statistical significance with 80% power
	<b>Analysis:</b> For the primary outcome of "improvement," modified intention-to-treat analysis excluding 1 participant who withdrew from the injection group immediately post randomisation was used; for all other outcomes, modified intention-to-treat analysis, where only participants with missing data were excluded from the analysis, regardless of what treatments they actually received, was used
	<b>Source of funding:</b> Netherlands Organisation for Scientific Research and the Fund for Investigative Medicine of the Health Insurance Council (non-industry)
Participants	Number of participants: 109 (56 and 53 participants in each group, respectively)
	Baseline characteristics
	Group receiving physiotherapy
	Mean (SD) age = 60.2 (10.7) years; male:female = 23:33
	Duration of symptoms: 6 (11%) less than 1 month; 26 (46%) ≥ 1-3 months; 9 (16%) > 3-6 months; 9 (16%) > 6-12 months; 6 (11%) > 12 months
	Group receiving glucocorticoid injection
	Mean (SD) age = 57.3 (10.2) years; male:female = 28:25
	Duration of symptoms: 7 (13%) less than 1 month; 21 (40%) ≥ 1-3 months; 13 (24%) > 3-6 months; 8 (15%) > 6-12 months; 4 (8%) > 12 months
	Inclusion criteria
	<ul> <li>Painful restriction of glenohumeral mobility</li> <li>Age 18 years or older</li> <li>Gave informed consent</li> </ul>

# van der Windt 1998 (Continued)

#### **Exclusion criteria**

- Bilateral symptoms
- Treatment with corticosteroid injections or physiotherapy during the preceding 6 months
- Contraindications to treatment
- Surgery, dislocation or fracture in the shoulder area
- Insulindependent diabetes mellitus, systemic disorders of the musculoskeletal system or neurological disorders

Interventions Physiotherapy (N = 56) Components of intervention: • Manual therapy: passive joint mobilisation (received by all participants in this group)

- Supervised exercise: not specified (received by all participants in this group)
- Other: Ice, hot packs or electrotherapy could be used to reduce pain

Dosage: 30 minutes

Frequency of administration: twice a week for 6 weeks (12 sessions)

Provider: physiotherapist

#### Glucocorticoid injection (N = 53)

Components of intervention: Intraarticular injections of 40 mg triamcinolone acetonide were given by general practitioners using the posterior route. Nearly all of the general practitioners had attended training in this technique before the study began, although most had had previous experience with the technique

Dosage: 40 mg triamcinolone acetonide

Frequency of administration: No more than 3 injections were given during the 6 weeks

Provider: general practitioner

Outcomes assessed at weeks 3, 7, 13, 26 and 52

#### **Primary outcomes**

- · Improvement as measured using a 6-point Likert scale, analysed as "success rates," defined as participants self-rating themselves as having complete recovery or much improvement
- Pain associated with their main complaint, day pain and night pain, each rated on a 100-mm visual analogue scale, where the score of 100 indicates very severe pain
- Functional disability using the Shoulder Disability Questionnaire (van der Windt 1998b), a 16-item scale consisting of common situations that might cause shoulder pain, with scores ranging from 0 to 100 (100 indicates severe disability)

#### Secondary outcomes

- Independent observer rated overall clinical severity using a visual analogue scale
- Passive range of motion (external rotation, abduction) using an inclinometer
- Adverse events

#### Notes

Outcomes

### **Risk of bias**

Bias

Authors' judgement Support for judgement

van der Windt 1998 (Continued)	)	
Random sequence genera- tion (selection bias)	Low risk	Quote: "The random sequence of the blocks was generated using random number tables" Comment: An adequate method was used to generate the allocation se- quence
Allocation concealment (selection bias)	Low risk	Quote: "Numbered, opaque, sealed envelopes containing the treatment allo- cation were prepared before the trial. After selection and baseline assessment an administrative assistant opened the next envelope in the appropriate stra- tum" Comment: An adequate method was used to conceal the allocation sequence
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Quote: "The independent observer did not know to which intervention a pa- tient had been allocated. To optimise blinding the patient was instructed by the administrative assistant not to reveal any information about their treat- ment. In all patients the actual or potential injection site was covered with gauze. Immediately after each examination the observer was asked to guess to which intervention the patient had been assigned" Comment: Given the nature of the interventions, participants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported "improve- ment" (i.e. global assessment of treatment success), pain and function
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "The independent observer did not know to which intervention a pa- tient had been allocated. To optimise blinding the patient was instructed by the administrative assistant not to reveal any information about their treat- ment. In all patients the actual or potential injection site was covered with gauze. Immediately after each examination the observer was asked to guess to which intervention the patient had been assigned" Quote: "The observer correctly guessed the allocated treatment for 65 (60%) out of 108 patients after 7 weeks and for 51 (48%) out of 105 after 26 weeks. The frequency of correct guesses was similar in both groups (30/52 (58%) for patients having injections and 35/56 (63%) for those having physiotherapy at 7 weeks)" Comment: Assessors of objective outcomes were probably blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "One patient withdrew from the study immediately after randomisa- tion, refusing to have any injections. A total of six patients (5.5%) withdrew from the study, four of whom reported complete recovery before withdraw- al. All patients who withdrew from the study were included in the statistical analysis until withdrawal" Quote: "At 3 and 13 weeks there is one missing value in each group. At 7 weeks there is one missing value in the injection group. At 26 weeks there are one missing value in the injection group and two in the physiotherapy group. At 52 weeks there are four missing values in the injection group and one in the phys- iotherapy group" Comment: 2 participants dropped out of the physiotherapy group and 4 par- ticipants dropped out of the control group. Reasons were balanced between groups, so the results are unlikely to be biased for these reasons
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Vermeulen 2006	
Methods	Design: parallel-group, 2-arm, single blind randomised controlled trial (The Netherlands)
	<b>Interventions:</b> intensive passive mobilisation techniques in end range positions of the glenohumeral joint (high-grade mobilisation) or passive mobilisation techniques within the pain-free zone (low-grade mobilisation)
	<b>Sample size calculation:</b> 45 participants per group were estimated to be needed based upon detec- tion of a difference of 18.6 degrees in active range of motion in abduction at the 5% level of statistical significance with 90% power, including a 15% rate of loss at follow-up
	Analysis: intention-to-treat analysis
	Source of funding: not reported
Participants	Number of participants: 100 (49 and 51 participants in each respective group)
	Baseline characteristics
	Group receiving high-grade mobilisation
	Mean (SD) age = 51.6 (7.6) years; male:female = 17:32
	Mean (range) duration of symptoms: 8 (5-14.5) months
	Group receiving low-grade mobilisation
	Mean (SD) age = 51.6 (8.6) years; male:female = 17:34
	Mean (range) duration of symptoms: 8 (6-14) months
	Inclusion criteria
	<ul> <li>Unilateral adhesive capsulitis defined as ≥ 50% loss of passive movement of the shoulder joint relative to the non-affected side, in 1 or more of 3 movement directions (i.e. abduction in the frontal plane, forward flexion or external rotation in 0° of abduction)</li> </ul>
	<ul> <li>Duration of complaints ≥ 3 months</li> <li>Ability to complete superior in Dutch</li> </ul>
	Ability to complete questionnaires in Dutch
	Exclusion criteria
	<ul> <li>Previous manipulation of the affected shoulder under anaesthesia</li> <li>Other conditions involving the shoulder (e.g. rheumatoid arthritis, osteoarthritis, damage of the glenohumeral cartilage, Hill-Sachs lesion, osteoporosis, malignancies in the shoulder region)</li> <li>Neurological deficits affecting shoulder function in normal daily activities</li> <li>Pain or disorders of the cervical spine, elbow, wrist or hand</li> <li>Injection with corticosteroids in the affected shoulder during the preceding 4 weeks</li> </ul>
Interventions	High-grade mobilisation (N = 49)
	<i>Components of intervention:</i> intensive passive mobilisation techniques in end range positions of the glenohumeral joint (high-grade mobilisation). Mobilisation techniques were applied with intensities according to Maitland grades III and IV. The duration of prolonged stress on the shoulder capsule in the end range position varied according to the participant's tolerance
	<i>Dosage:</i> 30 minutes
	Frequency of administration: twice a week for 12 weeks (24 sessions)
	Provider: physiotherapist
	Low-grade mobilisation (N = 51)



Vermeuten 2006 (Continued)	<i>Components of intervention:</i> passive mobilisation techniques within the pain-free zone (low-grade mobilisation). Participants were explicitly informed that all techniques should be performed without causing pain in the shoulder. Mobilisation techniques commenced in the basic starting positions, with translation and distraction techniques performed with the joint near its neutral position (grade I). Reflex muscle activity was carefully monitored because it can be a first indication of joint pain. If joint mobility increased, mobilisation techniques were adjusted and the amplitude of movements was increased without reaching the limits of ROM (grade II). During the last 3 minutes of each treatment session, passive PNF patterns within the pain-free zone in the supine position were applied. In addition, Codman's pendular exercises were performed for 2 minutes in a prone position to move the shoulder joint in more than 1 direction at a time and to obtain maximal relaxation of the shoulder muscles <i>Dosage:</i> 30 minutes
	Provider: physiotherapist
Outcomes	Outcomes assessed at the end of 3 months' treatment and at 6 months and 12 months (post randomi- sation)
	Primary outcome
	Active range of motion in abduction using a goniometer
	Secondary outcomes
	<ul> <li>Active and passive range of motion in abduction, flexion and external rotation using a goniometer</li> <li>Disability using the Shoulder Rating Questionnaire, a self-administered questionnaire including global assessment, pain, daily activities, recreational and athletic activities, work, satisfaction and areas for improvement. Total score ranges from a minimum of 17 points (worst functional status) to a maximum of 100 points (best functional status)</li> </ul>
	• Disability using the Shoulder Disability Questionnaire, which includes 16 items, each with 3 answering options—"yes," "no" and "not applicable"—calculated into a summary score. The score ranges from a minimum of 0 points (no functional limitation) to a maximum of 100 points (affirmative answer to all applicable items)
	• Pain at rest, during movement and during the night, using a 100-mm visual analogue scale, with 0 indicating no pain and 100 indicating very severe pain
	<ul> <li>General health status using the SF-36. Both the Physical Component Score and the Mental Score were calculated (possible scores range from 0 to 100, with higher score denoting better health)</li> </ul>
	<ul> <li>Overall opinion about changes from baseline in shoulder function using a 5-point Likert scale (1 = much worse to 5 = much better)</li> </ul>
Notes	Pain at rest was used as a measure of overall pain
Risk of bias	
Bias	Authors' judgement Support for judgement

Random sequence genera- tion (selection bias)	Low risk	Quote: "Randomization was done by a random-number generator with per- muted blocks of 4 and stratification for the presence of diabetes mellitus and for joint capacity as measured by arthrography (≤15 or >15 cm). The latter stratification was done because joint capacity may vary in people with adhe- sive capsulitis, and its potential influence on the recovery process remains un- known. After the baseline assessments were carried out, an administrative as- sistant assigned the subjects to the intervention groups according to the ran- domization scheme" Comment: An adequate method was used to generate the allocation se- quence



### Vermeulen 2006 (Continued)

Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported on how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Comment: Participants received different types of mobilisation, but it is un- clear whether they were provided any information that would make them per- ceive the type of mobilisation they received as superior or inferior to the alter- native type of mobilisation
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	Unclear risk	Comment: Participants self-reported several outcomes (e.g. pain, disability, general health status), but it is unclear whether they were provided any information that would make them perceive the type of mobilisation they received as superior or inferior to the alternative type of mobilisation
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "All examinations were carried out by a masked assessor who is a trained physical therapist and manual therapist (HMV). Subjects were instruct- ed not to reveal any details about the treatment or therapist to the assessor" Comment: Assessors of objective outcomes were probably blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Thus, 100 subjects entered the study and were randomly assigned to either the HGMT group (n=49) or the LGMT group (n=51) (Figure), In both groups, 2 subjects withdrew from the trial in the first 3 months and were lost to follow-up. One violation of the protocol occurred in the HGMT group after 3 weeks, as the subject did not want to be treated in either of the treatment groups anymore. She was further treated for 3 months by a physical therapist who was not involved in this study, but she did return for the follow-up visits" Quote: "The outcome analysis was based on an intention-to-treat principle, and all subjects were included in the analysis. For subjects lost to follow-up, all of the available data were used" Comment: Numbers of dropouts and losses to follow-up were low, and the reasons for this are unlikely to have biased the results
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified.

### Wen 2009

Methods	Design: parallel, 2-arm randomised controlled trial (China)		
	<b>Interventions:</b> functional exercises plus shoulder traction plus intermediate frequency electrical stim- ulation or shoulder traction plus intermediate frequency electrical stimulation		
	Sample size calculation: not reported		
	Analysis: intention-to-treat analysis		
	Source of funding: not reported		
Participants	Number of participants: 72 (36 per group)		
	Baseline characteristics: Baseline characteristics were not reported by group		
	Mean (range) age: 52 (44-63) years		
	Male:female = 19:53		
Library

Wen 2009 (Continued)	Mean (range) duration of symptoms: 4 (2-7) months
	Inclusion criterion
	Unilateral shoulder pain, recurrent and limited shoulder function
	Exclusion criteria
	Not reported
Interventions	Both groups received shoulder traction plus intermediate frequency electrical stimulation once a day for 15 days. Shoulder traction is translated as follows: Using a traction grid, the participant is in a sit- ting or lying position. A strap, attached to a rope pulley suspension and weight, is placed on the partici- pant's wrist. The angle and weight are selected appropriately according to the degree of pain and func- tional limitation. The participant performs shoulder flexion, abduction, extension, adduction, etc, at different traction angles. Each angle is continued for 20-30 minutes, with a rest period in the middle. An appropriate session has no more than 2 body positions. If the weight of the suspension does not cause obvious pain to the participant, the traction angle and weight are gradually increased according to the participant's improvement progress, to the point where recovery is that of normal range of motion.
	Intermediate-frequency electrical stimulation is translated as follows: Using the J48A model comput- er with diathermy instrument, the electrode plate is placed on the shoulder at the prominent pain site, with a frequency of 4-5 KHz, modulating the sine and square waveform, and is adjusted to the partici- pant's tolerance and at a comfortable heat. Participants received 1 session per day (lasting 20 minutes) for 15 days
	Functional exercises plus shoulder traction plus intermediate-frequency electrical stimulation (N = 36)
	<i>Components of intervention:</i> supervised functional exercises. Different exercises were performed depending on the duration of the participant's symptoms. If duration of symptoms was 1-2 months, the following exercises were performed: hand exercises, Codman's hanging and swinging movement, flexion in front of the body at 90 degrees, hanging the limb and swinging it backward and forward, inside and out and in circles and wall climbing the 'ladder' exercises. If duration of symptoms was 2-3 months, the following exercises were performed: passive
	range of motion exercises, active exercises with gym equipment, active exercises with a wooden stick and shoulder wheel exercises. If duration of symptoms was 3-6 months, pulley exercises were per- formed
	Dosage: not reported
	Frequency of administration: once a day for 15 days (15 sessions)
	Provider: physical therapist
	Shoulder traction plus intermediate-frequency electrical stimulation (N = 36)
	See above
Outcomes	Outcomes assessed at the end of 15 days' treatment. No primary outcome was reported by the trialists
	<ul> <li>Pain rated on a 30-point scale (direction of scale unclear)</li> <li>Function rated on a 30-point scale (direction of scale unclear)</li> <li>Range of motion (not reported whether active or passive) rated on a 25-point scale (direction of scale unclear)</li> </ul>
Notes	This article was written in Chinese and was translated by MC. As the direction of the scale was unclear for all outcomes, and no information about how range of motion was assessed on a 25-point scale was reported, no outcome data were extracted from this trial
Risk of higs	



#### Wen 2009 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: [Translated] "Patients were randomly divided into treatment and con- trol group, with each group having 36 patients"
		Comment: No information was reported about how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported about how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Comment: Given the nature of the interventions (the same multi-component physical therapy intervention with or without additional exercises), partici- pants were not blind to treatment and may have had different expectations about the benefits of each intervention
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported pain and function
Blinding of outcome as- sessment (detection bias) Objective outcomes	Unclear risk	Comment: No information was reported about whether assessors of range of motion were blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: No dropouts, losses to follow-up or exclusions were reported, and the analyses are reported as based on the number of randomly assigned par- ticipants
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

#### Yan 2005

Methods	Design: parallel-group, 2-arm randomised controlled trial (China)		
	Interventions: dumbbell gymnastics training exercises or bare-handed exercises		
	Sample size calculation: not reported		
	Analysis: intention-to-treat analysis		
	Source of funding: not reported		
Participants	Number of participants: 54 (26 and 28 in each respective group)		
	Baseline characteristics		
	Group receiving dumbbell gymnastics training exercises		
	Mean (SD) age = 56.6 (12.4) years; male:female = 23:3		
	Mean duration of symptoms: 6.8 years		
	Group receiving bare-handed exercises		
	Mean (SD) age = 54.2 (11.6) years; male:female = 20:8		

#### Yan 2005 (Continued)

#### Mean duration of symptoms: 5.8 years

#### Inclusion criterion

• Met the standard shoulder periarthritis diagnostics in "Clinical Pain Therapy"

#### **Exclusion criterion**

• Neurological, muscular, bone, joint cartilage and all joint-related functional barriers (cerebrovascular accident, peripheral nerve injury, progressive muscular dystrophy, etc)

#### Interventions

#### Dumbbell gymnastics training exercises (N = 26)

Components of intervention: Gymnastics training exercises with dumbbells weighing about 2-5 kg, corresponding to the participant's circumstances. In a preparatory standing position with both hands holding dumbbells down on the side of the body, the following specific exercises were performed: (1) elbow facing forward: hands facing forward and bending the elbows 10 times; (2) abduction-adduction: both shoulders in abduction, hands facing inwards, bending the elbow towards the chest 10 times; (3) swinging the arm back and forth: both arms holding the dumbbells swinging the arm back and forth 10 times or bending hips forward 90°, hanging the dumbbells down, with both arms abducted 90°, adducting and bending the elbows towards the chest 10 times; (4) lifting the dumbbells up: standing position, with both arms lifting up 10 times or both arms alternatively crossing each other 10 times; (5) extending and flexing forwards: both arms straight and extending forward, with hands facing inwards, extending and flexing the shoulder and elbow joints 10 times; (6) abduction, pushing and lifting: standing position, with both hands holding the dumbbells, both arms abducted 90°, hands facing forward, extending and flexing the elbow joint 10 times; (7) extending shoulder backwards: bending forward, with both hands holding the dumbbells, swinging both arms backward and back to the ankle area 10 times; (8) abduction of the elbows: both hands holding the dumbbells, with face left, right arm straight and extending both arms 90°, hands facing upwards, bending the elbow 10 times; (9) extending and flexing the elbows forwards: both hands holding the dumbbells, facing forward extending and straightening both arms 90°, with hands facing upwards, bending the elbows 10 times; (10) integrated movements: both hands holding the dumbbells, pushing forward horizontally, moving back to the shoulder, elbow, and then moving left/right, with both sides extending straight both arms, moving back and lifting up both arms, repeating 10 times

Dosage: 5-10 minutes

Frequency of administration: 2-3 times a day for 3 months (84 sessions)

Provider: physical therapist

#### Bare-handed exercises (N = 28)

*Components of intervention:* Specific exercises included (1) swinging back and forth: standing position, with both arms hanging down the side of the body, swinging both arms back and forth 10 times; (2) rotation method: standing position, with both arms moving in a clockwise direction and rotating the shoulder joints 10 times, then rotating the shoulder joint in an anticlockwise direction 10 times; (3) facing and climbing the wall method: standing position, facing the wall, affected limb straightened and extended, with fingers touching the wall and moving up along the wall 10 times; (4) climbing the wall on the side method: standing position, with the affected arm facing the wall, abduction upwards, the fingers touching the wall, during training, the body needs to be straight, not curved; (5) extending and touching the shoulder: affected limb extending to the back, rotating the elbow inwards, with backs of the fingers touching upwards 10 times; (6) flexing, bending and touching the shoulder: participants with limited adduction, using the affected hand, bending the elbow forward and touching the healthy, opposite side shoulder 10 times

Dosage: 5-10 minutes

Frequency of administration: 2-3 times a day for 3 months (84 sessions)

*Provider:* physical therapist



<b>/an 2005</b>	(Continued)
-----------------	-------------

Outcomes

Outcomes assessed at the end of 3 months' treatment. No primary outcome was reported by the trialists

- Treatment success, rated as "Excellent" = pain gone, function fully back to normal (abduction > 80°, flexing upwards > 160°, bending the elbow and rotating internally above TL9); "Good" = some pain when moving, most function recovered (abduction > 70°, flexing upwards > 140°, bending the elbow and rotating internally above TL12); "Acceptable" = pain and pressure aches reduced, joint range of movement improved; and "Bad" = no obvious improvement in pain and pressure aches and no change in joint range of movement
- Range of motion in flexion, extension and abduction using a protractor to measure the degree of the joints (not reported whether active or passive)

To analyse the "treatment success" outcome, we dichotomised participants into those who had a clinical improvement rating of "Excellent" and those who had a rating of "Good," "Acceptable" or "Bad"

Trialists reported that 35 participants had a left-affected shoulder, 16 had a right-affected shoulder and 3 had bilateral periarthritis. However, the group to which bilaterally affected participants were allocated was not reported, nor was mention made of controlling for the correlation between shoulders. We analysed data on the basis of number of participants, not number of shoulders, to produce conservative estimates of effect

#### **Risk of bias**

Notes

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: [Translated] "Randomised controlled observations of frozen shoulder patients"
		Comment: No information was reported about how the allocation sequence was generated
Allocation concealment (selection bias)	Unclear risk	Comment: No information was reported about how the allocation sequence was concealed
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Comment: Participants received different types of exercises, but it is unclear whether they were provided any information that would make them perceive the type of exercises they received as superior or inferior to the alternative types of exercise
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	Unclear risk	Comment: Participants self-reported pain, but it is unclear whether they were provided any information that would make them perceive the type of exercises they received as superior or inferior to the alternative type of exercises
Blinding of outcome as- sessment (detection bias) Objective outcomes	Unclear risk	Comment: No information was reported about whether assessors of range of motion were blind to treatment
Incomplete outcome data (attrition bias)	Low risk	Quote: [Translated] "According to intention-to-treat analysis, 54 patients with frozen shoulder all were analysed, there were no patients drop-out"
All outcomes		Comment: No dropouts, losses to follow-up or exclusions were reported, and outcome data were reported as analysed on the basis of the number of ran- domly assigned participants
Selective reporting (re- porting bias)	Unclear risk	Comment: Outcome data were fully reported for all outcomes reported in the methods section of the publication, but without a trial protocol, it is unclear whether other outcomes were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified



Yang 2007	
Methods	Design: multiple-treatment, 2-group, 3-arm randomised controlled trial (Taiwan)
	Interventions: end range mobilisation or midrange mobilisation or mobilisation with movement
	<b>Sample size calculation:</b> 15 participants per group were estimated to be needed based upon detec- tion of a difference of 5 degrees of ROM at the 5% level of statistical significance with 80% power
	<b>Analysis:</b> per-protocol analysed data reported (but intention-to-treat analysis was also performed, and results were similar to those of the per-protocol analysis)
	Source of funding: National Science Council, Taiwan (non-industry)
Participants	Number of participants: 30 (15 per group)
	Baseline characteristics
	Group receiving midrange mobilisation, then end range mobilisation, then midrange mobilisation, then mobilisation with movement
	Mean (SD) age = 53.3 (6.5) years; male:female = 1:13
	Mean (SD) duration of symptoms: 18.8 (8) weeks
	Group receiving midrange mobilisation, then mobilisation with movement, then midrange mobilisation, then end range mobilisation
	Mean (SD) age = 58 (10.1) years; male:female = 3:11
	Mean (SD) duration of symptoms: 22 (10) weeks
	Inclusion criteria
	<ul> <li>Painful stiff shoulder for at least 3 months</li> <li>Limited range of motion of a shoulder joint (range of motion losses of 25% or greater compared with the non-involved shoulder in at least 2 of the following shoulder motions: glenohumeral flexion, abduction or medial and lateral rotation)</li> <li>Consent of the participant's physician to participate in the study</li> </ul>
	Exclusion criteria
	<ul> <li>Diabetes mellitus</li> <li>History of surgery on the particular shoulder</li> <li>Rheumatoid arthritis</li> <li>Painful stiff shoulder after a severe trauma</li> <li>Fracture of the shoulder complex</li> <li>Rotator cuff rupture</li> <li>Tendon calcification</li> </ul>
Interventions	Midrange mobilisation, then end range mobilisation, then midrange mobilisation, then mobilisa-
	tion with movement (N = 15)
	<ul> <li>End range mobilisation: At the start of each intervention session, the physical therapist examined the participant's range of motion to obtain information about the end range position and the end-feel of the glenohumeral joint. Then, the therapist's hands were placed close to the glenohumeral joint, and the humerus was brought into a position of maximal range in different directions. 10-15 repetitions of intensive mobilisation techniques, varying the plane of elevation or varying the degree of rotation in the end range position, were applied</li> </ul>



Yang 2007 (Continued)	<ul> <li>Midrange mobilisati the resting position of the mobilisation if</li> <li>Mobilisation with m around the head of t used over the appro- to the scapula with movements to the e sets of 10 repetition</li> </ul>	on: With the participant in a relaxed supine position, the humerus was moved to (40° of abduction). While the humerus was held in this position, 10-15 repetitions techniques were applied novement: With the participant in a relaxed sitting position, a belt was placed the humerus to glide the humerus head appropriately, as the therapist's hand was opriate aspect of the head of the humerus. A counterpressure also was applied the therapist's other hand. The glide was sustained during slow active shoulder and of the pain-free range and was released after return to the starting position. 3 s were applied, with 1 minute between sets
	Dosage: 30 minutes	
	Frequency of administr	ation: Each treatment phase lasted twice a week for 3 weeks
	Provider: physical thera	apist
	Midrange mobilisation range mobilisation (N	n, then mobilisation with movement, then midrange mobilisation, then end = 15)
	See above (the only dif	ference is the order in which each phase of mobilisation was provided)
Outcomes	Outcomes assessed at 3, 6, 9 and 12 weeks (i.e. end of each 3-week treatment phase): No primary of come was reported by the trialists	
	<ul> <li>Function using the der-specific, fixed-it single item that gro only to the items that limited function, to</li> <li>Active range of moti tation, humeral meet</li> </ul>	Flexi-Level Scale of Shoulder Function (FLEX-SF), a self-administered, shoul- teem index consisting of 3 levels of function. In this scale, respondents answer a ssly classifies their level of function as low, medium or high. They then respond at targeted their level of function. Scores are recorded from 1, indicating the most 50, indicating the absence of limited function in the subject ion (arm elevation, scapular tipping, scapulohumeral rhythm, humeral lateral ro- dial rotation) using the FASTRAK motion analysis system
Notes	Unpublished outcome	data provided by trialist on request
	Trial was registered at ClinicalTrials.gov (http://clinicaltrials.gov/show/NCT00172601)	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "Consenting subjects were randomly assigned by computer-generated permuted block randomization of 5 by sequentially numbered, sealed, opaque envelopes to receive different mobilization treatments. In group 1, an A-B-A-C (A=MRM,B=ERM, and C=MWM) multiple treatment design was used. In group 2, an A-C-A-B multiple-treatment design was used. The 2 groups used here were intended to counterbalance the order effects of treatments" Comment: An adequate method was used to generate the allocation se- quence
Allocation concealment (selection bias)	Low risk	Quote: "Consenting subjects were randomly assigned by computer-generated permuted block randomization of 5 by sequentially numbered, sealed, opaque envelopes to receive different mobilization treatments. In group 1, an A-B-A-C (A=MRM,B=ERM, and C=MWM) multiple treatment design was used. In group 2, an A-C-A-B multiple-treatment design was used. The 2 groups used here were intended to counterbalance the order effects of treatments" Comment: An adequate method was used to conceal the allocation sequence

Unclear risk Comment: Participants received slightly different types of mobilisation, but it is unclear whether they were provided any information that would make them

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Blinding of participants

and personnel (perfor-

mance bias)



All outcomes		perceive the type of mobilisation they received as superior or inferior to the al- ternative type of mobilisation
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	Unclear risk	Comment: Participants self-reported function, but it is unclear whether they were provided any information that would make them perceive the type of mobilisation they received as superior or inferior to the alternative type of mo- bilisation
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "To minimize bias, an independent trained outcome assessor, masked to treatment allocation, evaluated the participants at baseline and at 3-week intervals for 12 weeks" Comment: Assessors of shoulder complex kinematics were probably blind to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Thirty subjects were recruited and randomly assigned to 2 groups (Tab. 1). Two subjects failed to attend the treatment. In addition, 3 subjects in the A-B-A-C group were lost to follow-up because there was no improvement during MRM treatment at 9 weeks. In the A-C-A-B group, 2 subjects were lost to follow-up because there was no improvement during MRM treatments at 3 weeks and 9 weeks" Quote: "For the analysis, dropout data were excluded. Additionally, inten- tion-to-treat analysis was performed by including the dropout data (carrying the last data point forward into analysis)" Quote: "Similar results were found between exclusion of dropout data and in- tention-to-treat analysis (inclusion of dropout data)" Quote: "No benefit was shown during MRM treatment, but different miss- ing data due to subjects dropping out due to lack of improvement at 3 and 9 weeks between the 2 groups makes interpretation difficult. We addressed this by secondary analysis (i.e. analysis of dropping out between 2 groups and survival analysis). There were no differences in numbers of subjects dropping out and no significant differences in the survival experiences of the 2 groups. These findings suggest that the multiple treatment trial on our 2 groups was balanced. It may be, however, that subjects continued in the treatment for reasons other than treatment effectiveness" Comment: The numbers of dropouts (and reasons for this) were similar be- tween groups, and results of intention-to-treat and per-protocol analysis were similar
Selective reporting (re- porting bias)	High risk	Comment: The following outcomes were specified in the trial registry entry but were not reported in the publication: Disabilities of the Arm, Shoulder and Hand (DASH), disability assessment by self-reports, pain perception and SF-36 health survey
Other bias	Low risk	Comment: No other sources of bias were identified

#### Yang 2012

Methods

**Design:** parallel-group, 2-arm, single blind randomised controlled trial (Taiwan)

**Interventions:** end range mobilisation and scapular mobilisation plus standardised physiotherapy (passive midrange mobilisation, flexion and abduction stretching techniques, physical modalities, i.e. ultrasound, short-wave diathermy and/or electrotherapy and active exercises) or standardised physiotherapy alone

**Sample size calculation:** 10 participants per group were estimated to be needed based upon detection of a clinically relevant difference of 5 degrees range of motion or a score of 4 on the Flexilevel Scale of Shoulder Function (FLEX-SF) at the 5% level of statistical significance with 80% power



Yang 2012 (Continued)	Analysis: intention-to-treat analysis			
	Source of funding: not reported			
Participants	Number of participants: 23 (11 and 12 participants in each respective group)			
	Baseline characteristics			
	Group receiving end range mobilisation and scapular mobilisation plus standardised physiotherapy			
	Mean (SD) age = 56.8 (7.2) years; male:female = 3:7			
	Mean (SD) duration of symptoms: 19.6 (12.8) weeks			
	Group receiving standardised physiotherapy			
	Mean (SD) age = 54.9 (10.3) years; male:female = 2:10			
	Mean (SD) duration of symptoms: 22.4 (9.2) weeks			
	Inclusion criteria			
	<ul> <li>At least 50% loss of passive movement of the shoulder joint relative to the non-affected side, in 2 or more of 3 movement directions (i.e. forward flexion, abduction in the frontal plane or external rotation in 0 degrees of abduction)</li> <li>Duration of complaints of at least 3 months</li> </ul>			
	Exclusion criteria			
	<ul> <li>History of stroke with residual upper-extremity involvement, diabetes mellitus, rheumatoid arthritis, rotator cuff tear, surgical stabilisation of the shoulder, osteoporosis or malignancies in the shoulder region</li> <li>Exhibited pain or had disorders of the cervical spine, elbow, wrist or hand, or pain radiating from the</li> </ul>			
	shoulder to the arm			
Interventions	Both groups received standardised physiotherapy comprising passive midrange mobilisation, flexion and abduction stretching techniques, physical modalities (i.e. ultrasound, short-wave diathermy and/ or electrotherapy) and active exercises, twice a week for 8 weeks.			
	End range mobilisation and scapular mobilisation plus standardised physiotherapy (N = 11)			
	Components of intervention			
	• End range mobilisation: The therapist's hands were placed close to the glenohumeral joint, and the humerus was brought to a position of maximal humeral elevation in the scapular plane with humer- al external rotation. Then 10-15 repetitions of intensive grade IV anterior-posterior mobilisation tech- niques were applied by one of the therapist's hands, while the scapula was stabilised by the other hand			
	• Scapular mobilisation: Participants lay on their sound side on the bed. The therapist stood before the participant's affected shoulder, placing the index finger of one hand under the medial scapular border, the other hand grasping the superior border of the scapula. The scapula was moved superiorly and inferiorly for superior and inferior glide, and then the scapula was rotated upward and downward for scapular rotation. Additionally, the physiotherapist put the ulnar fingers under the medial scapular border and distracted the scapula from the thorax. These patterns were chosen to increase scapular posterior tilt. Ten sets of 10 repetitions were applied, with rest intervals of 30 seconds between sets			
	Dosage: not reported			
	Frequency of administration: twice a week for 8 weeks (16 sessions)			
	Provider: physiotherapist			
	Standardised physiotherapy (N = 12)			



#### Yang 2012 (Continued)

(attrition bias)

All outcomes

	See above		
Outcomes	Outcomes assessed at weeks 4 and 8 (end of treatment). No primary outcome was reported by the trial- ists		
	<ul> <li>Passive range of motion in internal rotation, external rotation and abduction using an inclinometer</li> <li>Active range of motion (arm elevation in frontal plane, scapular posterior tipping, scapulohumeral rhythm, humeral external rotation, humeral internal rotation, hand-behind-back reach) using the FAS-TRAK motion analysis system</li> <li>Function using the Flexilevel Scale of Shoulder Function (FLEX-SF), a self- administered, shoulder-specific, fixed-item index consisting of 3 levels of function. With this scale, respondents answer a single item that grossly classifies their level of function as low, medium or high. They then respond only to items that target their level of function. Scores are recorded from 1, indicating the most limited function, to 50, indicating the absence of limited function</li> </ul>		
Notes	Another group of control participants was included in this study, but as they were not randomly a signed to any intervention, their data were not included in the review		
	Unpublished outcome	data were provided by trialist on request	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Quote: "Subjects who had less shoulder kinematics in at least one of the 3 cri- teria were randomized by computer generated permuted block randomiza- tions of 5 by sequentially numbered, sealed, opaque envelopes to 2 groups: the criteria-control group and criteria-intervention group" Comment: An adequate method was used to generate the allocation se- quence	
Allocation concealment (selection bias)	Low risk	Quote: "Subjects who had less shoulder kinematics in at least one of the 3 cri- teria were randomized by computer generated permuted block randomiza- tions of 5 by sequentially numbered, sealed, opaque envelopes to 2 groups: the criteria-control group and criteria-intervention group" Comment: An adequate method was used to conceal the allocation sequence	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Quote: "Because of our treatment procedures, the patient was not blinded to the intervention" Comment: Given the nature of the interventions (the same multi-component physical therapy intervention with or without additional mobilisation), partic- ipants were not blind to treatment and may have had different expectations about the benefits of each intervention	
Blinding of outcome as- sessment (detection bias) Self-reported outcomes	High risk	Comment: Unblinded participants, who may have had different expectations about the benefits of the intervention they received, self-reported function	
Blinding of outcome as- sessment (detection bias) Objective outcomes	Low risk	Quote: "To minimize bias, an independent trained outcome assessor, blinded to treatment allocation, evaluated the participants at baseline and at 4-week intervals for 8 weeks" Comment: Assessors of range of motion were blind to treatment	
Incomplete outcome data	Low risk	Quote: "Intention-to-treat analysis was performed by including the drop-out	

data, carrying the last data point forward into analysis" Quote: "In the criteria-intervention group, one subject was lost to follow-up due to personal factors" Quote: "Additionally, similar results were found between exclusion of dropout

and intention-to-treat analysis (inclusion of drop-out data)"



Yang 2012 (Continued)		Comment: Only 1 participant (in the intervention group) was lost to follow-up, for personal reasons. This is unlikely to bias the results
Selective reporting (re- porting bias)	Unclear risk	Comment: Trialists presented means and unlabelled error bars for all out- comes in figure format and reported numerical mean differences and 95% CIs in text only for outcomes and times points that were statistically significant. Means and standard deviations for all outcomes at all time points were provid- ed on request. However, without a trial protocol, it is unclear whether other outcomes (e.g. pain) were measured but not reported based on the results
Other bias	Low risk	Comment: No other sources of bias were identified

Abbreviations:

CI: confidence interval. FLEX-SF: Flexi-Level Scale of Shoulder Function. MRI: magnetic resonance imaging. NSAIDs: non-steroidal anti-inflammatory drugs. PNF: proprioceptive neuromuscular facilitation. RCT: randomised controlled trial. ROM: range of motion. SD: standard deviation. SF-36: Short Form-36. SPADI: Shoulder Pain and Disability Index. TENS: transcutaneous electrical nerve stimulation. VAS: visual analogue scale.

#### Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion	
Abdelshafi 2011	All 3 groups received the same manual therapy and exercise intervention with or without continu- ous suprascapular nerve block under ultrasound guidance or intra-articular steroid injection	
Alicicco 2000	Mobilisation was provided to all groups (with or without an electrotherapy modality)	
Amir-us-Saqlain 2007	Both groups received the same manual therapy intervention (manipulation) with or without steroid injection under anaesthesia	
Arslan 2001	Ineligible intervention: randomised controlled trial of glucocorticoid injection versus physical ther- apy plus non-steroidal anti-inflammatory drug. Not able to separate out the effects of physical therapy. Included in Cochrane review of corticosteroid injection for shoulder disorders	
Bumin 2001	Exercises were provided to all groups (with or without an electrotherapy modality)	
Calis 2006	Stretching and Codman exercises were provided to all groups (along with an electrotherapy modal- ity)	
Diercks 2004	Not a randomised controlled trial	
Khan 2005	Participants received physical therapies alone versus physical therapies and shoulder arthrogra- phy with intra-articular steroid	
Kivimaki 2007	The same manual therapy intervention was delivered to both treatment groups	
Koh 2013	Manual therapy and transcutaneous electrical nerve stimulation (TENS) were provided to all groups (with or without bee venom acupuncture)	

Study	Reason for exclusion
Leclaire 1991	Manual stretching and pulley exercises were provided to all groups (with or without an electrother- apy modality)
Lee 1973	Exercises were provided to all groups (with or without an electrotherapy modality)
Leung 2008	Stretching exercises were provided to all groups (with or without an electrotherapy modality)
Longbottom 2009	Not a randomised controlled trial
Ma 2013	Passive joint mobilisation was provided to all groups (with or without cryotherapy)
Rizk 1991	The same manual therapy intervention was delivered to all 4 treatment groups
Srour 2008	Conventional physiotherapy comprising passive mobilisation, specific mobilisations, stretches and muscle tension raises was provided to all groups; this RCT primarily tested the effect of cold pack versus cold air ventilation versus no cold intervention
Zhu 2004	Ineligible intervention: trial comparing exercises plus Chinese medicine iontophoresis versus pain block therapy. A manual therapist/physical therapist/physiotherapist would be unable to deliver the Chinese medicine components

#### Characteristics of studies awaiting assessment [ordered by study ID]

#### Doner 2013

Methods	Not yet assessed
Participants	Not yet assessed
Interventions	Not yet assessed
Outcomes	Not yet assessed
Notes	

Fink 2012	
Methods	Not yet assessed
Participants	Not yet assessed
Interventions	Not yet assessed
Outcomes	Not yet assessed
Notes	Requires translation (in German)



#### Ibrahim 2013

Methods	Not yet assessed
Participants	Not yet assessed
Interventions	Not yet assessed
Outcomes	Not yet assessed
Notes	

#### Russell 2014

Methods	Not yet assessed
Participants	Not yet assessed
Interventions	Not yet assessed
Outcomes	Not yet assessed
Notes	

#### Uddin 2012

Methods	Not yet assessed
Participants	Not yet assessed
Interventions	Not yet assessed
Outcomes	Not yet assessed
Notes	Currently available only as a conference abstract

Wies 2003	
Methods	Not yet assessed
Participants	Not yet assessed
Interventions	Not yet assessed
Outcomes	Not yet assessed
Notes	Currently available only as a conference abstract

#### Characteristics of ongoing studies [ordered by study ID]



#### NCT00873158

Trial name or title	Outcomes Following Dynamic Splinting and/or Physical Therapy for Patients With Adhesive Cap- sulitis
Methods	Parallel-group, 2-arm randomised controlled trial (United States)
Participants	Inclusion criteria
	<ul> <li>Diagnosis of idiopathic adhesive capsulitis</li> <li>Greater than 50% limitation in active flexion, internal rotation or external rotation</li> <li>Tight GHJ capsule in at least 2 directions</li> <li>Capsular end-feel primarily limiting ROM</li> <li>Age 40-64 years</li> <li>Normal x-rays</li> </ul>
Interventions	Dynasplint
	Along with standard manual physical therapy, participants will use a stretching device (Dynas- plint) in rehabilitation to regain ROM in stiff joints. Participants will use this device 20 to 30 minutes 2 times per day at home. Dynamic splinting utilises the protocols of low-load prolonged stretch (LLPS) with calibrated adjustable tension to increase total end range time (TERT) to reduce con- tracture. The Dynasplint or "experimental" group will add this therapy to its standard of care regi- men
	Physical therapy
	Participants in the physical therapy group will receive standard manual treatments during their usual physical therapy visits with no additional intervention
Outcomes	Primary outcome measures
	Number of physical therapy treatments required Weeks of Dynasplint treatment <b>Secondary outcome measures</b>
	Shoulder range of motion Sharp FAS neck and shoulder Disabilities of Arm, Hand and Shoulder Questionnaire
Starting date	January 2006
Contact information	Paul Gaspar, DPT, gasparPT@hotmail.com
Notes	http://clinicaltrials.gov/show/NCT00873158

NCT01249040	
Trial name or title	The Study of Different Treatment Programs for Patients With Frozen Shoulder
Methods	Parallel-group, 2-arm randomised controlled trial (Taiwan)
Participants	Inclusion criteria
	Patients with shoulder pain and range of motion limitation
	Exclusion criterion
	Rotator tear



NCT01249040 (Continued)	
Interventions	Group 1: Physical modalities + therapeutic exercise
	Group 2: Physical modalities + therapeutic exercise + intra-articular injection of steroid
	Group 3: Therapeutic exercise
Outcomes	Primary outcome measures
	Pain scale and range of motion within 6 weeks
Starting date	December 2010
Contact information	Sui-Foon Lo, MD, d4659@www.cmuh.org.tw
Notes	http://clinicaltrials.gov/show/NCT01249040

#### NCT01483963

Trial name or title	AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Methods	Parallel group, 2-arm randomised controlled trial (United States)
Participants	Inclusion criteria
	<ul> <li>Male or female 18 years of age or older</li> <li>Female of childbearing potential, with negative urine pregnancy test and using an effective contraception method (i.e. abstinence, intrauterine device (IUD), hormonal (oestrogen/progestin) contraceptives, or barrier control) for at least 1 menstrual cycle before study enrolment and for 1 menstrual cycle following end of study, or surgically sterile</li> <li>Unilateral idiopathic adhesive capsulitis of 1 shoulder for at least 3 months but not longer than 12 months before the screening visit, with stage 2 (frozen or adhesive stage) disease, as determined by investigator</li> <li>Normal range of motion in the contralateral shoulder, as determined by the investigator</li> <li>Restricted active range of motion (AROM) in the affected shoulder, defined as a deficit of at least 60 degrees in total AROM in the affected shoulder as compared with total AROM in the contralateral shoulder: forward flexion, abduction, external rotation with elbow up to 90 degrees of abduction, internal rotation with elbow up to 90 degrees of abduction, internal rotation with elbow up to 90 degrees of abduction informed consent agreement approved by the institutional review board/independent ethics committee (IRB/IEC). Participant must also sign an authorisation form to allow disclosure of protected health information (PHI). The PHI authorisation form and the informed consent form may be an provided as an integrated form or as separate forms, depending on the institution</li> <li>Completion and understanding of the various rating instruments available in English</li> </ul>
Interventions	Group 1: Collagenase <i>Clostridium histolyticum</i> (AA4500) Group 2: Shoulder exercises
Outcomes	Primary outcome measure
	Change (degrees) from baseline in active forward flexion in affected shoulder <b>Secondary outcome measures</b>
	Change (degrees) from baseline in passive forward flexion in affected shoulder Change (degrees) from baseline in abduction (active and passive) Change (degrees) from baseline in external rotation at 90° abduction (active and passive)



#### NCT01483963 (Continued)

Change from baseline in internal rotation with the elbow at 90° abduction (active and passive)

Starting date	November 2011
Contact information	Diane McCaul, dmccaul@auxilium.com
Notes	http://clinicaltrials.gov/show/NCT01483963

#### DATA AND ANALYSES

# Comparison 1. Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Overall pain	2		Std. Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
1.1 Change from baseline to 6 weeks	2	86	Std. Mean Difference (IV, Ran- dom, 95% CI)	0.21 [-0.65, 1.07]
1.2 Change from baseline to 6 months	2	78	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.08 [-1.10, 0.93]
1.3 Change from baseline to 12 months	1	49	Std. Mean Difference (IV, Ran- dom, 95% CI)	0.24 [-0.33, 0.80]
2 Function	2		Std. Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
2.1 Change from baseline to 6 weeks	2	86	Std. Mean Difference (IV, Ran- dom, 95% CI)	0.46 [0.03, 0.89]
2.2 Change from baseline to 6 months	2	78	Std. Mean Difference (IV, Ran- dom, 95% CI)	0.27 [-0.18, 0.72]
2.3 Change from baseline to 12 months	1	49	Std. Mean Difference (IV, Ran- dom, 95% CI)	0.11 [-0.45, 0.67]
3 Quality of life	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 SF-36 PCS change from baseline to 6 weeks	1	49	Mean Difference (IV, Fixed, 95% CI)	-3.30 [-8.57, 1.97]
3.2 SF-36 PCS change from baseline to 6 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-1.0 [-6.27, 4.27]
3.3 SF-36 PCS change from baseline to 12 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-1.70 [-6.97, 3.57]



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
3.4 SF-36 MCS change from baseline to 6 weeks	1	49	Mean Difference (IV, Fixed, 95% CI)	0.5 [-5.60, 6.60]
3.5 SF-36 MCS change from baseline to 6 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-2.8 [-8.90, 3.30]
3.6 SF-36 MCS change from baseline to 12 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-1.1 [-7.20, 5.00]
4 Active range of motion (degrees)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
4.1 Sum of amplitudes of movement in flexion, abduction and external rota- tion (degrees) change from baseline to 6 weeks	1	49	Mean Difference (IV, Fixed, 95% CI)	-12.0 [-37.09, 13.09]
4.2 Sum of amplitudes of movement in flexion, abduction and external rota- tion (degrees) change from baseline to 6 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-10.20 [-35.29, 14.89]
4.3 Sum of amplitudes of movement in flexion, abduction and external rota- tion (degrees) change from baseline to 12 months	1	49	Mean Difference (IV, Fixed, 95% CI)	2.5 [-22.59, 27.59]
5 Active range of motion (cm)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
5.1 Hand-behind-back (cm) change from baseline to 6 weeks	1	49	Mean Difference (IV, Fixed, 95% CI)	0.80 [-5.72, 7.32]
5.2 Hand-behind-back (cm) change from baseline to 6 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-0.70 [-7.22, 5.82]
5.3 Hand-behind-back (cm) change from baseline to 12 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-2.90 [-9.42, 3.62]
6 Passive range of motion	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
6.1 External rotation (degrees) change from baseline to 6 weeks	1	37	Mean Difference (IV, Fixed, 95% CI)	2.40 [-6.86, 11.66]
6.2 External rotation (degrees) change from baseline to 4 months	1	29	Mean Difference (IV, Fixed, 95% CI)	-1.10 [-13.59, 11.39]



# Analysis 1.1. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 1 Overall pain.

Study or subgroup	MT+ tro+	Ex+Elec- Saline Inj	Glu coid	cocorti- injection		Std. Mean	Difference		Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		Randon	n, 95% Cl			Random, 95% Cl
1.1.1 Change from baseline to 6 wee	ks									
Carette 2003	26	-21.8 (27)	23	-39.1 (26.9)					51.52%	0.63[0.06,1.21]
Ryans 2005	20	-17.6 (39.1)	17	-9.7 (18.5)		-	-		48.48%	-0.25[-0.9,0.4]
Subtotal ***	46		40						100%	0.21[-0.65,1.07]
Heterogeneity: Tau <sup>2</sup> =0.29; Chi <sup>2</sup> =3.93, df=1(P=0.05); l <sup>2</sup> =74.55%										
Test for overall effect: Z=0.47(P=0.64)										
1.1.2 Change from baseline to 6 mor	nths									
Carette 2003	26	-43.8 (27)	23	-54.9 (26.9)			+		52.96%	0.41[-0.16,0.97]
Ryans 2005	16	-29.3 (33.7)	13	-9.8 (24.7)			-		47.04%	-0.63[-1.38,0.12]
Subtotal ***	42		36						100%	-0.08[-1.1,0.93]
Heterogeneity: Tau <sup>2</sup> =0.42; Chi <sup>2</sup> =4.65, c	lf=1(P=0	0.03); I <sup>2</sup> =78.48%								
Test for overall effect: Z=0.16(P=0.87)										
1.1.3 Change from baseline to 12 mo	onths									
Carette 2003	26	-46.1 (27)	23	-52.6 (26.9)		-			100%	0.24[-0.33,0.8]
Subtotal ***	26		23			•	◆		100%	0.24[-0.33,0.8]
Heterogeneity: Not applicable										
Test for overall effect: Z=0.83(P=0.41)										
Test for subgroup differences: Chi <sup>2</sup> =0.3	3, df=1 (	P=0.86), I <sup>2</sup> =0%								
		F	avours M	T+Ex+Electro	-4	-2	0 2	4	Favours gl	ucocorticoid

## Analysis 1.2. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 2 Function.

Study or subgroup	MT+ tro+	-Ex+Elec- Saline Inj	Glu coid	icocorti- injection	Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% Cl
1.2.1 Change from baseline to 6 wee	eks						
Carette 2003	26	-22.7 (24)	23	-34.2 (24)		57%	0.47[-0.1,1.04]
Ryans 2005	20	-3.5 (4.9)	17	-6.1 (6.4)		43%	0.45[-0.2,1.11]
Subtotal ***	46		40		•	100%	0.46[0.03,0.89]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0, df=1(P	=0.96); I	<sup>2</sup> =0%					
Test for overall effect: Z=2.11(P=0.03)							
1.2.2 Change from baseline to 6 mo	nths						
Carette 2003	26	-42.3 (24)	23	-47.6 (24)		63.28%	0.22[-0.35,0.78]
Ryans 2005	16	-5.6 (5.8)	13	-7.8 (5.9)		36.72%	0.37[-0.37,1.1]
Subtotal ***	42		36			100%	0.27[-0.18,0.72]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.1, df=1	(P=0.75)	; I <sup>2</sup> =0%					
Test for overall effect: Z=1.19(P=0.23)							
1.2.3 Change from baseline to 12 m	onths						
Carette 2003	26	-45 (24)	23	-47.6 (24)		100%	0.11[-0.45,0.67]
Subtotal ***	26		23			100%	0.11[-0.45,0.67]
Heterogeneity: Not applicable							
		ŀ	avours N	IT+Ex+Electro	-1 -0.5 0 0.5 1	Favours gl	ucocorticoid



Study or subgroup	MT+Ex+Elec- tro+Saline Inj		Gl coid	ucocorti- d injection	Std. Mean Difference	Weight	Std. Mean Difference	
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% CI	
Test for overall effect: Z=0.37(P=0.71)								
Test for subgroup differences: Chi <sup>2</sup> =1.02, df=1 (P=0.6), I <sup>2</sup> =0%								
			Favours I	MT+Ex+Electro	-1 -0.5 0 0.5 1	Favours gli	ucocorticoid	

# Analysis 1.3. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 3 Quality of life.

Study or subgroup	MT+ tro+	Ex+Elec- Saline Inj	Glu coid	cocorti- injection	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
1.3.1 SF-36 PCS change from baselin	e to 6 w	/eeks					
Carette 2003	26	1.1 (9.7)	23	4.4 (9.1)		100%	-3.3[-8.57,1.97]
Subtotal ***	26		23			100%	-3.3[-8.57,1.97]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.23(P=0.22)							
1.3.2 SF-36 PCS change from baselin	e to 6 n	nonths					
Carette 2003	26	9.1 (9.7)	23	10.1 (9.1)		100%	-1[-6.27.4.27]
Subtotal ***	26		23			100%	-1[-6.27.4.27]
Heterogeneity: Not applicable							_[
Test for overall effect: Z=0.37(P=0.71)							
1 2 2 SE 26 DCS change from baselin	a ta 12	months					
Carette 2003	26	Q / (Q 7)	22	11 1 (9 1)		100%	-1 7[-6 97 3 57]
Subtotal ***	26	5.4 (5.1)	23	11.1 (5.1)		100%	-1 7[-6 97 3 57]
Heterogeneity: Not applicable	20		25			10070	-1.1[-0.31,3.31]
Test for overall effect: Z=0.63(P=0.53)							
1.3.4 SF-36 MCS change from baselir	ie to 6 v	veeks					
Carette 2003	26	2 (11.2)	23	1.5 (10.6)		100%	0.5[-5.6,6.6]
Subtotal ***	26		23		-	100%	0.5[-5.6,6.6]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.16(P=0.87)							
1.3.5 SF-36 MCS change from baselir	ie to 6 r	nonths					
Carette 2003	26	1 (11.2)	23	3.8 (10.6)		100%	-2.8[-8.9,3.3]
Subtotal ***	26		23			100%	-2.8[-8.9,3.3]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.9(P=0.37)							
1.3.6 SF-36 MCS change from baselir	ie to 12	months					
Carette 2003	26	2.4 (11.2)	23	3.5 (10.6)	<b></b>	100%	-1.1[-7.2,5]
Subtotal ***	26		23			100%	-1.1[-7.2,5]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.35(P=0.72)							
Test for subgroup differences: Chi <sup>2</sup> =1.0	)8, df=1	(P=0.96), I <sup>2</sup> =0%					
		F	avours g	lucocorticoid	-10 -5 0 5 10	Favours MT	+Ex+Electro



### Analysis 1.4. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 4 Active range of motion (degrees).

Study or subgroup	MT+ tro+9	Ex+Elec- Saline Inj	Glu coid	cocorti- injection	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	N	Mean(SD)	Fixed, 95% Cl		Fixed, 95% CI
1.4.1 Sum of amplitudes of moveme tion (degrees) change from baseline	nt in fle to 6 we	exion, abduction eks	n and ext	ernal rota-			
Carette 2003	26	37.2 (44.9)	23	49.2 (44.6)		100%	-12[-37.09,13.09]
Subtotal ***	26		23			100%	-12[-37.09,13.09]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.94(P=0.35)							
1.4.2 Sum of amplitudes of moveme tion (degrees) change from baseline	nt in fle to 6 mo	exion, abduction	n and ext	ernal rota-			
Carette 2003	26	74 (44.9)	23	84.2 (44.6)		100%	-10.2[-35.29,14.89]
Subtotal ***	26		23			100%	-10.2[-35.29,14.89]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.8(P=0.43)							
1.4.3 Sum of amplitudes of moveme tion (degrees) change from baseline	nt in fle to 12 m	exion, abduction nonths	n and ext	ernal rota-			
Carette 2003	26	89.3 (44.9)	23	86.8 (44.6)	<b></b>	100%	2.5[-22.59,27.59]
Subtotal ***	26		23			100%	2.5[-22.59,27.59]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.2(P=0.85)							
Test for subgroup differences: Chi <sup>2</sup> =0.7	76, df=1	(P=0.68), I <sup>2</sup> =0%					
		F	avours g	ucocorticoid	-50 -25 0 25 50	Favours MT	+Ex+Electro

# Analysis 1.5. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 5 Active range of motion (cm).

Study or subgroup	MT+ tro+	+Ex+Elec- ·Saline Inj	Glı coid	icocorti- injection	Mean Di	fference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed,	95% CI		Fixed, 95% CI
1.5.1 Hand-behind-back (cm) chan	ge from	baseline to 6 we	eeks					
Carette 2003	26	-10.5 (11.7)	23	-11.3 (11.5)		<b></b>	100%	0.8[-5.72,7.32]
Subtotal ***	26		23				100%	0.8[-5.72,7.32]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0, df=0(I	P<0.0001	L); I <sup>2</sup> =100%						
Test for overall effect: Z=0.24(P=0.81)								
1.5.2 Hand-behind-back (cm) chan	ge from	baseline to 6 m	onths					
Carette 2003	26	-18.1 (11.7)	23	-17.4 (11.5)			100%	-0.7[-7.22,5.82]
Subtotal ***	26		23				100%	-0.7[-7.22,5.82]
Heterogeneity: Not applicable								
Test for overall effect: Z=0.21(P=0.83)								
1.5.3 Hand-behind-back (cm) chan	ge from	baseline to 12 n	nonths					
Carette 2003	26	-21.3 (11.7)	23	-18.4 (11.5)			100%	-2.9[-9.42,3.62]
Subtotal ***	26		23		•	•	100%	-2.9[-9.42,3.62]
Heterogeneity: Not applicable								
Test for overall effect: Z=0.87(P=0.38)								
Test for subgroup differences: Chi <sup>2</sup> =0	.63, df=1	L (P=0.73), I <sup>2</sup> =0%		_			·	
		F	avours N	1T+Ex+Electro	-50 -25 0	) 25 50	Favours gluc	ocorticoid



## Analysis 1.6. Comparison 1 Manual therapy plus exercise plus electrotherapy plus placebo injection versus glucocorticoid injection, Outcome 6 Passive range of motion.

Study or subgroup	MT+ tro+	Ex+Elec- Saline Inj	Glu coid	cocorti- injection	Me	ean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	F	ixed, 95% CI		Fixed, 95% CI
1.6.1 External rotation (degrees) ch	ange fr	om baseline to	6 weeks					
Ryans 2005	20	16.7 (13.2)	17	14.3 (15.2)		<b></b>	100%	2.4[-6.86,11.66]
Subtotal ***	20		17			+	100%	2.4[-6.86,11.66]
Heterogeneity: Not applicable								
Test for overall effect: Z=0.51(P=0.61)								
1.6.2 External rotation (degrees) ch	ange fr	om baseline to	4 months					
Ryans 2005	16	18 (14)	13	19.1 (19.2)			100%	-1.1[-13.59,11.39]
Subtotal ***	16		13			+	100%	-1.1[-13.59,11.39]
Heterogeneity: Not applicable								
Test for overall effect: Z=0.17(P=0.86)								
Test for subgroup differences: Chi <sup>2</sup> =0	.19, df=1	(P=0.66), I <sup>2</sup> =0%						
			Four our of	lucocorticoid	-100 -50	0 50	100 Favours MT I	Ty I Flastra

Favours glucocorticoid -100 -50 0 50 100 Favours MT+Ex+Electro

#### Comparison 2. Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Overall pain	2		Std. Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
1.1 Change from baseline to 6 weeks	2	86	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.24 [-0.67, 0.18]
1.2 Change from baseline to 6 months	2	77	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.22 [-0.67, 0.23]
1.3 Change from baseline to 12 months	1	49	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.00 [-0.56, 0.56]
2 Function	2		Std. Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
2.1 Change from baseline to 6 weeks	2	86	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.09 [-0.52, 0.33]
2.2 Change from baseline to 6 months	2	77	Std. Mean Difference (IV, Ran- dom, 95% CI)	0.01 [-0.44, 0.46]
2.3 Change from baseline to 12 months	1	49	Std. Mean Difference (IV, Ran- dom, 95% CI)	0.14 [-0.42, 0.70]
3 Quality of life	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
3.1 SF-36 PCS change from baseline to 6 weeks	1	49	Mean Difference (IV, Fixed, 95% CI)	-1.4 [-6.67, 3.87]
3.2 SF-36 PCS change from baseline to 6 months	1	49	Mean Difference (IV, Fixed, 95% CI)	2.3 [-2.97, 7.57]
3.3 SF-36 PCS change from baseline to 12 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-0.70 [-5.97, 4.57]
3.4 SF-36 MCS change from baseline to 6 weeks	1	49	Mean Difference (IV, Fixed, 95% CI)	-0.60 [-6.70, 5.50]
3.5 SF-36 MCS change from baseline to 6 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-1.1 [-7.20, 5.00]
3.6 SF-36 MCS change from baseline to 12 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-0.80 [-6.90, 5.30]
4 Active range of motion (degrees)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
4.1 Sum of amplitudes of movement in flexion, abduction and external rota- tion (degrees) change from baseline to 6 weeks	1	49	Mean Difference (IV, Fixed, 95% CI)	15.6 [-9.49, 40.69]
4.2 Sum of amplitudes of movement in flexion, abduction and external rota- tion (degrees) change from baseline to 6 months	1	49	Mean Difference (IV, Fixed, 95% CI)	16.80 [-0.86, 34.46]
4.3 Sum of amplitudes of movement in flexion, abduction and external rota- tion (degrees) change from baseline to 12 months	1	49	Mean Difference (IV, Fixed, 95% CI)	2.5 [-22.59, 27.59]
5 Active range of motion (cm)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
5.1 Hand-behind-back (cm) change from baseline to 6 weeks	1	49	Mean Difference (IV, Fixed, 95% CI)	0.30 [-6.22, 6.82]
5.2 Hand-behind-back (cm) change from baseline to 6 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-1.20 [-7.72, 5.32]
5.3 Hand-behind-back (cm) change from baseline to 12 months	1	49	Mean Difference (IV, Fixed, 95% CI)	-0.10 [-6.62, 6.42]
6 Passive range of motion	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
6.1 External rotation (degrees) change from baseline to 6 weeks	1	37	Mean Difference (IV, Fixed, 95% CI)	10.1 [1.57, 18.63]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
6.2 External rotation (degrees) change from baseline to 4 months	1	28	Mean Difference (IV, Fixed, 95% CI)	-4.20 [-16.57, 8.17]

### Analysis 2.1. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 1 Overall pain.

Study or subgroup	MT+ tro+	Ex+Elec- Saline Inj	Saline injection		Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	N	Mean(SD)	Random, 95% Cl		Random, 95% CI
2.1.1 Change from baseline to 6 wee	ks						
Carette 2003	26	-21.8 (27)	23	-17.3 (26.9)	— <b>—</b>	57.36%	-0.16[-0.73,0.4]
Ryans 2005	20	-17.6 (39.1)	17	-5.4 (27.8)		42.64%	-0.35[-1,0.3]
Subtotal ***	46		40			100%	-0.24[-0.67,0.18]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.17, df=1	L(P=0.68	s); I²=0%					
Test for overall effect: Z=1.12(P=0.26)							
2.1.2 Change from baseline to 6 mon	ths						
Carette 2003	26	-43.8 (27)	23	-36.4 (26.9)		63.86%	-0.27[-0.83,0.29]
Ryans 2005	16	-29.3 (33.7)	12	-24.5 (34.2)		36.14%	-0.14[-0.89,0.61]
Subtotal ***	42		35			100%	-0.22[-0.67,0.23]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.08, df=1	L(P=0.78	s); I²=0%					
Test for overall effect: Z=0.97(P=0.33)							
2.1.3 Change from baseline to 12 mo	nths						
Carette 2003	26	-46.1 (27)	23	-46 (26.9)	— <u>—</u> —	100%	-0[-0.56,0.56]
Subtotal ***	26		23		-	100%	-0[-0.56,0.56]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0, df=0(P-	<0.0001	; I <sup>2</sup> =100%					
Test for overall effect: Z=0.01(P=0.99)							
Test for subgroup differences: Chi <sup>2</sup> =0.5	5, df=1 (	P=0.78), I <sup>2</sup> =0%					
			Favours M	T+Ex+Electro	-2 -1 0 1 2	Favours sa	line injection

### Analysis 2.2. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 2 Function.

Study or subgroup	MT+ tro+	-Ex+Elec- Saline Inj	Salin	e injection	Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% Cl
2.2.1 Change from baseline to 6 wee	eks						
Carette 2003	26	-22.7 (24)	23	-20.4 (23.5)	<b></b>	57.04%	-0.1[-0.66,0.47]
Ryans 2005	20	-3.5 (4.9)	17	-3.1 (3.4)	<b>_</b>	42.96%	-0.09[-0.74,0.56]
Subtotal ***	46		40		-	100%	-0.09[-0.52,0.33]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0, df=1(F	=0.99);	<sup>2</sup> =0%					
Test for overall effect: Z=0.43(P=0.67)							
2.2.2 Change from baseline to 6 mo	nths						
Carette 2003	26	-42.3 (24)	23	-40.5 (23.5)	· · · · · · · · · · · · · · · · · · ·	64.11%	-0.07[-0.64,0.49]
		F	avours N	1T+Ex+Electro	-1 -0.5 0 0.5 1	Favours sa	line injection



Study or subgroup	MT+ tro+	·Ex+Elec- Saline Inj	Salin	e injection	Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% Cl
Ryans 2005	16	-5.6 (5.8)	12	-6.6 (5.4)		35.89%	0.17[-0.58,0.92]
Subtotal ***	42		35		-	100%	0.01[-0.44,0.46]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.27, df=	1(P=0.6	1); I <sup>2</sup> =0%					
Test for overall effect: Z=0.06(P=0.95)							
2.2.3 Change from baseline to 12 m	onths						
Carette 2003	26	-45 (24)	23	-48.4 (23.5)		100%	0.14[-0.42,0.7]
Subtotal ***	26		23		-	100%	0.14[-0.42,0.7]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.49(P=0.62)							
Test for subgroup differences: Chi <sup>2</sup> =0.	43, df=1	(P=0.81), I <sup>2</sup> =0%					
		5			-1 -05 0 05 1		ling injection

Favours MT+Ex+Electro

Favours saline injection

# Analysis 2.3. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 3 Quality of life.

Study or subgroup	MT- tro+	+Ex+Elec- Saline Inj	Salin	e injection	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
2.3.1 SF-36 PCS change from baseli	ne to 6	weeks					
Carette 2003	26	1.1 (9.7)	23	2.5 (9.1)		100%	-1.4[-6.67,3.87]
Subtotal ***	26		23			100%	-1.4[-6.67,3.87]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.52(P=0.6)							
2.3.2 SF-36 PCS change from baseli	ne to 6	months					
Carette 2003	26	9.1 (9.7)	23	6.8 (9.1)		100%	2.3[-2.97,7.57]
Subtotal ***	26		23			100%	2.3[-2.97,7.57]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.86(P=0.39)							
2.3.3 SF-36 PCS change from baseli	ne to 12	2 months					
Carette 2003	26	9.4 (9.7)	23	10.1 (9.1)		100%	-0.7[-5.97,4.57]
Subtotal ***	26		23			100%	-0.7[-5.97,4.57]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.26(P=0.79)							
2.3.4 SF-36 MCS change from baseli	ne to 6	weeks					
Carette 2003	26	2 (11.2)	23	2.6 (10.6)		100%	-0.6[-6.7,5.5]
Subtotal ***	26		23			100%	-0.6[-6.7,5.5]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.19(P=0.85)							
2.3.5 SF-36 MCS change from baseli	ne to 6	months					
Carette 2003	26	1 (11.2)	23	2.1 (10.6)		100%	-1.1[-7.2,5]
Subtotal ***	26		23			100%	-1.1[-7.2,5]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.35(P=0.72)							
		F	avours s	aline injection	-10 -5 0 5 10	Favours MT-	+Ex+Electro



Study or subgroup	MT+ tro+	Ex+Elec- Saline Inj	Salin	e injection	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
2.3.6 SF-36 MCS change from baseli	ne to 12	months					
Carette 2003	26	2.4 (11.2)	23	3.2 (10.6)		100%	-0.8[-6.9,5.3]
Subtotal ***	26		23			100%	-0.8[-6.9,5.3]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.26(P=0.8)							
Test for subgroup differences: Chi <sup>2</sup> =1.	23, df=1	(P=0.94), I <sup>2</sup> =0%					
		Fa	vours sa	line injection	-10 -5 0 5 10	Favours MT+	+Ex+Electro

Analysis 2.4. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 4 Active range of motion (degrees).

Study or subgroup	MT+ tro+	Ex+Elec- Saline Inj	Saline	e injection	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	N	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
2.4.1 Sum of amplitudes of moveme tion (degrees) change from baseline	nt in fle to 6 we	exion, abduction eks	n and ext	ernal rota-			
Carette 2003	26	37.2 (44.9)	23	21.6 (44.6)		100%	15.6[-9.49,40.69]
Subtotal ***	26		23			100%	15.6[-9.49,40.69]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0, df=0(P	<0.0001	; I <sup>2</sup> =100%					
Test for overall effect: Z=1.22(P=0.22)							
2.4.2 Sum of amplitudes of moveme tion (degrees) change from baseline	nt in fle to 6 me	exion, abduction onths	n and ext	ernal rota-			
Carette 2003	26	74 (44.9)	23	57.2 (9.3)		100%	16.8[-0.86,34.46]
Subtotal ***	26		23			100%	16.8[-0.86,34.46]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.86(P=0.06)							
2.4.3 Sum of amplitudes of movemention (degrees) change from baseline	nt in fle to 12 n	exion, abduction nonths	n and ext	ernal rota-			
Carette 2003	26	89.3 (44.9)	23	86.8 (44.6)	<b>_</b>	100%	2.5[-22.59,27.59]
Subtotal ***	26		23			100%	2.5[-22.59,27.59]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.2(P=0.85)							
Test for subgroup differences: Chi <sup>2</sup> =0.	89, df=1	(P=0.64), I <sup>2</sup> =0%					
		Fa	avours sa	line injection	-50 -25 0 25 50	Favours MT	+Ex+Electro

## Analysis 2.5. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 5 Active range of motion (cm).

Study or subgroup	MT+ tro+	+Ex+Elec- Saline Inj	Saline injection			Mean Difference			Weight	Mean Difference	
	Ν	Mean(SD)	N	Mean(SD)		Fi	ed, 95%	CI			Fixed, 95% CI
2.5.1 Hand-behind-back (cm) chang	e from	baseline to 6 we	eks								
Carette 2003	26	-10.5 (11.7)	23	-10.8 (11.5)						100%	0.3[-6.22,6.82]
Subtotal ***	26		23				•			100%	0.3[-6.22,6.82]
Heterogeneity: Not applicable											
Test for overall effect: Z=0.09(P=0.93)											
		F	avours M	T+Ex+Electro	-50	-25	0	25	50	– Favours salir	ne injection



Study or subgroup	MT+ tro+	Ex+Elec- Saline Inj	Saline	e injection	Me	ean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	F	ixed, 95% CI		Fixed, 95% CI
2.5.2 Hand-behind-back (cm) chang	e from l	baseline to 6 mo	nths					
Carette 2003	26	-18.1 (11.7)	23	-16.9 (11.5)		<b></b>	100%	-1.2[-7.72,5.32]
Subtotal ***	26		23			•	100%	-1.2[-7.72,5.32]
Heterogeneity: Not applicable								
Test for overall effect: Z=0.36(P=0.72)								
2.5.3 Hand-behind-back (cm) chang	e from l	baseline to 12 m	onths					
Carette 2003	26	-21.3 (11.7)	23	-21.2 (11.5)		<b></b>	100%	-0.1[-6.62,6.42]
Subtotal ***	26		23			+	100%	-0.1[-6.62,6.42]
Heterogeneity: Not applicable								
Test for overall effect: Z=0.03(P=0.98)								
Test for subgroup differences: Chi <sup>2</sup> =0.	11, df=1	(P=0.95), I <sup>2</sup> =0%						
		Fa	ivours M	T+Ex+Electro	-50 -25	0 25	50 Favours s	aline injection

# Analysis 2.6. Comparison 2 Manual therapy plus exercise plus electrotherapy plus placebo injection versus placebo injection, Outcome 6 Passive range of motion.

Study or subgroup	MT+ tro+	·Ex+Elec- Saline Inj	Saline	e injection		Mean	Difference	2		Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)		Fixed	l, 95% CI				Fixed, 95% CI
2.6.1 External rotation (degrees) cl	nange fr	om baseline to 6	weeks								
Ryans 2005	20	16.7 (13.2)	17	6.6 (13.2)						100%	10.1[1.57,18.63]
Subtotal ***	20		17				•			100%	10.1[1.57,18.63]
Heterogeneity: Not applicable											
Test for overall effect: Z=2.32(P=0.02)											
2.6.2 External rotation (degrees) cl	nange fr	om baseline to 4	months								
Ryans 2005	16	18 (14)	12	22.2 (18.2)			+			100%	-4.2[-16.57,8.17]
Subtotal ***	16		12			•	•			100%	-4.2[-16.57,8.17]
Heterogeneity: Not applicable											
Test for overall effect: Z=0.67(P=0.51)											
Test for subgroup differences: Chi <sup>2</sup> =3	.48, df=1	(P=0.06), I <sup>2</sup> =71.2	4%								
		Fa	avours sa	line injection	-100	-50	0	50	100	Favours MT	+Ex+Electro

# Comparison 3. Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Overall pain	2		Std. Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
1.1 Change from baseline to 6 weeks	2	78	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.32 [-0.77, 0.13]



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1.2 Change from baseline to 6 months	2	74	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.05 [-0.51, 0.40]
1.3 Change from baseline to 12 months	1	44	Std. Mean Difference (IV, Ran- dom, 95% CI)	0.15 [-0.44, 0.75]
2 Function	2		Std. Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
2.1 Change from baseline to 6 weeks	2	78	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.35 [-0.80, 0.10]
2.2 Change from baseline to 6 months	2	74	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.10 [-0.56, 0.36]
2.3 Change from baseline to 12 months	1	44	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.02 [-0.61, 0.57]
3 Quality of life	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 SF-36 PCS change from baseline to 6 weeks	1	44	Mean Difference (IV, Fixed, 95% CI)	2.0 [-3.27, 7.27]
3.2 SF-36 PCS change from baseline to 6 months	1	44	Mean Difference (IV, Fixed, 95% CI)	-1.30 [-6.57, 3.97]
3.3 SF-36 PCS change from baseline to 12 months	1	44	Mean Difference (IV, Fixed, 95% CI)	0.40 [-4.87, 5.67]
3.4 SF-36 MCS change from baseline to 6 weeks	1	44	Mean Difference (IV, Fixed, 95% CI)	4.2 [-2.04, 10.44]
3.5 SF-36 MCS change from baseline to 6 months	1	44	Mean Difference (IV, Fixed, 95% CI)	5.40 [-0.84, 11.64]
3.6 SF-36 MCS change from baseline to 12 months	1	44	Mean Difference (IV, Fixed, 95% CI)	5.80 [-0.44, 12.04]
4 Active range of motion (degrees)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
4.1 Sum of amplitudes of movement in flexion, abduction and external rota- tion (degrees) change from baseline to 6 weeks	1	44	Mean Difference (IV, Fixed, 95% CI)	31.5 [5.30, 57.70]
4.2 Sum of amplitudes of movement in flexion, abduction and external rota- tion (degrees) change from baseline to 6 months	1	44	Mean Difference (IV, Fixed, 95% CI)	21.0 [-5.20, 47.20]
4.3 Sum of amplitudes of movement in flexion, abduction and external rota-	1	44	Mean Difference (IV, Fixed, 95% Cl)	25.70 [-0.50, 51.90]

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
tion (degrees) change from baseline to 12 months				
5 Active range of motion (cm)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
5.1 Hand-behind-back (cm) change from baseline to 6 weeks	1	44	Mean Difference (IV, Fixed, 95% CI)	-8.5 [-15.29, -1.71]
5.2 Hand-behind-back (cm) change from baseline to 6 months	1	44	Mean Difference (IV, Fixed, 95% CI)	-5.40 [-12.19, 1.39]
5.3 Hand-behind-back (cm) change from baseline to 12 months	1	44	Mean Difference (IV, Fixed, 95% CI)	-4.30 [-11.09, 2.49]
6 Passive range of motion	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
6.1 External rotation (degrees) change from baseline to 6 weeks	1	34	Mean Difference (IV, Fixed, 95% CI)	6.70 [-3.96, 17.36]
6.2 External rotation (degrees) change from baseline to 4 months	1	30	Mean Difference (IV, Fixed, 95% CI)	0.60 [-13.42, 14.62]

# Analysis 3.1. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 1 Overall pain.

Study or subgroup	MT+Ex	+Electro+GC	Glu coid	icocorti- injection	Std. Mean Difference	Weight	Std. Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% Cl
3.1.1 Change from baseline to 6 we	eks						
Carette 2003	21	-48.7 (27)	23	-39.1 (26.9)		56.23%	-0.35[-0.95,0.25]
Ryans 2005	17	-16.3 (26.4)	17	-9.7 (18.5)		43.77%	-0.28[-0.96,0.39]
Subtotal ***	38		40		•	100%	-0.32[-0.77,0.13]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.02, df	=1(P=0.8	8); I <sup>2</sup> =0%					
Test for overall effect: Z=1.4(P=0.16)							
3.1.2 Change from baseline to 6 me	onths						
Carette 2003	21	-52.8 (27)	23	-54.9 (26.9)		60.03%	0.08[-0.52,0.67]
Ryans 2005	17	-16.1 (24.4)	13	-9.8 (24.7)		39.97%	-0.25[-0.98,0.48]
Subtotal ***	38		36		<b></b>	100%	-0.05[-0.51,0.4]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.47, df	=1(P=0.4	9); I <sup>2</sup> =0%					
Test for overall effect: Z=0.23(P=0.82	)						
3.1.3 Change from baseline to 12 n	nonths						
Carette 2003	21	-48.4 (27)	23	-52.6 (26.9)		100%	0.15[-0.44,0.75]
Subtotal ***	21		23		-	100%	0.15[-0.44,0.75]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.51(P=0.61	)						
Test for subgroup differences: Chi <sup>2</sup> =3	L.67, df=1	. (P=0.43), I <sup>2</sup> =0%					
		Favo	urs MT+E	x+Electro+GC	-2 -1 0 1 2	Favours G	Cinjection



### Analysis 3.2. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 2 Function.

Study or subgroup	MT+Ex	+Electro+GC	Glu coid	cocorti- injection	Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% CI
3.2.1 Change from baseline to 6	weeks						
Carette 2003	21	-44.3 (23.8)	23	-34.2 (24)	<b>B</b>	56.05%	-0.41[-1.01,0.18]
Ryans 2005	17	-7.8 (5.7)	17	-6.1 (6.4)	<b>_</b>	43.95%	-0.27[-0.95,0.4]
Subtotal ***	38		40			100%	-0.35[-0.8,0.1]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.09,	df=1(P=0.7	6); I <sup>2</sup> =0%					
Test for overall effect: Z=1.54(P=0.	12)						
3.2.2 Change from baseline to 6	months						
Carette 2003	21	-52.1 (23.8)	23	-47.6 (24)		59.73%	-0.18[-0.78,0.41]
Ryans 2005	17	-7.6 (5.8)	13	-7.8 (5.9)		40.27%	0.03[-0.69,0.76]
Subtotal ***	38		36			100%	-0.1[-0.56,0.36]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.21,	df=1(P=0.6	5); I <sup>2</sup> =0%					
Test for overall effect: Z=0.41(P=0.	68)						
3.2.3 Change from baseline to 12	2 months						
Carette 2003	21	-48.1 (23.8)	23	-47.6 (24)		100%	-0.02[-0.61,0.57]
Subtotal ***	21		23			100%	-0.02[-0.61,0.57]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.07(P=0.	95)						
Test for subgroup differences: Chi <sup>4</sup>	<sup>2</sup> =0.98, df=1	L (P=0.61), I <sup>2</sup> =0%					
		Favo	urs MT+F	x+Electro+GC	-1 -0.5 0 0.5 1	Eavours GO	injection

# Analysis 3.3. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 3 Quality of life.

Study or subgroup	MT+Ex-	+Electro+GC	Glucocorti- coid injection		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
3.3.1 SF-36 PCS change from basel	ine to 6 v	weeks					
Carette 2003	21	6.4 (8.7)	23	4.4 (9.1)	<u> </u>	100%	2[-3.27,7.27]
Subtotal ***	21		23			100%	2[-3.27,7.27]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.74(P=0.46	i)						
3.3.2 SF-36 PCS change from basel	ine to 6 r	nonths					
Carette 2003	21	8.8 (8.7)	23	10.1 (9.1)		100%	-1.3[-6.57,3.97]
Subtotal ***	21		23			100%	-1.3[-6.57,3.97]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.48(P=0.63	:)						
3.3.3 SF-36 PCS change from basel	ine to 12	months					
Carette 2003	21	11.5 (8.7)	23	11.1 (9.1)	<b>+_</b>	100%	0.4[-4.87,5.67]
Subtotal ***	21		23			100%	0.4[-4.87,5.67]
Heterogeneity: Not applicable							
			Favour	s GC injection	-10 -5 0 5 10	Favours MT	+Ex+Electro+GC



Study or subgroup	MT+Ex	+Electro+GC	Glucocorti- coid injection		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
Test for overall effect: Z=0.15(P=0.88	)						
3.3.4 SF-36 MCS change from base	line to 6	weeks					
Carette 2003	21	5.7 (10.5)	23	1.5 (10.6)		100%	4.2[-2.04,10.44]
Subtotal ***	21		23			100%	4.2[-2.04,10.44]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.32(P=0.19	)						
3.3.5 SF-36 MCS change from base	line to 6	months					
Carette 2003	21	9.2 (10.5)	23	3.8 (10.6)		100%	5.4[-0.84,11.64]
Subtotal ***	21		23			100%	5.4[-0.84,11.64]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.7(P=0.09)							
3.3.6 SF-36 MCS change from base	line to 12	e months					
Carette 2003	21	9.3 (10.5)	23	3.5 (10.6)		100%	5.8[-0.44,12.04]
Subtotal ***	21		23			100%	5.8[-0.44,12.04]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0, df=0(	P<0.0001	.); I²=100%					
Test for overall effect: Z=1.82(P=0.07	)						
Test for subgroup differences: Chi <sup>2</sup> =4	4.82, df=1	(P=0.44), I <sup>2</sup> =0%					
			Favour	s GC injection	-10 -5 0 5 10	Favours MT+	+Ex+Electro+GC

# Analysis 3.4. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 4 Active range of motion (degrees).

Study or subgroup	MT+Ex+	Electro+GC	Glu coid	cocorti- injection	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
3.4.1 Sum of amplitudes of movem tion (degrees) change from baselin	ent in fle e to 6 we	exion, abductio eks	n and ext	ternal rota-			
Carette 2003	21	80.7 (44)	23	49.2 (44.6)	<mark></mark>	100%	31.5[5.3,57.7]
Subtotal ***	21		23			100%	31.5[5.3,57.7]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.36(P=0.02)	)						
3.4.2 Sum of amplitudes of movem tion (degrees) change from baselin	ent in fle ie to 6 m	exion, abductio onths	n and ext	ternal rota-			
Carette 2003	21	105.2 (44)	23	84.2 (44.6)		100%	21[-5.2,47.2]
Subtotal ***	21		23			100%	21[-5.2,47.2]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.57(P=0.12)	)						
3.4.3 Sum of amplitudes of movem tion (degrees) change from baselin	ent in fle ie to 12 n	exion, abductio nonths	n and ext	ternal rota-			
Carette 2003	21	112.5 (44)	23	86.8 (44.6)		100%	25.7[-0.5,51.9]
Subtotal ***	21		23			100%	25.7[-0.5,51.9]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0, df=0(	P<0.0001	); I <sup>2</sup> =100%					
Test for overall effect: Z=1.92(P=0.05)	)						
Test for subgroup differences: Chi <sup>2</sup> =0	).31, df=1	(P=0.86), I <sup>2</sup> =0%					
			Favours	GC injection	-50 -25 0 25 50	Favours MT-	+Ex+Electro+GC



## Analysis 3.5. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 5 Active range of motion (cm).

Study or subgroup	MT+Ex+	Electro+GC	Glucocorti- coid injection		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
3.5.1 Hand-behind-back (cm) chan	ge from	baseline to 6 we	eks				
Carette 2003	21	-19.8 (11.5)	23	-11.3 (11.5)		100%	-8.5[-15.29,-1.71]
Subtotal ***	21		23		•	100%	-8.5[-15.29,-1.71]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.45(P=0.01)							
3.5.2 Hand-behind-back (cm) chan	ge from	baseline to 6 mo	nths				
Carette 2003	21	-22.8 (11.5)	23	-17.4 (11.5)		100%	-5.4[-12.19,1.39]
Subtotal ***	21		23		•	100%	-5.4[-12.19,1.39]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.56(P=0.12)							
3.5.3 Hand-behind-back (cm) chan	ge from	baseline to 12 m	onths				
Carette 2003	21	-22.7 (11.5)	23	-18.4 (11.5)		100%	-4.3[-11.09,2.49]
Subtotal ***	21		23		•	100%	-4.3[-11.09,2.49]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.24(P=0.21)							
Test for subgroup differences: Chi <sup>2</sup> =0	.79, df=1	(P=0.67), I <sup>2</sup> =0%					
		Favou	rs MT+E	<+Electro+GC	-50 -25 0 25 50	Favours glue	cocorticoid

# Analysis 3.6. Comparison 3 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus glucocorticoid injection, Outcome 6 Passive range of motion.

Study or subgroup	MT+Ex-	Electro+GC	Glu coid	cocorti- injection		Mean Difference	2	Weight	Mean Difference
	Ν	Mean(SD)	N	Mean(SD)		Fixed, 95% CI			Fixed, 95% CI
3.6.1 External rotation (degrees)	change fr	om baseline t	o 6 weeks						
Ryans 2005	17	21 (16.5)	17	14.3 (15.2)				100%	6.7[-3.96,17.36]
Subtotal ***	17		17			•		100%	6.7[-3.96,17.36]
Heterogeneity: Not applicable									
Test for overall effect: Z=1.23(P=0.22	2)								
3.6.2 External rotation (degrees)	change fr	om baseline t	o 4 months						
Ryans 2005	17	19.7 (19.7)	13	19.1 (19.2)				100%	0.6[-13.42,14.62]
Subtotal ***	17		13			+		100%	0.6[-13.42,14.62]
Heterogeneity: Not applicable									
Test for overall effect: Z=0.08(P=0.93	3)								
Test for subgroup differences: Chi <sup>2</sup> =	0.46, df=1	(P=0.5), I <sup>2</sup> =0%	)						
			Favours g	ucocorticoid	-100 -50	0	50 100	Favours MT	+Ex+Electro+GC

### Comparison 4. Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus ultrasound plus exercises

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Overall pain (VAS 0-10)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1 At 3 weeks	2	48	Mean Difference (IV, Random, 95% CI)	0.23 [-1.00, 1.46]
2 Active range of motion	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 Internal rotation at 3 weeks	1	30	Mean Difference (IV, Fixed, 95% CI)	8.26 [4.58, 11.94]
2.2 External rotation change from baseline to 3 weeks	1	18	Mean Difference (IV, Fixed, 95% CI)	-28.3 [-36.73, -19.87]

### Analysis 4.1. Comparison 4 Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus ultrasound plus exercises, Outcome 1 Overall pain (VAS 0-10).

Study or subgroup	Ante +US+	rior mob Exercise	Poste +US-	erior mob +Exercise		Меа	an Differen	ce		Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		Ran	idom, 95%	CI			Random, 95% CI
4.1.1 At 3 weeks											
Johnson 2007	10	6.6 (3.8)	8	4.9 (2.5)				+		15.45%	1.7[-1.22,4.62]
Sirajuddin 2010	15	1.3 (1)	15	1.3 (1)			-			84.55%	-0.04[-0.76,0.68]
Subtotal ***	25		23				-			100%	0.23[-1,1.46]
Heterogeneity: Tau <sup>2</sup> =0.33; Chi <sup>2</sup> =1.28, c	lf=1(P=0	).26); I <sup>2</sup> =22.09%									
Test for overall effect: Z=0.36(P=0.72)											
			Favours	anterior mob	-5	-2.5	0	2.5	5	Favours post	erior mob

### Analysis 4.2. Comparison 4 Anterior glide mobilisation plus ultrasound plus exercises versus posterior glide mobilisation plus ultrasound plus exercises, Outcome 2 Active range of motion.

Study or subgroup	Anter +US+	ior mob Exercise	Poste +US+	rior mob Exercise	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
4.2.1 Internal rotation at 3 weeks							
Sirajuddin 2010	15	76.7 (3.5)	15	68.4 (6.4)		100%	8.26[4.58,11.94]
Subtotal ***	15		15		•	100%	8.26[4.58,11.94]
Heterogeneity: Not applicable							
Test for overall effect: Z=4.4(P<0.0001)							
4.2.2 External rotation change from	baselin	e to 3 weeks					
Johnson 2007	10	3 (10.8)	8	31.3 (7.4)		100%	-28.3[-36.73,-19.87]
Subtotal ***	10		8		•	100%	-28.3[-36.73,-19.87]
Heterogeneity: Not applicable							
Test for overall effect: Z=6.58(P<0.0001	L)						
Test for subgroup differences: Chi <sup>2</sup> =60	.66, df=1	. (P<0.0001), I <sup>2</sup> =9	8.35%				
		Fa	avours po	osterior mob	-20 -10 0 10 20	Favours ar	nterior mob



# Comparison 5. Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Overall pain	2		Std. Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
1.1 Change from baseline to 6 weeks	2	78	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.78 [-1.51, -0.04]
1.2 Change from baseline to 6 months	2	73	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.18 [-1.05, 0.68]
1.3 Change from baseline to 12 months	1	44	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.09 [-0.68, 0.50]
2 Function	2		Std. Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
2.1 Change from baseline to 6 weeks	2	78	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.99 [-1.46, -0.51]
2.2 Change from baseline to 6 months	2	73	Std. Mean Difference (IV, Ran- dom, 95% CI)	-0.36 [-0.83, 0.11]
2.3 Change from baseline to 12 months	1	44	Std. Mean Difference (IV, Ran- dom, 95% CI)	0.01 [-0.58, 0.60]
3 Quality of life	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 SF-36 PCS change from baseline to 6 weeks	1	44	Mean Difference (IV, Fixed, 95% CI)	3.90 [-1.37, 9.17]
3.2 SF-36 PCS change from baseline to 6 months	1	44	Mean Difference (IV, Fixed, 95% CI)	2.00 [-3.27, 7.27]
3.3 SF-36 PCS change from baseline to 12 months	1	44	Mean Difference (IV, Fixed, 95% CI)	1.40 [-3.87, 6.67]
3.4 SF-36 MCS change from baseline to 6 weeks	1	44	Mean Difference (IV, Fixed, 95% CI)	3.1 [-3.14, 9.34]
3.5 SF-36 MCS change from baseline to 6 months	1	44	Mean Difference (IV, Fixed, 95% CI)	7.1 [0.86, 13.34]
3.6 SF-36 MCS change from baseline to 12 months	1	44	Mean Difference (IV, Fixed, 95% CI)	6.10 [-0.14, 12.34]
4 Active range of motion (degrees)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
4.1 Sum of amplitudes of movement in flexion, abduction and external rota-	1	44	Mean Difference (IV, Fixed, 95% CI)	59.1 [32.90, 85.30]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
tion (degrees) change from baseline to 6 weeks				
4.2 Sum of amplitudes of movement in flexion, abduction and external rota- tion (degrees) change from baseline to 6 months	1	44	Mean Difference (IV, Fixed, 95% CI)	48.00 [28.80, 67.20]
4.3 Sum of amplitudes of movement in flexion, abduction and external rota- tion (degrees) change from baseline to 12 months	1	44	Mean Difference (IV, Fixed, 95% CI)	25.70 [-0.50, 51.90]
5 Active range of motion (cm)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
5.1 Hand-behind-back (cm) change from baseline to 6 weeks	1	44	Mean Difference (IV, Fixed, 95% CI)	-9.0 [-15.79, -2.21]
5.2 Hand-behind-back (cm) change from baseline to 6 months	1	44	Mean Difference (IV, Fixed, 95% CI)	-5.90 [-12.69, 0.89]
5.3 Hand-behind-back (cm) change from baseline to 12 months	1	44	Mean Difference (IV, Fixed, 95% CI)	-1.5 [-8.29, 5.29]
6 Passive range of motion	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
6.1 External rotation (degrees) change from baseline to 6 weeks	1	34	Mean Difference (IV, Fixed, 95% CI)	14.40 [4.36, 24.44]
6.2 External rotation (degrees) change from baseline to 4 months	1	29	Mean Difference (IV, Fixed, 95% CI)	-2.5 [-16.42, 11.42]

# Analysis 5.1. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 1 Overall pain.

Study or subgroup	MT+Ex+Electro+GC		Saline injection		Std. Mean Difference	Weight	Std. Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% Cl
5.1.1 Change from baseline to 6 we	eeks						
Carette 2003	21	-48.7 (27)	23	-17.3 (26.9)	— <u>—</u> —	51.13%	-1.14[-1.79,-0.5]
Ryans 2005	17	-16.3 (26.4)	17	-5.4 (27.8)		48.87%	-0.39[-1.07,0.29]
Subtotal ***	38		40			100%	-0.78[-1.51,-0.04]
Heterogeneity: Tau <sup>2</sup> =0.17; Chi <sup>2</sup> =2.48	, df=1(P=0	0.12); I <sup>2</sup> =59.73%					
Test for overall effect: Z=2.07(P=0.04	)						
5.1.2 Change from baseline to 6 m	onths						
Carette 2003	21	-52.8 (27)	23	-36.4 (26.9)		53.1%	-0.6[-1.2,0.01]
Ryans 2005	17	-16.1 (24.4)	12	-24.5 (34.2)		46.9%	0.28[-0.46,1.03]
Subtotal ***	38		35			100%	-0.18[-1.05,0.68]
Heterogeneity: Tau <sup>2</sup> =0.27; Chi <sup>2</sup> =3.25	, df=1(P=0	0.07); l <sup>2</sup> =69.19%					
		Favou	rs MT+E	x+Electro+GC	-2 -1 0 1 2	Favours sa	line injection



Study or subgroup	MT+Ex+Electro+GC		C Saline injection		Std. Mean Difference		Weight	Std. Mean Difference
	N	Mean(SD)	N	Mean(SD)		Random, 95% CI		Random, 95% Cl
Test for overall effect: Z=0.42(P=0.67	)							
5.1.3 Change from baseline to 12 n	nonths							
Carette 2003	21	-48.4 (27)	23	-46 (26.9)			100%	-0.09[-0.68,0.5]
Subtotal ***	21		23			-	100%	-0.09[-0.68,0.5]
Heterogeneity: Not applicable								
Test for overall effect: Z=0.29(P=0.77	)							
Test for subgroup differences: Chi <sup>2</sup> =2	2.17, df=1	(P=0.34), I <sup>2</sup> =7.68	%					
		Favou	Irs MT+E	x+Electro+GC	-2	-1 0 1 2	Favours sal	ine injection

#### Analysis 5.2. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 2 Function.

Study or subgroup	MT+Ex	IT+Ex+Electro+GC		e injection	Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% CI
5.2.1 Change from baseline to 6 we	eks						
Carette 2003	21	-44.3 (23.8)	23	-20.4 (23.5)		56.37%	-0.99[-1.62,-0.36]
Ryans 2005	17	-7.8 (5.7)	17	-3.1 (3.4)		43.63%	-0.98[-1.69,-0.26]
Subtotal ***	38		40			100%	-0.99[-1.46,-0.51]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0, df=1(	P=0.98);	I <sup>2</sup> =0%					
Test for overall effect: Z=4.08(P<0.00	01)						
5.2.2 Change from baseline to 6 mo	onths						
Carette 2003	21	-52.1 (23.8)	23	-40.5 (23.5)		60.3%	-0.48[-1.08,0.12]
Ryans 2005	17	-7.6 (5.8)	12	-6.6 (5.4)		39.7%	-0.17[-0.91,0.57]
Subtotal ***	38		35			100%	-0.36[-0.83,0.11]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.4, df=	1(P=0.53	); I <sup>2</sup> =0%					
Test for overall effect: Z=1.51(P=0.13)	)						
5.2.3 Change from baseline to 12 m	onths						
Carette 2003	21	-48.1 (23.8)	23	-48.4 (23.5)		100%	0.01[-0.58,0.6]
Subtotal ***	21		23			100%	0.01[-0.58,0.6]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.04(P=0.97)	)						
Test for subgroup differences: Chi <sup>2</sup> =7	.28, df=1	L (P=0.03), I <sup>2</sup> =72.5	55%				
		Favo	urs MT+F	x+Electro+GC	-1 -0.5 0 0.5 1	Eavours sa	line injection

Favours MT+Ex+Electro+GC

#### Favours saline injection

#### Analysis 5.3. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 3 Quality of life.

Study or subgroup	MT+Ex+Electro+GC		Saline injection		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
5.3.1 SF-36 PCS change from base	line to 6	weeks					
Carette 2003	21	6.4 (8.7)	23	2.5 (9.1)		100%	3.9[-1.37,9.17]
Subtotal ***	21		23			100%	3.9[-1.37,9.17]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.45(P=0.15	5)						
		F	avours sa	aline injection	-10 -5 0 5 10	Favours MT-	+Ex+Electro+GC

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews

Study or subgroup	MT+Ex	+Electro+GC	Saline injection		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	N	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
5.3.2 SF-36 PCS change from baseli	ine to 6	months					
Carette 2003	21	8.8 (8.7)	23	6.8 (9.1)	<u> </u>	100%	2[-3.27,7.27]
Subtotal ***	21		23			100%	2[-3.27,7.27]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.74(P=0.46)	)						
5.3.3 SF-36 PCS change from baseli	ine to 12	e months					
Carette 2003	21	11.5 (8.7)	23	10.1 (9.1)		100%	1.4[-3.87,6.67]
Subtotal ***	21		23			100%	1.4[-3.87,6.67]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.52(P=0.6)							
5.3.4 SF-36 MCS change from basel	ine to 6	weeks					
Carette 2003	21	5.7 (10.5)	23	2.6 (10.6)		100%	3.1[-3.14,9.34]
Subtotal ***	21		23			100%	3.1[-3.14,9.34]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.97(P=0.33)	)						
5.3.5 SF-36 MCS change from basel	ine to 6	months					
Carette 2003	21	9.2 (10.5)	23	2.1 (10.6)		100%	7.1[0.86,13.34]
Subtotal ***	21		23			100%	7.1[0.86,13.34]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.23(P=0.03)	)						
5.3.6 SF-36 MCS change from basel	ine to 1	2 months					
Carette 2003	21	9.3 (10.5)	23	3.2 (10.6)		100%	6.1[-0.14,12.34]
Subtotal ***	21		23			100%	6.1[-0.14,12.34]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.92(P=0.06)	)						
Test for subgroup differences: Chi <sup>2</sup> =2	2.88, df=1	L (P=0.72), I <sup>2</sup> =0%					
		F	avours sa	line injection	-10 -5 0 5 10	Favours MT	+Ex+Electro+GC

# Analysis 5.4. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 4 Active range of motion (degrees).

Study or subgroup	MT+Ex+Electro+GC		Salin	e injection	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% Cl		Fixed, 95% CI
5.4.1 Sum of amplitudes of mov tion (degrees) change from base	ement in flo eline to 6 wo	exion, abducti eeks	ion and ext	ternal rota-			
Carette 2003	21	80.7 (44)	23	21.6 (44.6)	<b>_</b>	100%	59.1[32.9,85.3]
Subtotal ***	21		23			100%	59.1[32.9,85.3]
Heterogeneity: Not applicable							
Test for overall effect: Z=4.42(P<0.	.0001)						
5.4.2 Sum of amplitudes of mov tion (degrees) change from base	ement in fle eline to 6 m	exion, abducti onths	ion and ext	ternal rota-			
Carette 2003	21	105.2 (44)	23	57.2 (9.3)		100%	48[28.8,67.2]
Subtotal ***	21		23			► 100%	48[28.8,67.2]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0, df	=0(P<0.0001	); I <sup>2</sup> =100%					
			Favours sa	line injection	-50 -25 0 25 50	Favours MT	+Ex+Electro+GC



Study or subgroup	MT+Ex	+Electro+GC	Saline	e injection	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
Test for overall effect: Z=4.9(P<0.00	01)						
5.4.3 Sum of amplitudes of mover tion (degrees) change from baseli	nent in fl ne to 12 i	exion, abduction nonths	n and ext	ternal rota-			
Carette 2003	21	112.5 (44)	23	86.8 (44.6)		100%	25.7[-0.5,51.9]
Subtotal ***	21		23			100%	25.7[-0.5,51.9]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0, df=0	(P<0.0001	.); I <sup>2</sup> =100%					
Test for overall effect: Z=1.92(P=0.0	5)						
Test for subgroup differences: Chi <sup>2</sup> =	3.29, df=1	(P=0.19), I <sup>2</sup> =39.2	24%				
		Fa	avours sa	line injection	-50 -25 0 25 50	Favours MT-	+Ex+Electro+GC

# Analysis 5.5. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 5 Active range of motion (cm).

Study or subgroup	MT+Ex+Electro+GC		Saline injection		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
5.5.1 Hand-behind-back (cm) char	nge from	baseline to 6 w	eeks				
Carette 2003	21	-19.8 (11.5)	23	-10.8 (11.5)		100%	-9[-15.79,-2.21]
Subtotal ***	21		23		•	100%	-9[-15.79,-2.21]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.6(P=0.01)							
5.5.2 Hand-behind-back (cm) char	nge from	baseline to 6 m	onths				
Carette 2003	21	-22.8 (11.5)	23	-16.9 (11.5)	<b></b>	100%	-5.9[-12.69,0.89]
Subtotal ***	21		23		•	100%	-5.9[-12.69,0.89]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.7(P=0.09)							
5.5.3 Hand-behind-back (cm) char	nge from	baseline to 12 r	nonths				
Carette 2003	21	-22.7 (11.5)	23	-21.2 (11.5)		100%	-1.5[-8.29,5.29]
Subtotal ***	21		23		•	100%	-1.5[-8.29,5.29]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.43(P=0.67	7)						
Test for subgroup differences: Chi <sup>2</sup> =	2.37, df=	1 (P=0.31), I <sup>2</sup> =15.	44%				
		Favo	urs MT+E	x+Electro+GC	-50 -25 0 25 5	0 Favours sali	ne injection

## Analysis 5.6. Comparison 5 Manual therapy plus exercise plus electrotherapy plus glucocorticoid injection versus placebo injection, Outcome 6 Passive range of motion.

Study or subgroup	MT+Ex+Electro+GC		Saline injection			Mean Difference			Weight	Mean Difference
	Ν	Mean(SD)	N	Mean(SD)		Fi	ixed, 95% CI			Fixed, 95% CI
5.6.1 External rotation (degrees)	change fr	om baseline to	o 6 weeks							
Ryans 2005	17	21 (16.5)	17	6.6 (13.2)					100%	14.4[4.36,24.44]
Subtotal ***	17		17				•		100%	14.4[4.36,24.44]
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0, df=0	(P<0.0001	); I <sup>2</sup> =100%								
Test for overall effect: Z=2.81(P=0)										
			Favours sa	line injection	-100	-50	0 50	100	Favours MT-	Ex+Electro+GC


Study or subgroup	MT+Ex	MT+Ex+Electro+GC		Saline injection		Mean Difference				Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		I	Fixed, 95% CI				Fixed, 95% CI
5.6.2 External rotation (degree	s) change fr	om baseline to 4	4 months	5							
Ryans 2005	17	19.7 (19.7)	12	22.2 (18.2)						100%	-2.5[-16.42,11.42]
Subtotal ***	17		12				$\bullet$			100%	-2.5[-16.42,11.42]
Heterogeneity: Not applicable											
Test for overall effect: Z=0.35(P=0	).72)										
Test for subgroup differences: Ch	i <sup>2</sup> =3.72, df=1	L (P=0.05), I <sup>2</sup> =73.1	15%								
		F	avours sa	line injection	-100	-50	0	50	100	Favours MT-	Ex+Electro+GC

### ADDITIONAL TABLES

### Table 1. Characteristics of manual therapy and exercise interventions

Study ID	Manual therapy componen- t(s)	Exercise component(s)	Duration of session (minutes)	No. ses- sions (per week)	No. weeks treatment	Total no. sessions
Buchbinder 2007	Both passive and self-ex- ecuted muscle stretching techniques to stretch mus- cles passing over the gleno- humeral joint; cervical and thoracic spine mobiliza- tion, glenohumeral joint pas- sive accessory glides; gleno- humeral joint passive physio- logic mobilization including rotation.	Supervised: strength and coordination exercis- es for rotator cuff and scapular stabilizers; pro- prioceptive challenge	30	2 per week in first 2 weeks; 1 per week in next 4 weeks	6	8
Bulgen 1984	Maitland's mobilisations (no other details provided)	NA	NR	3	6	18
Carette 2003	Mobilisation techniques (no other details provided)	Supervised: active ROM exercises (for acute ad- hesive capsulitis); active and auto-assisted ROM exercises and isometric strengthening exercis- es (for chronic adhesive capsulitis)	60	3	4	12
Celik 2010	NA	Supervised: scapulotho- racic strengthening (ser- ratus anterior, middle and lower trapezius, latissimus dorsi), upper trapezius stretching, and postural exercises.	Dependent on partici- pants pain and muscle strength	5	6	30
		Home: active assistive ROM exercises (flexion, scapular elevation, and internal and external ro- tation exercises), poste- rior and inferior capsule				

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review)

Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



### Table 1. Characteristics of manual therapy and exercise interventions (Continued)

stretching exercises, and self-stick exercises

		Sett Stick excicises				
Chan 2010	Passive mobilisation (Grade A and Grade B mobilisation techniques, as advocated by Cyriax for treatment of stage II capsulitis)	Home: active and ac- tive-assisted ROM exer- cises, capsular stretching exercise, postural correc- tion and scapular stabil- ising work	30	1	6	6
Chauhan 2011	Deep transverse friction massage of the two tendon supraspinatus and subscapu- laris as laid by Cyriax 1983, followed by inferior capsular stretching. Deep friction was given transverse to the fiber direction	Supervised: passive ROM exercises. Home: Not specified	60	3	2	6
Cheing 2008	NA	Home: exercises in four directions: (i) forward flexion; (ii) external rota- tion; (iii) horizontal ad- duction; and (iv) internal rotation	NR	2 to 3	4	10
Dacre 1989	Mobilisation (no other details provided)	NA	NR	1	4 to 6	4 to 6
Dundar 2009	NA	Supervised: active stretching and pendulum exercises	60	5	4	20
Ghosh 2012	NA	Supervised: active and passive shoulder mobil- isation exercises plus shoulder wheel and pul- ley exercise	NR	NR	NR	NR
Guler-Uysal 2004	Cyriax approach of deep fric- tion massage and manipula- tion	NA	60	3	2	6
Harsimran 2011	Either anterior or poste- rior glide mobilisation (Kaltenborn grade III)	NA	NR	5	1	5
Johnson 2007	Either anterior or poste- rior glide mobilisation (Kaltenborn grade III)	NA	NR	2 to 3	2 to 3	6
Ma 2006	Mobilisation (no other details provide)	Supervised: active exer- cises (not specified)	20	5	4	20
Maricar 1999	Mobilisation of shoulder quadrant, shoulder capsu- lar stretch, shoulder flexion, shoulder abduction, shoulder external and internal rotation	NA	NR	1	8	8

#### Table 1. Characteristics of manual therapy and exercise interventions (Continued)

using Maitland Grade III+ and IV

Maryam 2012	NA	Supervised: active ROM exercises	NR	NR	NR	10
Nellutla 2009	NA	Supervised: either pro- prioceptive neuromus- cular facilitation (PNF) movement patterns for exercises or convention- al free exercises, such as finger ladder exercis- es, Codman's pendu- lum exercises, and over- head shoulder pulley and shoulder wheel	NR	5	3	15
Nicholson 1985	Passive mobilisation. Gen- erally, in the early sessions gliding and distractive mobil- isation techniques were per- formed with the joint near its neutral position, progressing in the later sessions to mo- bilisation towards the end of the range of motion	NA	NR	2 to 3	4	8 to 12
Pajareya 2004	Passive mobilisation (no oth- er details provided)	Supervised: passive glenohumeral joint stretching exercises up to the participant's toler- ance, based on Cyriax. Home: pulley exercises (actively assisted exercis- es) and active non-assist- ed exercises using a tow- el and wall	NR	3	3	9
Rainbow 2008	Either high-velocity, low-am- plitude chiropractic manip- ulative therapy to the cervi- cal and thoracic spine and glenohumeral joint or Grade 4 mobilisation of the gleno- humeral joint according to the supine glenohumeral mo- bilisation technique	NA	NR	2	6	12
Ryans 2005	Maitland mobilizations which were progressed as the con- dition improved, and propri- oceptive neuromuscular fa- cilitation	Supervised: active exer- cise therapy with gym equipment	NR	2	4	8
Samnani 2004	NA	Passive ROM exercises	15	6	6	36



Table 1. Cha	racteristics of manual thera	py and exercise interven	tions (Continued	1)		
Sharad 2011	End range mobilisation tech- niques. Initially a few min- utes of warming up was given using mid-range mobilization with the patient positioned supine, after which intensive end rage mobilisation tech- niques, Grades 3 and 4 as de- scribed by Maitland in all the movement planes were de- livered, interspersed with ac- cessory movements (glides)	NA	Dependent on partici- pants pre- sentation and toler- ance	5	3	15
Shrivastava 2011	Either Maitland's Graded Oscillations Technique or Mulligan's Mobilisation with Movement technique	NA	Dependent on par- ticipants symptoms	6	2	12
Sirajuddin 2010	Either anterior or poste- rior glide mobilisation (Kaltenborn grade III)	NA	15	2	3	6
Tanaka 2010	Mobilization techniques used by Vermeulen 2000, which are performed in the end- ranges of limited joint mobil- ity	NA	40	2	18	36
van der Windt 1998	Passive mobilisation (no oth- er details provided)	Supervised: not specified	30	2	6	12
Vermeulen 2006	Either intensive passive mo- bilisation techniques in end- range positions of the gleno- humeral joint (applied with intensities according to Mait- land grades III and IV) or as- sive mobilisation techniques within the pain-free zone (ap- plied with intensities accord- ing to Maitland grades I and II)	NA	30	2	12	24
Wen 2009	NA	Supervised: hand ex- ercises, Codman hang- ing and swinging move- ment, flexion in front of the body at 90 degrees, hanging the limb and swinging it backwards and forwards, inside and out, and in circles, and wall climbing the 'lad- der' exercises (if dura- tion of symptoms was 1-2 months); passive range of motion exercis- es, active exercises with gym equipment, active	NR	7	2	15

Table 1. Ch						
Yan 2005	NA	Supervised: either gym- nastics training exercises with dumbbells weighing 2-5 kg or bare-handed ex- ercises	5 to 10	7	12	84
Yang 2007	Either end-range mobilisa- tion or mid-range mobili- sation or mobilisation with movement	NA	30	2	3	6
Yang 2012	End-range mobilisation and scapular mobilisation	NA	NR	2	8	16

NA = Not applicable

NR = Not reported

### Table 2. Outcome Reporting Bias In Trials (ORBIT) matrix

Study ID	Main outo	omes						Other outcomes					
	Partici- pant-re- port- ed pain relief ≥30%	Overall pain	Func- tion	Global assess- ment	Active shoul- der ab- duction	QoL	Adverse events	Night pain	Pain on motion	Other ROM	Work disabili- ty	Re- quiring surgery	
Buchbinder 2007	Not mea- sured	Full	Full	Full	Full	Full	Full	Full	Full	Full	Not mea- sured	Not mea- sured	
Bulgen 1984	?	Mea- sured	?	?	?	?	?	Mea- sured	Mea- sured	Partial	?	?	
Carette 2003	?	Full	Full	?	Mea- sured	Full	?	?	?	Full	?	?	
Celik 2010	?	Full	Full	?	?	?	?	?	?	Full	?	?	
Chan 2010	?	Partial	Partial	?	Partial	?	?	?	?	Partial	?	?	
Chauhan 2011	?	Partial	Partial	?	?	?	?	?	?	Partial	?	?	
Cheing 2008	?	Partial	Partial	?	?	?	?	?	?	?	?	?	
Dacre 1989	?	Partial	?	?	?	?	Full	Mea- sured	Partial	Partial	?	?	
Dundar 2009	?	Full	Full	?	?	?	Full	Full	Full	Full	?	?	
Ghosh 2012	?	?	?	Full	?	?	?	?	?	?	?	?	
Guler-Uysal 2004	?	Full	?	Full	?	?	?	Full	Full	Full	?	?	
Harsimran 2011	?	Partial	?	?	?	?	?	?	?	Partial	?	?	
Johnson 2007	?	Full	Partial	?	?	?	?	Partial	?	?	?	?	
Ma 2006	?	Partial	?	?	Partial	Partial	?	?	Partial	Partial	?	?	

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Maricar 1999	?	?	?	?	?	?	?	?	?	Partial	?	?
Maryam 2012	Not mea- sured	Full	Full	Not mea- sured	Not mea- sured	Not mea- sured	Not mea- sured	Not mea- sured	Not mea- sured	Full	Not mea- sured	Not mea- sured
Nellutla 2009	?	?	Full	?	?	?	?	?	?	Full	?	?
Nicholson 1985	?	Full	?	?	Full	?	?	?	?	Full	?	?
Pajareya 2004	?	?	Full	Full	?	?	Full	?	?	Full	?	?
Rainbow 2008	?	?	Full	?	?	?	Full	?	?	?	?	?
Ryans 2005	?	Full	Full	?	Mea- sured	Mea- sured	?	?	?	Full	?	?
Samnani 2004	?	?	?	?	?	?	?	?	?	Full	?	?
Sharad 2011	?	Partial	?	?	Partial	?	?	?	?	Partial	?	?
Shrivastava 2011	?	Partial	Partial	?	?	?	Full	?	?	Partial	?	?
Sirajuddin 2010	?	Full	Partial	?	Full	?	?	?	?	Full	?	?
Tanaka 2010	?	?	?	?	Full	?	?	?	?	Full	?	?
van der Windt 1998	?	Full	Full	Full	?	?	Full	Full	?	Full	?	?
Vermeulen 2006	?	Full	Full	Full	Full	Full	?	Full	Full	Full	?	?
Wen 2009	?	Partial	Partial	?	?	?	?	?	?	Partial	?	?
Yan 2005	?	?	?	Full	?	?	?	?	?	Full	?	?
Yang 2007	?	Mea- sured	Partial	?	?	Mea- sured	?	?	?	Partial	?	?
Yang 2012	?	?	Full	?	?	?	?	?	?	Full	?	?

"Full"= sufficient data for inclusion in a meta-analysis was reported (e.g. mean, standard deviation, and sample size per group for continuous outcomes) "Partial" = insufficient data for inclusion in a meta-analysis was reported (e.g. means only, with no measures of variation)

\_ \_ \_ \_\_\_\_

"Not measured" = outcome was not measured by the trialists "?" = unclear whether the outcome was measured or not (as a trial protocol was unavailable)

Table 3. van der Windt 1998: Passive mobilisation and su	pervised exercise (intervention	n) versus glucocorticoid injection (co	ontrol)
--	---------------------------------	--	---------

OUTCOME	INTERVEN	TION	·	CONTROL	CONTROL			
	Mean	SD	n	Mean	SD	n	Mean difference (95%CI)	
Overall pain (VAS 0-100) change from base- line to 3 weeks	17	21	55	32	26	52	-15.00 [-23.99, -6.01]	
Overall pain (VAS 0-100) change from base- line to 7 weeks	32	29	56	58	28	51	-26.00 [-36.80, -15.20]	
Overall pain (VAS 0-100) change from base- line to 6 months	54	33	54	63	31	51	-9.00 [-21.24, 3.24]	
Overall pain (VAS 0-100) change from base- line to 12 months	59	30	55	70	24	48	-11.00 [-21.44, -0.56]	
Function (Shoulder Disability Questionnaire 0-100) change from baseline to 3 weeks	6	22	55	19	27	52	-13.00 [-22.36, -3.64]	
Function (Shoulder Disability Questionnaire 0-100) change from baseline to 7 weeks	14	27	56	39	27	51	-25.00 [-35.24, -14.76]	
Function (Shoulder Disability Questionnaire 0-100) change from baseline to 6 months	33	34	54	45	30	51	-12.00 [-24.25, 0.25]	
Function (Shoulder Disability Questionnaire 0-100) change from baseline to 12 months	38	34	55	42	33	48	-4.00 [-16.96, 8.96]	
Night pain (VAS 0-100) change from baseline to 3 weeks	9	23	55	21	26	52	-12.00 [-21.32, -2.68]	
Night pain (VAS 0-100) change from baseline to 7 weeks	22	30	56	36	28	51	-14.00 [-24.99, -3.01]	
Night pain (VAS 0-100) change from baseline to 6 months	33	41	54	34	36	51	-1.00 [-15.74, 13.74]	

•<u>IIII</u> Cochrane Library

lable 3. van der Windt 1998: Passive me	oblusation a	na supervisea	excreise (inte	ivention) versus	glucocorticon		iciolj (Continuea)
Night pain (VAS 0-100) change from baseline to 12 months	35	39	55	37	33	48	-2.00 [-15.91, 11.91
Passive abduction (degrees) change from baseline to 3 weeks	-3	13	55	2	12	52	-5.00 [-9.74, -0.26]
Passive abduction (degrees) change from baseline to 7 weeks	-1	14	56	4	11	51	-5.00 [-9.75, -0.25]
Passive abduction (degrees) change from baseline to 6 months	7	17	54	9	12	51	-2.00 [-7.60, 3.60]
Passive external rotation (degrees) change from baseline to 3 weeks	-3	12	55	6	14	52	-9.00 [-13.95, -4.05]
Passive external rotation (degrees) change from baseline to 7 weeks	-2	14	56	13	16	51	-15.00 [-20.72, -9.28]
Passive external rotation (degrees) change from baseline to 6 months	7	21	54	16	18	51	-9.00 [-16.47, -1.53]
	Events	Total		Events	Total		Risk ratio (95%CI)
Total adverse events	32	57		30	57		1.07 [0.76, 1.49]
Adverse events: pain after treatment lasting <1 day	17	57		9	57		1.89 [0.92, 3.88]
Adverse events: pain after treatment lasting >2 days	13	57		16	57		0.81 [0.43, 1.53]
Adverse events: facial flushing	1	57		9	57		0.11 [0.01, 0.85]
Adverse events: irregular menstrual bleed- ing	0	57		6	57		0.08 [0.00, 1.33]
	1	57		4	57		0.25 [0.03, 2.17]
Adverse events: fever							
Adverse events: fever Adverse events: skin irritation	2	57		1	57		2.00 [0.19, 21.44]

Cochrane Database of Systematic Reviews

Cochrane Library

Trusted evidence. Informed decisions. Better health.

\_

150

Table 3. van der Windt 1998: Passive mobilisation and supervised exercise (intervention) versus glucocorticoid injection (control) (Continued)

Global assessment of treatment success	26	56	40	52	0.60 [0.44, 0.83]
("complete recovery or much improvement)					
at 7 weeks					

## Table 4. Buchbinder 2007: Passive mobilisation and supervised strength, stretching and coordination exercises following arthrographic joint distension (intervention) versus sham ultrasound following arthrographic joint distension (control)

OUTCOME	INTERVENT	ΓΙΟΝ		CONTROL	CONTROL		
	Mean	SD	n	Mean	SD	n	Mean difference (95%Cl)
Overall pain (VAS 0-10) change from base- line to 6 weeks	-3.4	2.1	75	-3.4	2.2	73	0.00 [-0.69, 0.69]
Overall pain (VAS 0-10) change from base- line to 6 months	-3.5	2.5	74	-3.6	2.6	70	0.10 [-0.73, 0.93]
Function (SPADI 0-100) change from base- line to 6 weeks	38	20.4	75	38.5	23.5	73	-0.50 [-7.60, 6.60]
Function (SPADI 0-100) change from base- line to 6 months	40	21.8	74	42.4	22.8	70	-2.40 [-9.69, 4.89]
Night pain (VAS 0-10) change from baseline to 6 weeks	-3.7	2.9	75	-3.6	2.5	73	-0.10 [-0.97, 0.77]
Night pain (VAS 0-10) change from baseline to 6 months	-3.9	3.2	74	-3.6	2.5	70	-0.30 [-1.24, 0.64]
Pain on motion (VAS 0-10) change from baseline to 6 weeks	-4.2	2.3	75	-4.4	2.7	73	0.20 [-0.61, 1.01]
Pain on motion (VAS 0-10) change from baseline to 6 months	-4.4	3	74	-4.5	2.9	70	0.10 [-0.86, 1.06]
Active hand behind back distance (cm) change from baseline to 6 weeks	-18.2	9.5	75	-13.1	9	73	-5.10 [-8.08, -2.12]

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cochrane Library

Active hand behind back distance (cm) change from baseline to 6 months	-22.8	11.6	74	-17.4	11.9	70	-5.40 [-9.24
Active abduction (degrees) change from baseline to 6 weeks	49.1	29	75	36	26.2	73	13.10 [4.20,
Active abduction (degrees) change from baseline to 6 months	55.9	31.1	74	48.6	32.3	70	7.30 [-3.07,
Active flexion (degrees) change from base- line to 6 weeks	37.2	19.9	75	28.1	19.3	73	9.10 [2.78, 2
Active flexion (degrees) change from base- line to 6 months	41.8	23.4	74	36.2	26.7	70	5.60 [-2.62,
Active external rotation (degrees) change from baseline to 6 weeks	25.3	16.7	75	16.2	15.8	73	9.10 [3.86, 1
Active external rotation (degrees) change from baseline to 6 months	31	16.9	74	25.9	17.9	70	5.10 [-0.59,
Quality of life (SF-36 PCS 0-100) change from baseline to 6 weeks	7.8	10.9	75	8.3	12.3	73	-0.50 [-4.25
Quality of life (SF-36 PCS 0-100) change from baseline to 6 months	9.4	12.4	74	9.4	11.5	70	0.00 [-3.90,
Quality of life (SF-36 MCS 0-100) change from baseline to 6 weeks	12.4	11.6	75	13.2	12.8	73	-0.80 [-4.74
Quality of life (SF-36 MCS 0-100) change from baseline to 6 months	13.3	12.2	74	13.7	11.2	70	-0.40 [-4.22
	Events	Total		Events	Total		Risk ratio (
Total adverse events	2	75		2	74		0.99 [0.14, 6
Global assessment of treatment success ("Success/much improved, and/or com-	56	75		41	73		1.33 [1.04, ]

 Table 4. Buchbinder 2007: Passive mobilisation and supervised strength, stretching and coordination exercises following arthrographic joint distension (intervention) versus sham ultrasound following arthrographic joint distension (control) (Continued)

 Classical distance of the strength of the strengt of the strength of the strength

Global assessment of treatment success	58	74	43	70	1.28 [1.02, 1.59]
("Success/much improved, and/or com-					
pletely recovered") at 6 months					

## Table 5. Pajareya 2004: Passive mobilisation, supervised stretching and pulley exercises, electrotherapy and oral glucocorticoid (intervention) versus oral glucocorticoid (control)

OUTCOME	INTERVENTIO	DN		CONTROL			EFFECT ESTI- MATE
	Mean	SD	n	Mean	SD	n	Mean difference (95%Cl)
Function (SPADI 0-100) change from baseline to 3 weeks	20.5	15.4	60	11.9	14.2	59	8.60 [3.28, 13.92]
Passive internal rotation (cm) change from baseline to 3 weeks	6.3	7.7	60	3	7	59	3.30 [0.66, 5.94]
Passive external rotation (degrees) change from baseline to 3 weeks	21.3	15.3	60	18.3	15.4	59	3.00 [-2.52, 8.52]
Passive abduction (degrees) change from baseline to 3 weeks	21.9	21	60	14.7	18.1	59	7.20 [0.16, 14.24]
	Events	Total		Events	Total		Risk ratio (95%Cl)
Adverse events: pain persisting more than 2 hours after treatment	4	60		0	59		8.85 [0.49, 160.87]
Global assessment of treatment success ("disappearance of shoulder complaints or some pain/limitation which does not interfere with everyday life") at 3 weeks	21	60		11	59		1.88 [0.99, 3.54]
Global assessment of treatment success ("disappearance of shoulder complaints or some pain/limitation which does not interfere with everyday life") at 6 weeks	35	57		22	52		1.45 [0.99, 2.12]

Library	Cochrane

Table 5. Pajareya 2004: Passive mobilisation, supervised stretching and pulley exercises, electrotherapy and oral glucocorticoid (intervention)         versus oral glucocorticoid (control) (Continued)									
Global assessment of treatment success ("disappearance of shoulder complaints or some pain/limitation which does not interfere with everyday life") at 6 months	45	56	42	51	0.98 [0.81, 1.17]				

OUTCOME	INTERVENTION			CONTROL		EFFECT ESTIMATE	
	Mean	SD	n	Mean	SD	n	Mean difference (95%CI)
Overall pain (VAS 0-100) at 2 weeks	15.2	18.5	20	21.2	17.9	20	-6.00 [-17.28, 5.28]
Night pain (VAS 0-100) at 2 weeks	39.1	28.1	20	42	25.6	20	-2.90 [-19.56, 13.76]
Pain on motion (VAS 0-100) at 2 weeks	50.4	24.5	20	62.5	12.6	20	-12.10 [-24.17, -0.03]
Passive internal rotation (degrees) at 2 weeks	66.7	10	20	56.1	14.7	20	10.60 [2.81, 18.39]
Passive external rotation (degrees) at 2 weeks	74.4	14.2	20	52.8	24.3	20	21.60 [9.27, 33.93]
Passive abduction (degrees) at 2 weeks	157.7	21.6	20	145.3	28.5	20	12.40 [-3.27, 28.07]
Passive flexion (degrees) at 2 weeks	155.5	14.2	20	146.4	22.7	20	9.10 [-2.63, 20.83]
	Events	Total		Events	Total		Risk ratio (95%CI)
Global assessment of treatment suc- cess (reaching 80% of normal ROM) at 2 weeks	19	20		13	20		1.46 [1.04, 2.05]

OUTCOME	INTERVENTIO	INTERVENTION				EFFECT ESTIMATE	
	Mean	SD	n	Mean	SD	n	Mean difference (95%Cl)
Overall pain (no scale units) change from baseline to 4 weeks	-5.1	4.56	10	-2.9	4.41	10	-2.20 [-6.13, 1.73]
Active internal rotation (degrees) change from baseline to 4 weeks	11.04	6.12	10	4.96	7.55	10	6.08 [0.06, 12.10]
Active external rotation (degrees) change from baseline to 4 weeks	17.62	13.23	10	13.22	17.14	10	4.40 [-9.02, 17.82]
Active abduction (degrees) change from baseline to 4 weeks	25.04	19.94	10	14.18	12.42	10	10.86 [-3.70, 25.42]

### Table 8. Sirajuddin 2010: Anterior glide mobilisation, exercise and electrotherapy (intervention) versus exercise and electrotherapy (control)

OUTCOME	INTERVENTION			CONTROL		EFFECT ESTIMATE	
	Mean	SD	n	Mean	SD	n	Mean difference (95%CI)
Overall pain (VAS 0-10) at 3 weeks	1.26	0.97	15	2.86	1.07	15	-1.60 [-2.33, -0.87]
Active internal rotation (degrees) at 3 weeks	76.66	3.45	15	57.93	7.33	15	18.73 [14.63, 22.83]

### Table 9. Sirajuddin 2010: Posterior glide mobilisation, exercise and electrotherapy (intervention) versus exercise and electrotherapy (control)

OUTCOME	INTERVENTION			CONTROL		EFFECT ESTIMATE	
	Mean	SD	n	Mean	SD	n	Mean difference (95%CI)
Overall pain (VAS 0-10) at 3 weeks	1.3	1.03	15	2.86	1.07	15	-1.56 [-2.31, -0.81]
Active internal rotation (degrees) at 3 weeks	68.4	6.4	15	57.93	7.33	15	10.47 [5.55, 15.39]

OUTCOME	INTERVEN	ΓΙΟΝ		CONTROL			EFFECT ESTIMATE
	Mean	SD	n	Mean	SD	n	Mean difference (95%Cl)
Function (Flexilevel Scale of Shoulder Function (FLEX-SF, 1-50 scale) at 4 weeks	32.7	1.7	11	31.8	1.5	12	0.90 [-0.42, 2.22]
Function (Flexilevel Scale of Shoulder Function (FLEX-SF, 1-50 scale) at 8 weeks	39.9	1.8	11	32.4	1.6	12	7.50 [6.10, 8.90]
Passive internal rotation (degrees) at 4 weeks	41.3	15.59	11	39.3	14.55	12	2.00 [-10.35, 14.35]
Passive internal rotation (degrees) at 8 weeks	45.6	20.89	11	42.9	19.75	12	2.70 [-13.95, 19.35]
Passive external rotation (degrees) at 4 weeks	41.5	15.59	11	38	14.90	12	3.50 [-8.99, 15.99]
Passive external rotation (degrees) at 8 weeks	60.1	16.58	11	37.7	15.59	12	22.40 [9.22, 35.58]

## Table 11. Celik 2010: Scapulothoracic exercises, ROM exercises, electrotherapy, cold pack and NSAID (intervention) versus ROM exercises, electrotherapy, cold pack and NSAID (control) electrotherapy, cold pack and NSAID (control)

ОИТСОМЕ	INTERVENTION			CONTROL		EFFECT ESTIMATE	
	Mean	SD	n	Mean	SD	n	Mean difference (95%CI)
Overall pain (VAS 0-10) at 6 weeks	0	1.6	15	1.5	1.4	14	-1.50 [-2.59, -0.41]
Overall pain (VAS 0-10) at 12 weeks	0	0.7	15	1	0.9	14	-1.00 [-1.59, -0.41]
Function (Constant score 0-100) at 6 weeks	60	13.3	15	53	7.9	14	7.00 [-0.90, 14.90]

Table 11. Celik 2010: Scapulothoracic exercises, ROM exercises, electrotherapy, cold pack and NSAID (intervention) versus ROM exercises, electrotherapy, cold pack and NSAID (control) (Continued)										
Function (Constant score 0-100) at 12 weeks	68	10.7	15	59	5.9	14	9.00 [2.77, 15.23]			
Passive internal rotation (degrees) at 6 weeks	70	9.2	15	70	3.3	14	0.00 [-4.97, 4.97]			
Passive internal rotation (degrees) at 12 weeks	78	8.4	15	78	3.9	14	0.00 [-4.72, 4.72]			
Passive external rotation (degrees) at 6 weeks	60	14.7	15	61.5	7.9	14	-1.50 [-10.01, 7.01]			
Passive external rotation (degrees) at 12 weeks	70	12.5	15	67.5	5.6	14	2.50 [-4.47, 9.47]			
Passive flexion (degrees) at 6 weeks	160.33	14.7	15	153.07	13	14	7.26 [-2.83, 17.35]			
Passive flexion (degrees) at 12 weeks	172.13	7.4	15	159.92	13.1	14	12.21 [4.39, 20.03]			

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### Table 12. Dundar 2009: Supervised stretching and pendulum exercises (intervention) versus continuous passive motion (control)

OUTCOME	INTERVEN	ΓΙΟΝ		CONTROL			EFFECT ESTIMATE
	Mean	SD	n	Mean	SD	n	Mean difference (95%Cl)
Overall pain (SPADI pain scale 0-10) at 4 weeks	4.58	1.28	28	4.01	2.1	29	0.57 [-0.33, 1.47]
Overall pain (SPADI pain scale 0-10) at 12 weeks	4.39	1.82	28	3.79	2.01	29	0.60 [-0.39, 1.59]
Function (SPADI disability scale 0-10) at 4 weeks	4.29	1.91	28	4.03	1.58	29	0.26 [-0.65, 1.17]
Function (SPADI disability scale 0-10) at 12 weeks	3.99	1.84	28	3.82	1.61	29	0.17 [-0.73, 1.07]
Night pain (VAS 0-10) at 4 weeks	4.84	1.66	28	3.91	2.61	29	0.93 [-0.20, 2.06]

Table 12. Dundar 2009: Supervised stretching and pendulum exercises (intervention) versus continuous passive motion (control) (Continued)										
Night pain (VAS 0-10) at 12 weeks	4.64	1.77	28	3.74	2.14	29	0.90 [-0.12, 1.92]			
Pain on motion (VAS 0-10) at 4 weeks	4.93	1.87	28	4.06	2.13	29	0.87 [-0.17, 1.91]			
Pain on motion (VAS 0-10) at 12 weeks	4.65	1.65	28	3.75	1.92	29	0.90 [-0.03, 1.83]			
Passive internal rotation (degrees) at 4 weeks	64.45	17.8	28	62.89	19.96	29	1.56 [-8.25, 11.37]			
Passive internal rotation (degrees) at 12 weeks	67.19	18.47	28	66.27	17.14	29	0.92 [-8.34, 10.18]			
Passive external rotation (degrees) at 4 weeks	64.9	21.52	28	65.82	17.54	29	-0.92 [-11.13, 9.29]			
Passive external rotation (degrees) at 12 weeks	68.98	14.22	28	68.22	17.11	29	0.76 [-7.40, 8.92]			
Passive abduction (degrees) at 4 weeks	127.67	26.66	28	137.96	16.26	29	-10.29 [-21.80, 1.22]			
Passive abduction (degrees) at 12 weeks	137.33	15.31	28	141.75	13.11	29	-4.42 [-11.83, 2.99]			
Passive flexion (degrees) at 4 weeks	132.78	15.96	28	133.96	10.09	29	-1.18 [-8.14, 5.78]			
Passive flexion (degrees) at 12 weeks	138.75	14.21	28	139.26	11.19	29	-0.51 [-7.17, 6.15]			

Cochrane Library

Trusted evidence. Informed decisions. Better health.

158

## Table 13. Ghosh 2012: Supervised active and passive mobilisation exercises and electrotherapy (intervention) versus manipulation under anaesthesia (control)

OUTCOME	INTERVENTION		CONTROL		EFFECT ESTIMATE
	Events	Total	Events	Total	Risk ratio (95%CI)
Global assessment of treatment suc- cess (clinical improvement rated as "good") at 6 months	16	24	19	24	0.84 [0.59, 1.19]

## Table 14. Ghosh 2012: Supervised active and passive mobilisation exercises and electrotherapy (intervention) versus glucocorticoid injection (control)

OUTCOME	INTERVENTION		CONTROL		EFFECT ESTIMATE
	Events	Total	Events	Total	Risk ratio (95%CI)
Global assessment of treatment suc- cess (clinical improvement rated as "good") at 6 months	16	24	19	23	0.81 [0.57, 1.13]

Table 15.	Maryam 2012: Supervised active ROI	A exercises, electrotherapy	and ice (intervention) versus	glucocorticoid injection (control)
	· · ·	<i>, , , , , ,</i>	• • •	

OUTCOME	INTERVEN	ΓΙΟΝ		CONTROL			EFFECT ESTIMATE
	Mean	SD	n	Mean	SD	n	Mean difference (95%Cl)
Overall pain (VAS 0-100) at 6 weeks	19.94	11.75	19	12.61	13.69	28	7.33 [0.01, 14.65]
Overall pain (VAS 0-100) at 6 months	8.62	4.2	8	12	14.18	14	-3.38 [-11.36, 4.60]
Function (SPADI 0-100) at 6 weeks	33.1	16.08	19	22.03	21.45	28	11.07 [0.33, 21.81]
Function (SPADI 0-100) at 6 months	19.87	16.23	8	19.92	15.62	14	-0.05 [-13.96, 13.86]
Passive flexion (degrees) change from baseline to 6 weeks	13.75	19.7	19	14.73	18.6	28	-0.98 [-12.20, 10.24]
Passive flexion (degrees) change from baseline to 6 months	6.66	34.3	8	15	14.4	14	-8.34 [-33.28, 16.60]
Passive abduction (degrees) change from baseline to 6 weeks	18.43	19.2	19	20.26	22.1	28	-1.83 [-13.73, 10.07]
Passive abduction (degrees) change from baseline to 6 months	12.5	22.3	8	18.57	20.7	14	-6.07 [-24.95, 12.81]
Passive external rotation (degrees) change from baseline to 6 weeks	1.56	16.9	19	9.8	10.7	28	-8.24 [-16.81, 0.33]
Passive external rotation (degrees) change from baseline to 6 months	5.62	5.6	8	9.61	17.6	14	-3.99 [-13.99, 6.01]
Passive hand behind back distance (cm) change from baseline to 6 weeks	-7.31	9.25	19	-5.07	5.95	28	-2.24 [-6.95, 2.47]
Passive hand behind back distance (cm) change from baseline to 6 months	-9.75	11.31	8	-6.64	7.22	14	-3.11 [-11.81, 5.59]

Cochrane Library

# Table 16. Maryam 2012: Supervised active ROM exercises, electrotherapy, ice and glucocorticoid injection (intervention) versus glucocorticoid injection (intervention) versus glucocorticoid injection (control)

OUTCOME	INTERVENTION		CONTROL		EFFECT ESTIMATE		
	Mean	SD	n	Mean	SD	n	Mean difference (95%Cl)
Overall pain (VAS 0-100) at 6 weeks	16.4	13.93	22	12.61	13.69	28	3.79 [-3.93, 11.51]
Overall pain (VAS 0-100) at 6 months	17	15.48	14	12	14.18	14	5.00 [-6.00, 16.00]
Function (SPADI 0-100) at 6 weeks	14.59	13.66	22	22.03	21.45	28	-7.44 [-17.22, 2.34]
Function (SPADI 0-100) at 6 months	18.57	22.35	14	19.92	15.62	14	-1.35 [-15.63, 12.93]
Passive flexion (degrees) change from baseline to 6 weeks	14.52	18.5	22	14.73	18.6	28	-0.21 [-10.56, 10.14]
Passive flexion (degrees) change from baseline to 6 months	11.07	29.5	14	15	14.4	14	-3.93 [-21.13, 13.27]
Passive abduction (degrees) change from baseline to 6 weeks	19.28	28.2	22	20.26	22.1	28	-0.98 [-15.33, 13.37]
Passive abduction (degrees) change from baseline to 6 months	7.5	18.4	14	18.57	20.7	14	-11.07 [-25.58, 3.44]
Passive external rotation (degrees) change from baseline to 6 weeks	3.8	12.3	22	9.8	10.7	28	-6.00 [-12.49, 0.49]
Passive external rotation (degrees) change from baseline to 6 months	5	11	14	9.61	17.6	14	-4.61 [-15.48, 6.26]
Passive hand behind back distance (cm) change from baseline to 6 weeks	-7.57	6.59	22	-5.07	5.95	28	-2.50 [-6.03, 1.03]
Passive hand behind back distance (cm) change from baseline to 6 months	-4.21	9.55	14	-6.64	7.22	14	2.43 [-3.84, 8.70]

Cochrane

OUTCOME	INTERVENTIO	INTERVENTION					EFFECT ESTIMATE
	Mean	SD	n	Mean	SD	n	Mean difference (95%Cl)
Function (Constant score 0-100) at 3 weeks	85.2	4.65	20	83.8	4.75	20	1.40 [-1.51, 4.31]
Internal rotation (degrees) at 3 weeks (un- clear if active or passive)	57	6.69	20	59.05	4.76	20	-2.05 [-5.65, 1.55]
External rotation (degrees) at 3 weeks (un- clear if active or passive)	63.55	11.15	20	53.35	5.88	20	10.20 [4.68, 15.72]
Abduction (degrees) at 3 weeks (unclear if active or passive)	140.65	10.24	20	135.55	9.26	20	5.10 [-0.95, 11.15]
Flexion (degrees) at 3 weeks (unclear if ac- tive or passive)	146.75	10.59	20	144.6	9.06	20	2.15 [-3.96, 8.26]

## Table 18. Rainbow 2008: High-velocity, low-amplitude chiropractic manipulative therapy to the cervical and thoracic spine and home exercises (intervention) versus grade IV mobilisation and home exercises (control)

<u></u>								
OUTCOME	INTERVENTION			CONTROL		EFFECT ESTIMATE		
	Mean	SD	n	Mean	SD	n	Mean difference (95%CI)	
Function (SPADI 0-100) at 3 weeks	35.25	27.77	4	52.83	16.2	4	-17.58 [-49.09, 13.93]	
Function (SPADI 0-100) at 6 weeks	14.1	4.15	4	35.08	15.16	4	-20.98 [-36.38, -5.58]	

## Table 19. Tanaka 2010: High-frequency (>twice a week) end-range mobilisation (intervention) versus moderate-frequency (once a week) end-range mobilisation (control)

OUTCOME	INTERVENTION	CONTROL	EFFECT ESTIMATE

Cochrane Library

	Mean	SD	n	Mean	SD	n	Mean difference (95%CI)
Active abduction (degrees) change from baseline to 6 months	56.4	24	39	49.9	24.2	35	6.50 [-4.50, 17.50]

## Table 20. Tanaka 2010: High-frequency (>twice a week) end-range mobilisation (intervention) versus low-frequency (<once a week) end-range mobilisation (control)

OUTCOME	INTERVENTION			CONTROL		EFFECT ESTIMATE	
	Mean	SD	n	Mean	SD	n	Mean difference (95%CI)
Active abduction (degrees) change from baseline to 6 months	56.4	24	39	49.3	28.1	36	7.10 [-4.77, 18.97]

## Table 21. Tanaka 2010: Moderate-frequency (once a week) end-range mobilisation (intervention) versus low-frequency (<once a week) end-range mobilisation (control)

OUTCOME	INTERVENTION			CONTROL		EFFECT ESTIMATE	
	Mean	SD	n	Mean	SD	n	Mean difference (95%CI)
Active abduction (degrees) change from baseline to 6 months	49.9	24.2	35	49.3	28.1	36	0.60 [-11.59, 12.79]

### Table 22. Vermeulen 2006: High-grade mobilisation (intervention) versus low-grade mobilisation (control)

OUTCOME				CONTROL			EFFECT ESTIMATE
	Mean	SD	n	Mean	SD	n	Mean difference (95%CI)

Cochrane Library

Overall pain (VAS 0-100) change from base- line to 6 months	-22.3	34.1	49	-24.3	24.9	51	2.00 [-9.74
Overall pain (VAS 0-100) change from base- line to 12 months	-23.9	27.2	49	-23	27.7	51	-0.90 [-11.0
Function (Shoulder Disability Questionnaire 0-100) change from baseline to 6 months	-38.9	35.5	49	-33.2	27.7	51	-5.70 [-18.2
Function (Shoulder Disability Questionnaire 0-100) change from baseline to 12 months	-50	30.3	49	-38.8	27.4	51	-11.20 [-22
Night pain (VAS 0-100) change from baseline to 6 months	-38.3	43.5	49	-31.7	29.9	51	-6.60 [-21.2
Night pain (VAS 0-100) change from baseline to 12 months	-43.7	34.5	49	-35.9	30.2	51	-7.80 [-20.
Pain on motion (VAS 0-100) change from baseline to 6 months	-31.4	27.9	49	-31.9	26.0	51	0.50 [-10.0
Pain on motion (VAS 0-100) change from baseline to 12 months	-39.2	27.9	49	-32.6	31.3	51	-6.60 [-18.2
Active abduction (degrees) change from baseline to 6 months	55.8	37.3	49	46.9	32.0	51	8.90 [-4.74
Active abduction (degrees) change from baseline to 12 months	72.9	31.7	49	60.3	32.7	51	12.60 [-0.0
Active flexion (degrees) change from base- line to 6 months	34.2	23.3	49	33.6	16.7	51	0.60 [-7.38
Active flexion (degrees) change from base- line to 12 months	47	24.4	49	42.9	19.9	51	4.10 [-4.64
Active external rotation (degrees) change from baseline to 6 months	15.9	12.9	49	13.2	13.2	51	2.70 [-2.40
Active external rotation (degrees) change	20.8	11.8	49	15.9	16.0	51	4.90 [-0.60

Cochrane Library

Table 22. Vermeulen 2006: High-grade mobilisation (intervention) versus low-grade mobilisation (control) (Continued)								
Quality of life (SF-36 PCS 0-100) change from baseline to 6 months	19.2	18.8	49	17.1	17.8	51	2.10 [-5.08, 9.28]	
Quality of life (SF-36 PCS 0-100) change from baseline to 12 months	23.2	21.9	49	22.8	19.9	51	0.40 [-7.82, 8.62]	
Quality of life (SF-36 MCS 0-100) change from baseline to 6 months	8.2	20.2	49	7.9	21.7	51	0.30 [-7.91, 8.51]	
Quality of life (SF-36 MCS 0-100) change from baseline to 12 months	7.7	20.5	49	10.2	22.4	51	-2.50 [-10.92, 5.92]	
	Events	Total		Events	Total		Risk ratio (95%CI)	
Global assessment of treatment success ("better or much better") at 6 months	40	49		43	51		0.97 [0.81, 1.16]	
Global assessment of treatment success ("better or much better") at 12 months	43	49		40	51		1.12 [0.94, 1.34]	

Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

### Table 23. Yan 2005: Dumbbell exercises (intervention) versus bare-handed exercises (control)

OUTCOME	INTERVENTION			CONTROL		EFFECT ESTIMATE		
	Events	Total		Events	Total		Risk ratio (95%CI)	
Global assessment of treatment success ("excellent" overall rating) at 3 months	24 26			0	28		52.63 [3.36, 823.64]	
	Mean	SD	n	Mean	SD	n	Mean difference (95%Cl)	
Flexion (degrees) at 3 months (unclear if active or passive)	92.46	17.14	26	85.41	13.34	28	7.05 [-1.19, 15.29]	
Abduction (degrees) at 3 months (un- clear if active or passive)	96.63	24.49	26	89.81	20.53	28	6.82 [-5.28, 18.92]	

## Table 24. Yang 2007: End-range mobilisation following mid-range mobilisation (intervention) versus mobilisation with movement following mid-range mobilisation (control)

OUTCOME	INTERVENT	ION	CONTROL				EFFECT ESTIMATE
	Mean	SD	n	Mean	SD	n	Mean difference (95%Cl)
Function (Flexilevel Scale of Shoulder Function (FLEX-SF, 1-50 scale) percentage change from baseline to 6 weeks	19.90%	8.10%	15	17.25%	12.20%	15	Not estimable

Cochrane Library

#### Table 25. Additional data reported in trials (partially reported)

#### Ma 2006: Mobilisation plus exercise (intervention) versus acupuncture (control)

Outcome	Intervention	Control
	Mean; SD not reported	
Static pain (VAS 0-10) at 4 weeks	0.4	0.7
Dynamic pain (VAS 0-10) at 4 weeks	3.7	4.3
Active flexion (degrees) at 4 weeks	129.9	129.3
Active abduction (degrees) at 4 weeks	98.3	115.7
Active internal rotation (degrees) at 4 weeks	43.9	51.7

#### Ma 2006: Mobilisation plus exercise plus acupuncture (intervention) versus acupuncture (control)

Outcome	Intervention	Control
	Mean; SD not reported	
Static pain (VAS 0-10) at 4 weeks	0.7	0.7
Dynamic pain (VAS 0-10) at 4 weeks	3.3	4.3
Active flexion (degrees) at 4 weeks	137.2	129.3
Active abduction (degrees) at 4 weeks	110.1	115.7
Active internal rotation (degrees) at 4 weeks	54.4	51.7

### Chan 2010: Passive mobilisation plus home care plus glucocorticoid injection (intervention) versus home care programme plus glucocorticoid injection (control)

Outcome	Intervention	Control
	Mean change; SD not reported	
Overall pain (VAS 0-10) change from baseline to 10 weeks	5.7	6.2
Active abduction (degrees) change from baseline to 10 weeks	40.7	80
Active internal rotation (cm) change from baseline to 10 weeks	28.4	38.9

#### Dacre 1989: Mobilisation (intervention) versus glucocorticoid injection (control)

Outcome	Intervention	Control
	Mean extracted from Figures; SD not reported	
Day pain (VAS 0-100) at 6 weeks	23.9	25.9
Day pain (VAS 0-100) at 6 months	18.7	17.2

#### Table 25. Additional data reported in trials (partially reported) (Continued)

Pain on motion (VAS 0-100) at 6 weeks	35.4	35
Pain on motion (VAS 0-100) at 6 months	21.5	28.5
Passive abduction (degrees) at 6 weeks	128.4	127.2
Passive abduction (degrees) at 6 months	133.1	140.5
Passive internal rotation (mm) at 6 weeks	259.6	290.8
Passive internal rotation (mm) at 6 months	247.5	235.4

#### Dacre 1989: Mobilisation plus glucocorticoid injection (intervention) versus glucocorticoid injection (control)

Outcome	Intervention	Control
	Mean extracted from Figures; SD not reported	
Day pain (VAS 0-100) at 6 weeks	21.7	25.9
Day pain (VAS 0-100) at 6 months	22.6	17.2
Pain on motion (VAS 0-100) at 6 weeks	34.2	35
Pain on motion (VAS 0-100) at 6 months	18.1	28.5
Passive abduction (degrees) at 6 weeks	124.8	127.2
Passive abduction (degrees) at 6 months	138.6	140.5
Passive internal rotation (mm) at 6 weeks	276.9	290.8
Passive internal rotation (mm) at 6 months	240.6	235.4

#### Maricar 1999: Manual therapy plus exercise (intervention) versus exercise (control)

Outcome	Intervention	Control
	Mean; SD not reported	
Active flexion (degrees) at 3 weeks	151.8	146.2
Active flexion (degrees) at 5 weeks	159.5	155.6
Active flexion (degrees) at 8 weeks	170.9	164
Active internal rotation (degrees) at 3 weeks	56.1	50
Active internal rotation (degrees) at 5 weeks	67.4	58.9
Active internal rotation (degrees) at 8 weeks	78.3	70.3

#### Samnani 2004: Passve ROM exercises and therapeutic activity program (intervention) versus therapeutic activity program (control)

Outcome	Intervention	Control	
Manual therapy and exercise for adhesive capsulitis (frozen shoulder) (Review)			168

Copyright  ${\ensuremath{\mathbb C}}$  2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



### Table 25. Additional data reported in trials (partially reported) (Continued)

	Mean (SD); n not repo	rted
Active functional-hand-to-back score (0-10 scale, higher scores=increased ROM) at 6 weeks	5.8 (1.9)	2.6 (0.9)
Sharad 2011: End-range mobilisation plus ultrasound plus exercises (intervo	ention) versus ultrasou	nd plus exercises (control)
Outcome	Intervention	Control
	Mean; SD not reported	
Overall pain (VAS 0-10) at 3 weeks	0.9	1.09
Active abduction (degrees) at 3 weeks	40.26	22
Active flexion (degrees) at 3 weeks	36.82	21.18
Harsimran 2011: Anterior glide mobilization (intervention) versus posterior	glide mobilisation (con	trol)
Outcome	Intervention	Control
	Median change; SD not	reported
Overall pain (VAS 0-10) change from baseline to 5 days	2.5	3
Johnson 2007: Anterior glide mobilization (intervention) versus posterior g	lide mobilisation (contr	ol)
Outcome	Intervention	Control
	Median (range); SD not reported	
Night pain (0-4 ordinal scale) at 3 weeks	3 (1-4)	4 (1-4)
Overall function (0-4 ordinal scale) at 3 weeks	2.5 (1-3)	2 (0-3)
Shrivastava 2011: Maitland's mobilisation (intervention) versus Mulligan's	mobilisation with move	ment (control)
Outcome	Intervention	Control
	Mean; SD not reported	
Overal pain (VAS 0-10) at 4 weeks	4.05	3.6
Function (SPADI 0-100) at 4 weeks	40	42
Flexion (degrees) at 4 weeks (unclear if active or passive)	121.25	122
Abduction (degrees) at 4 weeks (unclear if active or passive)	91.25	99.5
Internal rotation (degrees) at 4 weeks (unclear if active or passive)	46.5	41.25



#### APPENDICES

#### **Appendix 1. Search strategies**

Search strategy for CENTRAL:

- 1. MeSH descriptor: [Shoulder Pain] explode all trees
- 2. MeSH descriptor: [Shoulder Impingement Syndrome] explode all trees
- 3. MeSH descriptor: [Rotator Cuff] explode all trees
- 4. MeSH descriptor: [Bursitis] explode all trees
- 5. ((shoulder\* in All Text or rotator\* in All Text) and (bursitis in All Text or frozen in All Text or impinge\* in All Text or tendonitis in All Text or tendonitis in All Text or pain\* in All Text))
- 6. "rotator cuff" in All Text
- 7. "adhesive capsulitis" in All Text
- 8. #1 or #2 or #3 or #4 or #5 or #6 or #7
- 9. MeSH descriptor: [Rehabilitation] explode all trees
- 10.MeSH descriptor: [Physical Therapy Modalities] explode all trees
- 11.MeSH descriptor: [Exercise Movement Techniques] explode all trees
- 12.MeSH descriptor: [Ultrasonography, Interventional] explode all trees
- 13. rehabilitat\* in All Text or physiotherapy\* in All Text or "physical therap\*" in All Text or "manual therap\*" in All Text or exercis\* in All Text
- 14.(ultrasound in All Text or ultrasonograph\* in All Text or tns in All Text or tens in All Text or shockwave in All Text or electrotherap\* in All Text or mobili\* in All Text)

15.#9 or #10 or #11 or #12 or #13 or #14

16.#8 and #15

#### Search strategy for MEDLINE:

- 1. shoulder pain/
- 2. shoulder impingement syndrome/
- 3. rotator cuff/
- 4. exp bursitis/
- 5. ((shoulder\$ or rotator cuff) adj5 (bursitis or frozen or impinge\$ or tendinitis or tendonitis or tendinopathy or pain\$)).mp.
- 6. rotator cuff.mp.
- 7. adhesive capsulitis.mp.
- 8. or/1-7
- 9. exp rehabilitation/
- 10.exp physical therapy techniques/
- 11.exp musculoskeletal manipulations/
- 12.exp exercise movement techniques/
- 13.exp ultrasonography, interventional/
- 14. (rehabilitat\$ or physiotherap\$ or physical therap\$ or manual therap\$ or exercis\$ or ultrasound or ultrasonograph\$ or TNS or TENS or shockwave or electrotherap\$ or mobili\$). mp.
- 15.or/9-14
- 16.clinical trial.pt
- 17.random\$.mp.
- 18.((single or double) adj (blind\$ or mask\$)).mp.
- 19.placebo\$.mp.
- 20.or/16-19
- 21.8 and 15 and 20

#### Search strategy for EMBASE:

- 1. 'shoulder pain'/exp
- 2. 'shoulder impingement syndrome'/exp
- 3. 'rotator cuff'/exp
- 4. 'bursitis'/exp



- 5. ((shoulder\* OR rotator\*) AND ('bursitis'/de OR frozen OR impinge\* OR 'tendonitis'/de OR 'tendinitis'/de OR 'tendinopathy'/de OR pain\*))
- 6. 'rotator cuff'
- 7. 'adhesive capsulitis'
- 8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
- 9. 'rehabilitation'/exp
- 10. 'physiotherapy'/exp
- 11. 'kinesiotherapy'/exp
- 12.'endoscopic echography'/exp
- 13. rehabilitat\* OR physiotherapy\* OR 'physical therapy' OR 'manual therapy' OR kinesiotherap\* OR exercis\*
- 14. 'ultrasound'/de OR ultrasonograph\* OR 'transcutaneous nerve stimulation' OR 'transcutaneous electrical nerve stimulation' OR shockwave OR electrotherap\* OR mobili\*
- 15.#9 OR #10 OR #11 OR #12 OR #13 OR #14
- 16.'randomized controlled trial'/exp
- 17.#8 AND #15 AND #16

Search strategy for CINAHL Plus:

- S1 MH "shoulder pain"
- S2 MH "shoulder impingement syndrome"
- S3 MH "rotator cuff"
- S4 MH bursitis+
- S5 TX (shoulder\* N5 bursitis) or TX(shoulder\* N5 frozen) or TX(shoulder\* N5 impinge\*) or TX(shoulder\* N5 tend?nitis) or TX(shoulder\* N5 pain\*)
- S6 TX (rotator cuff N5 bursitis) or TX(rotator cuff N5 frozen) or TX(rotator cuff N5 impinge\*) or TX(rotator cuff N5 tend?nitis) or TX(rotator cuff N5 tend?nitis) or TX(rotator cuff N5 tend?nitis)
- S7 TX rotator cuff
- S8 TX adhesive capsulitis
- S9 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8
- S10 MH Rehabilitation+
- S11 MH physical therapy+
- S12 MH Manual Therapy+
- S13 MH Therapeutic Exercise+
- S14 MHUltrasonography+
- S15 TX rehabilitat\* or physiotherapy\* or physical therap\* or manual therap\* or exercise\* or ultrasound or ultrasonograph\* or TNS or TENS or shockwave or electrotherapy\* or mobili\*
- S16 S10 or S11 or S12 or S13 or S14 or S15
- S17 PT clinical trial
- S18 TX random\*
- S19 TX(single blind\*) or TX(single mask\*)
- S20 TX(double blind\*) or TX(double mask\*)
- S21 placebo\*
- S22 S17 or S18 or S19 or S20 or S21
- S23 S9 and S16 and S22

#### HISTORY

Review first published: Issue 8, 2014

Date	Event	Description
1 May 2008	Amended	Converted to RM5. CMSG ID C067-R
24 February 2003	New citation required and conclusions have changed	Substantive amendment



Date	Event	Description
24 February 2003	Amended	This review is based on the original review, 'Interventions for shoulder pain.' Please see published notes for further details

#### CONTRIBUTIONS OF AUTHORS

MJP was responsible for writing the review, performing the searches, selecting trials, performing risk of bias assessment, extracting data, analysing data and interpreting the results of the updated review. SG was responsible for performing the searches, selecting trials and performing data extraction and quality assessment for the original review, defining the review comparisons and outcomes of interest of the original and updated reviews, analysing and interpreting the results and contributing to writing both original and updated reviews. SK was responsible for performing risk of bias assessment, extracting data and contributing to writing the manuscript for the updated review. RJ was responsible for performing risk of bias assessment, extracting data and contributing to writing the manuscript for the updated review. BM was responsible for selecting trials and contributing to writing the manuscript for the updated review. MC was responsible for performing risk of bias assessment, extracting data from three included trials written in Chinese and contributing to writing the manuscript for the original review, defining the review comparisons and outcomes of interest for both original and updated reviews, analysing and interpreting the results and contributing to writing the review comparisons and outcomes of interest for both original and updated reviews, analysing and interpreting the results and contributing to writing the review comparisons and outcomes of interest for both original and updated reviews, analysing and interpreting the results and contributing to writing both original and updated review.

#### DECLARATIONS OF INTEREST

SG and RB are authors of one of the trials included in this review (Buchbinder 2007). To avoid bias, this paper was sent to an independent review author for assessment of whether it met the inclusion criteria for this review. Neither review author was involved in data extraction or risk of bias assessment for this trial. RB is Joint Co-ordinating Editor and RJ is Managing Editor of the Cochrane Musculoskeletal Group. To avoid bias, they excluded themselves from the editorial and publication processes for this review. SG and BMcB are practicing physiotherapists in part-time private physiotherapy practice (self employed) and in this role receive remuneration for the delivery of physiotherapy interventions.

#### SOURCES OF SUPPORT

#### Internal sources

- Australasian Cochrane Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
- Monash Department of Clinical Epidemiology at Cabrini Hospital, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

#### **External sources**

• No sources of support supplied

#### DIFFERENCES BETWEEN PROTOCOL AND REVIEW

The original review outcomes were pain, range of motion (active and passive), function/disability and quality of life, strength, return to work, participants' perception of overall effect, global preference, physicians' preference and adverse effects. The outcomes reported in this review have been modified from those of the original review to make them as consistent as possible with other Cochrane reviews on shoulder disorders and other chronic pain conditions. To improve succinctness of the review, we included only one measurement instrument per outcome domain. We assessed study risk of bias using the 'Risk of bias' tool of The Cochrane Collaboration in this update of the review. We have included a 'Summary of findings' table and an ORBIT outcome matrix.

#### NOTES

The original review, 'Physiotherapy interventions for shoulder pain,' was split into four reviews upon updating: 'Manual therapy and exercise for adhesive capsulitis (frozen shoulder),' 'Electrotherapy modalities for adhesive capsulitis (frozen shoulder),' 'Manual therapy, exercise and taping for rotator cuff disorders' and 'Electrotherapy modalities for rotator cuff disorders.' This review has also been broadened by inclusion of all randomised and quasi-randomised clinical trials, regardless of whether outcome assessment was blinded.

#### INDEX TERMS

#### **Medical Subject Headings (MeSH)**

Bursitis [\*therapy]; Exercise Therapy [\*methods]; Glucocorticoids [therapeutic use]; Injections, Intra-Articular; Musculoskeletal Manipulations [\*methods]; Randomized Controlled Trials as Topic; Shoulder Pain [therapy]



#### **MeSH check words**

Adult; Female; Humans; Male; Middle Aged